US20130012496A1 - Benzazepine compound - Google Patents

Benzazepine compound Download PDF

Info

Publication number
US20130012496A1
US20130012496A1 US13/583,410 US201113583410A US2013012496A1 US 20130012496 A1 US20130012496 A1 US 20130012496A1 US 201113583410 A US201113583410 A US 201113583410A US 2013012496 A1 US2013012496 A1 US 2013012496A1
Authority
US
United States
Prior art keywords
alkyl
substituted
octahydro
benzazepine
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/583,410
Inventor
Hiroyuki Koshio
Norio Asai
Taisuke Takahashi
Takafumi Shimizu
Yasuhito NAGAI
Keiko Kawabata
Karl Bruce Thor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Priority to US13/583,410 priority Critical patent/US20130012496A1/en
Assigned to ASTELLAS PHARMA INC. reassignment ASTELLAS PHARMA INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ASAI, NORIO, KAWABATA, KEIKO, KOSHIO, HIROYUKI, NAGAI, YASUHITO, SHIMIZU, TAKAFUMI, TAKAHASHI, TAISUKE, THOR, KARL BRUCE
Publication of US20130012496A1 publication Critical patent/US20130012496A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Definitions

  • the present invention relates to a benzazepine compound which is useful as an active ingredient of a pharmaceutical composition, particularly a pharmaceutical composition for treating or preventing 5-HT 2C receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like.
  • 5-HT 2C receptor-related diseases particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like
  • sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like.
  • a serotonin 2C (5-HT 2C ) receptor is one of the receptors for serotonin, a transmitter related to various physiological functions in the biological body. Its expression has been recognized mainly in the central nervous system (brain/spinal cord).
  • Non-Patent Documents 1 and 2 An anorectic action is known as a physiological function of the central 5-HT 2C receptor, and the lowering action of various 5-HT 2C receptor agonists on food intake has been reported in rats (Non-Patent Documents 1 and 2). Further, it has been confirmed that an anti-obesity action in humans is exhibited due to the anorectic action of the 5-HT 2C receptor agonist (Non-Patent Document 3).
  • the central 5-HT 2C receptor is involved in the control of peripheral nerve functions and it has been reported that the rat penile erection is induced by a 5-HT 2C receptor agonist (Non-Patent Document 4) and that the time taken from insertion to ejaculation in the experiment for mating behavior of monkeys is prolonged (Non-Patent Document 5). Moreover, it has been reported that a 5-HT 2C receptor agonist increases the urethral resistance when the abdominal pressure is increased in rats (Non-Patent Document 6). In addition, it has been reported that in disease models with neuropathic/inflammatory pain in rats, efficacy is exhibited by intraspinal administration of a 5-HT 2C receptor agonist (Non-Patent Documents 7 and 8).
  • 5-HT 2C receptor agonists particularly as anti-obesity drugs, drugs for treating male erectile dysfunction, drugs for treating premature ejaculation, drugs for treating stress urinary incontinence, drugs for treating neuropathic/inflammatory pain, or the like.
  • a benzazepine derivative As the 5-HT 2C receptor agonist, a benzazepine derivative has been reported, and as a tricyclic benzazepine derivative, for example, Compound A (Patent Document 1) and Compound B (Patent Document 2) are known.
  • Patent Document 3 As other 5-HT 2C receptor agonists, bicyclic benzazepine derivatives have been reported (Patent Document 3, Patent Document 4, and Patent Document 5).
  • a compound of the formula (AA) is known to be a Dopamine D3 modulator and be useful for central drug abuse and drug dependence (Patent Document 6).
  • Non-Patent Document 9 there is a report on the structure-activity relationship of a specific compound of the formula (AA) (Non-Patent Document 9), and in this report, it is described that the following compound was used in the preparation of the compound of the formula (AA).
  • Non-Patent Document 10 there is a report on a 5-HT 6 receptor antagonist (Non-Patent Document 10), and it is disclosed that for the compound below, potency on the 5-HT 6 receptor is lost by changing a ring condensed with benzazepine from a 5-membered ring to a 6-membered ring.
  • a benzazepine compound which is useful as an active ingredient for a pharmaceutical composition particularly a pharmaceutical composition for treating or preventing 5-HT 2C receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like is provided.
  • the present inventors have extensively studied compounds having a 5-HT 2C receptor agonist activity, and as a result, they have found that the benzazepine compound of the present invention has a 5-HT 2C receptor agonist activity, thereby completing the present invention.
  • the present invention relates to a pharmaceutical composition including the compound of the formula (I) or a salt thereof and a pharmaceutically acceptable excipient.
  • R 1a and R 1b are the same or different and each represents —H or C 1-6 alkyl, or are combined to form oxo,
  • R 2a and R 2b are the same or different and each represents —H or C 1-6 alkyl which may be substituted with —O—C 1-6 alkyl,
  • R 3 represents —H, C 1-6 alkyl which may be substituted, C 3-8 cycloalkyl, aryl which may be substituted, —SO 2 —C 1-6 alkyl, or a hetero ring which may be substituted,
  • R 4 represents —H, halogen, cyano, C 1-6 alkyl which may be substituted, C 2-6 alkenyl, aryl which may be substituted, C 3-8 cycloalkyl which may be substituted, an aromatic hetero ring, or an oxygen-containing hetero ring,
  • R 5 represents —H, halogen, C 1-6 alkyl, C 3-8 cycloalkyl, aryl, or an aromatic hetero ring,
  • R 6 and R 7 are the same or different and each represents —H or C 1-6 alkyl
  • X represents —C(R A )(R B )— or —O—
  • R A and R B are the same or different and each represents —H or C 1-6 alkyl.
  • the present invention relates to a compound of the formula (II) or a salt thereof.
  • R 11a and R 11b are the same or different and each represents —H or C 1-6 alkyl, or are combined to form oxo
  • R 21a and R 21b are the same or different and each represents —H or C 1-6 alkyl which may be substituted with —O—C 1-6 alkyl,
  • R 31 represents —H, C 1-6 alkyl which may be substituted, C 3-8 cycloalkyl, aryl which may be substituted, —SO 2 —C 1-6 alkyl, or a hetero ring which may be substituted,
  • R 41 represents —H, halogen, cyano, C 1-6 alkyl which may be substituted, C 2-6 alkenyl, aryl which may be substituted, C 3-8 cycloalkyl which may be substituted, an aromatic hetero ring, or an oxygen-containing hetero ring,
  • R 51 represents —H, halogen, C 1-6 alkyl, C 3-8 cycloalkyl, aryl, or an aromatic hetero ring,
  • R 61 and R 71 are the same or different and each represents —H or C 1-6 alkyl
  • X 1 represents —C(R A1 )(R B1 )— or —O—
  • R A1 and R B1 are the same or different and each represents —H or C 1-6 alkyl
  • R 11a , R 11b , R 21a , R 21b , R 41 , R 51 , R 61 , and R 71 are respectively —H and X 1 is —O—
  • R 31 is a group other than —H, —CO-methyl, or —SO 2 -methyl, and
  • R 11a and R 11b are combined to form oxo, R 21a , R 21b , R 41 , R 51 , R 61 , and R 71 are respectively —H, and X 1 is —O—, R 31 is a group other than —H or methyl.
  • the present invention relates to a pharmaceutical composition for preventing or treating 5-HT 2C receptor-related diseases, including the compound of the formula (I) or a salt thereof, or the compound of the formula (II) or a salt thereof.
  • the pharmaceutical composition includes an agent for preventing or treating 5-HT 2C receptor-related diseases, including the compound of the formula (I) or a salt thereof, or the compound of the formula (II) or a salt thereof.
  • the present invention relates to use of the compound of the formula (I) or a salt thereof, or the compound of the formula (II) or a salt thereof for preparation of a pharmaceutical composition for preventing or treating 5-HT 2C receptor-related diseases; the compound of the formula (I) or a salt thereof, or the compound of the formula (II) or a salt thereof for prevention or treatment of 5-HT 2C receptor-related diseases; and a method for preventing or treating 5-HT 2C receptor-related diseases, including administering to a subject an effective amount of the compound of the formula (I) or a salt thereof, or the compound of the formula (II) or a salt thereof.
  • the “subject” is human or other animals in need of the prevention or treatment, and in a certain embodiment, human in need of the prevention or treatment.
  • the compound of the formula (II) or a salt thereof is included in the compound of the formula (I) or a salt thereof. Accordingly, in the present specification, the explanation of the compound of the formula (I) includes that of the compound of the formula (II).
  • the compound of the formula (I) or a salt thereof, or the compound of the formula (II) or a salt thereof has a 5-HT 2C receptor agonist activity and can be used as an agent for preventing or treating 5-HT 2C receptor-related diseases.
  • examples of the 5-HT 2C receptor-related diseases include incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like.
  • the “alkyl” includes straight alkyl and branched alkyl.
  • the “C 1-6 alkyl” is a straight or branched alkyl having 1 to 6 carbon atoms, and specific examples thereof include methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, pentyl, hexyl, and the like, in another embodiment, methyl, ethyl, propyl, isopropyl, in a further embodiment, methyl, ethyl, in a still further embodiment, methyl, and in a still further embodiment, ethyl.
  • the “alkylene” is a divalent group formed by the removal of any one hydrogen atom of the “alkyl” above. Accordingly, the “C 1-6 alkylene” is straight or branched alkylene having 1 to 6 carbon atoms, and specific examples thereof include methylene, ethylene, trimethylene, tetramethylene, pentamethylene, hexamethylene, methylmethylene, dimethylmethylene, ethylmethylene, methylethylene, dimethylethylene, ethylethylene, and the like, in another embodiment, methylene, ethylene, and in a further embodiment methylene.
  • aryl is a monocyclic to tricyclic aromatic hydrocarbon ring group having 6 to 14 carbon atoms. Specific examples thereof include phenyl and naphthyl, in another embodiment, phenyl, and in a further embodiment, naphthyl.
  • the “cycloalkyl” is a saturated hydrocarbon ring group, the cycloalkyl may have a bridge and may be condensed with a benzene ring, and a part of the bonds may be unsaturated. Accordingly, specific examples of the “C 3-8 cycloalkyl” include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, cyclooctadienyl, norbornyl, bicyclo[2.2.2]octyl, indanyl, indenyl, 1,2-dihydronaphthyl, 1,2,3,4-tetrahydronaphthyl, and the like.
  • the “hetero ring” is a monovalent group of a 3- to 15-membered, in another embodiment, a 5- to 10-membered, monocyclic to tricyclic heterocyclic group containing 1 to 4 hetero atoms selected from oxygen, sulfur, and nitrogen, and includes a saturated ring, an aromatic ring, and a partially hydrogenated ring group thereof.
  • the ring atom, sulfur or nitrogen, may be oxidized to form an oxide or a dioxide.
  • monocyclic aromatic hetero rings such as pyrrolyl, furyl, thienyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, and the like, bicyclic aromatic hetero rings such as indolyl, isoindolyl, benzofuranyl, benzothienyl, indazolyl, benzimidazolyl, benzoxazolyl, benzoisoxazolyl, benzothiazolyl, benzoisothiazolyl, quinolyl, isoquinolyl, quinoxalinyl, quinazolinyl, phthalazinyl, benzothiadiazolyl
  • the “aromatic hetero ring” is a 5- to 10-membered monocyclic to bicyclic aromatic hetero ring among the “hetero rings” above, and specific examples thereof include pyrrolyl, furyl, thienyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, indolyl, isoindolyl, benzofuranyl, benzothienyl, indazolyl, benzimidazolyl, benzoxazolyl, benzoisoxazolyl, benzothiazolyl, benzoisothiazolyl, quinolyl, isoquinolyl, quinoxalinyl, quinazolinyl, phthalazinyl,
  • the “cyclic amino” is a 5- to 7-membered non-aromatic hetero ring having a binding position at a nitrogen atom among the “hetero rings” above, and specific examples thereof include pyrrolidinyl, piperidyl, piperazinyl, azepanyl, diazepanyl, morpholinyl, and thiomorpholinyl.
  • the “oxygen-containing hetero ring” is a monovalent group of a non-aromatic 5- to 6-membered ring which may be condensed with a benzene ring having one or two oxygen atoms as ring-constituting atoms.
  • Specific examples thereof include tetrahydrofuranyl, tetrahydropyranyl, dioxolanyl, dioxanyl, dihydrobenzofuranyl, dihydrochromenyl, benzodioxolyl, benzodioxinyl, dihydrodioxinyl, dihydrobenzodioxinyl, dihydropyranyl, dioxinyl, chromenyl, and benzodioxinyl.
  • halogen means —F, —Cl, —Br, or —I, and in another embodiment, —F, —Cl, or —Br.
  • halogeno-C 1-6 alkyl is C 1-6 alkyl substituted with one or more halogen atoms, and specific examples thereof include fluoromethyl, difluoromethyl, trifluoromethyl, trifluoroethyl, fluoroethyl, chloroethyl, bromoethyl, fluoropropyl, dichloropropyl, fluorochloropropyl, and the like, and in another embodiment, difluoromethyl, trifluoromethyl, difluoroethyl, trifluoroethyl, and fluoropropyl.
  • the expression “which may be substituted” means unsubstituted or substituted with 1 to 5 substituents. Further, if it has a plurality of substituents, the substituents may be the same as or different from each other.
  • substituents for the “C 1-6 alkyl which may be substituted”, “C 1-6 alkylene which may be substituted”, “(C 3-8 ) cycloalkyl which may be substituted”, “aryl which may be substituted”, or “hetero ring which may be substituted” of R 3 and R 4 include amino, nitro, cyano, halogen, C 1-6 alkyl, halogeno-C 1-6 alkyl, —OH, —C 1-6 alkylene-OH, —O—C 1-6 alkyl, —C 1-6 alkylene-O—C 1-6 alkyl, —C 1-6 alkylene-cycloalkyl, —C 1-6 alkylene-aryl, —C 1-6 alkylene-hetero ring, —CO—C 1-6 alkyl, —CO—C 1-6 alkylene-O—C 1-6 alkyl, —CO-cycloalkyl, —CO-aryl, —CO—NR 8 R
  • R 8 and R 9 are the same or different and each represents —H or C 1-6 alkyl.
  • examples of the substituent for “C 1-6 alkyl which may be substituted” in R 3 include:
  • phenyl which may be substituted with one or more groups selected from the group consisting of R Z , —O—R Z , halogen, and cyano,
  • R Z herein represents C 1-6 alkyl which may be substituted with one or more groups selected from the group consisting of halogen, —O—C 1-6 alkyl, C 3-8 cycloalkyl, and phenyl (in which the phenyl may be substituted with one or more groups selected from the group consisting of halogen and —O—C 1-6 alkyl).
  • examples of the substituent for the “aryl which may be substituted” in R 3 include halogen, and the aryl may be substituted with one or more substituents.
  • examples of the substituent for the “C 1-6 alkyl which may be substituted” in R 4 include halogen and aryl, and the C 1-6 alkyl may be substituted with one or more substituents.
  • examples of the substituent of the “aryl which may be substituted” in R 4 include halogen, C 1-6 alkyl, and —O—C 1-6 alkyl, and the aryl may be substituted with one or more substituents.
  • R 3 is C 1-6 alkyl which may be substituted with one or more groups selected from the group consisting of (a) to (e) below:
  • R 3 is C 1-6 alkyl which may be substituted with one or more groups selected from the group consisting of (f) to (j) below:
  • the compound or a salt thereof, wherein R 3 is isobutyl.
  • the compound or a salt thereof, wherein R 3 is ethyl or propyl, which respectively is substituted with one or more groups selected from the group consisting of fluoro, methoxy, and ethoxy.
  • the compound or a salt thereof, wherein R 3 is ethyl substituted with phenoxy which may be substituted with one or more groups selected from the group consisting of fluoro and cyano.
  • the compound or a salt thereof, wherein R 3 is methyl substituted with a group selected from the group consisting of tetrahydrofuranyl, tetrahydropyranyl and dihydrobenzodioxinyl.
  • the compound or a salt thereof, wherein R 3 is methyl substituted with phenyl which may be substituted with one or more groups selected from the group consisting of fluoro, chloro, methyl, and methoxymethyl.
  • R 3 is —H, C 1-6 alkyl which may be substituted, C 3-8 cycloalkyl, aryl which may be substituted, —SO 2 —C 1-6 alkyl, or an oxygen-containing hetero ring
  • R 4 is —H, halogen, cyano, C 1-6 alkyl which may be substituted, C 2-6 alkenyl, aryl which may be substituted, C 3-8 cycloalkyl, an aromatic hetero ring, or an oxygen-containing hetero ring.
  • R 3 is C 1-6 alkyl which may be substituted with one or more groups selected from the group consisting of (a) halogen, (b) —O—C 1-6 alkyl, (c) phenoxy which may be substituted with one or more groups selected from the group consisting of halogen and cyano, (d) an oxygen-containing hetero ring, and (e) phenyl which may be substituted with one or more groups selected from the group consisting of C 1-6 alkyl which may be substituted with —O—C 1-6 alkyl, halogen, and —O—C 1-6 alkyl.
  • Examples of the specific compounds included in the compound of the formula (I) or a salt thereof include:
  • the compound of the formula (I) may exist in the form of tautomers or geometrical isomers depending on the kind of substituents.
  • the compound of the formula (I) shall be described in only one form of isomer, yet the present invention includes other isomer, such as an isolated forms of the isomers, or a mixture thereof.
  • the compound of the formula (I) may have asymmetric carbon atoms or axial asymmetry in some cases, and correspondingly, it may exist in the form of optical isomers.
  • the present invention includes both an isolated form of the optical isomers of the compound of the formula (I) or a mixture thereof.
  • the present invention also includes a pharmaceutically acceptable prodrug of the compound of the formula (I).
  • the pharmaceutically acceptable prodrug is a compound having a group that can be converted into an amino group, a hydroxyl group, a carboxyl group, or the like through solvolysis or under physiological conditions. Examples of the group forming the prodrug include the groups described in Prog. Med., 5, 2157-2161 (1985) and Pharmaceutical Research and Development, Drug Design, Hirokawa Publishing Company (1990), vol. 7, 163-198.
  • the salt of the compound of the formula (I) is a pharmaceutically acceptable salt of the compound of the formula (I) and may form an acid addition salt or a salt with a base depending on the kind of substituents.
  • Specific examples thereof include acid addition salts with inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid, and the like, and with organic acids such as formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, mandelic acid, tartaric acid, dibenzoyltartaric acid, ditoluoyltartaric acid, citric acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, aspartic acid, glutamic acid, and the like, and salts with
  • the present invention also includes various hydrates or solvates, and polymorphic crystal substances of the compound of the formula (I) and a salt thereof.
  • the present invention also includes compounds labeled with various radioactive or non-radioactive isotopes.
  • the compound of the formula (I) and a salt thereof can be prepared using the characteristics based on the basic structure or the type of substituents thereof and by applying various known synthesis methods.
  • a suitable protective group a group that can be easily converted into the functional group
  • the protective group for such a functional group may include, for example, the protective groups described in “Greene's Protective Groups in Organic Synthesis (4 th Ed., 2006)” written by P. G. M. Wuts and T. W. Greene, and one of these may be selected and used as necessary depending on the reaction conditions.
  • a desired compound can be obtained by introducing the protective group, by carrying out the reaction and by eliminating the protective group as necessary.
  • the prodrug of the compound of the formula (I) can be produced by introducing a specific group or by carrying out the reaction using the obtained compound of the formula (I) at the stage from a starting material to an intermediate, just as in the case of the above-mentioned protective group.
  • the reaction can be carried out using methods known to those skilled in the art, such as ordinary esterification, amidation, dehydration, and the like.
  • the compound of the formula (I) can be obtained by removing P which is a protective group for an amino group.
  • the protective group for P may be any protective group for an amino group which is usually used by a person skilled in the art, and carbonyl such as trifluoroacetyl and the like; oxycarbonyl such as t-butylcarboxyl, ethylcarboxyl, benzylcarboxyl, and the like; or sulfonyl such as methanesulfonyl, p-toluenesulfonyl, trifluoromethanesulfonyl, p-nitrophenylsulfonyl, 2,4-dinitrophenylsulfonyl, and the like is suitably used.
  • the conditions for deprotection usually used by a person skilled in the art can be employed.
  • preparation can be performed by acid treatment, hydrolysis, hydrogenolysis, or the like.
  • acid treatment for example, trifluoroacetic acid, hydrochloric acid gas, sulfuric acid, or the like can be used.
  • inorganic bases for example NaOH, KOH, NaHCO 3 , Cs 2 CO 3 , and the like
  • acid hydrolysis hydrochloric acid and the like can be used.
  • the reaction can be performed under the condition from under ice-cooling to under refluxing and under the condition which does not allow the substrate to be decomposed.
  • the solvent dioxane, tetrahydrofuran, dichloromethane, chloroform, ethyl acetate, alcohols (MeOH, EtOH, and the like), N,N-dimethylformamide (DMF), dimethylsulfoxide (DMSO), water, or a mixed solvent thereof, and the like may be used, but are not limited thereto.
  • the reaction can usually be performed under a hydrogen atmosphere in the presence of a palladium catalyst. Usually, the reaction can be performed under the condition of from room temperature to under refluxing and under the condition which does not allow the substrate to be decomposed.
  • DMF dimethyl methacrylate
  • EtOH ethacrylate
  • the solvent DMF or alcohols (MeOH, EtOH, and the like) may be used, but are not limited thereto.
  • the conditions for the de-carboxamide reaction, the de-carbamate reaction, the de-sulfonamide reaction described in “Greene's Protective Groups in Organic Synthesis (4 th Ed., 2006)” above can be employed.
  • R 1a , R 1b , R 2a , R 2b , R 3 , R 4 , R 5 , R 6 , and R 7 can be easily converted to other functional groups by using the compound of the formula (I) as a starting material or using the synthetic intermediate of the compound of the formula (I) as a starting material by means of the reaction described in Examples as described later, the reaction apparent to a person skilled in the art, or modified methods thereof.
  • the step that can be usually employed by a person skilled in the art, such as O-alkylation, N-alkylation, reduction, hydrolysis, amidation, and the like can be arbitrarily combined and performed.
  • the starting compound in the preparation method above can be prepared by, for example, the following method, the method described in Preparation Examples as described later, known methods, or modified methods thereof.
  • a compound represented by the general formula (1) which is a starting material for synthesizing a compound of the general formula (2) is commercially available or prepared by a means known to a person skilled in the art.
  • the compound of the general formula (2) can be prepared by nitrating the compound of the general formula (1).
  • a number of known nitration reactions can be used, examples of which include a method using nitric acid, fumed nitric acid, potassium nitrate, or the like in an acid solvent, a method using nitronium tetrafluoroborate, and the like.
  • the compound of the general formula (3) can be prepared by reducing a nitro group of the compound of the general formula (2) to an amino group.
  • a number of known reduction methods can be used, examples of which include a method using metal hydrides such as lithium aluminum hydride and the like, a method using reduced iron or the like, and the like.
  • catalytic hydrogenation using noble metal catalysts such as Raney nickel, palladium, ruthenium, rhodium, platinum, and the like can also be used.
  • R Xa is C 1-6 alkyl
  • a compound of the general formula (4) can be prepared by halogenating the compound of the general formula (3).
  • a number of known halogenation reactions can be used, examples of which include a method using N-bromosuccinimide or N-chlorosuccinimide, and the like.
  • the compound of the general formula (5) can be prepared from the compound of the general formula (4) by a coupling reaction using a transition metal catalyst.
  • the coupling reaction include a Heck reaction.
  • the reaction conditions for the Heck reaction vary depending on the starting materials, solvents, and transition metal catalysts used, and techniques known to a person skilled in the art can be used.
  • the transition metal catalyst is preferably a palladium complex, and more preferably known palladium complexes such as palladium(II) acetate, dichlorobis(triphenylphosphine)palladium(II), tetrakis(triphenylphosphine)palladium(0), and the like.
  • a phosphorous ligand preferably, triphenylphosphine, tri-o-tolylphosphine, tri-tert-butylphosphine, 2-(di-tert-butylphosphino)biphenyl, or the like
  • the present reaction can yield preferable results in the presence of a base, and the base used herein is not particularly limited as long as it is used for the coupling reaction of the present reaction, but it is preferably triethylamine, N,N-diisopropylethylamine, or the like.
  • the compound of the general formula (IIIa) can be obtained by allowing an intramolecular amide condensation cyclization reaction to proceed by carrying out a hydrogenation reaction of the double bond of the ⁇ , ⁇ -unsaturated esters of the compound of the general formula (5).
  • the compound of the general formula (5) is stirred in the presence of a metal catalyst, usually for 1 hour to 5 days, in a solvent inert to the reaction, under a hydrogen atmosphere.
  • This reaction is usually carried out in the range from cooling to heating, preferably at room temperature.
  • solvent used herein examples include alcohols such as methanol, ethanol, 2-propanol, and the like, ethers such as diethylether, tetrahydrofuran, dioxane, dimethoxyethane, and the like, water, ethyl acetate, DMF, DMSO and a mixture thereof.
  • alcohols such as methanol, ethanol, 2-propanol, and the like
  • ethers such as diethylether, tetrahydrofuran, dioxane, dimethoxyethane, and the like
  • water ethyl acetate, DMF, DMSO and a mixture thereof.
  • palladium catalysts such as palladium on carbon, palladium black, palladium hydroxide, and the like
  • platinum catalysts such as a platinum plate, platinum oxide, and the like
  • nickel catalysts such as reduced nickel, Raney nickel, and the like
  • rhodium catalysts such as tetrakistriphenylphosphine chlororhodium, and the like
  • iron catalysts such as reduced iron and the like, etc.
  • hydrogen gas formic acid or ammonium formate in an equivalent amount or in an excess amount to the compound of the general formula (5) can be used as a hydrogen source.
  • an R 2b group other than —H can be introduced to a desired position by using an electrophilic substitution reaction to the ⁇ -position of carbonyl by the use of a base or by a method which can be usually employed by a person skilled in the art for the compound (IIIa).
  • a compound of the general formula (IIIb) can be obtained by carrying out reduction of a carbonyl group of the compound of the general formula (IIIa). This reaction is usually carried out in the presence of a reducing agent in a solvent.
  • a reducing agent in a solvent.
  • the solvent used herein are not particularly limited, but include ethers such as diethylether, tetrahydrofuran, dioxane, dimethoxyethane, and the like, and aromatic hydrocarbons such as benzene, toluene, xylene, and the like.
  • Examples of the reducing agent include aluminum hydride compounds such as lithium aluminum hydride, sodium bis(2-methoxyethoxy)aluminum hydride, and the like, and borohydride compounds such as sodium borohydride, diborane, a borane-tetrahydrofuran complex, and the like.
  • aluminum hydride compounds such as lithium aluminum hydride, sodium bis(2-methoxyethoxy)aluminum hydride, and the like
  • borohydride compounds such as sodium borohydride, diborane, a borane-tetrahydrofuran complex, and the like.
  • R 4a represents C 1-6 alkyl, halogeno-C 1-6 alkyl, cycloalkyl which may be substituted, or aryl which may be substituted, and Hal represents halogen).
  • a compound of the general formula (IIId) can be obtained by a coupling reaction of a compound of the general formula (IIIc).
  • a coupling reaction of a compound of the general formula (IIIc) for example, the Suzuki coupling described in the following references, the Heck reaction described for the Starting Material Synthesis 2 above, or the like can be employed.
  • the compound of the general formula (IIId) can also be obtained by the method described in Examples as described later.
  • R 1a represents a group other than —H among the groups defined as R 3 ).
  • a compound of the general formula (IIIe) can be obtained by alkylation, acylation, or the like of the compound of the general formula (IIIb).
  • the conditions described in the following references can be employed.
  • the compound of the general formula (IIIe) can also be obtained by the method described in the Examples as described later and the method described for the Starting Material Synthesis 4 above.
  • a compound of the general formula (8) can be obtained by the reaction of a compound of the general formula (6) with a compound of the general formula (7).
  • examples of the leaving group of L 1 include halogen, methanesulfonyloxy, p-toluenesulfonyloxy groups, and the like.
  • the compound of the general formula (6) and the compound of the general formula (7) are used in equivalent amounts, or with either one of them in an excess amount, and a mixture thereof is stirred under a temperature condition from cooling to heating and refluxing, preferably at 0° C. to 80° C., usually for 0.1 hours to 5 days, in a solvent inert to the reaction in the presence of a base.
  • solvent used herein examples include aromatic hydrocarbons such as benzene, toluene, xylene, and the like, ethers such as diethylether, tetrahydrofuran, dioxane, dimethoxyethane, and the like, halogenated hydrocarbons such as dichloromethane, 1,2-dichloroethane, chloroform, and the like, DMF, DMSO, ethyl acetate, acetonitrile, and a mixture thereof.
  • aromatic hydrocarbons such as benzene, toluene, xylene, and the like
  • ethers such as diethylether, tetrahydrofuran, dioxane, dimethoxyethane, and the like
  • halogenated hydrocarbons such as dichloromethane, 1,2-dichloroethane, chloroform, and the like
  • DMF dimethyl methoxyethane
  • DMSO ethyl
  • the base examples include organic bases such as triethylamine, N,N-diisopropylethylamine, 1,8-diazabicyclo[5.4.0]-7-undecene, n-butyllithium, and the like, and inorganic bases such as sodium carbonate, potassium carbonate, sodium hydride, potassium tert-butoxide, and the like. It may be advantageous to carry out a reaction in the presence of a phase transfer catalyst such as tetra-n-butylammonium chloride and the like in some cases.
  • a compound of the general formula (IIIf) can be obtained by the method described in the Starting Material Synthesis 3 above and a compound of the general formula (Mg) can be obtained by the method described in the Starting Material Synthesis 4 above.
  • R 3b represents C 1-6 alkyl which may be substituted, C 3-8 cycloalkyl, aryl which may be substituted, or a hetero ring which may be substituted, among the groups defined as R 3 . Further, among the C 1-6 alkyl which may be substituted, one having oxo substituted on a carbon atom directly bonded to a nitrogen atom connected with R 3b is excluded).
  • the compound of the general formula (10) can be obtained by using the compound of the general formula (9) and a suitable aldehyde or ketone compound in equivalent amounts, and stirring a mixture thereof under a temperature condition from ⁇ 45° C. to heating and refluxing, preferably at 0° C. to room temperature, usually for 0.1 hours to 5 days, in a solvent inert to the reaction in the presence of a reducing agent.
  • a solvent inert examples of the solvent used herein are not particularly limited, but include alcohols such as methanol, ethanol, and the like, ethers such as diethylether, tetrahydrofuran, dioxane, dimethoxyethane, and the like, and a mixture thereof.
  • the reducing agent examples include sodium cyanoborohydride, sodium triacetoxyborohydride, sodium borohydride, and the like. It is preferable in some cases to carry out the reaction in the presence of a dehydrating agent such as molecular sieves, and the like or an acid such as acetic acid, hydrochloric acid, a titanium(IV) isopropoxide complex, and the like. Further, the reaction can be carried out in a solvent such as methanol, ethanol, ethyl acetate, and the like, in the presence or absence of an acid such as acetic acid, hydrochloric acid, and the like, using a reduction catalyst (for example, palladium on carbon, Raney nickel, and the like), instead of treatment with the reducing agent. In this case, it is preferable to carry out the reaction under a hydrogen atmosphere from normal pressure to 50 atmospheres under a temperature condition ranging from cooling to heating.
  • a dehydrating agent such as molecular sieves, and the like or an acid such as
  • a compound of the general formula (IIIh) can be obtained by using the compound of the general formula (10) and a suitable halogenocarboxylic ester and reacting them in the presence of a base.
  • the compound of the general formula (IIIi) can be obtained by using the method described in the Starting Material Synthesis 4 above and carrying out reduction of a carbonyl group of the compound of the general formula (IIIh).
  • the compounds of the formula (I) can be isolated and purified as their free compounds, salts, hydrates, solvates, or polymorphic crystal substances thereof.
  • the salts of the compound of the formula (I) can be prepared by carrying out the treatment of a conventional salt forming reaction.
  • Isolation and purification are carried out by employing ordinary scientific operations such as extraction, fractional crystallization, various types of fractional chromatography, and the like.
  • Various isomers can be prepared by selecting an appropriate starting compound or separated by using the difference in the physicochemical properties between the isomers.
  • the optical isomers can be obtained by means of a general method for designing optical resolution of racemic products (for example, fractional crystallization for inducing diastereomer salts with optically active bases or acids, chromatography using a chiral column or the like, and others), and further, the isomers can also be prepared from an appropriate optically active starting material.
  • the agonist activity of the compound of the formula (I) on the 5-HT 2C receptor was confirmed by the method shown below.
  • the human 5-HT 2C receptor agonist activity was evaluated by measuring the increase of the ligand-dependent intracellular calcium concentration.
  • CHO cells which stably expressing a human 5-HT 2C receptor were used.
  • the receptor-expressing cells were prepared by transfecting the genes of the human 5-HT 2C receptor (Accession numbers: AF498983 (5-HT 2C )) into CHO cells (dihydrofolic acid-deficient strain, DS Pharma Biomedical Co., Ltd.)) using a pEF-BOS vector (Nucleic Acids Research, vol. 18, No. 17). After transcription, the 5-HT 2C is known to be subjected to RNA editing to cause differences in three kinds of amino acids, resulting in fourteen receptor isoforms.
  • FBS fetal bovine serum
  • the cells were suspended in a serum-free medium (trade name: CD-CHO, Invitrogen) containing 8 mM L-glutamine (trade name: L-glutamine 200 mM, Invitrogen, added to the medium at a final concentration of 8 mM) and dispensed into a 96-well poly-D-lysine-coated plate (trade name: Biocoat PDL96W Black/Clear, Japan Becton, Dickinson and Company)) at 4 ⁇ 104 cells/well and cultured at 37° C. and 5% carbon dioxide overnight.
  • a serum-free medium (trade name: CD-CHO, Invitrogen) containing 8 mM L-glutamine (trade name: L-glutamine 200 mM, Invitrogen, added to the medium at a final concentration of 8 mM) and dispensed into a 96-well poly-D-lysine-coated plate (trade name: Biocoat PDL96W Black/Clear, Japan Becton,
  • a solution including a washing solution (mixture of Hank's Balanced Salt Solution (HBSS)-sodium hydroxide (NaOH), 20 mM 2-[4-(2-hydroxyethyl)-1-piperazinyl]ethanesulfonic acid (HEPES)-sodium hydroxide (NaOH), 2.5 mM probenecid, and 0.1% bovine serum albumin (BSA)), and a 4 ⁇ M fluorescent reagent (trade name: Fluo-4-AM, Dojindo Co., Ltd.) was used as a loading buffer and the medium of the 96-well plate which had been cultured overnight was replaced with a loading buffer.
  • HBSS Hank's Balanced Salt Solution
  • NaOH 20 mM 2-[4-(2-hydroxyethyl)-1-piperazinyl]ethanesulfonic acid
  • BSA bovine serum albumin
  • fluorescent reagent trade name: Fluo-4-AM, Dojindo Co., Ltd.
  • the cells were washed with a plate washer (trade name: ELx405, BioTek Instruments, Inc.) in which a washing solution had been set up.
  • the plates of the washed cells were set up in a system for measuring a calcium (Ca) concentration in a cell (trade name: FLIPR, Molecular Devices, Inc.).
  • a test compound that had been dissolved in dimethyl sulfoxide and diluted in the washing solution at a predetermined concentration was added and set up to measure a change in the Ca concentrations in a cell. The difference between a maximum value and a minimum value in the change of the intracellular Ca concentration was determined and kept as measurement data.
  • Hartley female guinea pigs with a body weight of 250 to 350 g were anesthetized with urethane (Sigma).
  • the guinea pigs were fixed in a supine position and catheters (PE-50; Clay Adams) for administration of test compounds were inserted into the jugular vein.
  • catheters PE-160; Clay Adams
  • a catheters PE-160; Clay Adams
  • two electrodes were inserted into both the left and right sides of the urethral opening to the urethral sphincter.
  • the electrodes for measuring base voltages were placed under the skin of the hind part.
  • the bladder catheter was branched over a three-way stopcock, and one was connected with a 50 mL syringe (Terumo) fixed to an infusion pump (Terumo).
  • the other was connected to a pressure transducer (DX-100; Nihon Kohden Corporation) to transfer the signal of the transducer through an amplifier (AP-630G; Nihon Kohden Corporation) and a data acquisition system (PowerLab; AD Instruments) to a computer and record on a hard disk.
  • DX-100 pressure transducer
  • AP-630G Nihon Kohden Corporation
  • PowerLab PowerLab; AD Instruments
  • the electrodes for electromyography measurement were connected to a control unit (JB-101J; Nihon Kohden Corporation) to transfer the signal through an amplifier (AP-651J; Nihon Kohden Corporation) and a data acquisition system (PowerLab; AD Instruments) to a computer and record on a hard disk. Further, the data were analyzed on the computer using a software (Chart; AD Instruments). Physiological saline was continuously injected into the bladder using an infusion pump at a rate of 18 mL/hour and it was confirmed that a micturition reflexes were stably induced. The electromyography activity was analyzed by taking the lowest potential amplitude as a standard during the stabilization period and using the firing frequency over the standard amplitude as an indicator.
  • the activity of the urethral sphincter electromyography was analyzed and its average value was calculated.
  • the solvent and the test compound were administered at an increased dose at an interval of 40 minutes through the catheter placed into the jugular vein.
  • the urethral sphincter electromyography activity after the administration of the solvent was taken as 100% and the urethral sphincter electromyography activity after the administration of the test compound was denoted as a percentage (%) of the electromyography activity after the administration of the solvent.
  • Example 81, Example 59, Example 88, Example 104, Example 106, Example 141, Example 38, Example 135, Example 215, Example 243, Example 265, Example 287, Example 258, Example 263, Example 267, Example 268, Example 276, Example 277, Example 283, Example 288, Example 290, Example 291, Example 292, Example 297, Example 299, Example 313, and Example 315 as shown later showed an external urethral sphincter electromyography activity of 200% or more with intravenous administration at 3 mg/kg.
  • the compound of the formula (I) has a 5-HT 2C receptor agonist activity, and the compound of the formula (I) can be used for treatment or prevention of 5-HT 2C receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like as a pharmaceutical.
  • 5-HT 2C receptor-related diseases particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like as a pharmaceutical.
  • the compound has a 5-HT 2C receptor agonist activity and thus has substantially the same or a higher activity value than Lorcaserin under development as an anti-obesity drug (The Journal of Pharmacology and Experimental Therapeutics vol. 325, No. 2 p. 577-587 (2008)).
  • a pharmaceutical composition containing one or two or more kinds of the compound of the formula (I) or a salt thereof as an active ingredient can be prepared using excipients that are usually used in the art, that is, excipients for pharmaceutical preparation, carriers for pharmaceutical preparation, and the like according to the methods usually used.
  • Administration can be accomplished either by oral administration via tablets, pills, capsules, granules, powders, solutions, and the like, or parenteral administration injections, such as intraarticular, intravenous, or intramuscular injections, and the like, suppositories, ophthalmic solutions, eye ointments, transdermal liquid preparations, ointments, transdermal patches, transmucosal liquid preparations, transmucosal patches, inhalations, and the like.
  • parenteral administration injections such as intraarticular, intravenous, or intramuscular injections, and the like, suppositories, ophthalmic solutions, eye ointments, transdermal liquid preparations, ointments, transdermal patches, transmucosal liquid preparations, transmucosal patches, inhalations, and the like.
  • the solid composition for oral administration is used in the form of tablets, powders, granules, or the like.
  • one or more active ingredient(s) are mixed with at least one inactive excipient.
  • the composition may contain inactive additives, such as lubricants, disintegrating agents, stabilizing agents, and solubilization assisting agents. If necessary, tablets or pills may be coated with sugar or a film of a gastric or enteric coating substance.
  • the liquid composition for oral administration contains pharmaceutically acceptable emulsions, solutions, suspensions, syrups, elixirs, or the like, and also contains generally used inert diluents, for example, purified water or ethanol.
  • the liquid composition may also contain auxiliary agents, such as a solubilization assisting agent, a moistening agent, and a suspending agent, as well as sweeteners, flavors, aromatics, and antiseptics.
  • the injections for parenteral administration contain sterile aqueous or non-aqueous solutions, suspensions, or emulsions.
  • aqueous solvent include distilled water for injection use and physiological saline.
  • non-aqueous solvent include alcohols such as ethanol.
  • Such a composition may further contain a tonicity agent, an antiseptic, a moistening agent, an emulsifying agent, a dispersing agent, a stabilizing agent, and a solubilization assisting agent. These are sterilized by filtration through a bacteria retaining filter, blending of a germicide, or irradiation. Furthermore, they may also be prepared in the form of sterile solid compositions and dissolved or suspended in sterile water or a sterile solvent for injecting prior to their use.
  • Examples of the formulation for external use include ointments, plasters, creams, jellies, patches, sprays, lotions, eye-drops, eye ointments, and the like.
  • the drug contains generally used ointment bases, lotion bases, aqueous or non-aqueous liquid preparations, suspensions, emulsions, or the like.
  • Transmucosal agents such as inhalers, transnasal agents, and the like are used in the form of solids, liquids, or semisolids and can be prepared according to conventional known methods.
  • known excipients and further, pH adjusters, antiseptics, surfactants, lubricants, stabilizing agents, thickeners, or the like may also be added where appropriate.
  • suitable devices for inhalation or insufflation can be used.
  • the compound can be administered independently or in the form of prescribed mixture powders.
  • the compound combined with pharmaceutically acceptable carriers can also be administered in the form of solutions or suspensions.
  • Dry powder inhalers and the like may be devices for single or multiple administrations, and dry powders or capsules containing powders can also be used. Still further, the devices may be in the form of a pressure aerosol spray or the like that use suitable ejection agents, for example, chlorofluoroalkane, hydrofluoroalkane, or a suitable gas such as carbon dioxide and the like.
  • suitable ejection agents for example, chlorofluoroalkane, hydrofluoroalkane, or a suitable gas such as carbon dioxide and the like.
  • the daily dose is suitably from 0.001 to 100 mg/kg per body weight, preferably from 0.1 to 30 mg/kg, and more preferably from 0.1 to 10 mg/kg, and this is administered in one portion or dividing it into 2 to 4 portions.
  • the daily dose is suitably from about 0.0001 to 10 mg/kg per body weight, and this is administered once a day or two or more times a day.
  • a transmucosal agent is administered at a dose from about 0.001 to 100 mg/kg per body weight, and this is administered once a day or two or more times a day.
  • the dose is appropriately decided in response to an individual case by taking the symptoms, the age, the gender, and the like into consideration.
  • the pharmaceutical composition of the present invention contains 0.01 to 100% by weight, and in a certain embodiment, 0.01 to 50% by weight of one or more kinds of the compound of the formula (I) or a salt thereof, which is an active ingredient.
  • the compound of the formula (I) can be used in combination with various agents for treating or preventing the diseases, in which the compound of the formula (I) is considered effective, as described above.
  • the combined preparation may be administered simultaneously or separately and continuously, or at a desired time interval.
  • the preparations to be co-administered may be prepared individually or may be a pharmaceutical composition including various agents for treating or preventing the diseases, in which the compound of the formula (I) is considered effective, as described above, and the compound of the formula (I).
  • the present invention is not limited to the compounds described in the Examples described below. Furthermore, the production processes for the starting compounds will be described in Preparation Examples.
  • the preparation methods for the compound of the formula (I) are not limited to the preparation methods of the specific Examples as below, but the compound of the formula (I) can be prepared by any combination of the preparation methods or the methods that are apparent to a person skilled in the art.
  • HCl in the structural formula indicates that the Example compound is isolated as a hydrochloride.
  • a case where the structural formula of fumaric acid is described together in the structural formula indicates that the Example compound is isolated as fumarate.
  • a case where the structural formula of oxalic acid is described together in the structural formula indicates that the Example compound is isolated as an oxalate.
  • a case where the structural formula of succinic acid is described together in the structural formula indicates that the Example compound is isolated as a succinate.
  • the numeral means a molar ratio of the compound to hydrochloric acid.
  • 2HCl represents dihydrochloride.
  • M described under the Example No. indicates that the Example Compound is isolated as monofumarate
  • H described as such indicates that the Example Compound is isolated as hemifumarate
  • S described as such indicates that the Example Compound is isolated as sesquifumarate.
  • T of Example 267 indicates that the compound is isolated as 0.75 fumarate.
  • a concentration mol/l is expressed as M.
  • a 1 M aqueous sodium hydroxide solution means a 1 mol/l aqueous sodium hydroxide solution.
  • the solid was collected by filtration.
  • the resulting solid was suspended in 400 ml of water which had been heated to 80° C., and 31.2 g of sodium acetate was added thereto, followed by stirring at 90° C. for 3 hours.
  • the reaction mixture was cooled to room temperature and then the solid was collected by filtration to obtain 22.506 g of 6-chloro-1H-3-benzazepine-2,4(3H,5H)-dione as a brown solid.
  • the mixture was alkalified by the addition of aqueous ammonia and a 1 M aqueous sodium hydroxide solution, followed by extraction with chloroform.
  • the organic layer was dried over anhydrous sodium sulfate and then filtered.
  • the filtrate was concentrated under reduced pressure, the residue was dissolved in EtOH, and activated carbon was added thereto, followed by heating and refluxing, and then filtering on amino silica gel, and the filtrate was concentrated under reduced pressure.
  • To a solution of 18.7 g of the resulting residue in 180 ml of dichloromethane was added 17 ml of pyridine, followed by ice-cooling, and 13 ml of ethyl chlorocarbonate was added dropwise thereto, followed by stirring for 1.5 hours.
  • the reaction mixture was concentrated under reduced pressure, the residue was diluted with EtOAc, then washed with 1 M hydrochloric acid and water, dried over anhydrous sodium sulfate, and then filtered, and the filtrate was concentrated under reduced pressure.
  • the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 9.653 g of ethyl 6-chloro-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate as a reddish brown oily substance.
  • reaction mixture was filtered through celite and the filtrate was concentrated under reduced pressure to obtain 2.256 g of ethyl 11-chloro-2-oxo-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate as a milky white solid.
  • reaction mixture was concentrated under reduced pressure and the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 1.779 g of t-butyl 11-chloro-2-oxo-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate as a milky white solid.
  • reaction mixture 0.226 ml of isopropyl iodide and 0.394 ml of diisopropylethylamine, followed by stirring at 100° C. for 19 hours.
  • the reaction mixture was cooled to room temperature, and water added, followed by extraction with EtOAc twice.
  • the combined organic layer was washed with saturated brine, the organic layer was dried over anhydrous sodium sulfate and then filtered, and the solvent was evaporated under reduced pressure.
  • the filtrate was concentrated under reduced pressure to obtain 9.701 g of an orange viscous substance.
  • To a solution of 9.53 g of the resulting substance in 100 ml of dichloromethane were added dropwise 22 ml of diisopropylethylamine and 4.75 ml of chloromethylmethylether under ice-cooling, followed by stirring for 24 hours. 10 ml of chloromethylmethylether was added thereto, followed by further stirring for 24 hours.
  • the reaction mixture was concentrated under reduced pressure and the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 11.26 g of a yellow oily substance.
  • reaction mixture was concentrated under reduced pressure and the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 200 mg of t-butyl 1-(ethylcarbamoyl)-11-methyl-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate as a colorless viscous substance.
  • reaction mixture was concentrated under reduced pressure and the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 261 mg of 8-t-butyl 1-ethyl 11-methyl-3,4,6,7,9,10-hexahydro-1H-azepino[4,5-g]quinoline-1,8(2H)-dicarboxylate as a colorless viscous substance.
  • the organic layer was dried over anhydrous magnesium sulfate and then filtered, and the filtrate was concentrated under reduced pressure.
  • To the resulting residue was added 60 ml of a 17% aqueous sulfuric acid solution, followed by stirring at 100° C. for 1 hour.
  • the reaction mixture was ice-cooled and alkalified by the addition of 15 g of sodium hydroxide, and 50 ml of dioxane and 1.21 g of di-t-butyl dicarbonate were added thereto, followed by stirring at room temperature for 3 hours.
  • the reaction mixture was diluted with water and extracted with EtOAc.
  • the organic layer was dried over anhydrous magnesium sulfate and then filtered, and the filtrate was concentrated under reduced pressure.
  • reaction mixture was concentrated under reduced pressure and the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 68 mg of 8-t-butyl 1-(2-phenylethyl) 3,4,6,7,9,10-hexahydro-1H-azepino[4,5-g]quinoline-1,8(2H)-carboxylate as a yellow viscous substance.
  • reaction mixture was concentrated under reduced pressure and the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) and basic silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 243 mg of 8-t-butyl 1-[2-(methoxyphenyl)ethyl]-3,4,6,7,9,10-hexahydro-1H-azepino[4,5-g]quinoline-1,8(2H)-carboxylate as a pale yellow viscous substance.
  • reaction mixture was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 132 mg of t-butyl 11-cyano-1-(2-methoxyethyl)-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate as a colorless viscous substance.
  • the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain a crude purified product having ethyl 7-hydroxy-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate as a main component.
  • the crude purified product was recrystallized from ethyl acetate twice to obtain 15.66 g of ethyl 7-hydroxy-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate.
  • reaction mixture was concentrated under reduced pressure and to the residue was added diethylether to wash the solid, thereby obtaining 26.45 g of ethyl 7-acetamide-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate as a white solid.
  • the mixed liquid of 12 g of ethyl 7-acetamide-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate, 1.93 g of copper iodide, 1.89 g of 1,10-phenanthroline, and 33.12 g of cesium carbonate in 240 ml of dioxane was substituted with argon, followed by stirring at 100° C. for 18 hours.
  • the reaction mixture was diluted with ethyl acetate, the insoluble materials were removed using celite, and the filtrate was concentrated under reduced pressure to obtain a milky white solid.
  • the resulting residue was suspended in 240 ml of dioxane, and 1.93 g of copper iodide, 1.89 g of 1,10-phenanthroline, and 33.1 g of cesium carbonate were added thereto, followed by stirring at 100° C. for 3 days.
  • the reaction mixture was cooled to room temperature, diluted with ethyl acetate, and filtered through celite to remove the solid, and the filtrate was concentrated under reduced pressure to obtain 9.245 g of ethyl 2-methyl-5,6,8,9-tetrahydro-7H-[1,3]oxazolo[4,5-h][3]benzazepine-7-carboxylate as a milky white solid.
  • reaction mixture was concentrated under reduced pressure, the residue was extracted by the addition of ethyl acetate and water, and the organic layer was washed with 1 N aqueous hydrochloric acid and saturated brine, dried over anhydrous magnesium sulfate, and then filtered, and the filtrate was concentrated under reduced pressure to obtain 6.67 g of ethyl 7-bromo-8-hydroxy-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate as a beige solid.
  • reaction mixture was extracted with ethyl acetate, the organic layer was dried over anhydrous magnesium sulfate and then filtered, and the filtrate was concentrated under reduced pressure to obtain 1.373 g of t-butyl 11-bromo-3-oxo-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]bensazepine-8(2H)-carboxylate.
  • the reaction mixture was concentrated, to the residue were added ethyl acetate and water, and the organic layer was washed with saturated brine and dried over anhydrous sodium sulfate.
  • the solvent was evaporated, and to a solution of 578 mg of the resulting residue in 10 ml of dichloromethane was added 620 mg of sodium hydrogen carbonate. Further, a solution of 280 mg of bromine in 5 ml of dichloromethane was added dropwise thereto over about 30 minutes, followed by stirring at room temperature.
  • To the reaction mixture was slowly added a 3% aqueous sodium thiosulfate solution, followed by stirring vigorously and extracting with chloroform twice.
  • reaction mixture 0.15 ml of MeOH, and then 150 mg of potassium t-butoxide was added portionwise thereto, followed by elevating the temperature to 0° C. and stirring for additional 14 hours.
  • the reaction mixture was diluted with ethyl acetate, washed with water and saturated brine, dried over anhydrous magnesium sulfate, and then filtered, and the filtrate was concentrated under reduced pressure.
  • reaction mixture was concentrated under reduced pressure and the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc)) to obtain 220 mg of t-butyl 5-cyclopropyl-4- ⁇ 2-[2,6-difluoro-4-(hydroxymethyl)phenoxy]ethyl ⁇ -3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]bensazepine-8(2H)-carboxylate as a white solid.
  • reaction mixture was concentrated under reduced pressure and the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 541 mg of t-butyl 5-cyclopropyl-4-(2- ⁇ [(4-methylphenyl)sulfonyl]oxy ⁇ ethyl)-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]bensazepine-8(2H)-carboxylate as a white solid.
  • the reaction mixture was cooled to room temperature and a saturated aqueous sodium hydrogen carbonate solution was added thereto, followed by extraction with ethyl acetate twice.
  • the combined organic layer was dried over anhydrous sodium sulfate and then filtered, and the filtrate was concentrated under reduced pressure.
  • reaction mixture was concentrated under reduced pressure and the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 277 mg of t-butyl 5-cyclopropyl-4-[2-(2-fluorophenoxy)-3-methoxypropyl]-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]bensazepine-8(2H)-carboxylate as a pale yellow viscous substance.
  • the precipitated solid was collected by filtration to obtain 23.2 mg of 11-chloro-1-isobutyl-2,3,4,6,7,8,9,10-octahydro-1H-azepino[4,5-g]quinoline monofumarate as a white solid.
  • the mixed solution was diluted with water, followed by extraction with chloroform.
  • the organic layer was dried over anhydrous sodium sulfate and then filtered, and the filtrate was concentrated under reduced pressure.
  • the residue was dissolved in 1.6 ml of dichloromethane, and 0.4 ml of trifluoroacetic acid was added thereto, followed by stirring at room temperature for 1 hour and then concentrating under reduced pressure.
  • the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc), and the resulting solid was dissolved in 0.25 ml of hot EtOH, followed by addition of 21 mg of fumaric acid.
  • reaction mixture was cooled to room temperature, and then the reaction mixture was diluted with EtOAc, washed with 1 M hydrochloric acid, water, a 1 M aqueous sodium hydroxide solution, and saturated brine, and concentrated, and the residue was purified by silica gel column chromatography (elution solvent: HEX-EtOAc).
  • the resulting substance was dissolved in chloroform, followed by adding 0.005 ml of trifluoroacetic acid and stirring for 30 minutes. After concentration under reduced pressure, the resultant was dissolved in EtOH, neutralized by the addition of triethylamine, and then concentrated under reduced pressure.
  • the resulting substance was dissolved in 6 ml of chloroform, followed by adding 3 ml of trifluoroacetic acid and stirring for 30 minutes. After concentration under reduced pressure, the resultant was dissolved in 4.5 ml of EtOH, neutralized by the addition of triethylamine, and then concentrated under reduced pressure. Then, the residue was purified by silica gel column chromatography (elution solvent: chloroform-MeOH-aqueous ammonia). The resulting substance was dissolved in 4.5 ml of EtOH and 115 mg of fumaric acid was added thereto.
  • the resulting substance was dissolved in 4 ml of chloroform, followed by adding 2 ml of trifluoroacetic acid and stirring for 30 minutes. After concentration under reduced pressure, the resultant was dissolved in 4.5 ml of EtOH, neutralized by the addition of triethylamine, and then concentrated under reduced pressure. Then, the residue was purified by silica gel column chromatography (elution solvent: chloroform-MeOH-aqueous ammonia). The resulting substance was dissolved in EtOH and 76 mg of fumaric acid was added thereto.
  • the compound of the formula (I) or a salt thereof, or the compound of the formula (II) or a salt thereof has a 5-HT 2C receptor agonist activity and can be used as an agent for preventing or treating 5-HT 2C receptor-related diseases.
  • examples of the 5-HT 2C receptor-related diseases include incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Provided is a compound which is useful as an agent for treating or preventing 5-HT2C receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like. The present inventors have investigated compounds having a 5-HT2C receptor agonist activity and have found that the benzazepine compounds of the present invention have an excellent 5-HT2C receptor agonist activity, thereby completing the present invention. That is, the benzazepine compounds of the present invention have a 5-HT2C receptor agonist activity and can be used as an agent for treating or preventing 5-HT2C receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like.

Description

    TECHNICAL FIELD
  • The present invention relates to a benzazepine compound which is useful as an active ingredient of a pharmaceutical composition, particularly a pharmaceutical composition for treating or preventing 5-HT2C receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like.
    • BACKGROUND ART
  • A serotonin 2C (5-HT2C) receptor is one of the receptors for serotonin, a transmitter related to various physiological functions in the biological body. Its expression has been recognized mainly in the central nervous system (brain/spinal cord).
  • An anorectic action is known as a physiological function of the central 5-HT2C receptor, and the lowering action of various 5-HT2C receptor agonists on food intake has been reported in rats (Non-Patent Documents 1 and 2). Further, it has been confirmed that an anti-obesity action in humans is exhibited due to the anorectic action of the 5-HT2C receptor agonist (Non-Patent Document 3).
  • The central 5-HT2C receptor is involved in the control of peripheral nerve functions and it has been reported that the rat penile erection is induced by a 5-HT2C receptor agonist (Non-Patent Document 4) and that the time taken from insertion to ejaculation in the experiment for mating behavior of monkeys is prolonged (Non-Patent Document 5). Moreover, it has been reported that a 5-HT2C receptor agonist increases the urethral resistance when the abdominal pressure is increased in rats (Non-Patent Document 6). In addition, it has been reported that in disease models with neuropathic/inflammatory pain in rats, efficacy is exhibited by intraspinal administration of a 5-HT2C receptor agonist (Non-Patent Documents 7 and 8). Various clinical applications are considered for 5-HT2C receptor agonists, particularly as anti-obesity drugs, drugs for treating male erectile dysfunction, drugs for treating premature ejaculation, drugs for treating stress urinary incontinence, drugs for treating neuropathic/inflammatory pain, or the like.
  • As the 5-HT2C receptor agonist, a benzazepine derivative has been reported, and as a tricyclic benzazepine derivative, for example, Compound A (Patent Document 1) and Compound B (Patent Document 2) are known.
  • Figure US20130012496A1-20130110-C00001
  • As other 5-HT2C receptor agonists, bicyclic benzazepine derivatives have been reported (Patent Document 3, Patent Document 4, and Patent Document 5).
  • As a 2,3,4,6,7,8,9,10-octahydro-1H-azepino[4,5-g]quinoline derivative or a 3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepine derivative, which is a tricyclic benzazepine derivative, a compound of the formula (AA) is known to be a Dopamine D3 modulator and be useful for central drug abuse and drug dependence (Patent Document 6).
  • Figure US20130012496A1-20130110-C00002
  • In addition, in this document, the following compounds are disclosed as a synthetic intermediate for the formula (AA).
  • Figure US20130012496A1-20130110-C00003
  • Furthermore, there is a report on the structure-activity relationship of a specific compound of the formula (AA) (Non-Patent Document 9), and in this report, it is described that the following compound was used in the preparation of the compound of the formula (AA).
  • Figure US20130012496A1-20130110-C00004
  • Moreover, there is a report on a 5-HT6 receptor antagonist (Non-Patent Document 10), and it is disclosed that for the compound below, potency on the 5-HT6 receptor is lost by changing a ring condensed with benzazepine from a 5-membered ring to a 6-membered ring.
  • Figure US20130012496A1-20130110-C00005
  • However, in the documents which disclose such tricyclic benzazepine derivatives, there is no disclosure on the 5-HT2C receptor agonist activity of the 2,3,4,6,7,8,9,10-octahydro-1H-azepino[4,5-g]quinoline derivative or the 3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepine derivative.
    • PRIOR ART DOCUMENT Patent Document
    • [Patent Document 1] WO 2002/074746
    • [Patent Document 2] WO 2003/086306
    • [Patent Document 3] WO 2005/042490
    • [Patent Document 4] WO 2005/042491
    • [Patent Document 5] WO 2005/003096
    • [Patent Document 6] WO 2005/118549
    Non-Patent Document
    • [Non-Patent Document 1] Obesity, 2008, vol. 17, pp. 494-503
    • [Non-Patent Document 2] Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2002, vol. 26, pp. 441-449
    • [Non-Patent Document 3] Journal of Pharmacology and Experimental Therapeutics, 2008, vol. 325, pp. 577-587
    • [Non-Patent Document 4] European Journal of Pharmacology, 2004, vol. 483, pp. 37-43
    • [Non-Patent Document 5] Psychopharmacology, 1993, vol. 111, pp. 47-54
    • [Non-Patent Document 6] American Journal of Physiology: Renal Physiology, 2009, vol. 297, pp. 1024-1031
    • [Non-Patent Document 7] Pain, 2004, vol. 108, pp. 163-169
    • [Non-Patent Document 8] Anesthesia and Analgesia, 2003, vol. 96, pp. 1072-1078
    • [Non-Patent Document 9] Bioorganic & Medicinal Chemistry Letters, 2008, vol. 18, pp. 901-907
    • [Non-Patent Document 10] Bioorganic & Medicinal Chemistry Letters, 2008, vol. 18, pp. 5698-5700
    SUMMARY OF THE INVENTION Problems to be Solved by the Invention
  • A benzazepine compound which is useful as an active ingredient for a pharmaceutical composition, particularly a pharmaceutical composition for treating or preventing 5-HT2C receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like is provided.
    • Means for Solving the Problem
  • The present inventors have extensively studied compounds having a 5-HT2C receptor agonist activity, and as a result, they have found that the benzazepine compound of the present invention has a 5-HT2C receptor agonist activity, thereby completing the present invention.
  • That is, the present invention relates to a pharmaceutical composition including the compound of the formula (I) or a salt thereof and a pharmaceutically acceptable excipient.
  • Figure US20130012496A1-20130110-C00006
  • (wherein
  • R1a and R1b are the same or different and each represents —H or C1-6 alkyl, or are combined to form oxo,
  • R2a and R2b are the same or different and each represents —H or C1-6 alkyl which may be substituted with —O—C1-6 alkyl,
  • R3 represents —H, C1-6 alkyl which may be substituted, C3-8 cycloalkyl, aryl which may be substituted, —SO2—C1-6 alkyl, or a hetero ring which may be substituted,
  • R4 represents —H, halogen, cyano, C1-6 alkyl which may be substituted, C2-6 alkenyl, aryl which may be substituted, C3-8 cycloalkyl which may be substituted, an aromatic hetero ring, or an oxygen-containing hetero ring,
  • R5 represents —H, halogen, C1-6 alkyl, C3-8 cycloalkyl, aryl, or an aromatic hetero ring,
  • R6 and R7 are the same or different and each represents —H or C1-6 alkyl,
  • X represents —C(RA)(RB)— or —O—, and
  • RA and RB are the same or different and each represents —H or C1-6 alkyl.)
  • Furthermore, the present invention relates to a compound of the formula (II) or a salt thereof.
  • Figure US20130012496A1-20130110-C00007
  • (wherein R11a and R11b are the same or different and each represents —H or C1-6 alkyl, or are combined to form oxo,
  • R21a and R21b are the same or different and each represents —H or C1-6 alkyl which may be substituted with —O—C1-6 alkyl,
  • R31 represents —H, C1-6 alkyl which may be substituted, C3-8 cycloalkyl, aryl which may be substituted, —SO2—C1-6 alkyl, or a hetero ring which may be substituted,
  • R41 represents —H, halogen, cyano, C1-6 alkyl which may be substituted, C2-6 alkenyl, aryl which may be substituted, C3-8 cycloalkyl which may be substituted, an aromatic hetero ring, or an oxygen-containing hetero ring,
  • R51 represents —H, halogen, C1-6 alkyl, C3-8 cycloalkyl, aryl, or an aromatic hetero ring,
  • R61 and R71 are the same or different and each represents —H or C1-6 alkyl,
  • X1 represents —C(RA1)(RB1)— or —O—, and
  • RA1 and RB1 are the same or different and each represents —H or C1-6 alkyl,
  • provided that
  • (i) in the case where R11a, R11b, R21a, R21b, R41, R51, R61, and R71 are respectively —H and X1 is —O—, R31 is a group other than —H, —CO-methyl, or —SO2-methyl, and
  • (ii) in the case where R11a and R11b are combined to form oxo, R21a, R21b, R41, R51, R61, and R71 are respectively —H, and X1 is —O—, R31 is a group other than —H or methyl.)
  • Furthermore, in the case where the symbols in any of the formulas in the present specification are also used in other formulas, the same symbols denote the same meanings, unless specifically described otherwise.
  • Furthermore, the present invention relates to a pharmaceutical composition for preventing or treating 5-HT2C receptor-related diseases, including the compound of the formula (I) or a salt thereof, or the compound of the formula (II) or a salt thereof. In this connection, the pharmaceutical composition includes an agent for preventing or treating 5-HT2C receptor-related diseases, including the compound of the formula (I) or a salt thereof, or the compound of the formula (II) or a salt thereof.
  • Moreover, the present invention relates to use of the compound of the formula (I) or a salt thereof, or the compound of the formula (II) or a salt thereof for preparation of a pharmaceutical composition for preventing or treating 5-HT2C receptor-related diseases; the compound of the formula (I) or a salt thereof, or the compound of the formula (II) or a salt thereof for prevention or treatment of 5-HT2C receptor-related diseases; and a method for preventing or treating 5-HT2C receptor-related diseases, including administering to a subject an effective amount of the compound of the formula (I) or a salt thereof, or the compound of the formula (II) or a salt thereof. In addition, the “subject” is human or other animals in need of the prevention or treatment, and in a certain embodiment, human in need of the prevention or treatment.
  • In addition, the compound of the formula (II) or a salt thereof is included in the compound of the formula (I) or a salt thereof. Accordingly, in the present specification, the explanation of the compound of the formula (I) includes that of the compound of the formula (II).
    • Effects of the Invention
  • The compound of the formula (I) or a salt thereof, or the compound of the formula (II) or a salt thereof has a 5-HT2C receptor agonist activity and can be used as an agent for preventing or treating 5-HT2C receptor-related diseases.
  • Here, examples of the 5-HT2C receptor-related diseases include incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like.
    • EMBODIMENTS FOR CARRYING OUT THE INVENTION
  • Hereinafter, the present invention will be described in detail.
  • In the present specification, the “alkyl” includes straight alkyl and branched alkyl. Accordingly, the “C1-6 alkyl” is a straight or branched alkyl having 1 to 6 carbon atoms, and specific examples thereof include methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, pentyl, hexyl, and the like, in another embodiment, methyl, ethyl, propyl, isopropyl, in a further embodiment, methyl, ethyl, in a still further embodiment, methyl, and in a still further embodiment, ethyl.
  • The “alkylene” is a divalent group formed by the removal of any one hydrogen atom of the “alkyl” above. Accordingly, the “C1-6 alkylene” is straight or branched alkylene having 1 to 6 carbon atoms, and specific examples thereof include methylene, ethylene, trimethylene, tetramethylene, pentamethylene, hexamethylene, methylmethylene, dimethylmethylene, ethylmethylene, methylethylene, dimethylethylene, ethylethylene, and the like, in another embodiment, methylene, ethylene, and in a further embodiment methylene.
  • The “aryl” is a monocyclic to tricyclic aromatic hydrocarbon ring group having 6 to 14 carbon atoms. Specific examples thereof include phenyl and naphthyl, in another embodiment, phenyl, and in a further embodiment, naphthyl.
  • The “cycloalkyl” is a saturated hydrocarbon ring group, the cycloalkyl may have a bridge and may be condensed with a benzene ring, and a part of the bonds may be unsaturated. Accordingly, specific examples of the “C3-8 cycloalkyl” include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, cyclooctadienyl, norbornyl, bicyclo[2.2.2]octyl, indanyl, indenyl, 1,2-dihydronaphthyl, 1,2,3,4-tetrahydronaphthyl, and the like.
  • The “hetero ring” is a monovalent group of a 3- to 15-membered, in another embodiment, a 5- to 10-membered, monocyclic to tricyclic heterocyclic group containing 1 to 4 hetero atoms selected from oxygen, sulfur, and nitrogen, and includes a saturated ring, an aromatic ring, and a partially hydrogenated ring group thereof. The ring atom, sulfur or nitrogen, may be oxidized to form an oxide or a dioxide. Specific examples thereof include monocyclic aromatic hetero rings such as pyrrolyl, furyl, thienyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, and the like, bicyclic aromatic hetero rings such as indolyl, isoindolyl, benzofuranyl, benzothienyl, indazolyl, benzimidazolyl, benzoxazolyl, benzoisoxazolyl, benzothiazolyl, benzoisothiazolyl, quinolyl, isoquinolyl, quinoxalinyl, quinazolinyl, phthalazinyl, benzothiadiazolyl, and the like, tricyclic aromatic hetero rings such as carbazolyl, dibenzo[b,d]furanyl, dibenzo[b,d]thienyl, and the like, monocyclic non-aromatic hetero rings such as azetidinyl, pyrrolidinyl, piperidyl, piperazinyl, azepanyl, diazepanyl, morpholinyl, thiomorpholinyl, tetrahydropyridinyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, dioxolanyl, dioxanyl, tetrahydrothiopyranyl, and the like, bicyclic non-aromatic hetero rings such as indolinyl, tetrahydroquinolyl, tetrahydroisoquinolyl, dihydrobenzimidazolyl, tetrahydrobenzimidazolyl, tetrahydroquinoxalinyl, dihydroquinoxalinyl, dihydrobenzoxazolyl, dihydrobenzoxazinyl, dihydrobenzofuryl, chromanyl, chromenyl, methylenedioxyphenyl, ethylenedioxyphenyl, and the like, bridged hetero rings such as quinuclidinyl and the like, in another embodiment, a 5- to 10-membered monocyclic to bicyclic hetero ring, in a further embodiment, a 5- to 6-membered monocyclic hetero ring, and in a still further embodiment, a 5- to 6-membered monocyclic aromatic hetero ring.
  • The “aromatic hetero ring” is a 5- to 10-membered monocyclic to bicyclic aromatic hetero ring among the “hetero rings” above, and specific examples thereof include pyrrolyl, furyl, thienyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, indolyl, isoindolyl, benzofuranyl, benzothienyl, indazolyl, benzimidazolyl, benzoxazolyl, benzoisoxazolyl, benzothiazolyl, benzoisothiazolyl, quinolyl, isoquinolyl, quinoxalinyl, quinazolinyl, phthalazinyl, and the like, and in another embodiment, furyl, thienyl, pyrazolyl, thiazolyl, pyridyl, pyrimidinyl, and pyrazyl.
  • The “cyclic amino” is a 5- to 7-membered non-aromatic hetero ring having a binding position at a nitrogen atom among the “hetero rings” above, and specific examples thereof include pyrrolidinyl, piperidyl, piperazinyl, azepanyl, diazepanyl, morpholinyl, and thiomorpholinyl.
  • The “oxygen-containing hetero ring” is a monovalent group of a non-aromatic 5- to 6-membered ring which may be condensed with a benzene ring having one or two oxygen atoms as ring-constituting atoms. Specific examples thereof include tetrahydrofuranyl, tetrahydropyranyl, dioxolanyl, dioxanyl, dihydrobenzofuranyl, dihydrochromenyl, benzodioxolyl, benzodioxinyl, dihydrodioxinyl, dihydrobenzodioxinyl, dihydropyranyl, dioxinyl, chromenyl, and benzodioxinyl.
  • The “halogen” means —F, —Cl, —Br, or —I, and in another embodiment, —F, —Cl, or —Br.
  • The “halogeno-C1-6 alkyl” is C1-6 alkyl substituted with one or more halogen atoms, and specific examples thereof include fluoromethyl, difluoromethyl, trifluoromethyl, trifluoroethyl, fluoroethyl, chloroethyl, bromoethyl, fluoropropyl, dichloropropyl, fluorochloropropyl, and the like, and in another embodiment, difluoromethyl, trifluoromethyl, difluoroethyl, trifluoroethyl, and fluoropropyl.
  • In the present specification, the expression “which may be substituted” means unsubstituted or substituted with 1 to 5 substituents. Further, if it has a plurality of substituents, the substituents may be the same as or different from each other.
  • Specific examples of the substituent for the “C1-6 alkyl which may be substituted”, “C1-6 alkylene which may be substituted”, “(C3-8) cycloalkyl which may be substituted”, “aryl which may be substituted”, or “hetero ring which may be substituted” of R3 and R4 include amino, nitro, cyano, halogen, C1-6 alkyl, halogeno-C1-6 alkyl, —OH, —C1-6 alkylene-OH, —O—C1-6 alkyl, —C1-6 alkylene-O—C1-6 alkyl, —C1-6 alkylene-cycloalkyl, —C1-6 alkylene-aryl, —C1-6 alkylene-hetero ring, —CO—C1-6 alkyl, —CO—C1-6 alkylene-O—C1-6 alkyl, —CO-cycloalkyl, —CO-aryl, —CO—NR8R9, —CO—O—C1-6 alkyl, —CO—O—C1-6 alkylene-aryl, —SO2—C1-6 alkyl, aryl, a hetero ring, and the like.
  • Here, R8 and R9 are the same or different and each represents —H or C1-6 alkyl.
  • In another embodiment, examples of the substituent for “C1-6 alkyl which may be substituted” in R3 include:
  • (1) halogen,
  • (2) oxo, —OH, and —O—RZ,
  • (3) —O-(phenyl which may be substituted with one or more groups selected from the group consisting of RZ, —O—RZ, halogen, and cyano),
  • (4) —O-aromatic hetero ring,
  • (5) amino which may be substituted with one or two RZ,
  • (6) phenyl which may be substituted with one or more groups selected from the group consisting of RZ, —O—RZ, halogen, and cyano,
  • (7) C3-8 cycloalkyl which may be substituted with RZ,
  • (8) an oxygen-containing hetero ring which may be substituted with halogen,
  • (9) a cyclic amino which may be substituted with RZ, and
  • (10) an aromatic hetero ring,
  • in which the C1-6 alkyl may be substituted with one or more substituents.
  • Furthermore, RZ herein represents C1-6 alkyl which may be substituted with one or more groups selected from the group consisting of halogen, —O—C1-6 alkyl, C3-8 cycloalkyl, and phenyl (in which the phenyl may be substituted with one or more groups selected from the group consisting of halogen and —O—C1-6 alkyl).
  • In another embodiment, examples of the substituent for the “aryl which may be substituted” in R3 include halogen, and the aryl may be substituted with one or more substituents.
  • In a further embodiment, examples of the substituent for the “C1-6 alkyl which may be substituted” in R4 include halogen and aryl, and the C1-6 alkyl may be substituted with one or more substituents.
  • In a still further embodiment, examples of the substituent of the “aryl which may be substituted” in R4 include halogen, C1-6 alkyl, and —O—C1-6 alkyl, and the aryl may be substituted with one or more substituents.
  • Some embodiments of the compound of the formula (I) or a salt thereof are presented below.
  • (1) The compound or a salt thereof, wherein R1a and R1b are the same or different and each represents —H or methyl. In another embodiment, the compound or a salt thereof, wherein R1a and R1b are respectively —H. In a further embodiment, the compound or a salt thereof, wherein R1a is —H and R1b is methyl. In a still further embodiment, the compound or a salt thereof, wherein R1a and R1b are combined to form oxo.
  • (2) The compound or a salt thereof, wherein R2a is —H and R2b is —H or C1-6 alkyl. In another embodiment, the compound or a salt thereof, wherein R2a is —H and R2b is —H or methyl. In a further embodiment, the compound or a salt thereof, wherein R2a and R2b are respectively —H.
  • (3) The compound or a salt thereof, wherein R3 is C1-6 alkyl which may be substituted with one or more groups selected from the group consisting of (a) to (e) below:
  • (a) halogen, (b) —O—C1-6 alkyl, (c) phenoxy which may be substituted with one or more groups selected from the group consisting of halogen and cyano, (d) an oxygen-containing hetero ring, and (e) phenyl which may be substituted with one or more groups selected from the group consisting of C1-6 alkyl which may be substituted with —O—C1-6 alkyl, halogen, and —O—C1-6 alkyl.
  • In another embodiment, the compound or a salt thereof, wherein R3 is C1-6 alkyl which may be substituted with one or more groups selected from the group consisting of (f) to (j) below:
  • (f) fluoro, (g) methoxy, ethoxy, (h) phenoxy which may be substituted with one or more groups selected from the group consisting of fluoro and cyano, (i) tetrahydrofuranyl, tetrahydropyranyl, or dihydrobenzodioxinyl, and (j) phenyl which may be substituted with one or more groups selected from the group consisting of fluoro, chloro, methyl, and methoxymethyl.
  • In another embodiment, the compound or a salt thereof, wherein R3 is isobutyl. In another embodiment, the compound or a salt thereof, wherein R3 is ethyl or propyl, which respectively is substituted with one or more groups selected from the group consisting of fluoro, methoxy, and ethoxy. In a further embodiment, the compound or a salt thereof, wherein R3 is ethyl substituted with phenoxy which may be substituted with one or more groups selected from the group consisting of fluoro and cyano. In a still further embodiment, the compound or a salt thereof, wherein R3 is methyl substituted with a group selected from the group consisting of tetrahydrofuranyl, tetrahydropyranyl and dihydrobenzodioxinyl. In a still further embodiment, the compound or a salt thereof, wherein R3 is methyl substituted with phenyl which may be substituted with one or more groups selected from the group consisting of fluoro, chloro, methyl, and methoxymethyl.
  • (4) The compound or a salt thereof, wherein R4 is —H, halogen, or C3-8 cycloalkyl. In another embodiment, the compound or a salt thereof, wherein R4 is —H, bromo, or cyclopropyl. In a further embodiment, the compound or a salt thereof, wherein R4 is —H. In a further embodiment, the compound or a salt thereof, wherein R4 is bromo. In a still further embodiment, the compound or a salt thereof, wherein R4 is cyclopropyl.
  • (5) The compound or a salt thereof, wherein R5 is —H or C1-6 alkyl. In another embodiment, the compound or a salt thereof, wherein R5 is —H or methyl. In a further embodiment, the compound or a salt thereof, wherein R5 is —H.
  • (6) The compound or a salt thereof, wherein R6 and R7 are the same or different and each represents —H or methyl. In another embodiment, the compound or a salt thereof, wherein R6 is methyl and R7 is —H. In a further embodiment, the compound or a salt thereof, wherein R6 is —H and R7 is methyl. In a still further embodiment, the compound or a salt thereof, wherein R6 and R7 are respectively —H.
  • (7) The compound or a salt thereof, wherein X is —CH2— or —O—. In another embodiment, the compound or a salt thereof, wherein X is —CH2—. In a further embodiment, the compound or a salt thereof, wherein X is —O—.
  • (8) The compound or a salt thereof, which is a combination of two or more of (1) to (7) as described above.
  • The compound or a salt thereof as described above in (8), which is a combination of two or more of (1) to (7) as described above, is included in the present invention, and the following embodiments including the specific examples thereof can be exemplified as below.
  • (9) The compound or a salt thereof, wherein R3 is —H, C1-6 alkyl which may be substituted, C3-8 cycloalkyl, aryl which may be substituted, —SO2—C1-6 alkyl, or an oxygen-containing hetero ring, and R4 is —H, halogen, cyano, C1-6 alkyl which may be substituted, C2-6 alkenyl, aryl which may be substituted, C3-8 cycloalkyl, an aromatic hetero ring, or an oxygen-containing hetero ring.
  • (10) The compound or a salt thereof as described in (9), wherein R3 is a group other than —H, methyl, —CO-methyl, or —SO2-methyl.
  • (11) The compound or a salt thereof as described in (10), wherein R1a is —H or methyl, and R1b, R2a, R2b, R5, R6, and R7 are respectively —H.
  • (12) The compound or a salt thereof as described in (11), wherein R4 is —H, halogen, or C3-8 cycloalkyl.
  • (13) The compound or a salt thereof as described in (12), wherein R4 is cyclopropyl.
  • (14) The compound or a salt thereof as described in (13), wherein R3 is C1-6 alkyl which may be substituted with one or more groups selected from the group consisting of (a) halogen, (b) —O—C1-6 alkyl, (c) phenoxy which may be substituted with one or more groups selected from the group consisting of halogen and cyano, (d) an oxygen-containing hetero ring, and (e) phenyl which may be substituted with one or more groups selected from the group consisting of C1-6 alkyl which may be substituted with —O—C1-6 alkyl, halogen, and —O—C1-6 alkyl.
  • (15) The compound or a salt thereof as described in any one of (1) to (14), wherein X is —CH2— or —O—. In another embodiment, the compound or a salt thereof as described in any one of (1) to (14), wherein X is —O—. In a still further embodiment, the compound or a salt thereof as described in any one of (1) to (14), wherein X is —CH2—.
  • Examples of the specific compounds included in the compound of the formula (I) or a salt thereof include:
    • 11-cyclopropyl-1-(2-methoxyethyl)-2,3,4,6,7,8,9,10-octahydro-1H-azepino[4,5-g]quinoline,
    • 4-(3-methoxypropyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine,
    • 5-cyclopropyl-4-(2-methoxyethyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine,
    • 5-cyclopropyl-4-(2-ethoxyethyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine,
    • 5-cyclopropyl-4-(3-methoxypropyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine,
    • 5-cyclopropyl-4-(3-fluoropropyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine,
    • 1-isobutyl-2,3,4,6,7,8,9,10-octahydro-1H-azepino[4,5-g]quinoline,
    • 5-bromo-4-(2-methoxyethyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine,
    • 5-cyclopropyl-4-[(2S)-tetrahydrofuran-2-ylmethyl]-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine,
    • 5-cyclopropyl-4-[(2R)-2-methoxypropyl]-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine,
    • 5-cyclopropyl-4-(2-fluorobenzyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine,
    • 5-cyclopropyl-4-[(2S)-3-fluoro-2-methoxypropyl]-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine,
    • 4-(3-chlorobenzyl)-5-cyclopropyl-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine,
    • 5-cyclopropyl-4-(tetrahydro-2H-pyran-3-ylmethyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine,
    • 5-cyclopropyl-4-(2,3-dihydro-1,4-benzodioxin-2-ylmethyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine,
    • 5-cyclopropyl-4-(2-phenoxyethyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine,
    • 5-cyclopropyl-4-(2-methylbenzyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine,
    • 5-cyclopropyl-4-(3-methylbenzyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine,
    • 5-cyclopropyl-4-(2,5-difluorobenzyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine,
    • 5-cyclopropyl-4-[3-(methoxymethyl)benzyl]-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine,
    • 4-(5-chloro-2-fluorobenzyl)-5-cyclopropyl-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine,
    • 5-cyclopropyl-4-(2,3-dihydro-1,4-benzodioxin-6-ylmethyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine,
    • (3S)-5-cyclopropyl-4-(2-methoxyethyl)-3-methyl-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine,
    • 4-[2-(5-cyclopropyl-2,3,7,8,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepin-4(6H)-yl)ethoxy]-3,5-difluorobenzonitrile,
    • 5-cyclopropyl-4-(3-methoxybenzyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine,
    • 5-cyclopropyl-4-(3,5-difluorobenzyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine, and
    • 5-cyclopropyl-4-[(2R)-2-ethoxypropyl]-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine, and salts thereof.
  • The compound of the formula (I) may exist in the form of tautomers or geometrical isomers depending on the kind of substituents. In the present specification, the compound of the formula (I) shall be described in only one form of isomer, yet the present invention includes other isomer, such as an isolated forms of the isomers, or a mixture thereof.
  • In addition, the compound of the formula (I) may have asymmetric carbon atoms or axial asymmetry in some cases, and correspondingly, it may exist in the form of optical isomers. The present invention includes both an isolated form of the optical isomers of the compound of the formula (I) or a mixture thereof.
  • Moreover, the present invention also includes a pharmaceutically acceptable prodrug of the compound of the formula (I). The pharmaceutically acceptable prodrug is a compound having a group that can be converted into an amino group, a hydroxyl group, a carboxyl group, or the like through solvolysis or under physiological conditions. Examples of the group forming the prodrug include the groups described in Prog. Med., 5, 2157-2161 (1985) and Pharmaceutical Research and Development, Drug Design, Hirokawa Publishing Company (1990), vol. 7, 163-198.
  • Moreover, the salt of the compound of the formula (I) is a pharmaceutically acceptable salt of the compound of the formula (I) and may form an acid addition salt or a salt with a base depending on the kind of substituents. Specific examples thereof include acid addition salts with inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid, and the like, and with organic acids such as formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, mandelic acid, tartaric acid, dibenzoyltartaric acid, ditoluoyltartaric acid, citric acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, aspartic acid, glutamic acid, and the like, and salts with inorganic bases such as sodium, potassium, magnesium, calcium, aluminum, and the like or organic bases such as methylamine, ethylamine, ethanolamine, lysine, ornithine, and the like, salts with various amino acids or amino acid derivatives such as acetylleucine and the like, ammonium salts, etc.
  • In addition, the present invention also includes various hydrates or solvates, and polymorphic crystal substances of the compound of the formula (I) and a salt thereof. In addition, the present invention also includes compounds labeled with various radioactive or non-radioactive isotopes.
  • (Preparation Methods)
  • The compound of the formula (I) and a salt thereof can be prepared using the characteristics based on the basic structure or the type of substituents thereof and by applying various known synthesis methods. During the preparation, replacing the relevant functional group with a suitable protective group (a group that can be easily converted into the functional group) at the stage from starting material to an intermediate may be effective depending on the type of the functional group in production technology in some cases. The protective group for such a functional group may include, for example, the protective groups described in “Greene's Protective Groups in Organic Synthesis (4th Ed., 2006)” written by P. G. M. Wuts and T. W. Greene, and one of these may be selected and used as necessary depending on the reaction conditions. In this kind of method, a desired compound can be obtained by introducing the protective group, by carrying out the reaction and by eliminating the protective group as necessary.
  • In addition, the prodrug of the compound of the formula (I) can be produced by introducing a specific group or by carrying out the reaction using the obtained compound of the formula (I) at the stage from a starting material to an intermediate, just as in the case of the above-mentioned protective group. The reaction can be carried out using methods known to those skilled in the art, such as ordinary esterification, amidation, dehydration, and the like.
  • Hereinbelow, the representative preparation methods for the compound of the formula (I) will be described. Each of the production processes may also be carried out with reference to the References appended in the present description. Further, the preparation methods of the present invention are not limited to the examples as shown below.
  • Figure US20130012496A1-20130110-C00008
  • The compound of the formula (I) can be obtained by removing P which is a protective group for an amino group. The protective group for P may be any protective group for an amino group which is usually used by a person skilled in the art, and carbonyl such as trifluoroacetyl and the like; oxycarbonyl such as t-butylcarboxyl, ethylcarboxyl, benzylcarboxyl, and the like; or sulfonyl such as methanesulfonyl, p-toluenesulfonyl, trifluoromethanesulfonyl, p-nitrophenylsulfonyl, 2,4-dinitrophenylsulfonyl, and the like is suitably used.
  • For the deprotection in the present step, the conditions for deprotection usually used by a person skilled in the art can be employed. For example, preparation can be performed by acid treatment, hydrolysis, hydrogenolysis, or the like. For acid treatment, for example, trifluoroacetic acid, hydrochloric acid gas, sulfuric acid, or the like can be used. In the case of alkali hydrolysis, inorganic bases (for example NaOH, KOH, NaHCO3, Cs2CO3, and the like) can be used. In the case of acid hydrolysis, hydrochloric acid and the like can be used. For any reaction temperature, the reaction can be performed under the condition from under ice-cooling to under refluxing and under the condition which does not allow the substrate to be decomposed. As the solvent, dioxane, tetrahydrofuran, dichloromethane, chloroform, ethyl acetate, alcohols (MeOH, EtOH, and the like), N,N-dimethylformamide (DMF), dimethylsulfoxide (DMSO), water, or a mixed solvent thereof, and the like may be used, but are not limited thereto. In the case of hydrogenolysis, the reaction can usually be performed under a hydrogen atmosphere in the presence of a palladium catalyst. Usually, the reaction can be performed under the condition of from room temperature to under refluxing and under the condition which does not allow the substrate to be decomposed. As the solvent, DMF or alcohols (MeOH, EtOH, and the like) may be used, but are not limited thereto. Further, the conditions for the de-carboxamide reaction, the de-carbamate reaction, the de-sulfonamide reaction described in “Greene's Protective Groups in Organic Synthesis (4th Ed., 2006)” above can be employed.
  • Various substituents defined as the groups in the compound of the formula (I), R1a, R1b, R2a, R2b, R3, R4, R5, R6, and R7 can be easily converted to other functional groups by using the compound of the formula (I) as a starting material or using the synthetic intermediate of the compound of the formula (I) as a starting material by means of the reaction described in Examples as described later, the reaction apparent to a person skilled in the art, or modified methods thereof. For example, the step that can be usually employed by a person skilled in the art, such as O-alkylation, N-alkylation, reduction, hydrolysis, amidation, and the like can be arbitrarily combined and performed.
  • (Preparation of Starting Compound)
  • The starting compound in the preparation method above can be prepared by, for example, the following method, the method described in Preparation Examples as described later, known methods, or modified methods thereof.
  • (Starting Material Synthesis 1)
  • Figure US20130012496A1-20130110-C00009
  • A compound represented by the general formula (1) which is a starting material for synthesizing a compound of the general formula (2) is commercially available or prepared by a means known to a person skilled in the art. Then, the compound of the general formula (2) can be prepared by nitrating the compound of the general formula (1). For example, a number of known nitration reactions can be used, examples of which include a method using nitric acid, fumed nitric acid, potassium nitrate, or the like in an acid solvent, a method using nitronium tetrafluoroborate, and the like. Then, the compound of the general formula (3) can be prepared by reducing a nitro group of the compound of the general formula (2) to an amino group. For example, a number of known reduction methods can be used, examples of which include a method using metal hydrides such as lithium aluminum hydride and the like, a method using reduced iron or the like, and the like. Further, catalytic hydrogenation using noble metal catalysts such as Raney nickel, palladium, ruthenium, rhodium, platinum, and the like can also be used.
  • (Starting Material Synthesis 2)
  • Figure US20130012496A1-20130110-C00010
  • (wherein RXa is C1-6 alkyl).
  • A compound of the general formula (4) can be prepared by halogenating the compound of the general formula (3). For example, a number of known halogenation reactions can be used, examples of which include a method using N-bromosuccinimide or N-chlorosuccinimide, and the like. Then, the compound of the general formula (5) can be prepared from the compound of the general formula (4) by a coupling reaction using a transition metal catalyst. Examples of the coupling reaction include a Heck reaction. The reaction conditions for the Heck reaction vary depending on the starting materials, solvents, and transition metal catalysts used, and techniques known to a person skilled in the art can be used. Examples of the preferred solvent include acetonitrile, tetrahydrofuran, 1,4-dioxane or DMF, and the like, but are not limited thereto. The transition metal catalyst is preferably a palladium complex, and more preferably known palladium complexes such as palladium(II) acetate, dichlorobis(triphenylphosphine)palladium(II), tetrakis(triphenylphosphine)palladium(0), and the like. Further, for the present reaction, a phosphorous ligand (preferably, triphenylphosphine, tri-o-tolylphosphine, tri-tert-butylphosphine, 2-(di-tert-butylphosphino)biphenyl, or the like) may be added in order to obtain excellent results. Also, the present reaction can yield preferable results in the presence of a base, and the base used herein is not particularly limited as long as it is used for the coupling reaction of the present reaction, but it is preferably triethylamine, N,N-diisopropylethylamine, or the like.
  • (Starting Material Synthesis 3)
  • Figure US20130012496A1-20130110-C00011
  • The compound of the general formula (IIIa) can be obtained by allowing an intramolecular amide condensation cyclization reaction to proceed by carrying out a hydrogenation reaction of the double bond of the α,β-unsaturated esters of the compound of the general formula (5). In this reaction, the compound of the general formula (5) is stirred in the presence of a metal catalyst, usually for 1 hour to 5 days, in a solvent inert to the reaction, under a hydrogen atmosphere. This reaction is usually carried out in the range from cooling to heating, preferably at room temperature. Examples of the solvent used herein are not particularly limited, but include alcohols such as methanol, ethanol, 2-propanol, and the like, ethers such as diethylether, tetrahydrofuran, dioxane, dimethoxyethane, and the like, water, ethyl acetate, DMF, DMSO and a mixture thereof. As the metal catalyst, palladium catalysts such as palladium on carbon, palladium black, palladium hydroxide, and the like, platinum catalysts such as a platinum plate, platinum oxide, and the like, nickel catalysts such as reduced nickel, Raney nickel, and the like, rhodium catalysts such as tetrakistriphenylphosphine chlororhodium, and the like, iron catalysts such as reduced iron and the like, etc. are preferably used. Instead of hydrogen gas, formic acid or ammonium formate in an equivalent amount or in an excess amount to the compound of the general formula (5) can be used as a hydrogen source.
  • Furthermore, for the compound in which R2b is other than —H, an R2b group other than —H can be introduced to a desired position by using an electrophilic substitution reaction to the α-position of carbonyl by the use of a base or by a method which can be usually employed by a person skilled in the art for the compound (IIIa).
    • REFERENCES
    • “Reductions in Organic Chemistry, 2nd Ed. (ACS Monograph: 188)” written by M. Hudlicky, ACS, 1996
  • (Starting Material Synthesis 4)
  • Figure US20130012496A1-20130110-C00012
  • A compound of the general formula (IIIb) can be obtained by carrying out reduction of a carbonyl group of the compound of the general formula (IIIa). This reaction is usually carried out in the presence of a reducing agent in a solvent. Examples of the solvent used herein are not particularly limited, but include ethers such as diethylether, tetrahydrofuran, dioxane, dimethoxyethane, and the like, and aromatic hydrocarbons such as benzene, toluene, xylene, and the like. Examples of the reducing agent include aluminum hydride compounds such as lithium aluminum hydride, sodium bis(2-methoxyethoxy)aluminum hydride, and the like, and borohydride compounds such as sodium borohydride, diborane, a borane-tetrahydrofuran complex, and the like.
  • (Starting Material Synthesis 5)
  • Figure US20130012496A1-20130110-C00013
  • (wherein R4a represents C1-6 alkyl, halogeno-C1-6 alkyl, cycloalkyl which may be substituted, or aryl which may be substituted, and Hal represents halogen).
  • A compound of the general formula (IIId) can be obtained by a coupling reaction of a compound of the general formula (IIIc). For example, the Suzuki coupling described in the following references, the Heck reaction described for the Starting Material Synthesis 2 above, or the like can be employed.
    • REFERENCES
    • Chemical Reviews, vol. 95, No. 7, p. 2457 (1995), Journal of American Chemical Society, vol. 127, p. 4685 (2005), Synlett, No. 13, p. 2327 (2004), Tetrahedron letters, No. 41, p. 4363 (2000), or Tetrahedron letters, No. 43, p. 2695 (2002)
  • The compound of the general formula (IIId) can also be obtained by the method described in Examples as described later.
  • (Starting Material Synthesis 6)
  • Figure US20130012496A1-20130110-C00014
  • (wherein R1a represents a group other than —H among the groups defined as R3).
  • A compound of the general formula (IIIe) can be obtained by alkylation, acylation, or the like of the compound of the general formula (IIIb). For the specific reaction conditions, the conditions described in the following references can be employed.
    • REFERENCES
    • “Organic Functional Group Preparations” written by S. R. Sandler and W. Karo, 2″ Ed., vol. 1, Academic Press Inc., 1991
    • “Courses in Experimental Chemistry (5th Ed.)”, edited by The Chemical Society of Japan, vol. 14 (2005) (Maruzen)
  • The compound of the general formula (IIIe) can also be obtained by the method described in the Examples as described later and the method described for the Starting Material Synthesis 4 above.
  • (Starting Material Synthesis 7)
  • Figure US20130012496A1-20130110-C00015
  • A compound of the general formula (8) can be obtained by the reaction of a compound of the general formula (6) with a compound of the general formula (7). In this regard, examples of the leaving group of L1 include halogen, methanesulfonyloxy, p-toluenesulfonyloxy groups, and the like.
  • In this reaction, the compound of the general formula (6) and the compound of the general formula (7) are used in equivalent amounts, or with either one of them in an excess amount, and a mixture thereof is stirred under a temperature condition from cooling to heating and refluxing, preferably at 0° C. to 80° C., usually for 0.1 hours to 5 days, in a solvent inert to the reaction in the presence of a base. Examples of the solvent used herein are not particularly limited, but include aromatic hydrocarbons such as benzene, toluene, xylene, and the like, ethers such as diethylether, tetrahydrofuran, dioxane, dimethoxyethane, and the like, halogenated hydrocarbons such as dichloromethane, 1,2-dichloroethane, chloroform, and the like, DMF, DMSO, ethyl acetate, acetonitrile, and a mixture thereof. Examples of the base include organic bases such as triethylamine, N,N-diisopropylethylamine, 1,8-diazabicyclo[5.4.0]-7-undecene, n-butyllithium, and the like, and inorganic bases such as sodium carbonate, potassium carbonate, sodium hydride, potassium tert-butoxide, and the like. It may be advantageous to carry out a reaction in the presence of a phase transfer catalyst such as tetra-n-butylammonium chloride and the like in some cases.
  • A compound of the general formula (IIIf) can be obtained by the method described in the Starting Material Synthesis 3 above and a compound of the general formula (Mg) can be obtained by the method described in the Starting Material Synthesis 4 above.
    • REFERENCES
    • “Organic Functional Group Preparations” written by S. R. Sandler and W. Karo, 2nd Ed., vol. 1, Academic Press Inc., 1991
    • “Courses in Experimental Chemistry (5th Ed.)”, edited by The Chemical Society of Japan, vol. 14 (2005) (Maruzen)
  • (Starting Material Synthesis 8)
  • Figure US20130012496A1-20130110-C00016
  • (wherein R3b represents C1-6 alkyl which may be substituted, C3-8 cycloalkyl, aryl which may be substituted, or a hetero ring which may be substituted, among the groups defined as R3. Further, among the C1-6 alkyl which may be substituted, one having oxo substituted on a carbon atom directly bonded to a nitrogen atom connected with R3b is excluded).
  • The compound of the general formula (10) can be obtained by using the compound of the general formula (9) and a suitable aldehyde or ketone compound in equivalent amounts, and stirring a mixture thereof under a temperature condition from −45° C. to heating and refluxing, preferably at 0° C. to room temperature, usually for 0.1 hours to 5 days, in a solvent inert to the reaction in the presence of a reducing agent. Examples of the solvent used herein are not particularly limited, but include alcohols such as methanol, ethanol, and the like, ethers such as diethylether, tetrahydrofuran, dioxane, dimethoxyethane, and the like, and a mixture thereof. Examples of the reducing agent include sodium cyanoborohydride, sodium triacetoxyborohydride, sodium borohydride, and the like. It is preferable in some cases to carry out the reaction in the presence of a dehydrating agent such as molecular sieves, and the like or an acid such as acetic acid, hydrochloric acid, a titanium(IV) isopropoxide complex, and the like. Further, the reaction can be carried out in a solvent such as methanol, ethanol, ethyl acetate, and the like, in the presence or absence of an acid such as acetic acid, hydrochloric acid, and the like, using a reduction catalyst (for example, palladium on carbon, Raney nickel, and the like), instead of treatment with the reducing agent. In this case, it is preferable to carry out the reaction under a hydrogen atmosphere from normal pressure to 50 atmospheres under a temperature condition ranging from cooling to heating.
  • A compound of the general formula (IIIh) can be obtained by using the compound of the general formula (10) and a suitable halogenocarboxylic ester and reacting them in the presence of a base.
  • The compound of the general formula (IIIi) can be obtained by using the method described in the Starting Material Synthesis 4 above and carrying out reduction of a carbonyl group of the compound of the general formula (IIIh).
    • REFERENCES
    • “Comprehensive Organic Functional Group Transformations II” written by A. R. Katritzky and R. J. K. Taylor, vol. 2, Elsevier Pergamon, 2005
    • “Courses in Experimental Chemistry (5th Ed.)”, edited by The Chemical Society of Japan, vol. 14 (2005) (Maruzen)
  • The compounds of the formula (I) can be isolated and purified as their free compounds, salts, hydrates, solvates, or polymorphic crystal substances thereof. The salts of the compound of the formula (I) can be prepared by carrying out the treatment of a conventional salt forming reaction.
  • Isolation and purification are carried out by employing ordinary scientific operations such as extraction, fractional crystallization, various types of fractional chromatography, and the like.
  • Various isomers can be prepared by selecting an appropriate starting compound or separated by using the difference in the physicochemical properties between the isomers. For example, the optical isomers can be obtained by means of a general method for designing optical resolution of racemic products (for example, fractional crystallization for inducing diastereomer salts with optically active bases or acids, chromatography using a chiral column or the like, and others), and further, the isomers can also be prepared from an appropriate optically active starting material.
  • The pharmacological activity of the compound of the formula (I) was confirmed by the tests shown below.
    • Test Example 1 Evaluation of 5-HT2C Receptor Agonist Activity
  • The agonist activity of the compound of the formula (I) on the 5-HT2C receptor was confirmed by the method shown below.
  • The human 5-HT2C receptor agonist activity was evaluated by measuring the increase of the ligand-dependent intracellular calcium concentration. CHO cells which stably expressing a human 5-HT2C receptor were used. The receptor-expressing cells were prepared by transfecting the genes of the human 5-HT2C receptor (Accession numbers: AF498983 (5-HT2C)) into CHO cells (dihydrofolic acid-deficient strain, DS Pharma Biomedical Co., Ltd.)) using a pEF-BOS vector (Nucleic Acids Research, vol. 18, No. 17). After transcription, the 5-HT2C is known to be subjected to RNA editing to cause differences in three kinds of amino acids, resulting in fourteen receptor isoforms. Among them, cells stably expressing an INI type of 5-HT2C receptor which had not been subjected to editing were used. Cells used for evaluation were cultured in a 10% fetal bovine serum (FBS)-containing medium (trade name: α-MEM, Invitrogen) at 37° C. and 5% carbon dioxide. On the day before the evaluation, the cells were suspended in a serum-free medium (trade name: CD-CHO, Invitrogen) containing 8 mM L-glutamine (trade name: L-glutamine 200 mM, Invitrogen, added to the medium at a final concentration of 8 mM) and dispensed into a 96-well poly-D-lysine-coated plate (trade name: Biocoat PDL96W Black/Clear, Japan Becton, Dickinson and Company)) at 4×104 cells/well and cultured at 37° C. and 5% carbon dioxide overnight. A solution including a washing solution (mixture of Hank's Balanced Salt Solution (HBSS)-sodium hydroxide (NaOH), 20 mM 2-[4-(2-hydroxyethyl)-1-piperazinyl]ethanesulfonic acid (HEPES)-sodium hydroxide (NaOH), 2.5 mM probenecid, and 0.1% bovine serum albumin (BSA)), and a 4 μM fluorescent reagent (trade name: Fluo-4-AM, Dojindo Co., Ltd.) was used as a loading buffer and the medium of the 96-well plate which had been cultured overnight was replaced with a loading buffer. After leaving to stand (with light-shielding) at room temperature for 3 hours, the cells were washed with a plate washer (trade name: ELx405, BioTek Instruments, Inc.) in which a washing solution had been set up. The plates of the washed cells were set up in a system for measuring a calcium (Ca) concentration in a cell (trade name: FLIPR, Molecular Devices, Inc.). In this device, a test compound that had been dissolved in dimethyl sulfoxide and diluted in the washing solution at a predetermined concentration was added and set up to measure a change in the Ca concentrations in a cell. The difference between a maximum value and a minimum value in the change of the intracellular Ca concentration was determined and kept as measurement data.
  • Taking the maximum reaction of the 5-HT (agonist action with addition of 5-HT 10 μM) as 100% and the reaction of a solvent alone as 0%, efficacy (Emax (%)) of the present invention compound to the maximum reaction of the 5-HT was obtained and potency (EC50 (nM)) was calculated with a logistic regression method, as the agonist activity.
  • The results of several compounds are shown in Table 1. In the Table, Ex represents Example Compound No. below.
  • TABLE 1
    5-HT2C agonist activity
    Ex EC50 (nM) Emax (%)
    2 0.64 99
    16 1.5 109
    21 0.81 101
    33 32.9 94
    35 0.42 100
    36 12 97
    38 2.1 94
    42 1.9 97
    45 3.9 107
    50 68 98
    56 3.2 112
    58 4.0 117
    59 7.1 108
    76 1.9 116
    78 36 98
    81 0.84 114
    88 1.1 105
    90 8.3 113
    92 79 84
    98 4.4 107
    104 1.1 107
    105 8.0 111
    106 1.1 112
    108 5.9 106
    135 2.9 112
    141 0.36 100
    215 10. 96
    243 0.53 96
    258 1.9 97
    263 2.8 96
    265 1.3 97
    267 0.51 99
    268 0.92 99
    276 6.4 104
    277 2.3 95
    283 1.7 90
    287 1.0 97
    288 0.64 90
    290 3.8 93
    291 1.2 93
    292 0.65 93
    297 0.71 96
    299 1.0 98
    313 4.2 97
    315 2.8 108
    • Test Example 2 Measurement of External Urethral Sphincter Electromyography
  • The activating action of the compound of the formula (I) on the urethral sphincter electromyography was confirmed with the method shown below.
  • Hartley female guinea pigs with a body weight of 250 to 350 g were anesthetized with urethane (Sigma). The guinea pigs were fixed in a supine position and catheters (PE-50; Clay Adams) for administration of test compounds were inserted into the jugular vein. Further, a catheters (PE-160; Clay Adams), for an infusion of physiological saline into bladder and measurement of the intravesical pressure, were inserted through an incision into the dome of the bladder. Further, in order to measure the external urethral sphincter electromyography, two electrodes were inserted into both the left and right sides of the urethral opening to the urethral sphincter. The electrodes for measuring base voltages were placed under the skin of the hind part. The bladder catheter was branched over a three-way stopcock, and one was connected with a 50 mL syringe (Terumo) fixed to an infusion pump (Terumo). The other was connected to a pressure transducer (DX-100; Nihon Kohden Corporation) to transfer the signal of the transducer through an amplifier (AP-630G; Nihon Kohden Corporation) and a data acquisition system (PowerLab; AD Instruments) to a computer and record on a hard disk. The electrodes for electromyography measurement were connected to a control unit (JB-101J; Nihon Kohden Corporation) to transfer the signal through an amplifier (AP-651J; Nihon Kohden Corporation) and a data acquisition system (PowerLab; AD Instruments) to a computer and record on a hard disk. Further, the data were analyzed on the computer using a software (Chart; AD Instruments). Physiological saline was continuously injected into the bladder using an infusion pump at a rate of 18 mL/hour and it was confirmed that a micturition reflexes were stably induced. The electromyography activity was analyzed by taking the lowest potential amplitude as a standard during the stabilization period and using the firing frequency over the standard amplitude as an indicator. At internvals between the respective urinations (urine filling phase), the activity of the urethral sphincter electromyography was analyzed and its average value was calculated. After the stabilization period, the solvent and the test compound were administered at an increased dose at an interval of 40 minutes through the catheter placed into the jugular vein. The urethral sphincter electromyography activity after the administration of the solvent was taken as 100% and the urethral sphincter electromyography activity after the administration of the test compound was denoted as a percentage (%) of the electromyography activity after the administration of the solvent.
  • As a result, the compounds of Example 81, Example 59, Example 88, Example 104, Example 106, Example 141, Example 38, Example 135, Example 215, Example 243, Example 265, Example 287, Example 258, Example 263, Example 267, Example 268, Example 276, Example 277, Example 283, Example 288, Example 290, Example 291, Example 292, Example 297, Example 299, Example 313, and Example 315 as shown later showed an external urethral sphincter electromyography activity of 200% or more with intravenous administration at 3 mg/kg.
  • As a result of each test above, it was confirmed that the compound of the formula (I) has a 5-HT2C receptor agonist activity, and the compound of the formula (I) can be used for treatment or prevention of 5-HT2C receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like as a pharmaceutical.
  • According to the results obtained by the tests above, it is considered that the compound has a 5-HT2C receptor agonist activity and thus has substantially the same or a higher activity value than Lorcaserin under development as an anti-obesity drug (The Journal of Pharmacology and Experimental Therapeutics vol. 325, No. 2 p. 577-587 (2008)).
  • A pharmaceutical composition containing one or two or more kinds of the compound of the formula (I) or a salt thereof as an active ingredient can be prepared using excipients that are usually used in the art, that is, excipients for pharmaceutical preparation, carriers for pharmaceutical preparation, and the like according to the methods usually used.
  • Administration can be accomplished either by oral administration via tablets, pills, capsules, granules, powders, solutions, and the like, or parenteral administration injections, such as intraarticular, intravenous, or intramuscular injections, and the like, suppositories, ophthalmic solutions, eye ointments, transdermal liquid preparations, ointments, transdermal patches, transmucosal liquid preparations, transmucosal patches, inhalations, and the like.
  • The solid composition for oral administration is used in the form of tablets, powders, granules, or the like. In such a solid composition, one or more active ingredient(s) are mixed with at least one inactive excipient. According to a usual method, the composition may contain inactive additives, such as lubricants, disintegrating agents, stabilizing agents, and solubilization assisting agents. If necessary, tablets or pills may be coated with sugar or a film of a gastric or enteric coating substance.
  • The liquid composition for oral administration contains pharmaceutically acceptable emulsions, solutions, suspensions, syrups, elixirs, or the like, and also contains generally used inert diluents, for example, purified water or ethanol. In addition to the inert diluent, the liquid composition may also contain auxiliary agents, such as a solubilization assisting agent, a moistening agent, and a suspending agent, as well as sweeteners, flavors, aromatics, and antiseptics.
  • The injections for parenteral administration contain sterile aqueous or non-aqueous solutions, suspensions, or emulsions. Examples of the aqueous solvent include distilled water for injection use and physiological saline. Examples of the non-aqueous solvent include alcohols such as ethanol. Such a composition may further contain a tonicity agent, an antiseptic, a moistening agent, an emulsifying agent, a dispersing agent, a stabilizing agent, and a solubilization assisting agent. These are sterilized by filtration through a bacteria retaining filter, blending of a germicide, or irradiation. Furthermore, they may also be prepared in the form of sterile solid compositions and dissolved or suspended in sterile water or a sterile solvent for injecting prior to their use.
  • Examples of the formulation for external use include ointments, plasters, creams, jellies, patches, sprays, lotions, eye-drops, eye ointments, and the like. The drug contains generally used ointment bases, lotion bases, aqueous or non-aqueous liquid preparations, suspensions, emulsions, or the like.
  • Transmucosal agents such as inhalers, transnasal agents, and the like are used in the form of solids, liquids, or semisolids and can be prepared according to conventional known methods. For example, known excipients, and further, pH adjusters, antiseptics, surfactants, lubricants, stabilizing agents, thickeners, or the like may also be added where appropriate. For administration, suitable devices for inhalation or insufflation can be used. For example, using known devices and sprayers such as a metered dose inhaler, the compound can be administered independently or in the form of prescribed mixture powders. Furthermore, the compound combined with pharmaceutically acceptable carriers can also be administered in the form of solutions or suspensions. Dry powder inhalers and the like may be devices for single or multiple administrations, and dry powders or capsules containing powders can also be used. Still further, the devices may be in the form of a pressure aerosol spray or the like that use suitable ejection agents, for example, chlorofluoroalkane, hydrofluoroalkane, or a suitable gas such as carbon dioxide and the like.
  • Usually, in the case of oral administration, the daily dose is suitably from 0.001 to 100 mg/kg per body weight, preferably from 0.1 to 30 mg/kg, and more preferably from 0.1 to 10 mg/kg, and this is administered in one portion or dividing it into 2 to 4 portions. In the case of intravenous administration, the daily dose is suitably from about 0.0001 to 10 mg/kg per body weight, and this is administered once a day or two or more times a day. In addition, a transmucosal agent is administered at a dose from about 0.001 to 100 mg/kg per body weight, and this is administered once a day or two or more times a day. The dose is appropriately decided in response to an individual case by taking the symptoms, the age, the gender, and the like into consideration.
  • Although varying depending on administration routes, dosage forms, administration sites, or the types of excipients and additives, the pharmaceutical composition of the present invention contains 0.01 to 100% by weight, and in a certain embodiment, 0.01 to 50% by weight of one or more kinds of the compound of the formula (I) or a salt thereof, which is an active ingredient.
  • The compound of the formula (I) can be used in combination with various agents for treating or preventing the diseases, in which the compound of the formula (I) is considered effective, as described above. The combined preparation may be administered simultaneously or separately and continuously, or at a desired time interval. The preparations to be co-administered may be prepared individually or may be a pharmaceutical composition including various agents for treating or preventing the diseases, in which the compound of the formula (I) is considered effective, as described above, and the compound of the formula (I).
    • EXAMPLES
  • Hereinbelow, the preparation methods for the compound of the formula (I) and the starting compounds thereof will be described in more detail with reference to Examples.
  • The present invention is not limited to the compounds described in the Examples described below. Furthermore, the production processes for the starting compounds will be described in Preparation Examples. The preparation methods for the compound of the formula (I) are not limited to the preparation methods of the specific Examples as below, but the compound of the formula (I) can be prepared by any combination of the preparation methods or the methods that are apparent to a person skilled in the art.
  • Furthermore, the following abbreviations may be used in some cases in the Preparation Examples, Examples, and Tables below.
  • PEx: Preparation Example No., Ex: Example No., PSyn: Preparation Example No. prepared by the same method, Syn: Example No. prepared by the same method, No: Compound No., Str: Structural formula, Dat: Physicochemical Data, EI: m/z values in mass spectroscopy (Ionization EI, representing (M)+ unless otherwise specified), ESI+: m/z values in mass spectroscopy (Ionization ESI, representing (M+H)+unless otherwise specified), ESI−: m/z values in mass spectroscopy (Ionization ESI, representing (M−H)− unless otherwise specified), FAB+: m/z values in mass spectroscopy (Ionization FAB, representing (M+H)+ unless otherwise specified), FAB−: m/z values in mass spectroscopy (Ionization FAB, representing (M−H)− unless otherwise specified), APCI+: tm/z values in mass spectroscopy (Ionization APCI, representing (M+H)+ unless otherwise specified), NMR: δ (ppm) in 1H NMR in DMSO-d6, NMR-A: δ (ppm) in 1H NMR in DMSO-d6 (with addition of trifluoroacetic acid), NMR-C: δ (ppm) in 1H NMR in CDCl3, s: singlet (spectrum), d: doublet (spectrum), t: triplet (spectrum), q: quartet (spectrum), br: broad line (spectrum) (e.g.: br-s), mp: melting point (° C.).
  • Me: methyl, Et: ethyl, nPr: normal propyl, iPr: isopropyl, nBu: normal butyl, iBu: isobutyl, t-Bu: tert-butyl, cPr: cyclopropyl, cBu: cyclobutyl, cPen: cyclopentyl, cHex: cyclohexyl, Bz: benzyl, Boc: t-butoxycarbonyl, MeOH: methanol, EtOH: ethanol, EtOAc: ethyl acetate, HEX: n-hexane, DMF: N,N-dimethylformamide, TFA: trifluoroacetic acid, THF: tetrahydrofuran, DPPA: diphenylphosphorylazide, HOBt: 1-hydroxybenzotriazole.
  • HCl in the structural formula indicates that the Example compound is isolated as a hydrochloride. Further, a case where the structural formula of fumaric acid is described together in the structural formula indicates that the Example compound is isolated as fumarate. Also, a case where the structural formula of oxalic acid is described together in the structural formula indicates that the Example compound is isolated as an oxalate. In addition, a case where the structural formula of succinic acid is described together in the structural formula indicates that the Example compound is isolated as a succinate.
  • Furthermore, in the case where a numeral is prefixed to HCl, the numeral means a molar ratio of the compound to hydrochloric acid. For example, 2HCl represents dihydrochloride. Further, in the Example Compounds in which the structural formula of fumaric acid is described together in the structural formula, “M” described under the Example No. indicates that the Example Compound is isolated as monofumarate, “H” described as such indicates that the Example Compound is isolated as hemifumarate, and “S” described as such indicates that the Example Compound is isolated as sesquifumarate. Also, “T” of Example 267 indicates that the compound is isolated as 0.75 fumarate. Further, description of these “M”, “H”, and “S” has the same meanings in the Example Compound in which the structural formula of oxalic acid is described together in the structural formula and the Example Compound in which where the structural formula of succinic acid is described together in the structural formula.
  • Furthermore, for the sake of convenience, a concentration mol/l is expressed as M. For example, a 1 M aqueous sodium hydroxide solution means a 1 mol/l aqueous sodium hydroxide solution.
    • Preparation Example 1
  • To a solution of 27.11 g of 3-chloro-o-xylene in 300 ml of carbon tetrachloride were added 75 g of N-bromosuccinimide and 0.81 g of azaisobutyronitrile, followed by heating and refluxing for 2 hours. The reaction mixture was washed with water and saturated sodium hydrogen carbonate, the organic layer was dried over anhydrous magnesium sulfate and then filtered, and the filtrate was concentrated under reduced pressure to obtain 63.297 g of 1,2-bis(bromomethyl)-3-chlorobenzene as a reddish orange oily substance.
    • Preparation Example 2
  • To a solution of 9.5 g of sodium cyanide in 120 ml of water was added a solution of 57.533 g of 1,2-bis(bromomethyl)-3-chlorobenzene in 120 ml of EtOH, followed by heating and refluxing for 30 minutes. The reaction mixture was poured into ice, followed by stirring, and the precipitated solid was collected by filtration to obtain 32.941 g of 2,2′-(3-chloro-1,2-phenylene)diacetonitrile as a yellowish brown solid.
    • Preparation Example 3
  • To a suspension of 32.94 g of 2,2′-(3-chloro-1,2-phenylene)diacetonitrile in 100 ml of acetic acid was added dropwise 100 ml of a 33% hydrogen bromide-acetic acid solution over 1.5 hours while keeping the inner temperature at 20° C. or lower. The reaction mixture was stirred at room temperature for 3 hours, and then to the reaction mixture were added diethylether and acetone. The resulting candy-like dark brown solid substance and the suspension were separated, the suspension was concentrated under reduced pressure, and the candy-like substance was pulverized in acetone to obtain a suspension. The concentrated residue and the acetone suspension were combined and concentrated under reduced pressure, and to the residue was added EtOAc, followed by stirring. The solid was collected by filtration. The resulting solid was suspended in 400 ml of water which had been heated to 80° C., and 31.2 g of sodium acetate was added thereto, followed by stirring at 90° C. for 3 hours. The reaction mixture was cooled to room temperature and then the solid was collected by filtration to obtain 22.506 g of 6-chloro-1H-3-benzazepine-2,4(3H,5H)-dione as a brown solid.
    • Preparation Example 4
  • To a solution of 22.5 g of 6-chloro-1H-3-benzazepine-2,4(3H,5H)-dione in 200 ml of THF were added dropwise 38 ml of a 10 M borane-dimethyl sulfide complex at 0° C. for 20 minutes, followed by stirring for 2.5 hours. The reaction mixture was heated and refluxed, and further stirred. To the reaction mixture was added dropwise 30 ml of MeOH under ice-cooling, followed by stirring, and then 30 ml of 4 M hydrochloric acid was added dropwise thereto, followed by heating and refluxing for 1 hour after generation of bubbles substantially settled. The mixture was alkalified by the addition of aqueous ammonia and a 1 M aqueous sodium hydroxide solution, followed by extraction with chloroform. The organic layer was dried over anhydrous sodium sulfate and then filtered. The filtrate was concentrated under reduced pressure, the residue was dissolved in EtOH, and activated carbon was added thereto, followed by heating and refluxing, and then filtering on amino silica gel, and the filtrate was concentrated under reduced pressure. To a solution of 18.7 g of the resulting residue in 180 ml of dichloromethane was added 17 ml of pyridine, followed by ice-cooling, and 13 ml of ethyl chlorocarbonate was added dropwise thereto, followed by stirring for 1.5 hours. The reaction mixture was concentrated under reduced pressure, the residue was diluted with EtOAc, then washed with 1 M hydrochloric acid and water, dried over anhydrous sodium sulfate, and then filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 9.653 g of ethyl 6-chloro-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate as a reddish brown oily substance.
    • Preparation Example 5
  • A solution of 11.86 g of ethyl 6-chloro-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate in 30 ml of chloroform was ice-cooled, and while maintaining the inner temperature at 10° C. or lower, 60 ml of concentrated hydrochloric acid was added thereto. Then, 32 ml of concentrated nitric acid was added dropwise thereto, followed by stirring for 30 minutes. The reaction mixture was poured into ice, followed by extraction with chloroform, the organic layer was dried over anhydrous sodium sulfate and then filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 6.442 g of ethyl 6-chloro-7-nitro-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate as a reddish orange viscous substance and 5.201 g of ethyl 6-chloro-9-nitro-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate as a pale yellow solid.
    • Preparation Example 6
  • To 6.431 g of ethyl 6-chloro-7-nitro-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate was added 120 ml of EtOH, followed by stirring at 60° C. for dissolution, and 12.15 g of reduced iron and 60 ml of 1 M hydrochloric acid were added thereto, followed by heating and refluxing for 1 hour. The reaction mixture was alkalified by the addition of a 1 M aqueous sodium hydroxide solution and then filtered through celite, and then the organic solvent was evaporated under reduced pressure. The residue was extracted with chloroform, the organic layer was dried over anhydrous sodium sulfate and then filtered, and the filtrate was concentrated under reduced pressure to obtain 5.743 g of ethyl 7-amino-6-chloro-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate as a reddish orange viscous substance.
    • Preparation Example 7
  • To a solution of 5.74 g of ethyl 7-amino-6-chloro-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate in 100 ml of dichloromethane was added portionwise 3.9 g of N-bromosuccinimide under ice-cooling, followed by stirring for 40 minutes. The reaction mixture was concentrated under reduced pressure and the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 5.769 g of ethyl 7-amino-8-bromo-6-chloro-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate as a brown solid.
    • Preparation Example 8
  • To a solution of 4.37 g of ethyl 7-amino-8-bromo-6-chloro-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate in 40 ml of DMF were added 2.1 ml of ethyl acrylate, 230 mg of tris-o-tolylphosphine, 85 mg of palladium(II) acetate, and 3.6 ml of triethylamine, followed by stirring at 120° C. for 3 hours. The reaction mixture was diluted with EtOAc, washed with water and saturated brine, dried over anhydrous sodium sulfate, and then filtered, and the filtrate was concentrated under reduced pressure. The resulting yellow solid was stirred and washed in diisopropylether to obtain 3.125 g of ethyl 7-amino-6-chloro-8-[(1E)-3-ethoxy-3-oxoprop-1-en-1-yl]-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate as a pale yellow solid.
    • Preparation Example 9
  • To a solution of 2.12 g of ethyl 7-amino-6-chloro-8-[(1E)-3-ethoxy-3-oxoprop-1-en-1-yl]-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate in 20 ml of chloroform and 20 ml of MeOH was added 65 mg of platinum(IV) oxide, followed by stirring for 20 hours at 1 atm under a hydrogen atmosphere. The reaction mixture was filtered through celite and the filtrate was concentrated under reduced pressure to obtain 2.256 g of ethyl 11-chloro-2-oxo-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate as a milky white solid.
    • Preparation Example 10
  • To a suspension of 1.403 g of 11-chloro-1,3,4,6,7,8,9,10-octahydro-2H-azepino[4,5-g]quinolin-2-one in 15 ml of dioxane were added 12 ml of triethylamine and 1.5 g of di-t-butyl dicarbonate, followed by stirring at room temperature for 2 hours. The reaction mixture was concentrated under reduced pressure and the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 1.779 g of t-butyl 11-chloro-2-oxo-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate as a milky white solid.
    • Preparation Example 11
  • To a solution of 1.772 g of t-butyl 11-chloro-2-oxo-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate in 10 ml of THF was added 10.1 ml of a 1 M solution of a borane-THF complex in THF under ice-cooling, followed by elevating to room temperature and stirring for 3 hours. To the reaction mixture was added dropwise 10 ml of EtOH, and subsequently 10 ml of a 1 M aqueous sodium hydroxide solution was added dropwise thereto, followed by stirring. The mixed solution was diluted with water, followed by extraction with EtOAc. The organic layer was dried over anhydrous sodium sulfate and then filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 2.0707 g of t-butyl 11-chloro-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate as a colorless viscous substance.
    • Preparation Example 12
  • To a solution of 205 mg of t-butyl 11-chloro-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate in 3 ml of acetonitrile were added 0.077 ml of 36% formalin, 58 mg of sodium cyanoborohydride, and 0.5 ml of acetic acid, followed by stirring at room temperature. To the reaction mixture was added water, followed by extraction with EtOAc, the organic layer was dried over anhydrous sodium sulfate and then filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 96 mg of t-butyl 11-chloro-1-methyl-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate as an orange viscous substance.
    • Preparation Example 13
  • To a solution of 193 mg of t-butyl 11-chloro-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate in 2 ml of toluene was added 0.121 ml of isobutyric chloride, followed by stirring at 60° C. The reaction mixture was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 80 mg of t-butyl 1-acetyl-11-chloro-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate as a colorless solid.
    • Preparation Example 14
  • To a solution of 1.75 g of 2,3,4,5-tetrahydro-1H-3-benzazepine in 20 ml of dichloromethane was added 2.884 ml of pyridine. The reaction mixture was ice-cooled, and 1.705 ml of ethyl chloroformate which had been dissolved in 5 ml of dichloromethane was added dropwise thereto, followed by stirring overnight. The reaction mixture was concentrated under reduced pressure and the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 2.15 g of ethyl 1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate as a pale yellow oily substance.
    • Preparation Example 15
  • 287 mg of ethyl 2-oxo-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate was dissolved in 5 ml of DMF, and 65 mg of 60% sodium hydride was added thereto in an ice-bath, followed by stirring for 1 hour. 0.3 ml of methyl iodide was added thereto, followed by stirring at room temperature for 3 hours. Then, a saturated aqueous sodium hydrogen carbonate solution was added thereto, followed by extraction with chloroform. The solvent was concentrated under reduced pressure and the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 94 mg of ethyl 1-methyl-2-oxo-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate as a colorless solid.
    • Preparation Example 16
  • To 5 g of ethyl 2-oxo-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate were added 40 ml of ethylene glycol and 28 ml of a 4 M aqueous sodium hydroxide solution, followed by stirring at 150° C. After stirring overnight, the reaction mixture was ice-cooled, then acidified by the addition of concentrated hydrochloric acid, and stirred at room temperature for 1 hour. The reaction mixture was concentrated under reduced pressure, and then the residue was alkalified by the addition of a 1 M aqueous sodium hydroxide solution, followed by extraction with chloroform. The solvent was concentrated under reduced pressure and then the resulting dark brown residue was dissolved in dichloromethane, followed by addition of 4 g of di-t-butyl dicarbonate and 3.5 ml of triethylamine. The reaction mixture was stirred at room temperature overnight and concentrated under reduced pressure, and the residue was purified by silica gel chromatography (elution solvent: chloroform-MeOH) to obtain 3.39 g of t-butyl 2-oxo-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate.
    • Preparation Example 17
  • To a solution of 250 mg of t-butyl 1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate in 2.5 ml of dichloroethane were added 0.175 ml of isobutyryl chloride and 0.4 ml of triethylamine, followed by elevating the temperature to 60° C. and stirring for 30 minutes. The reaction mixture was diluted with EtOAc and washed with 1 M hydrochloric acid, water, a 1 M aqueous sodium hydroxide solution, and saturated brine, and the solvent was concentrated. To the resulting residue was added 2 ml of THF and 3.5 ml of a 1 M solution of a borane-THF complex in THF was added thereto in an ice-bath, followed by stirring at room temperature overnight. The reaction mixture was ice-cooled, and EtOH was added thereto, followed by stirring at room temperature for 30 minutes. The reaction mixture was concentrated and the resulting residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 213 mg of t-butyl 1-isobutyl-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate.
    • Preparation Example 18
  • To a solution of 460 mg of t-butyl 11-bromo-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate in 9 ml of dioxane were added 1.6 ml of a 2 M aqueous potassium carbonate solution under an argon atmosphere, and subsequently 449 mg of trimethylboroxine and 70 mg of tetrakistriphenylphosphine palladium, followed by stirring at 90° C. for 13 hours. The reaction mixture was allowed to cool, filtered, and then concentrated under reduced pressure, the resulting residue was diluted with EtOAc, and the organic layer was washed with water and saturated brine. The solvent was evaporated under reduced pressure and the resulting residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 380 mg of t-butyl 11-methyl-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate.
    • Preparation Example 19
  • To a solution of 670 mg of t-butyl 11-isopropenyl-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate in 10 ml of MeOH was added 200 mg of palladium on carbon, followed by stirring at room temperature for 3.5 hours at normal pressure under a hydrogen atmosphere. Further, after stirring overnight at 4.5 atm under a hydrogen atmosphere, the reaction mixture was filtered through celite, and the solvent was evaporated under reduced pressure. The resulting residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 512 mg of t-butyl 11-isopropyl-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate.
    • Preparation Example 20
  • To a solution of 140 mg of t-butyl 11-ethyl-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate in 1.86 ml of acetonitrile was added 0.12 ml of glycidylmethylether, followed by substitution with argon. In an ice-bath, 9 mg of ytterbium(III) trifluoromethanesulfonate was added thereto, followed by stirring at room temperature for 2 hours, then elevating the temperature to 50° C., and stirring overnight. To the reaction mixture were added EtOAc and aqueous sodium bicarbonate, and the organic layer was washed with water and saturated brine. The solvent was evaporated under reduced pressure and the resulting residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 147 mg of t-butyl 11-ethyl-1-(2-hydroxy-3-methoxypropyl)-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate.
    • Preparation Example 21
  • To a solution of 215 mg of t-butyl 7-hydroxy-8-(tetrahydro-2H-pyran-4-ylamino)-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate in 4 ml of DMF were added 98 mg of potassium carbonate and 0.062 ml of methyl bromoacetate, followed by stirring at room temperature for 6 hours. To the reaction mixture was added water, followed by extraction with EtOAc twice. The combined organic layer was washed with saturated brine three times, dried over anhydrous sodium sulfate, and then filtered, and the solvent was evaporated under reduced pressure. To a solution of 259 mg of the resulting residue in 7 ml of EtOH was added 1.2 ml of a 1 M aqueous sodium hydroxide solution, followed by stirring at 50° C. overnight. Further, 1.2 ml of a 1 M aqueous hydrochloric acid solution was added thereto under ice-cooling, followed by extraction with chloroform twice, and the combined organic layer was dried over anhydrous sodium sulfate and then filtered. The solvent was evaporated under reduced pressure. To a solution of 239 mg of the resulting residue in 4 ml of DMF were added 120 mg of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride and 84 mg of HOBt at room temperature, followed by stirring at room temperature overnight. Water was added thereto, followed by extraction with EtOAc twice. The combined organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and then filtered, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 153 mg of t-butyl 3-oxo-4-(tetrahydro-2H-pyran-4-yl)-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepine-8(2H)-carboxylate as a white solid.
    • Preparation Example 22
  • To a solution of 828 mg of t-butyl 7-hydroxy-6-methyl-8-nitro-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate in 25 ml of DMF were added 0.268 ml of methyl bromoacetate and 390 mg of potassium carbonate, followed by stirring at 55° C. for 13 hours. The reaction mixture was allowed to cool, and water added, followed by extraction with EtOAc twice. The combined organic layer was washed with saturated brine, the organic layer was dried over anhydrous sodium sulfate and then filtered, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 1.076 g of t-butyl 7-(2-methoxy-2-oxoethoxy)-6-methyl-8-nitro-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate as a yellowish white solid.
    • Preparation Example 23
  • To a mixture of 967 mg of t-butyl 7-(2-methoxy-2-oxoethoxy)-6-methyl-8-nitro-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate in 25 ml of EtOH was added 97 mg of 10% palladium on carbon under an argon atmosphere, followed by stirring for 2 hours at normal pressure under a hydrogen atmosphere. To the reaction mixture was added 200 ml of THF, then the catalyst was removed using celite, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 629 mg of t-butyl 11-methyl-3-oxo-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepine-8(2H)-carboxylate as a white solid.
    • Preparation Example 24
  • To a solution of 120 mg of t-butyl 2-methyl-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepine-8(2H)-carboxylate in 4 ml of DMF were added 0.026 ml of methyl iodide and 104 mg of potassium carbonate at room temperature, followed by stirring for 13 hours. To the reaction mixture were added 0.012 ml of methyl iodide and 26 mg of potassium carbonate, followed by further stirring for 3 hours. To the reaction mixture was added water, followed by extraction with EtOAc twice. The combined organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and then filtered, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 55 mg of t-butyl 2,4-dimethyl-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepine-8(2H)-carboxylate as a brown solid.
    • Preparation Example 25
  • To a solution of 120 mg of t-butyl 2-methyl-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepine-8(2H)-carboxylate in 4 ml of DMF were added 0.113 ml of isopropyl iodide and 0.197 ml of diisopropylethylamine, followed by stirring at 100° C. for 6.5 hours. Further, to the reaction mixture were added 0.113 ml of isopropyl iodide and 0.197 ml of diisopropylethylamine, followed by stirring at 100° C. for 4 hours. Further, to the reaction mixture were added 0.226 ml of isopropyl iodide and 0.394 ml of diisopropylethylamine, followed by stirring at 100° C. for 19 hours. The reaction mixture was cooled to room temperature, and water added, followed by extraction with EtOAc twice. The combined organic layer was washed with saturated brine, the organic layer was dried over anhydrous sodium sulfate and then filtered, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 90 mg of t-butyl 4-isopropyl-2-methyl-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepine-8(2H)-carboxylate as a pale brown solid.
    • Preparation Example 26
  • To a solution of 130 mg of t-butyl 3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepine-8(2H)-carboxylate in 4 ml of dichloromethane were added 0.036 ml of methanesulfonyl chloride and 0.089 ml of diisopropylethylamine under ice-cooling, followed by stirring at room temperature for 16 hours. To the reaction mixture were added 0.036 ml of methanesulfonyl chloride and 0.089 ml of diisopropylethylamine, followed by stirring at room temperature for additional 9 hours. To the reaction mixture was added water, followed by extraction with chloroform. The organic layer was dried over anhydrous sodium sulfate and then filtered, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 152 mg of t-butyl 4-(methylsulfonyl)-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepine-8(2H)-carboxylate as a colorless solid.
    • Preparation Example 27
  • To a mixture of 5 g of sodium borohydride and 30 ml of anhydrous THF was added a solution of 10.27 g of 2-methyl-3-nitrophenylacetic acid in 60 ml of anhydrous THF under ice-cooling, and then a solution of 35 ml of methanesulfonic acid in 10 ml of anhydrous THF was added dropwise thereto. The reaction mixture was heated to 70° C. and then stirred for 30 minutes, and 80 ml of 3 M hydrochloric acid was then added thereto under ice-cooling, followed by stirring. The mixed liquid was extracted with chloroform, and the organic layer was dried over anhydrous magnesium sulfate and then filtered. The filtrate was concentrated under reduced pressure to obtain 9.701 g of an orange viscous substance. To a solution of 9.53 g of the resulting substance in 100 ml of dichloromethane were added dropwise 22 ml of diisopropylethylamine and 4.75 ml of chloromethylmethylether under ice-cooling, followed by stirring for 24 hours. 10 ml of chloromethylmethylether was added thereto, followed by further stirring for 24 hours. The reaction mixture was concentrated under reduced pressure and the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 11.26 g of a yellow oily substance. To a solution of 11.26 g of the resulting substance in 200 ml of EtOH was added 340 mg of platinum(IV) dioxide, followed by stirring at room temperature for 1 hour under a hydrogen atmosphere of 4 atm. The reaction mixture was removed using celite and the filtrate was concentrated under reduced pressure to obtain 9.21 g of an orange viscous substance. To a solution of the residue in 200 ml of dichloromethane and 40 ml of MeOH were added 14.2 g of calcium carbonate and 36.5 g of benzyl trimethylammonium dichloroiodate, followed by stirring at room temperature for 13 hours. The insoluble materials were removed by filtration and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 15.93 g of 4,6-diiodo-3-[2-(methoxymethoxy)ethyl]-2-methylaniline as a dark red viscous substance.
    • Preparation Example 28
  • To a mixed liquid of 400 mg of palladium(II) acetate, 934 mg of triphenylphosphine, 9.91 g of tetrabutylammonium chloride, and 7 g of potassium acetate in 150 ml of DMF was added a solution of 15.93 g of 4,6-diiodo-3-[2-(methoxymethoxy)ethyl]-2-methylaniline in 150 ml of DMF, and 16 ml of ethyl acrylate was added thereto, followed by stirring at 80° C. for 3 hours. The reaction mixture was diluted with EtOAc, washed with water and saturated brine, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 12.11 g of a yellow solid. To a solution of 12.11 g of the resulting substance in 250 ml of EtOH and 250 ml of THF was added 701 mg of platinum(IV) oxide, followed by stirring at room temperature for 4 hours under a hydrogen atmosphere of 4 atm. The reaction mixture was removed using celite and the filtrate was concentrated under reduced pressure to obtain 11.39 g of ethyl 3-{7-[2-(methoxymethoxy)ethyl]-6-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl}pronanoate as a milky white solid.
    • Preparation Example 29
  • To a solution of 10.81 g of ethyl 3-{7-[2-(methoxymethoxy)ethyl]-6-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl}pronanoate in 100 ml of EtOH and 100 ml of THF was added 100 ml of a 1 M aqueous sodium hydroxide solution, followed by stirring at room temperature for 1 hour. The reaction mixture was neutralized by the addition of hydrochloric acid and then concentrated under reduced pressure to one third of the liquid amount, and the residue was extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate and then filtered, and the filtrate was concentrated under reduced pressure. To a solution of the resulting residue in 300 ml of t-butanol were added 90 ml of triethylamine and 70 ml of DPPA, followed by heating and refluxing for 24 hours. The reaction mixture was concentrated under reduced pressure, the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc), and then the resulting solid was washed with HEX to obtain 8.006 g of t-butyl (2-{7-[2-(methoxymethoxy)ethyl]-8-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl}ethyl)carbamate as a milky white solid.
    • Preparation Example 30
  • To a suspension of 1.01 g of t-butyl (2-{7-[2-(methoxymethoxy)ethyl]-8-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl}ethyl)carbamate in 10 ml of THF was added 10 ml of 6 M hydrochloric acid, followed by stirring at 50° C. for 1 hour. The reaction mixture was alkalified by the addition of sodium hydroxide and then 675 mg of di-t-butyl dicarbonate was added thereto, followed by stirring at room temperature for 15 hours. The reaction mixture was extracted with chloroform, and the organic layer was dried over anhydrous magnesium sulfate and then filtered. The filtrate was concentrated under reduced pressure to obtain 1.105 g of t-butyl {2-[7-(2-hydroxyethyl)-6-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl]ethyl}carbamate as a white foamed substance.
    • Preparation Example 31
  • To a solution of 1.793 g of t-butyl {2-[7-(2-hydroxyethyl)-6-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl]ethyl}carbamate in 30 ml of THF were added 0.48 ml of methanesulfonyl chloride and 15 ml of triethylamine under ice-cooling, followed by stirring for 30 minutes. To the reaction mixture was added portionwise 1.8 g of potassium t-butoxide under ice-cooling, followed by stirring for 1.5 hours. To the reaction mixture was added a saturated aqueous ammonium chloride solution, followed by extraction with EtOAc. The organic layer was dried over anhydrous magnesium sulfate and then filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 1.06 g of t-butyl 11-methyl-2-oxo-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate as a white foamed substance.
    • Preparation Example 32
  • To a solution of 167 mg of t-butyl 11-methyl-oxo-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate in 2 ml of dichloromethane were added 0.221 ml of triethylamine and 0.062 ml of ethyl isocyanate, followed by stirring at room temperature for 15 hours. To the reaction mixture were added 3 ml of toluene and 0.062 ml of ethyl isocyanate, followed by heating to 60° C. and stirring for 15 hours. Then, the reaction mixture was concentrated under reduced pressure and the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 200 mg of t-butyl 1-(ethylcarbamoyl)-11-methyl-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate as a colorless viscous substance.
    • Preparation Example 33
  • To a solution of 201 mg of t-butyl 11-methyl-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate in 2 ml of pyridine was added 0.1 ml of ethyl chloroformate, followed by stirring at room temperature for 30 minutes. The reaction mixture was concentrated under reduced pressure and the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 261 mg of 8-t-butyl 1-ethyl 11-methyl-3,4,6,7,9,10-hexahydro-1H-azepino[4,5-g]quinoline-1,8(2H)-dicarboxylate as a colorless viscous substance.
    • Preparation Example 34
  • To a suspension of 2 g of 3-(2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)propionic acid in 40 ml of t-butanol were added 2.1 ml of DPPA and 2.6 ml of triethylamine, followed by heating and refluxing at 100° C. for 18 hours. The reaction mixture was concentrated under reduced pressure and the residue was purified by silica gel chromatography (elution solvent: chloroform-MeOH) to obtain 1.832 g of t-butyl[2-(2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)ethyl]carbamate as an orange solid.
    • Preparation Example 35
  • To a mixed solution of 770 mg of t-butyl[2-(1,2,3,4-tetrahydroquinolin-7-yl)ethyl]carbamate in 15 ml of dichloromethane and 3 ml of MeOH were added 420 mg of calcium carbonate and 970 mg of benzyltrimethylammonium dichloroiodate, followed by stirring at room temperature for 2 hours. The insoluble materials were removed by filtration and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 595 mg of t-butyl[2-(6-iodo-1,2,3,4-tetrahydroquinolin-7-yl)ethyl]carbamate as a reddish brown viscous substance.
    • Preparation Example 36
  • To a solution of 595 mg of t-butyl[2-(6-iodo-1,2,3,4-tetrahydroquinolin-7-yl)ethyl]carbamate in 3 ml of dichloromethane were added 3 ml of water and 376 mg of sodium hydrogen carbonate, and a solution of 0.273 ml of benzyl chloroformate in 3 ml of dichloromethane wad added dropwise under ice-cooling while stirring, followed by stirring for additional 5 hours. The reaction mixture was extracted with EtOAc, the organic layer was dried over anhydrous magnesium sulfate and then filtered, and the filtrate was concentrated under reduced pressure to obtain 877 mg of benzyl 7-{2-[(t-butoxycarbonyl)amino]ethyl}-6-iodo-3,4-dihydroquirolin-1(2H)-carboxylate as a reddish orange solid.
    • Preparation Example 37
  • To a solution of 793 mg of benzyl 7-{2-[(t-butoxycarbonyl)amino]ethyl}-6-iodo-3,4-dihydroquirolin-1(2H)-carboxylate in 10 ml of THF was added dropwise 1.8 ml of a 1 M solution of sodium bistrimethylsilylamide in THF under ice-cooling, followed by stirring for 5 minutes. Then, 0.166 ml of allyl bromide was added thereto, followed by stirring for 18 hours while slowly elevating the temperature to room temperature. To the reaction mixture were added a saturated aqueous ammonium chloride solution and water, followed by extraction with EtOAc, the organic layer was dried over anhydrous magnesium sulfate and then filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 788 mg of benzyl 7-{2-[alkyl(t-butoxycarbonyl)amino]ethyl}-6-iodo-3,4-dihydroquirolin-1(2H)-carboxylate.
    • Preparation Example 38
  • To a mixture of 403 mg of potassium acetate, 441 mg of tetrabutylammonium bromide, 9 mg of triphenylphosphine, and 4 mg of palladium(II) acetate was added a solution of 788 mg of benzyl 7-{2-[allyl(t-butoxycarbonyl)amino]ethyl}-6-iodo-3,4-dihydroquirolin-1(2H)-carboxylate in 25 ml of DMF, followed by substitution with argon and stirring at 80° C. for 4 hours. The reaction mixture was diluted with EtOAc, washed with water and saturated brine, and concentrated under reduced pressure. To 25 ml of a solution of the resulting residue in MeOH was added 36 mg of platinum(IV) oxide, followed by stirring at room temperature overnight under a hydrogen atmosphere of 4 atm. The reaction mixture was filtered through celite and the filtrate was concentrated under reduced pressure to obtain 570 mg of 1-benzyl 8-t-butyl 6-methyl-3,4,6,7,9,10-hexahydro-1H-azepino[4,5-g]quinoline-1,8(2H)-dicarboxylate as an orange foamed substance.
    • Preparation Example 39
  • To a mixed liquid of 9.3 g of aluminum chloride in 30 ml of dichloromethane was added dropwise 1.6 ml of acetyl chloride under ice-cooling, followed by stirring. Then, a solution of 5 g of 7-methoxy-1-methyl-3-(trifluoroacetyl)-2,3,4,5-tetrahydro-1H-3-benzazepine in 70 ml of dichloromethane was added thereto, followed by stirring for 13 hours while slowly elevating the temperature to room temperature. The reaction mixture was ice-cooled, and 30 ml of 1 M hydrochloric acid was added dropwise thereto, followed by addition of water and extraction with chloroform. The organic layer was dried over anhydrous magnesium sulfate and then filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by flash chromatography (elution solvent: HEX-EtOAc) to obtain 5.137 g of 1-[8-hydroxy-5-methyl-3-(trifluoroacetyl)-2,3,4,5-tetrahydro-1H-3-benzazepine-7-yl]ethanone as a pale brown solid.
    • Preparation Example 40
  • To a suspension of 5.13 g of 1-[8-hydroxy-5-methyl-3-(trifluoroacetyl)-2,3,4,5-tetrahydro-1H-3-benzazepine-7-yl]ethanone in 50 ml of MeOH was added 50 ml of a 1 M aqueous sodium hydroxide solution, followed by stirring at room temperature for 30 minutes. The reaction mixture was concentrated under reduced pressure to a half of the amount, and to the residue were added 50 ml of dioxane and 4.27 g of di-t-butyl dicarbonate, followed by stirring at room temperature for 30 minutes. The reaction mixture was neutralized by the addition of 1 M hydrochloric acid and extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate and then filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 4.385 g of t-butyl 8-acetyl-7-hydroxy-1-methyl-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate as a yellow viscous substance.
    • Preparation Example 41
  • To a solution of 1.715 g of t-butyl 8-acetyl-7-(2-ethoxy-2-oxoethoxy)-1-methyl-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate in 20 ml of EtOH was added 325 mg of hydroxylamine hydrochloride, followed by heating and refluxing for 3 hours. 500 mg of hydroxylamine hydrochloride was added thereto, followed by further heating and refluxing for 2 hours. The reaction mixture was concentrated under reduced pressure, and to the residue was added water, followed by extraction with chloroform. The organic layer was dried over anhydrous sodium sulfate and then filtered, and the filtrate was concentrated under reduced pressure. To 10 ml of a solution of the resulting residue in acetonitrile were added 24 mg of cyanuric chloride and 33 mg of zinc(II) chloride, followed by heating and refluxing for 12 hours. The reaction mixture was concentrated under reduced pressure. To the resulting residue were added 10 ml of dioxane, 10 ml of a 1 M aqueous sodium hydroxide solution and 1.2 g of di-t-butyl dicarbonate, followed by stirring at room temperature for 24 hours. The reaction mixture was concentrated under reduced pressure to a half of the amount, made weakly acidic by the addition of 1 M hydrochloric acid, and extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate and then filtered, and the filtrate was concentrated under reduced pressure. To the resulting residue was added 60 ml of a 17% aqueous sulfuric acid solution, followed by stirring at 100° C. for 1 hour. The reaction mixture was ice-cooled and alkalified by the addition of 15 g of sodium hydroxide, and 50 ml of dioxane and 1.21 g of di-t-butyl dicarbonate were added thereto, followed by stirring at room temperature for 3 hours. The reaction mixture was diluted with water and extracted with EtOAc. The organic layer was dried over anhydrous magnesium sulfate and then filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 735 mg of t-butyl 6-methyl-3-oxo-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepine-8(2H)-carboxylate as a pale yellow solid.
    • Preparation Example 42
  • To a solution of 704 mg of t-butyl 6-methyl-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepine-8(2H)-carboxylate in 15 ml of dichloromethane was added portionwise 438 mg of N-bromosuccinimide under ice-cooling, followed by stirring for 30 minutes. The reaction mixture was concentrated under reduced pressure and the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 446 mg of a pale yellow foamed substance. To a mixture of 445 mg of the resulting compound, 144 mg of cyclopropylboric acid, 724 mg of potassium phosphate, 65 mg of tricyclohexylphosphine, and 28 mg of palladium(II) acetate were added 10 ml of toluene and 0.5 ml of water, followed by stirring at 110° C. for 12 hours. The reaction mixture was filtered through celite and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 379 mg of t-butyl 5-cyclopropyl-6-methyl-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepine-8(2H)-carboxylate as a pale brown foamed substance.
    • Preparation Example 334
  • To a solution of 500 mg of t-butyl 3-oxo-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]bensazepine-8(2H)-carboxylate in 10 ml of DMF were added 250 μl of 1-(bromomethyl)-3-fluorobenzoate and 800 mg of cesium carbonate, followed by stirring at 50° C. for 16 hours under an argon atmosphere. The reaction mixture was cooled to room temperature, and water added, followed by extraction with ethyl acetate twice. The combined organic layer was washed with saturated brine and then dried over anhydrous sodium sulfate. The solvent was evaporated and the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 609 mg of t-butyl 4-(3-fluorobenzyl)-3-oxo-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]bensazepine-8(2H)-carboxylate.
    • Preparation Example 339
  • To a solution of 600 mg of t-butyl 2-oxo-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate in 9 ml DMF were added 426 mg of potassium t-butoxide and 451 μl of benzyl bromide in an ice-bath, followed by stirring at room temperature for 3 hours. Water and ethyl acetate were added thereto, and the organic layer was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 644 mg of t-butyl 1-benzyl-2-oxo-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate as a pale yellow solid.
    • Preparation Example 344
  • To a solution of 3.83 g of t-butyl 1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate in 40 ml of dichloromethane were added 1.3 ml of pyridine and 1.29 g of triphosgene under ice-cooling, followed by stirring for 3 hours. The reaction mixture was concentrated under reduced pressure, diluted with ethyl acetate, washed with water and an aqueous ammonium chloride solution, dried over anhydrous magnesium sulfate, and then filtered, and the filtrate was concentrated under reduced pressure. To the residue was added hexane, followed by stirring, and the solid was collected by filtration and dried to obtain 3.07 g of t-butyl 1-(chlorocarbonyl)-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate as a white solid.
    • Preparation Example 345
  • To a solution of 200 mg of t-butyl 1-(chlorocarbonyl)-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate in 2 ml of pyridine was added 140 μl of phenethyl alcohol, followed by stirring at 100° C. for 5.5 hours. The reaction mixture was concentrated under reduced pressure and the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 68 mg of 8-t-butyl 1-(2-phenylethyl) 3,4,6,7,9,10-hexahydro-1H-azepino[4,5-g]quinoline-1,8(2H)-carboxylate as a yellow viscous substance.
    • Preparation Example 349
  • To a solution of 200 mg of t-butyl 1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate and 318 mg of 2-(2-methoxyphenyl)ethyl 4-nitrophenylcarbonate in 5 ml of dichloroethane was added 0.11 ml of pyridine, followed by stirring at room temperature for 2 days. The reaction mixture was concentrated under reduced pressure and the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) and basic silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 243 mg of 8-t-butyl 1-[2-(methoxyphenyl)ethyl]-3,4,6,7,9,10-hexahydro-1H-azepino[4,5-g]quinoline-1,8(2H)-carboxylate as a pale yellow viscous substance.
    • Preparation Example 367
  • To a solution of 150 mg of t-butyl 11-chloro-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]bensazepine-8(2H)-carboxylate in 3 ml of tetrahydrofuran was added 1.5 ml of a 1 M aqueous sodium hydrogen carbonate solution, followed by ice-cooling, and 64 μl of ethyl chloroformate was added dropwise thereto followed by stirring. The reaction mixture was diluted with ethyl acetate, washed with water and saturated brine, dried over anhydrous magnesium sulfate, and then filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 149 mg of 8-t-butyl 4-ethyl-11-chloro-2,3,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepine-4,8-dicarboxylate as a colorless foamed substance.
    • Preparation Example 375
  • To 500 mg of t-butyl 11-bromo-1-methyl-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate, 350 mg of potassium carbonate, 290 mg of copper iodide, 173 mg of 1H-pyrazole, and 313 mg of N,N-dimethylglycine was added 6.25 ml of dimethylsulfoxide under argon, followed by stirring at 135° C. for 36 hours. To the reaction mixture were added water and ethyl acetate, followed by stirring, and then the solid was separated by filtration. The organic layer was washed with aqueous sodium bicarbonate and concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 43 mg of t-butyl 1-methyl-11-(1H-pyrazol-1-yl)-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate as a colorless viscous liquid.
    • Preparation Example 376
  • A solution of 200 mg of t-butyl 11-bromo-1-(2-methoxyethyl)1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate, 34 mg of zinc cyanide, 13 mg of bis(tri-t-butylphosphine)palladium, and 10 mg of zinc powder in 4 ml of DMF was substituted with argon and then stirred at 100° C. for 15 hours. The reaction mixture was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 132 mg of t-butyl 11-cyano-1-(2-methoxyethyl)-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate as a colorless viscous substance.
    • Preparation Example 377
  • 1.1946 g of 1-[11-bromo-1-(2-methoxyethyl)-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-yl]-2,2,2-trifluoroethanone, 2.2395 g of sodium trifluoroacetate, and 1.568 g of copper iodide were added to 24 ml of N-methylpyrrolidone under an argon atmosphere, followed by stirring at 170° C. for 18 hours. To the reaction mixture were added water and ethyl acetate, and filtered through celite was performed. The filtrate was subjected to liquid separation, the organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and then filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: Hex-AcOEt) to obtain 239 mg of 2,2,2-trifluoro-1-[1-(2-methoxyethyl)-11-(trifluoromethyl)-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-yl]ethanone as a pale yellow solid.
    • Preparation Example 379
  • To 7.87 g of 3-(6-iodo-2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)propanoic acid were added 25 ml of t-butanol, 1.1 ml of triethylamine, and 0.83 ml of diphenylphosphoryl azide, followed by heating and refluxing for 70 hours. The reaction mixture was cooled to room temperature, then diluted by the addition of water, and stirred, and the solid was collected by filtration and dried to obtain 1.40 g of t-butyl[2-(6-iodo-2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)ethyl]carbamate as a pale brown solid. Further, the solid precipitated from the filtrate was collected by filtration to obtain 665 mg of t-butyl[2-(6-iodo-2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)ethyl]carbamate as a white solid.
    • Preparation Example 380
  • 168 mg of t-butyl 1-[(benzyloxy)methyl]-6-methyl-2-oxo-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate was stirred at room temperature for 3.5 hours in a 48% aqueous hydrobromic acid solution. The reaction mixture was extracted with hexane and a side-product, benzyl bromide, was removed. Then, the aqueous layer was alkalified by the addition of a 1 M aqueous sodium hydroxide solution, and 20 ml of tetrahydrofuran was added thereto. To the mixed liquid was added 500 mg of di-t-butyl dicarbonate, followed by stirring at room temperature for 2 hours. The reaction mixture was extracted with ethyl acetate and the organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and then filtered. The filtrate was concentrated under reduced pressure to obtain 513 mg of t-butyl 6-methyl-2-oxo-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate as a colorless foamed substance.
    • Preparation Example 381
  • Under an argon atmosphere, to a solution of 1.7 g of ethyl 7-bromo-8-hydroxy-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate in 30 ml of DMF was added 283 mg of sodium hydride under ice-cooling, followed by stirring at the same temperature for 10 minutes. Then, 1.54 g of t-butyl (4R)-4-methyl-1,2,3-oxathiazolidine-3-carboxylate was added thereto, followed by stirring at room temperature for 18 hours. To the reaction was added water and 1 M aqueous hydrochloric acid sequentially, followed by stirring, and the precipitated solid was collected by filtration. To 20 ml of a suspension of the resulting solid in ethanol was added 10 ml of a 4 M hydrochloric acid-ethyl acetate solution under ice-cooling, followed by stirring at 60° C. for 1 hour. The reaction mixture was evaporated under reduced pressure, and to the residue were added chloroform and saturated aqueous sodium bicarbonate. After extraction with chloroform, the combined organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure to obtain 2.26 g of ethyl 7-{[(2R)-2-aminopropyl]oxy}-8-bromo-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate as an opaque cream-colored oily substance.
    • Preparation Example 383
  • Under an argon atmosphere, to a solution of 1.64 g of ethyl 7-{[(2R)-2-aminopropyl]oxy}-8-bromo-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate in 41 ml of toluene were added 509 mg of sodium t-butoxide, 275 mg of 2,2′-bis(diphenylphosphino)-1,1′-binaphthyl, and 202 mg of tris(dibenzylideneacetone)dipalladium (0) in this order, followed by heating at 100° C. for 24 hours. Further, 509 mg of sodium t-butoxide, 275 mg of 2,2′-bis(diphenylphosphino)-1,1′-binaphthyl, and 202 mg of tris(dibenzylideneacetone)dipalladium (0) were added thereto, followed by stirring at 100° C. for additional 24 hours. The reaction mixture was returned to room temperature, then filtered through celite, and washed with ethyl acetate, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: Hex-AcOEt) to obtain 610 mg of ethyl (3R)-3-methyl-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepine-8(2H)-carboxylate.
    • Preparation Example 385
  • Under an argon atmosphere, to a solution of 1.032 g of ethyl 7-[(3-methylbut-2-enoyl)amino]-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate in 10.5 ml of dichloromethane was added 870 mg of aluminum chloride at room temperature, followed by stirring at room temperature for 3 hours. Further, 435 mg of aluminum chloride was added thereto, followed by stirring at room temperature for 2 hours. The reaction mixture was poured into ice-water, followed by extraction with chloroform. The combined organic layer was washed with water, a saturated aqueous sodium hydrogen carbonate solution, water, and saturated brine, dried over anhydrous magnesium sulfate, and then filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: Hex-AcOEt) to obtain 431 mg of ethyl 4,4-dimethyl-2-oxo-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate as a white solid.
    • Preparation Example 386
  • Under an argon atmosphere, to a solution of 1 g of ethyl 7-amino-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate and 539 mg of 1,1-dimethylprop-2-in-1-yl acetate in 10 ml of tetrahydrofuran was added 43 mg of copper chloride, followed by heating at 90° C. for 5 hours. The reaction mixture was concentrated under reduced pressure, ethyl acetate added, and washed with a saturated aqueous ammonium chloride solution, and saturated brine. The aqueous layer was extracted with ethyl acetate twice, the combined organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and then filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by preparative thin layer chromatography to obtain 272 mg of ethyl 2,2-dimethyl-1,2,6,7,9,10-hexahydro-8H-azepine[4,5-g]quinoline-8-carboxylate.
    • Preparation Example 387
  • To ethyl 7-amino-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate was added a 5% aqueous sulfuric acid solution, followed by stirring under ice-cooling. An aqueous solution (30 ml) of 10.22 g of sodium nitrite was added dropwise in portions thereto, and followed by stirring at the same temperature for 0.5 hours and then stirring at 60° C. for 3 hours. The reaction mixture was extracted with ethyl acetate, the organic layer was dried over anhydrous magnesium sulfate and then filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain a crude purified product having ethyl 7-hydroxy-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate as a main component. The crude purified product was recrystallized from ethyl acetate twice to obtain 15.66 g of ethyl 7-hydroxy-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate.
    • Preparation Example 388
  • To a solution of 30 g of ethyl 7-nitro-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate in 300 ml of ethanol was added 3 g of 10% palladium on carbon, followed by stirring at room temperature for 16 hours under a hydrogen atmosphere of 4 atm. The reaction mixture was filtered through celite, and the filtrate was ice-cooled and then 21.6 ml of anhydrous acetic acid was added dropwise thereto, followed by stirring for 16 hours. The reaction mixture was concentrated under reduced pressure and to the residue was added diethylether to wash the solid, thereby obtaining 26.45 g of ethyl 7-acetamide-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate as a white solid.
    • Preparation Example 389
  • The mixed liquid of 12 g of ethyl 7-acetamide-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate, 1.93 g of copper iodide, 1.89 g of 1,10-phenanthroline, and 33.12 g of cesium carbonate in 240 ml of dioxane was substituted with argon, followed by stirring at 100° C. for 18 hours. The reaction mixture was diluted with ethyl acetate, the insoluble materials were removed using celite, and the filtrate was concentrated under reduced pressure to obtain a milky white solid. The resulting residue was suspended in 240 ml of dioxane, and 1.93 g of copper iodide, 1.89 g of 1,10-phenanthroline, and 33.1 g of cesium carbonate were added thereto, followed by stirring at 100° C. for 3 days. The reaction mixture was cooled to room temperature, diluted with ethyl acetate, and filtered through celite to remove the solid, and the filtrate was concentrated under reduced pressure to obtain 9.245 g of ethyl 2-methyl-5,6,8,9-tetrahydro-7H-[1,3]oxazolo[4,5-h][3]benzazepine-7-carboxylate as a milky white solid.
    • Preparation Example 390
  • To a solution of 7 g of ethyl 2-methyl-5,6,8,9-tetrahydro-7H-[1,3]oxazolo[4,5-h][3]benzazepine-7-carboxylate in 130 ml of ethanol was added 130 ml of 1 M aqueous hydrochloric acid, followed by stirring for 16 hours. Ethanol was evaporated under reduced pressure, dried, dissolved in chloroform, and washed with water. The organic layer was dried over anhydrous sodium sulfate and then the solvent was evaporated under reduced pressure to obtain 6.84 g of ethyl 7-acetamide-8-hydroxy-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate as a brownish white solid.
    • Preparation Example 408
  • To a solution of 860 mg of t-butyl 4-ethyl-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]bensazepine-8(2H)-carboxylate in 25 ml of dichloromethane was added 1.1 g of sodium hydrogen carbonate, and further, a solution of 200 μl of bromine in 5 ml of dichloromethane was added dropwise thereto over about 30 minutes, followed by stirring at room temperature. To the reaction mixture was slowly added a 3% aqueous sodium thiosulfate solution, followed by stirring vigorously and extracting with chloroform twice. The combined organic layer was washed with saturated brine and then dried over anhydrous sodium sulfate. The solvent was evaporated and the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 490 mg of t-butyl 5-bromo-4-ethyl-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]bensazepine-8(2H)-carboxylate.
    • Preparation Example 409
  • Under an argon atmosphere, to a mixed solution of 5.0 g of ethyl 7-hydroxy-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate in 100 ml of dichloromethane and 20 ml of methanol was added portionwise 8.05 g of N,N,N-trimethylanilinium tribromide under ice-cooling, followed by stirring at the same temperature for 1 hour. The reaction mixture was concentrated under reduced pressure, the residue was extracted by the addition of ethyl acetate and water, and the organic layer was washed with 1 N aqueous hydrochloric acid and saturated brine, dried over anhydrous magnesium sulfate, and then filtered, and the filtrate was concentrated under reduced pressure to obtain 6.67 g of ethyl 7-bromo-8-hydroxy-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate as a beige solid.
    • Preparation Example 411
  • To a solution of t-butyl 1-(3-methoxypropyl)-2-oxo-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate in 4.2 ml of acetonitrile were added 107 mg of N-bromosuccinimide and 3.7 mg of ammonium nitrate, followed by stirring at room temperature for 3.5 hours. The reaction mixture was concentrated to about ¼, and ethyl acetate, an aqueous sodium thiosulfate solution, and aqueous sodium bicarbonate was added thereto. The organic layer was washed with saturated brine and then dried over anhydrous magnesium sulfate. The solvent was evaporated to obtain 198 mg of t-butyl 11-bromo-1-(3-methoxypropyl)-2-oxo-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate.
    • Preparation Example 426
  • To a solution of ethyl 3-(6-iodo-2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)propanoate in 200 ml of ethanol was added 150 ml of a 1 M aqueous sodium hydroxide solution, followed by stirring at room temperature for 2 hours. The reaction mixture was made weakly acidic by the addition dropwise of concentrated hydrochloric acid and diluted by the addition of water. The precipitated solid was collected by filtration and dried to obtain 8.88 g of 3-(6-iodo-2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)propanoic acid as a pale brown solid.
    • Preparation Example 427
  • To 3.421 g of ethyl 8-acetamide-6-bromo-7-(2-ethoxy-2-oxoethoxy)-1,2,4,5-tetrahydro-3H-benzazepine-3-carboxylate were added 30 ml of acetic acid and 30 ml of 8 M hydrochloric acid, followed by stirring at 150° C. for 16 hours. The reaction mixture was concentrated under reduced pressure, and the residue was dissolved in 35 ml of THF, and alkalified by the addition of 35 ml of a 1 M aqueous sodium hydroxide solution. 2 g of di-t-butyl dicarbonate was added thereto, followed by stirring at room temperature for 1 hour. The reaction mixture was extracted with ethyl acetate, the organic layer was dried over anhydrous magnesium sulfate and then filtered, and the filtrate was concentrated under reduced pressure to obtain 1.373 g of t-butyl 11-bromo-3-oxo-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]bensazepine-8(2H)-carboxylate.
    • Preparation Example 495
  • To a solution of 590 mg of t-butyl 4-benzyl-3-oxo-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]bensazepine-8(2H)-carboxylate in 10 ml of tetrahydrofuran was added 3.5 ml of a 1 M solution of a borane-THF complex in THF under ice-cooling, followed by stirring at room temperature for 14 hours. The reaction mixture was cooled, and MeOH and a 1 M aqueous sodium hydroxide solution were added thereto, followed by stirring at room temperature for 3 hours. The reaction mixture was concentrated, to the residue were added ethyl acetate and water, and the organic layer was washed with saturated brine and dried over anhydrous sodium sulfate. The solvent was evaporated, and to a solution of 578 mg of the resulting residue in 10 ml of dichloromethane was added 620 mg of sodium hydrogen carbonate. Further, a solution of 280 mg of bromine in 5 ml of dichloromethane was added dropwise thereto over about 30 minutes, followed by stirring at room temperature. To the reaction mixture was slowly added a 3% aqueous sodium thiosulfate solution, followed by stirring vigorously and extracting with chloroform twice. The combined organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and then filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 518 mg of t-butyl 4-benzyl-5-bromo-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepine-8(2H)-carboxylate.
    • Preparation Example 540
  • To a solution of 1.10 g of 2,4,5-trifluorobenzonitrile and 500 mg of t-butyl 5-cyclopropyl-4-(2-hydroxyethyl)-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]bensazepine-8(2H)-carboxylate in 15 ml of THF was added portionwise 150 mg of potassium t-butoxide, followed by stirring at −30° C. for 2 hours. Further, to the reaction mixture was added 0.15 ml of MeOH and then 150 mg of potassium t-butoxide was added portionwise thereto, followed by elevating the temperature to −10° C. and stirring for 15 hours. Further, to the reaction mixture were added 0.15 ml of MeOH, and then 150 mg of potassium t-butoxide was added portionwise thereto, followed by elevating the temperature to 0° C. and stirring for additional 14 hours. The reaction mixture was diluted with ethyl acetate, washed with water and saturated brine, dried over anhydrous magnesium sulfate, and then filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc)) to obtain 726 mg of t-butyl 4-[2-(4-cyano-2-fluoro-5-methoxyphenyl)ethyl]-5-cyclopropyl-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]bensazepine-8(2H)-carboxylate as a colorless viscous substance.
    • Preparation Example 543
  • To a solution of 270 mg of t-butyl 5-cyclopropyl-4-[2-(2,6-difluoro-4-formylphenoxy)ethyl]-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]bensazepine-8(2H)-carboxylate in 6 ml of MeOH was added 30 mg of sodium borohydride, followed by stirring at room temperature for 4 hours. The reaction mixture was concentrated under reduced pressure and the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc)) to obtain 220 mg of t-butyl 5-cyclopropyl-4-{2-[2,6-difluoro-4-(hydroxymethyl)phenoxy]ethyl}-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]bensazepine-8(2H)-carboxylate as a white solid.
    • Preparation Example 545
  • To a solution of 400 mg of t-butyl 5-cyclopropyl-4-(2-hydroxyethyl)-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]bensazepine-8(2H)-carboxylate in 4 ml of dichloromethane were added 217 mg of p-toluenesulfonyl chloride, 0.22 ml of triethylamine, and 125 μl of N-methylimidazole in this order, followed by stirring for 1 hour. The reaction mixture was concentrated under reduced pressure and the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 541 mg of t-butyl 5-cyclopropyl-4-(2-{[(4-methylphenyl)sulfonyl]oxy}ethyl)-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]bensazepine-8(2H)-carboxylate as a white solid.
    • Preparation Example 549
  • To 400 mg of t-butyl 5-cyclopropyl-4-[(2R)-2-methoxy-3-{[(4-methylphenyl)sulfonyl]oxy}propyl]-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]bensazepine-8(2H)-carboxylate was added 7 ml of a 1 M solution of t-butylammonium fluoride in THF, followed by heating and stirring at 60° C. for 13 hours under an argon atmosphere. The reaction mixture was cooled to room temperature and a saturated aqueous sodium hydrogen carbonate solution was added thereto, followed by extraction with ethyl acetate twice. The combined organic layer was dried over anhydrous sodium sulfate and then filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 257 mg of t-butyl 5-cyclopropyl-4-[(2R)-3-fluoro-2-methoxypropyl]-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepine-8(2H)-carboxylate as a white foamed solid.
    • Preparation Example 565
  • To a solution of 300 mg of t-butyl 5-cyclopropyl-4-(2-hydroxy-3-methoxypropyl)-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]bensazepine-8(2H)-carboxylate in 3 ml of toluene were added 0.1 ml of o-fluorophenol and 250 mg of cyanomethylenetributylphosphorane, followed by stirring at 80° C. for 20 hours. The reaction mixture was concentrated under reduced pressure and the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 277 mg of t-butyl 5-cyclopropyl-4-[2-(2-fluorophenoxy)-3-methoxypropyl]-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]bensazepine-8(2H)-carboxylate as a pale yellow viscous substance.
  • In the same manner as in the methods of Preparation Examples above, the compounds of Preparation Examples as shown in the Tables below were prepared. For the compounds of the Preparation Examples, the structures are shown in Tables 2 to 81 and the preparation methods and the physicochemical data are shown in Tables 82 to 96.
    • Example 1
  • To 1.865 g of ethyl 1-methyl-2-oxo-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate were added 20 mL of ethylene glycol and 20 mL of a 40% aqueous potassium hydroxide solution, followed by heating to 120° C. for 18 hours. The reaction mixture was ice-cooled and adjusted to pH 1 by the addition of concentrated hydrochloric acid, followed by stirring for 1 hour. The reaction mixture was alkalified by the addition of a 1 M aqueous sodium hydroxide solution, followed by extraction with chloroform. The organic layer was dried over anhydrous sodium sulfate and then filtered. The filtrate was concentrated under reduced pressure to obtain 1.451 g of 11-chloro-1,3,4,6,7,8,9,10-octahydro-2H-azepino[4,5-g]quinolin-2-one as a brown solid. To 60 mg of 11-chloro-1,3,4,6,7,8,9,10-octahydro-2H-azepino[4,5-g]quinolin-2-one were added 1 ml of EtOAc and then EtOH, followed by dissolution under heating. The precipitated solid was collected by filtration to obtain 29.5 mg of 11-chloro-1,3,4,6,7,8,9,10-octahydro-2H-azepino[4,5-g]quinolin-2-one as a white solid.
    • Example 2
  • To 47 mg of t-butyl 11-chloro-1-isobutyl-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate was added 1 ml of a 4 M hydrogen chloride solution in EtOAc, followed by stirring at room temperature for 3 hours. The reaction mixture was concentrated under reduced pressure and the residue was purified by silica gel chromatography (elution solvent: chloroform-MeOH). 26 mg of the resulting pale yellow viscous substance was dissolved in EtOH, followed by addition of 10.3 mg of fumaric acid and stirring. The precipitated solid was collected by filtration to obtain 23.2 mg of 11-chloro-1-isobutyl-2,3,4,6,7,8,9,10-octahydro-1H-azepino[4,5-g]quinoline monofumarate as a white solid.
    • Example 3
  • To a solution of 200 mg of t-butyl 2-oxo-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate in 2 ml of THF was added 1.9 ml of a 1 M solution of a borane-THF complex in THF under ice-cooling, followed by elevating the temperature to room temperature and stirring for 6 hours, and then elevating the temperature to 45° C. After stirring for 3 hours, 1.9 ml of a 1 M solution of a borane-THF complex in THF was added thereto in an ice-bath. After an additional 2 hours, MeOH was added dropwise thereto, followed by stirring for 20 minutes. The mixed solution was diluted with water, followed by extraction with chloroform. The organic layer was dried over anhydrous sodium sulfate and then filtered, and the filtrate was concentrated under reduced pressure. The residue was dissolved in 1.6 ml of dichloromethane, and 0.4 ml of trifluoroacetic acid was added thereto, followed by stirring at room temperature for 1 hour and then concentrating under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc), and the resulting solid was dissolved in 0.25 ml of hot EtOH, followed by addition of 21 mg of fumaric acid. While stirring, the resultant was cooled to room temperature and the precipitated solid was filtered to obtain 36 mg of 2,3,4,6,7,8,9,10-octahydro-1H-azepino[4,5-g]quinoline monofumarate as a pale yellow solid.
    • Example 4
  • To 150 mg of ethyl 1-methyl-2-oxo-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate were added 4 ml of ethylene glycol and 2 ml of a 40% aqueous potassium hydroxide solution, followed by heating at 120° C. and stirring for 18 hours. The reaction mixture was ice-cooled and the liquid was made acidic by the addition of concentrated hydrochloric acid, followed by stirring for an additional 1 hour. The reaction mixture was neutralized with a 1 M aqueous sodium hydroxide solution and then extracted with chloroform, the organic layer was dried over anhydrous sodium sulfate and then filtered, and the filtrate was concentrated under reduced pressure. Then, the residue was purified by silica gel chromatography (elution solvent: chloroform-MeOH-aqueous ammonia). To a solution of the resulting residue in 2 ml of EtOAc was added 0.2 ml of a 4 M hydrogen chloride solution in EtOAc, followed by stirring. The solvent was concentrated under reduced pressure and the resulting solid was dissolved in 2 ml of EtOH under heating, followed by stirring at room temperature. The precipitated solid was collected by filtration to obtain 43.7 mg of 1-methyl-1,3,4,6,7,8,9,10-octahydro-2H-azepino[4,5-g]quinolin-2-one monohydrochloride as a pale yellow solid.
    • Example 5
  • To a solution of 140 mg of t-butyl 11-cyclopropyl-1-(methoxyacetyl)-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate in 1 ml of EtOH was added 2 ml of 4 M hydrogen chloride solution in EtOAc, followed by stirring at room temperature for 3 hours. The reaction mixture was poured into a 1 M aqueous sodium hydroxide solution, the aqueous layer was extracted with chloroform, and the organic layer was dried over sodium sulfate. The solvent was concentrated under reduced pressure and the resulting residue was purified by silica gel chromatography (elution solvent: chloroform-MeOH-aqueous ammonia) to obtain 102 mg of 11-cyclopropyl-1-(methoxyacetyl)-2,3,4,6,7,8,9,10-octahydro-8H-azepino[4,5-g]quinoline as a pale yellow oily substance.
    • Example 6
  • To a solution of 200 mg of t-butyl 1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate in 2.13 ml of dichloroethane were added 0.553 ml of triethylamine and 0.19 ml of ethyl chloroformate, followed by stirring at 60° C. for 2 hours. The reaction mixture was cooled to room temperature, and then the reaction mixture was diluted with EtOAc, washed with 1 M hydrochloric acid, water, a 1 M aqueous sodium hydroxide solution, and saturated brine, and concentrated, and the residue was purified by silica gel column chromatography (elution solvent: HEX-EtOAc). The resulting substance was dissolved in chloroform, followed by adding 0.005 ml of trifluoroacetic acid and stirring for 30 minutes. After concentration under reduced pressure, the resultant was dissolved in EtOH, neutralized by the addition of triethylamine, and then concentrated under reduced pressure. Then, the residue was purified by silica gel column chromatography (elution solvent: chloroform-MeOH-aqueous ammonia). The resulting substance was dissolved in EtOH and 76 mg of fumaric acid was added thereto. The resulting white solid was collected by filtration and dried to obtain 79 mg of ethyl 2,3,4,6,7,8,9,10-octahydro-1H-azepino[4.5-g]quinoline-1-carboxylate hemifumarate.
    • Example 7
  • To a solution of 300 mg of t-butyl 1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate in 5.26 ml of pyridine was added 0.455 ml of N,N-dimethylcarbamoyl chloride, followed by stirring at 80° C. for 3 hours. To the reaction mixture was added 1 M hydrochloric acid, followed by extraction with EtOAc. The organic layer was washed with saturated brine and the solvent was evaporated. The resulting residue was purified by silica gel column chromatography (elution solvent: HEX-EtOAc). The resulting substance was dissolved in 6 ml of chloroform, followed by adding 3 ml of trifluoroacetic acid and stirring for 30 minutes. After concentration under reduced pressure, the resultant was dissolved in 4.5 ml of EtOH, neutralized by the addition of triethylamine, and then concentrated under reduced pressure. Then, the residue was purified by silica gel column chromatography (elution solvent: chloroform-MeOH-aqueous ammonia). The resulting substance was dissolved in 4.5 ml of EtOH and 115 mg of fumaric acid was added thereto. The resulting white solid was collected by filtration and dried to obtain 120 mg of N,N-dimethyl-2,3,4,6,7,8,9,10-octahydro-1H-azepino[4,5-g]quinoline-1-carboxamide fumarate.
    • Example 8
  • To a solution of 300 mg of t-butyl 1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate in 6 ml of toluene was added 1.16 ml of ethyl isocyanate, followed by stirring at 90° C. overnight. The reaction mixture was concentrated under reduced pressure and then purified by silica gel column chromatography (elution solvent: HEX-EtOAc). The resulting substance was dissolved in 7.5 ml of chloroform, followed by adding 3 ml of trifluoroacetic acid and stirring for 30 minutes. After concentration under reduced pressure, the resultant was dissolved in 4.5 ml of EtOH, neutralized by the addition of triethylamine, and then concentrated under reduced pressure. Then, the residue was purified by silica gel column chromatography (elution solvent: chloroform-MeOH-aqueous ammonia). The resulting substance was dissolved in EtOH and 115 mg of fumaric acid was added thereto. The resulting white solid was collected by filtration and dried to obtain 247 mg of N-ethyl-2,3,4,6,7,8,9,10-octahydro-1H-azepino[4,5-g]quinoline-1-carboxamide monofumarate.
    • Example 9
  • To a solution of 200 mg of t-butyl 1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate in 6 ml of dichloromethane were added 0.148 ml of triethylamine, 0.093 ml of ethanesulfonyl chloride, and 54 mg of 1-methylimidazole under ice-cooling, followed by stirring at room temperature overnight. To the reaction mixture were added EtOAc and saturated brine, and the organic layer was washed with saturated brine and then concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc). The resulting substance was dissolved in 4 ml of chloroform, followed by adding 2 ml of trifluoroacetic acid and stirring for 30 minutes. After concentration under reduced pressure, the resultant was dissolved in 4.5 ml of EtOH, neutralized by the addition of triethylamine, and then concentrated under reduced pressure. Then, the residue was purified by silica gel column chromatography (elution solvent: chloroform-MeOH-aqueous ammonia). The resulting substance was dissolved in EtOH and 76 mg of fumaric acid was added thereto. The resulting white solid was collected by filtration and dried to obtain 61 mg of 1-(ethylsulfonyl)-2,3,4,6,7,8,9,10-octahydro-1H-azepino[4,5-g]quinoline monofumarate.
    • Example 112
  • To a solution of 283 mg of t-butyl 4-(3-chlorobenzyl)-3-oxo-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]bensazepine-8(2H)-carboxylate in 1.8 ml of tetrahydrofuran was added 1.46 ml of a 1 M solution of a borane-THF complex in THF, followed by stirring at 50° C. for 4 hours. The reaction mixture was ice-cooled, and MeOH was added thereto, followed by stirring at room temperature for 30 minutes. The reaction mixture was concentrated under reduced pressure and MeOH was added thereto, followed by concentration again. The residue was dissolved in 2.8 ml of EtOH, and 1M hydrochloric acid was added thereto, followed by stirring overnight. After concentration under reduced pressure, the resultant was dissolved in EtOH, neutralized by the addition of obtain ethylamine, and concentrated under reduced pressure. Then, the residue was purified by silica gel column chromatography (elution solvent: CHCl3-MeOH). The resulting substance was dissolved in ethanol and fumaric acid was added thereto, followed by stirring for a while. The solid was generated, then dissolved by heating once, and stirred at room temperature for 3 hours. The resulting white solid was collected by filtration and dried to obtain 23 mg of 4-(3-chlorobenzyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]bensazepine fumarate.
    • Example 282
  • To a solution of 606 mg of t-butyl 11-bromo-1-(2-methoxyethyl)-10-methyl-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate in 6 ml of dichloromethane was added 3 ml of trifluoroacetic acid, followed by stirring at room temperature for 1 hour. The reaction mixture was concentrated under reduced pressure and the residue was purified by basic silica gel chromatography (elution solvent: CHCl3-MeOH). 150 mg of the resulting residue was collected by separation using DAICEL CHIRALPAK AD-H (2 cmΦ×25 cm) to obtain 51 mg of a low-polarity material and 45 mg of a high-polarity material. Each was dissolved in ethanol and fumaric acid was added thereto to form a salt. The precipitated solid was recrystallized from ethanol to obtain 42 mg and 36 mg of enantiomers of 11-bromo-1-(2-methoxyethyl)-10-methyl-2,3,4,6,7,8,9,10-octahydro-1H-azepino[4,5-g]quinoline fumarate as white solids, respectively.
  • In this regard, while the products are shown with a single planar structure in the Tables below with respect to the compounds of Example 282, and Example 280 and Example 281 in which preparation was performed as in Example 282, each of two kinds of enantiomers was isolated and obtained similarly as described above but the stereochemistry indentification was not carried out.
  • In the same manner as in the methods of Examples above, the compounds of Examples shown in the Tables below were prepared. The structure of the compounds of the Examples are shown in Tables 97 to 147 and the preparation methods and the physicochemical data are shown in Tables 148 to 181.
  • Furthermore, the structures of the other compounds of the present invention are shown in Tables 182 to 190. These can be easily synthesized by the methods described in the preparation methods and Examples above, methods apparent to a person skilled in the art, or modified methods thereof.
  • TABLE 2
    PEx Str
    1
    Figure US20130012496A1-20130110-C00017
    2
    Figure US20130012496A1-20130110-C00018
    3
    Figure US20130012496A1-20130110-C00019
    4
    Figure US20130012496A1-20130110-C00020
    5
    Figure US20130012496A1-20130110-C00021
    6
    Figure US20130012496A1-20130110-C00022
    7
    Figure US20130012496A1-20130110-C00023
    8
    Figure US20130012496A1-20130110-C00024
  • TABLE 3
    PEx Str
    9
    Figure US20130012496A1-20130110-C00025
    10
    Figure US20130012496A1-20130110-C00026
    11
    Figure US20130012496A1-20130110-C00027
    12
    Figure US20130012496A1-20130110-C00028
    13
    Figure US20130012496A1-20130110-C00029
    14
    Figure US20130012496A1-20130110-C00030
    15
    Figure US20130012496A1-20130110-C00031
    16
    Figure US20130012496A1-20130110-C00032
    17
    Figure US20130012496A1-20130110-C00033
  • TABLE 4
    PEx Str
    18
    Figure US20130012496A1-20130110-C00034
    19
    Figure US20130012496A1-20130110-C00035
    20
    Figure US20130012496A1-20130110-C00036
    21
    Figure US20130012496A1-20130110-C00037
    22
    Figure US20130012496A1-20130110-C00038
    23
    Figure US20130012496A1-20130110-C00039
    24
    Figure US20130012496A1-20130110-C00040
    25
    Figure US20130012496A1-20130110-C00041
  • TABLE 5
    PEx Str
    26
    Figure US20130012496A1-20130110-C00042
    27
    Figure US20130012496A1-20130110-C00043
    28
    Figure US20130012496A1-20130110-C00044
    29
    Figure US20130012496A1-20130110-C00045
    30
    Figure US20130012496A1-20130110-C00046
    31
    Figure US20130012496A1-20130110-C00047
    32
    Figure US20130012496A1-20130110-C00048
    33
    Figure US20130012496A1-20130110-C00049
  • TABLE 6
    PEx Str
    34
    Figure US20130012496A1-20130110-C00050
    35
    Figure US20130012496A1-20130110-C00051
    36
    Figure US20130012496A1-20130110-C00052
    37
    Figure US20130012496A1-20130110-C00053
    38
    Figure US20130012496A1-20130110-C00054
    39
    Figure US20130012496A1-20130110-C00055
    40
    Figure US20130012496A1-20130110-C00056
    41
    Figure US20130012496A1-20130110-C00057
  • TABLE 7
    PEx Str
    42
    Figure US20130012496A1-20130110-C00058
    43
    Figure US20130012496A1-20130110-C00059
    44
    Figure US20130012496A1-20130110-C00060
    45
    Figure US20130012496A1-20130110-C00061
    46
    Figure US20130012496A1-20130110-C00062
    47
    Figure US20130012496A1-20130110-C00063
    48
    Figure US20130012496A1-20130110-C00064
    49
    Figure US20130012496A1-20130110-C00065
    50
    Figure US20130012496A1-20130110-C00066
    51
    Figure US20130012496A1-20130110-C00067
  • TABLE 8
    PEx Str
    52
    Figure US20130012496A1-20130110-C00068
    53
    Figure US20130012496A1-20130110-C00069
    54
    Figure US20130012496A1-20130110-C00070
    55
    Figure US20130012496A1-20130110-C00071
    56
    Figure US20130012496A1-20130110-C00072
    57
    Figure US20130012496A1-20130110-C00073
    58
    Figure US20130012496A1-20130110-C00074
    59
    Figure US20130012496A1-20130110-C00075
    60
    Figure US20130012496A1-20130110-C00076
  • TABLE 9
    PEx Str
    61
    Figure US20130012496A1-20130110-C00077
    62
    Figure US20130012496A1-20130110-C00078
    63
    Figure US20130012496A1-20130110-C00079
    64
    Figure US20130012496A1-20130110-C00080
    65
    Figure US20130012496A1-20130110-C00081
    66
    Figure US20130012496A1-20130110-C00082
    67
    Figure US20130012496A1-20130110-C00083
    68
    Figure US20130012496A1-20130110-C00084
    69
    Figure US20130012496A1-20130110-C00085
  • TABLE 10
    PEx Str
    70
    Figure US20130012496A1-20130110-C00086
    71
    Figure US20130012496A1-20130110-C00087
    72
    Figure US20130012496A1-20130110-C00088
    73
    Figure US20130012496A1-20130110-C00089
    74
    Figure US20130012496A1-20130110-C00090
    75
    Figure US20130012496A1-20130110-C00091
    76
    Figure US20130012496A1-20130110-C00092
    77
    Figure US20130012496A1-20130110-C00093
    78
    Figure US20130012496A1-20130110-C00094
  • TABLE 11
    PEx Str
    79
    Figure US20130012496A1-20130110-C00095
    80
    Figure US20130012496A1-20130110-C00096
    81
    Figure US20130012496A1-20130110-C00097
    82
    Figure US20130012496A1-20130110-C00098
    83
    Figure US20130012496A1-20130110-C00099
    84
    Figure US20130012496A1-20130110-C00100
    85
    Figure US20130012496A1-20130110-C00101
    86
    Figure US20130012496A1-20130110-C00102
  • TABLE 12
    PEx Str
    87
    Figure US20130012496A1-20130110-C00103
    88
    Figure US20130012496A1-20130110-C00104
    89
    Figure US20130012496A1-20130110-C00105
    90
    Figure US20130012496A1-20130110-C00106
    91
    Figure US20130012496A1-20130110-C00107
    92
    Figure US20130012496A1-20130110-C00108
    93
    Figure US20130012496A1-20130110-C00109
    94
    Figure US20130012496A1-20130110-C00110
  • TABLE 13
    PEx Str
    95
    Figure US20130012496A1-20130110-C00111
    96
    Figure US20130012496A1-20130110-C00112
    97
    Figure US20130012496A1-20130110-C00113
    98
    Figure US20130012496A1-20130110-C00114
    99
    Figure US20130012496A1-20130110-C00115
    100 
    Figure US20130012496A1-20130110-C00116
    101 
    Figure US20130012496A1-20130110-C00117
    102 
    Figure US20130012496A1-20130110-C00118
  • TABLE 14
    PEx Str
    103
    Figure US20130012496A1-20130110-C00119
    104
    Figure US20130012496A1-20130110-C00120
    105
    Figure US20130012496A1-20130110-C00121
    106
    Figure US20130012496A1-20130110-C00122
    107
    Figure US20130012496A1-20130110-C00123
    108
    Figure US20130012496A1-20130110-C00124
    109
    Figure US20130012496A1-20130110-C00125
  • TABLE 15
    PEx Str
    110
    Figure US20130012496A1-20130110-C00126
    111
    Figure US20130012496A1-20130110-C00127
    112
    Figure US20130012496A1-20130110-C00128
    113
    Figure US20130012496A1-20130110-C00129
    114
    Figure US20130012496A1-20130110-C00130
    115
    Figure US20130012496A1-20130110-C00131
  • TABLE 16
    PEx Str
    116
    Figure US20130012496A1-20130110-C00132
    117
    Figure US20130012496A1-20130110-C00133
    118
    Figure US20130012496A1-20130110-C00134
    119
    Figure US20130012496A1-20130110-C00135
    120
    Figure US20130012496A1-20130110-C00136
    121
    Figure US20130012496A1-20130110-C00137
  • TABLE 17
    PEx Str
    122
    Figure US20130012496A1-20130110-C00138
    123
    Figure US20130012496A1-20130110-C00139
    124
    Figure US20130012496A1-20130110-C00140
    125
    Figure US20130012496A1-20130110-C00141
    126
    Figure US20130012496A1-20130110-C00142
    127
    Figure US20130012496A1-20130110-C00143
    128
    Figure US20130012496A1-20130110-C00144
    129
    Figure US20130012496A1-20130110-C00145
  • TABLE 18
    PEx Str
    130
    Figure US20130012496A1-20130110-C00146
    131
    Figure US20130012496A1-20130110-C00147
    132
    Figure US20130012496A1-20130110-C00148
    133
    Figure US20130012496A1-20130110-C00149
    134
    Figure US20130012496A1-20130110-C00150
    135
    Figure US20130012496A1-20130110-C00151
    136
    Figure US20130012496A1-20130110-C00152
  • TABLE 19
    PEx Str
    137
    Figure US20130012496A1-20130110-C00153
    138
    Figure US20130012496A1-20130110-C00154
    139
    Figure US20130012496A1-20130110-C00155
    140
    Figure US20130012496A1-20130110-C00156
    143
    Figure US20130012496A1-20130110-C00157
  • TABLE 20
    PEx Str
    144
    Figure US20130012496A1-20130110-C00158
    145
    Figure US20130012496A1-20130110-C00159
    146
    Figure US20130012496A1-20130110-C00160
    149
    Figure US20130012496A1-20130110-C00161
    150
    Figure US20130012496A1-20130110-C00162
    151
    Figure US20130012496A1-20130110-C00163
  • TABLE 21
    PEx Str
    152
    Figure US20130012496A1-20130110-C00164
    153
    Figure US20130012496A1-20130110-C00165
    154
    Figure US20130012496A1-20130110-C00166
    155
    Figure US20130012496A1-20130110-C00167
    156
    Figure US20130012496A1-20130110-C00168
    157
    Figure US20130012496A1-20130110-C00169
    158
    Figure US20130012496A1-20130110-C00170
  • TABLE 22
    PEx Str
    159
    Figure US20130012496A1-20130110-C00171
    160
    Figure US20130012496A1-20130110-C00172
    161
    Figure US20130012496A1-20130110-C00173
    162
    Figure US20130012496A1-20130110-C00174
    163
    Figure US20130012496A1-20130110-C00175
    164
    Figure US20130012496A1-20130110-C00176
    165
    Figure US20130012496A1-20130110-C00177
  • TABLE 23
    PEx Str
    166
    Figure US20130012496A1-20130110-C00178
    167
    Figure US20130012496A1-20130110-C00179
    168
    Figure US20130012496A1-20130110-C00180
    169
    Figure US20130012496A1-20130110-C00181
    170
    Figure US20130012496A1-20130110-C00182
    171
    Figure US20130012496A1-20130110-C00183
    172
    Figure US20130012496A1-20130110-C00184
    173
    Figure US20130012496A1-20130110-C00185
  • TABLE 24
    PEx Str
    175
    Figure US20130012496A1-20130110-C00186
    176
    Figure US20130012496A1-20130110-C00187
    177
    Figure US20130012496A1-20130110-C00188
    178
    Figure US20130012496A1-20130110-C00189
    179
    Figure US20130012496A1-20130110-C00190
    180
    Figure US20130012496A1-20130110-C00191
    181
    Figure US20130012496A1-20130110-C00192
  • TABLE 25
    PEx Str
    182
    Figure US20130012496A1-20130110-C00193
    183
    Figure US20130012496A1-20130110-C00194
    184
    Figure US20130012496A1-20130110-C00195
    185
    Figure US20130012496A1-20130110-C00196
    186
    Figure US20130012496A1-20130110-C00197
    187
    Figure US20130012496A1-20130110-C00198
    188
    Figure US20130012496A1-20130110-C00199
    189
    Figure US20130012496A1-20130110-C00200
  • TABLE 26
    PEx Str
    190
    Figure US20130012496A1-20130110-C00201
    192
    Figure US20130012496A1-20130110-C00202
    193
    Figure US20130012496A1-20130110-C00203
    195
    Figure US20130012496A1-20130110-C00204
    196
    Figure US20130012496A1-20130110-C00205
    197
    Figure US20130012496A1-20130110-C00206
  • TABLE 27
    PEx Str
    198
    Figure US20130012496A1-20130110-C00207
    199
    Figure US20130012496A1-20130110-C00208
    200
    Figure US20130012496A1-20130110-C00209
    201
    Figure US20130012496A1-20130110-C00210
    202
    Figure US20130012496A1-20130110-C00211
    203
    Figure US20130012496A1-20130110-C00212
    204
    Figure US20130012496A1-20130110-C00213
  • TABLE 28
    PEx Str
    205
    Figure US20130012496A1-20130110-C00214
    206
    Figure US20130012496A1-20130110-C00215
    207
    Figure US20130012496A1-20130110-C00216
    208
    Figure US20130012496A1-20130110-C00217
    209
    Figure US20130012496A1-20130110-C00218
    210
    Figure US20130012496A1-20130110-C00219
    211
    Figure US20130012496A1-20130110-C00220
  • TABLE 29
    PEx Str
    212
    Figure US20130012496A1-20130110-C00221
    213
    Figure US20130012496A1-20130110-C00222
    214
    Figure US20130012496A1-20130110-C00223
    215
    Figure US20130012496A1-20130110-C00224
    216
    Figure US20130012496A1-20130110-C00225
    217
    Figure US20130012496A1-20130110-C00226
  • TABLE 30
    PEx Str
    218
    Figure US20130012496A1-20130110-C00227
    219
    Figure US20130012496A1-20130110-C00228
    220
    Figure US20130012496A1-20130110-C00229
    221
    Figure US20130012496A1-20130110-C00230
    222
    Figure US20130012496A1-20130110-C00231
    223
    Figure US20130012496A1-20130110-C00232
  • TABLE 31
    PEx Str
    224
    Figure US20130012496A1-20130110-C00233
    225
    Figure US20130012496A1-20130110-C00234
    226
    Figure US20130012496A1-20130110-C00235
    227
    Figure US20130012496A1-20130110-C00236
    228
    Figure US20130012496A1-20130110-C00237
    229
    Figure US20130012496A1-20130110-C00238
    230
    Figure US20130012496A1-20130110-C00239
  • TABLE 32
    PEx Str
    231
    Figure US20130012496A1-20130110-C00240
    232
    Figure US20130012496A1-20130110-C00241
    233
    Figure US20130012496A1-20130110-C00242
    234
    Figure US20130012496A1-20130110-C00243
    235
    Figure US20130012496A1-20130110-C00244
    236
    Figure US20130012496A1-20130110-C00245
    237
    Figure US20130012496A1-20130110-C00246
  • TABLE 22
    PEx Str
    238
    Figure US20130012496A1-20130110-C00247
    239
    Figure US20130012496A1-20130110-C00248
    240
    Figure US20130012496A1-20130110-C00249
    241
    Figure US20130012496A1-20130110-C00250
    242
    Figure US20130012496A1-20130110-C00251
    243
    Figure US20130012496A1-20130110-C00252
    244
    Figure US20130012496A1-20130110-C00253
  • TABLE 34
    PEx Str
    245
    Figure US20130012496A1-20130110-C00254
    246
    Figure US20130012496A1-20130110-C00255
    247
    Figure US20130012496A1-20130110-C00256
    248
    Figure US20130012496A1-20130110-C00257
    249
    Figure US20130012496A1-20130110-C00258
    250
    Figure US20130012496A1-20130110-C00259
  • TABLE 35
    PEx Str
    251
    Figure US20130012496A1-20130110-C00260
    252
    Figure US20130012496A1-20130110-C00261
    253
    Figure US20130012496A1-20130110-C00262
    254
    Figure US20130012496A1-20130110-C00263
    255
    Figure US20130012496A1-20130110-C00264
    256
    Figure US20130012496A1-20130110-C00265
    257
    Figure US20130012496A1-20130110-C00266
  • TABLE 36
    PEx Str
    258
    Figure US20130012496A1-20130110-C00267
    259
    Figure US20130012496A1-20130110-C00268
    260
    Figure US20130012496A1-20130110-C00269
    261
    Figure US20130012496A1-20130110-C00270
    262
    Figure US20130012496A1-20130110-C00271
    263
    Figure US20130012496A1-20130110-C00272
    264
    Figure US20130012496A1-20130110-C00273
  • TABLE 37
    PEx Str
    265
    Figure US20130012496A1-20130110-C00274
    266
    Figure US20130012496A1-20130110-C00275
    267
    Figure US20130012496A1-20130110-C00276
    268
    Figure US20130012496A1-20130110-C00277
    269
    Figure US20130012496A1-20130110-C00278
    270
    Figure US20130012496A1-20130110-C00279
    271
    Figure US20130012496A1-20130110-C00280
  • TABLE 38
    PEx Str
    272
    Figure US20130012496A1-20130110-C00281
    273
    Figure US20130012496A1-20130110-C00282
    274
    Figure US20130012496A1-20130110-C00283
    275
    Figure US20130012496A1-20130110-C00284
    276
    Figure US20130012496A1-20130110-C00285
    277
    Figure US20130012496A1-20130110-C00286
  • TABLE 39
    PEx Str
    278
    Figure US20130012496A1-20130110-C00287
    279
    Figure US20130012496A1-20130110-C00288
    280
    Figure US20130012496A1-20130110-C00289
    281
    Figure US20130012496A1-20130110-C00290
    282
    Figure US20130012496A1-20130110-C00291
    283
    Figure US20130012496A1-20130110-C00292
  • TABLE 40
    PEx Str
    284
    Figure US20130012496A1-20130110-C00293
    285
    Figure US20130012496A1-20130110-C00294
    286
    Figure US20130012496A1-20130110-C00295
    287
    Figure US20130012496A1-20130110-C00296
    288
    Figure US20130012496A1-20130110-C00297
    289
    Figure US20130012496A1-20130110-C00298
  • TABLE 41
    PEx Str
    290
    Figure US20130012496A1-20130110-C00299
    291
    Figure US20130012496A1-20130110-C00300
    292
    Figure US20130012496A1-20130110-C00301
    293
    Figure US20130012496A1-20130110-C00302
    294
    Figure US20130012496A1-20130110-C00303
    295
    Figure US20130012496A1-20130110-C00304
    296
    Figure US20130012496A1-20130110-C00305
    297
    Figure US20130012496A1-20130110-C00306
  • TABLE 42
    PEx Str
    298
    Figure US20130012496A1-20130110-C00307
    299
    Figure US20130012496A1-20130110-C00308
    300
    Figure US20130012496A1-20130110-C00309
    301
    Figure US20130012496A1-20130110-C00310
    302
    Figure US20130012496A1-20130110-C00311
    303
    Figure US20130012496A1-20130110-C00312
  • TABLE 43
    PEx Str
    304
    Figure US20130012496A1-20130110-C00313
    305
    Figure US20130012496A1-20130110-C00314
    306
    Figure US20130012496A1-20130110-C00315
    307
    Figure US20130012496A1-20130110-C00316
    308
    Figure US20130012496A1-20130110-C00317
    309
    Figure US20130012496A1-20130110-C00318
    310
    Figure US20130012496A1-20130110-C00319
  • TABLE 44
    PEx Str
    311
    Figure US20130012496A1-20130110-C00320
    312
    Figure US20130012496A1-20130110-C00321
    313
    Figure US20130012496A1-20130110-C00322
    314
    Figure US20130012496A1-20130110-C00323
    315
    Figure US20130012496A1-20130110-C00324
    316
    Figure US20130012496A1-20130110-C00325
  • TABLE 45
    PEx Str
    317
    Figure US20130012496A1-20130110-C00326
    318
    Figure US20130012496A1-20130110-C00327
    319
    Figure US20130012496A1-20130110-C00328
    320
    Figure US20130012496A1-20130110-C00329
    321
    Figure US20130012496A1-20130110-C00330
    322
    Figure US20130012496A1-20130110-C00331
    323
    Figure US20130012496A1-20130110-C00332
  • TABLE 46
    PEx Str
    324
    Figure US20130012496A1-20130110-C00333
    325
    Figure US20130012496A1-20130110-C00334
    326
    Figure US20130012496A1-20130110-C00335
    327
    Figure US20130012496A1-20130110-C00336
    328
    Figure US20130012496A1-20130110-C00337
    329
    Figure US20130012496A1-20130110-C00338
    330
    Figure US20130012496A1-20130110-C00339
  • TABLE 47
    PEx Str
    331
    Figure US20130012496A1-20130110-C00340
    332
    Figure US20130012496A1-20130110-C00341
    333
    Figure US20130012496A1-20130110-C00342
    334
    Figure US20130012496A1-20130110-C00343
    335
    Figure US20130012496A1-20130110-C00344
    336
    Figure US20130012496A1-20130110-C00345
    337
    Figure US20130012496A1-20130110-C00346
  • TABLE 48
    PEx Str
    338
    Figure US20130012496A1-20130110-C00347
    339
    Figure US20130012496A1-20130110-C00348
    340
    Figure US20130012496A1-20130110-C00349
    341
    Figure US20130012496A1-20130110-C00350
    342
    Figure US20130012496A1-20130110-C00351
    343
    Figure US20130012496A1-20130110-C00352
    344
    Figure US20130012496A1-20130110-C00353
    345
    Figure US20130012496A1-20130110-C00354
  • TABLE 49
    PEx Str
    346
    Figure US20130012496A1-20130110-C00355
    347
    Figure US20130012496A1-20130110-C00356
    348
    Figure US20130012496A1-20130110-C00357
    349
    Figure US20130012496A1-20130110-C00358
    350
    Figure US20130012496A1-20130110-C00359
    351
    Figure US20130012496A1-20130110-C00360
    352
    Figure US20130012496A1-20130110-C00361
    353
    Figure US20130012496A1-20130110-C00362
  • TABLE 50
    PEx Str
    354
    Figure US20130012496A1-20130110-C00363
    355
    Figure US20130012496A1-20130110-C00364
    356
    Figure US20130012496A1-20130110-C00365
    357
    Figure US20130012496A1-20130110-C00366
    358
    Figure US20130012496A1-20130110-C00367
    359
    Figure US20130012496A1-20130110-C00368
    360
    Figure US20130012496A1-20130110-C00369
    361
    Figure US20130012496A1-20130110-C00370
  • TABLE 51
    PEx Str
    362
    Figure US20130012496A1-20130110-C00371
    363
    Figure US20130012496A1-20130110-C00372
    364
    Figure US20130012496A1-20130110-C00373
    365
    Figure US20130012496A1-20130110-C00374
    366
    Figure US20130012496A1-20130110-C00375
    367
    Figure US20130012496A1-20130110-C00376
    368
    Figure US20130012496A1-20130110-C00377
    369
    Figure US20130012496A1-20130110-C00378
  • TABLE 52
    PEx Str
      370
    Figure US20130012496A1-20130110-C00379
    371
    Figure US20130012496A1-20130110-C00380
    372
    Figure US20130012496A1-20130110-C00381
    373
    Figure US20130012496A1-20130110-C00382
    374
    Figure US20130012496A1-20130110-C00383
    375
    Figure US20130012496A1-20130110-C00384
    376
    Figure US20130012496A1-20130110-C00385
    377
    Figure US20130012496A1-20130110-C00386
  • TABLE 53
    PEx Str
      378
    Figure US20130012496A1-20130110-C00387
    379
    Figure US20130012496A1-20130110-C00388
    380
    Figure US20130012496A1-20130110-C00389
    381
    Figure US20130012496A1-20130110-C00390
    382
    Figure US20130012496A1-20130110-C00391
    383
    Figure US20130012496A1-20130110-C00392
    384
    Figure US20130012496A1-20130110-C00393
    385
    Figure US20130012496A1-20130110-C00394
    386
    Figure US20130012496A1-20130110-C00395
  • TABLE 54
    PEx Str
      387
    Figure US20130012496A1-20130110-C00396
    388
    Figure US20130012496A1-20130110-C00397
    389
    Figure US20130012496A1-20130110-C00398
    390
    Figure US20130012496A1-20130110-C00399
    391
    Figure US20130012496A1-20130110-C00400
    392
    Figure US20130012496A1-20130110-C00401
    393
    Figure US20130012496A1-20130110-C00402
  • TABLE 55
    PEx Str
      394
    Figure US20130012496A1-20130110-C00403
    395
    Figure US20130012496A1-20130110-C00404
    396
    Figure US20130012496A1-20130110-C00405
    397
    Figure US20130012496A1-20130110-C00406
    398
    Figure US20130012496A1-20130110-C00407
    399
    Figure US20130012496A1-20130110-C00408
    400
    Figure US20130012496A1-20130110-C00409
    401
    Figure US20130012496A1-20130110-C00410
  • TABLE 56
    PEx Str
      402
    Figure US20130012496A1-20130110-C00411
    403
    Figure US20130012496A1-20130110-C00412
    404
    Figure US20130012496A1-20130110-C00413
    405
    Figure US20130012496A1-20130110-C00414
    406
    Figure US20130012496A1-20130110-C00415
    407
    Figure US20130012496A1-20130110-C00416
    408
    Figure US20130012496A1-20130110-C00417
  • TABLE 57
    PEx Str
    409
    Figure US20130012496A1-20130110-C00418
    410
    Figure US20130012496A1-20130110-C00419
    411
    Figure US20130012496A1-20130110-C00420
    412
    Figure US20130012496A1-20130110-C00421
    413
    Figure US20130012496A1-20130110-C00422
    414
    Figure US20130012496A1-20130110-C00423
    415
    Figure US20130012496A1-20130110-C00424
    416
    Figure US20130012496A1-20130110-C00425
  • TABLE 58
    PEx Str
      417
    Figure US20130012496A1-20130110-C00426
    418
    Figure US20130012496A1-20130110-C00427
    419
    Figure US20130012496A1-20130110-C00428
    420
    Figure US20130012496A1-20130110-C00429
    421
    Figure US20130012496A1-20130110-C00430
    422
    Figure US20130012496A1-20130110-C00431
    423
    Figure US20130012496A1-20130110-C00432
  • TABLE 59
    PEx Str
      424
    Figure US20130012496A1-20130110-C00433
    425
    Figure US20130012496A1-20130110-C00434
    426
    Figure US20130012496A1-20130110-C00435
    427
    Figure US20130012496A1-20130110-C00436
    428
    Figure US20130012496A1-20130110-C00437
    429
    Figure US20130012496A1-20130110-C00438
    430
    Figure US20130012496A1-20130110-C00439
    431
    Figure US20130012496A1-20130110-C00440
  • TABLE 60
    PEx Str
      432
    Figure US20130012496A1-20130110-C00441
    433
    Figure US20130012496A1-20130110-C00442
    434
    Figure US20130012496A1-20130110-C00443
    435
    Figure US20130012496A1-20130110-C00444
    436
    Figure US20130012496A1-20130110-C00445
    437
    Figure US20130012496A1-20130110-C00446
    438
    Figure US20130012496A1-20130110-C00447
    439
    Figure US20130012496A1-20130110-C00448
  • TABLE 61
    PEx Str
      440
    Figure US20130012496A1-20130110-C00449
    441
    Figure US20130012496A1-20130110-C00450
    442
    Figure US20130012496A1-20130110-C00451
    443
    Figure US20130012496A1-20130110-C00452
    444
    Figure US20130012496A1-20130110-C00453
    445
    Figure US20130012496A1-20130110-C00454
    446
    Figure US20130012496A1-20130110-C00455
  • TABLE 62
    PEx Str
      447
    Figure US20130012496A1-20130110-C00456
    448
    Figure US20130012496A1-20130110-C00457
    449
    Figure US20130012496A1-20130110-C00458
    450
    Figure US20130012496A1-20130110-C00459
    451
    Figure US20130012496A1-20130110-C00460
    452
    Figure US20130012496A1-20130110-C00461
    453
    Figure US20130012496A1-20130110-C00462
  • TABLE 63
    PEx Str
      454
    Figure US20130012496A1-20130110-C00463
    455
    Figure US20130012496A1-20130110-C00464
    456
    Figure US20130012496A1-20130110-C00465
    457
    Figure US20130012496A1-20130110-C00466
    458
    Figure US20130012496A1-20130110-C00467
    459
    Figure US20130012496A1-20130110-C00468
  • TABLE 64
    PEx Str
      460
    Figure US20130012496A1-20130110-C00469
    461
    Figure US20130012496A1-20130110-C00470
    462
    Figure US20130012496A1-20130110-C00471
    463
    Figure US20130012496A1-20130110-C00472
    464
    Figure US20130012496A1-20130110-C00473
    465
    Figure US20130012496A1-20130110-C00474
    466
    Figure US20130012496A1-20130110-C00475
    467
    Figure US20130012496A1-20130110-C00476
  • TABLE 65
    PEx Str
      468
    Figure US20130012496A1-20130110-C00477
    469
    Figure US20130012496A1-20130110-C00478
    470
    Figure US20130012496A1-20130110-C00479
    471
    Figure US20130012496A1-20130110-C00480
    472
    Figure US20130012496A1-20130110-C00481
    473
    Figure US20130012496A1-20130110-C00482
    474
    Figure US20130012496A1-20130110-C00483
  • TABLE 66
    PEx Str
      475
    Figure US20130012496A1-20130110-C00484
    476
    Figure US20130012496A1-20130110-C00485
    477
    Figure US20130012496A1-20130110-C00486
    478
    Figure US20130012496A1-20130110-C00487
    479
    Figure US20130012496A1-20130110-C00488
    480
    Figure US20130012496A1-20130110-C00489
    481
    Figure US20130012496A1-20130110-C00490
  • TABLE 67
    PEx Str
    482
    Figure US20130012496A1-20130110-C00491
    483
    Figure US20130012496A1-20130110-C00492
    484
    Figure US20130012496A1-20130110-C00493
    485
    Figure US20130012496A1-20130110-C00494
    486
    Figure US20130012496A1-20130110-C00495
    487
    Figure US20130012496A1-20130110-C00496
  • TABLE 68
    PEx Str
    488
    Figure US20130012496A1-20130110-C00497
    489
    Figure US20130012496A1-20130110-C00498
    490
    Figure US20130012496A1-20130110-C00499
    491
    Figure US20130012496A1-20130110-C00500
    492
    Figure US20130012496A1-20130110-C00501
    493
    Figure US20130012496A1-20130110-C00502
  • TABLE 69
    PEx Str
    494
    Figure US20130012496A1-20130110-C00503
    495
    Figure US20130012496A1-20130110-C00504
    496
    Figure US20130012496A1-20130110-C00505
    497
    Figure US20130012496A1-20130110-C00506
    498
    Figure US20130012496A1-20130110-C00507
    499
    Figure US20130012496A1-20130110-C00508
  • TABLE 70
    PEx Str
    500
    Figure US20130012496A1-20130110-C00509
    501
    Figure US20130012496A1-20130110-C00510
    502
    Figure US20130012496A1-20130110-C00511
    503
    Figure US20130012496A1-20130110-C00512
    504
    Figure US20130012496A1-20130110-C00513
    505
    Figure US20130012496A1-20130110-C00514
  • TABLE 71
    PEx Str
    506
    Figure US20130012496A1-20130110-C00515
    507
    Figure US20130012496A1-20130110-C00516
    508
    Figure US20130012496A1-20130110-C00517
    509
    Figure US20130012496A1-20130110-C00518
    510
    Figure US20130012496A1-20130110-C00519
    511
    Figure US20130012496A1-20130110-C00520
    512
    Figure US20130012496A1-20130110-C00521
    513
    Figure US20130012496A1-20130110-C00522
  • TABLE 72
    PEx Str
    514
    Figure US20130012496A1-20130110-C00523
    515
    Figure US20130012496A1-20130110-C00524
    516
    Figure US20130012496A1-20130110-C00525
    517
    Figure US20130012496A1-20130110-C00526
    518
    Figure US20130012496A1-20130110-C00527
    519
    Figure US20130012496A1-20130110-C00528
    520
    Figure US20130012496A1-20130110-C00529
    521
    Figure US20130012496A1-20130110-C00530
  • TABLE 73
    PEx Str
    522
    Figure US20130012496A1-20130110-C00531
    523
    Figure US20130012496A1-20130110-C00532
    524
    Figure US20130012496A1-20130110-C00533
    525
    Figure US20130012496A1-20130110-C00534
    526
    Figure US20130012496A1-20130110-C00535
    527
    Figure US20130012496A1-20130110-C00536
  • TABLE 74
    PEx Str
    528
    Figure US20130012496A1-20130110-C00537
    529
    Figure US20130012496A1-20130110-C00538
    530
    Figure US20130012496A1-20130110-C00539
    531
    Figure US20130012496A1-20130110-C00540
    532
    Figure US20130012496A1-20130110-C00541
    533
    Figure US20130012496A1-20130110-C00542
  • TABLE 75
    PEx Str
    534
    Figure US20130012496A1-20130110-C00543
    535
    Figure US20130012496A1-20130110-C00544
    536
    Figure US20130012496A1-20130110-C00545
    537
    Figure US20130012496A1-20130110-C00546
    538
    Figure US20130012496A1-20130110-C00547
    539
    Figure US20130012496A1-20130110-C00548
  • TABLE 76
    PEx Str
    540
    Figure US20130012496A1-20130110-C00549
    541
    Figure US20130012496A1-20130110-C00550
    542
    Figure US20130012496A1-20130110-C00551
    543
    Figure US20130012496A1-20130110-C00552
    544
    Figure US20130012496A1-20130110-C00553
  • TABLE 77
    PEx Str
    545
    Figure US20130012496A1-20130110-C00554
    546
    Figure US20130012496A1-20130110-C00555
    547
    Figure US20130012496A1-20130110-C00556
    548
    Figure US20130012496A1-20130110-C00557
    549
    Figure US20130012496A1-20130110-C00558
    550
    Figure US20130012496A1-20130110-C00559
  • TABLE 78
    PEx Str
    551
    Figure US20130012496A1-20130110-C00560
    552
    Figure US20130012496A1-20130110-C00561
    553
    Figure US20130012496A1-20130110-C00562
    554
    Figure US20130012496A1-20130110-C00563
    555
    Figure US20130012496A1-20130110-C00564
    556
    Figure US20130012496A1-20130110-C00565
  • TABLE 79
    PEx Str
    557
    Figure US20130012496A1-20130110-C00566
    558
    Figure US20130012496A1-20130110-C00567
    559
    Figure US20130012496A1-20130110-C00568
    560
    Figure US20130012496A1-20130110-C00569
    561
    Figure US20130012496A1-20130110-C00570
    562
    Figure US20130012496A1-20130110-C00571
  • TABLE 80
    PEx Str
    563
    Figure US20130012496A1-20130110-C00572
    564
    Figure US20130012496A1-20130110-C00573
    565
    Figure US20130012496A1-20130110-C00574
    566
    Figure US20130012496A1-20130110-C00575
    567
    Figure US20130012496A1-20130110-C00576
    568
    Figure US20130012496A1-20130110-C00577
  • TABLE 81
    PEx Str
    569
    Figure US20130012496A1-20130110-C00578
    570
    Figure US20130012496A1-20130110-C00579
    571
    Figure US20130012496A1-20130110-C00580
    572
    Figure US20130012496A1-20130110-C00581
    573
    Figure US20130012496A1-20130110-C00582
    574
    Figure US20130012496A1-20130110-C00583
  • TABLE 82
    PEx Psyn Dat
    1 1 EI: 296, 298, 300
    2 2 EI: 190, 192
    3 3 EI: 209, 211
    4 4 ESI+: 254, 256
    5 5 FAB+: 299, 301
    6 6 EI: 268, 270
    7 7 EI: 346, 348, 350
    8 8 ESI+: 367, 369
    9 9 EI: 322, 324
    10 10 ESI+: 351, 353
    11 11 ESI+: 337, 339
    12 12 ESI+: 351, 353
    13 13 ESI+: 379
    14 14 APCI+: 220
    15 15 ESI+; 303
    16 16 ESI+; 331
    17 17 ESI+; 359
    18 18 ESI+; 317
    19 19 ESI+; 345
    20 20 ESI+; 419
    21 21 ESI+: 403
    22 22 ESI+: 417
    23 23 FAB−: 331
    24 24 ESI+: 333
    25 25 ESI+: 361
    26 26 ESI+: 383, 405 ([M + Na]+)
    27 27 ESI+: 447
    28 28 ESI+: 350
    29 29 ESI+: 393
    30 30 ESI+: 349
    31 31 ESI+: 331
    32 32 ESI+: 388
    33 33 ESI+: 389
    34 34 ESI+: 291
    35 35 ESI+: 403
    36 36 FAB+: 537
    37 37 ESI+: 577
    38 38 ESI+: 473 ([M + Na]+)
    39 39 EI: 315
    40 40 FAB+: 320
  • TABLE 83
    PEx Psyn Dat
    41 41 FAB+: 333
    42 42 ESI+: 359
    43 27 EI: 181
    44 4 ESI+: 182, 184
    45 19 ESI+: 235
    46 7 EI; 312
    47 8 ESI+; 333
    48 5 EI; 264
    49 9 EI; 288
    50 22 ESI+: 403 ([M + Na]+)
    51 15 ESI+: 333
    52 11 ESI+: 319
    53 11 ESI+: 365, 367
    54 11 ESI+: 305
    55 13 ESI+: 393, 395
    56 13 ESI+: 407, 409
    57 13 ESI+: 409, 411
    58 23 FAB−: 317
    59 11 ESI+; 317
    60 15 ESI+: 347, 369 ([M + Na]+)
    61 11 ESI+: 379, 381
    62 11 ESI+: 395, 397
    63 11 ESI+: 393, 395
    64 11 ESI+: 333
    65 11 ESI+: 319
    66 25 ESI+: 333
    67 7 ESI+: 383, 385
    68 18 ESI+: 319
    69 25 ESI+: 347
    70 24 APCI+: 333
    71 16 ESI+; 317
    72 11 ESI+; 203
    73 7 ESI+: 381, 383
    74 11 ESI+; 331
    75 13 FAB+; 345
    76 24 ESI+: 397, 399
    77 13 ESI+; 373
    78 18 ESI+: 345
    79 13 ESI+: 405, 407
    80 13 ESI+: 419, 421
  • TABLE 84
    PEx Psyn Dat
    81 11 ESI+: 391, 393
    82 11 ESI+: 405, 407
    83 13 ESI+: 433, 435
    84 13 ESI+: 441, 443
    85 18 ESI+; 379
    86 15 ESI+; 331
    87 11 ESI+: 419, 421
    88 11 ESI+: 427, 429
    89 13 ESI+: 447, 449
    90 11 ESI+: 433, 435
    91 22 ESI+: 431 ([M + Na]+)
    92 23 FAB−: 331
    93 11 ESI+: 319
    94 24 ESI+: 363
    95 24 ESI+: 359
    96 13 ESI+: 375
    97 24 ESI+: 361
    98 15 ESI+: 391
    99 11 ESI+: 377
    100 15 ESI+: 431 ([M + Na]+)
    101 15 ESI+: 375
    102 17 ESI+: 437
    103 11 ESI+: 395
    104 11 ESI+: 361
    105 15 ESI+: 391
    106 11 ESI+: 377
    107 15 ESI+: 417
    108 11 ESI+: 403
    109 7 ESI+: 361
    110 18 ESI+: 381
    111 17 ESI+; 361
    112 18 ESI+; 409
    113 18 ESI+; 447, 449
    114 18 ESI+; 413, 415
    115 17 ESI+; 471, 473
    116 17 ESI+; 505, 507
    117 18 ESI+; 397
    118 17 ESI+; 465
    119 12 ESI+: 363
    120 13 ESI+: 403
  • TABLE 85
    PEx Psyn Dat
    121 17 ESI+; 467
    122 17 ESI+; 455
    123 15 ESI+; 375
    124 18 ESI+; 343
    125 17 ESI+; 399
    126 17 ESI+; 401
    127 15 ESI+: 405
    128 11 ESI+: 391
    129 11 ESI+: 389
    130 18 ESI+: 395
    131 13 ESI+: 467
    132 11 ESI+: 453
    133 15 ESI+: 391
    134 15 ESI+: 405
    135 11 ESI+: 377
    136 11 ESI+: 391
    137 18 ESI+; 343
    138 13 ESI+: 439 ([M + Na]+)
    139 12 ESI+: 347
    140 11 ESI+: 403
    143 11 ESI+: 389
    144 22 ESI+: 406
    145 27 ESI+: 226
    146 27 EI: 195
    149 21 ESI+: 387
    150 17 ESI+; 403
    151 28 ESI+: 392
    152 13 ESI+: 391
    153 29 ESI+: 322
    154 41 ESI+: 421
    155 41 ESI+: 393
    156 11 ESI+: 319
    157 42 ESI+: 397, 399
    158 11 ESI+: 373
    159 18 ESI+: 395, 417 ([M + Na]+)
    160 13 ESI+: 431
  • TABLE 86
    PEx Psyn Dat
    161 13 ESI+: 389
    162 13 ESI+: 417
    163 11 ESI+: 417
    164 11 ESI+: 377
    165 11 ESI+: 381
    166 12 ESI+: 351
    167 18 ESI+: 331
    168 18 ESI+: 345
    169 19 ESI+: 333
    170 11 ESI+: 375
    171 11 ESI+: 361
    172 18 ESI+: 329
    173 19 ESI+; 331
    175 13 ESI+: 405
    176 21 ESI+: 391
    177 17 ESI+; 389
    178 18 ESI+; 359
    179 11 ESI+: 391
    180 11 ESI+: 377
    181 19 ESI+: 347
    182 13 FAB+: 419
    183 11 ESI+: 277
    184 11 ESI+: 405
    185 15 FAB+: 379
    186 11 ESI+: 365
    187 13 ESI+: 453 ([M + Na]+)
    188 11 ESI+: 417
    189 13 ESI+: 457, 479 ([M + Na]+)
    190 11 ESI+: 443
    192 13 ESI+: 431, 453 ([M + Na]+)
    193 11 ESI+: 417
    195 22 NMR: 1.19 (3H, t, J = 7.1 Hz), 1.38
    (9H, s), 1.54 (6H, s), 2.80-2.93 (4H, br),
    3.39-3.51 (4H, br), 4.20 (2H, q, J =
    7.1 Hz), 6.79 (1H, s), 7.68 (1H, s)
    196 22 ESI+: 457, 459
    197 22 ESI+: 413, 415
    198 22 ESI+: 431 ([M + Na]+)
    199 22 ESI+: 447 ([M + Na]+)
    200 22 ESI+: 459 ([M + Na]+)
  • TABLE 87
    PEx Psyn Dat
    201 18 ESI+: 439
    202 18 ESI+: 435
    203 18 ESI+: 399
    204 18 ESI+: 405
    205 18 ESI+: 345
    206 18 ESI+: 417
    207 18 ESI+: 359
    208 18 ESI+: 457
    209 18 ESI+: 417
    210 18 ESI+: 465
    211 18 ESI+: 403
    212 18 ESI+: 439
    213 18 ESI+: 445
    214 18 ESI+: 445
    215 18 ESI+: 427
    216 18 ESI+: 493
    217 18 ESI+: 453
    218 18 ESI+: 383
    219 18 ESI+: 493
    220 18 ESI+: 529
    221 18 ESI+: 535
    222 18 ESI+: 385
    223 18 ESI+: 427
    224 18 ESI+: 417
    225 18 ESI+: 403
    226 18 ESI+: 429, 451 ([M + Na]+)
    227 18 ESI+: 417
    228 18 ESI+: 405, 427 ([M + Na]+)
    229 18 ESI+: 401
    230 18 ESI+: 395
    231 18 ESI+: 345
    232 18 ESI+: 359
    233 18 ESI+: 383
    234 18 ESI+: 415
    235 18 ESI+: 415
    236 18 ESI+: 429
    237 18 ESI+: 405
    238 18 ESI+: 431
    239 18 ESI+: 347
    240 18 ESI+: 391
  • TABLE 88
    PEx Psyn Dat
    241 18 ESI+: 401
    242 18 ESI+: 391
    243 18 ESI+: 379
    244 18 ESI+: 427
    245 18 ESI+: 427
    246 18 ESI+: 403
    247 18 ESI+: 403
    248 18 ESI+: 379
    249 18 ESI+: 435
    250 18 ESI+: 469, 471
    251 18 ESI+: 469, 471
    252 18 ESI+: 453
    253 18 ESI+: 391
    254 18 ESI+: 453
    255 13 ESI+: 459, 481 ([M + Na]+)
    256 13 ESI+: 317
    257 13 ESI+: 401
    258 13 ESI+: 403
    259 13 ESI+: 427
    260 13 ESI+: 391
    261 13 ESI+: 391
    262 13 ESI+: 445, 467 ([M + Na]+)
    263 13 ESI+: 485, 507 ([M + Na]+)
    264 13 ESI+: 459, 481 ([M + Na]+)
    265 13 ESI+: 467 ([M + Na]+)
    266 13 ESI+: 457
    267 13 ESI+: 443
    268 13 ESI+: 457, 479 ([M + Na]+)
    269 13 ESI+: 457
    270 13 ESI+: 415, 437 ([M + Na]+)
    271 13 ESI+: 445, 467 ([M + Na]+)
    272 13 ESI+: 507
    273 13 ESI+: 419
    274 13 ESI+: 479
    275 13 ESI+: 493
    276 13 ESI+: 323 ([M − Boc]+)
    277 13 ESI+: 529
    278 13 ESI+: 529
    279 13 ESI+: 491
    280 13 ESI+: 507
  • TABLE 89
    PEx Psyn Dat
    281 13 ESI+: 463
    282 13 ESI+: 463
    283 13 ESI+: 485
    284 13 ESI+: 385 ([M − Boc]+)
    285 13 ESI+: 501
    286 13 ESI+: 491
    287 13 ESI+: 493
    288 13 ESI+: 485
    289 13 ESI+: 501
    290 13 ESI+: 507
    291 17 ESI+: 389
    292 17 ESI+: 387
    293 17 ESI+: 373
    294 15 ESI+: 536.9
    295 15 ESI+: 361, 383 ([M + Na]+)
    296 15 ESI+: 375
    297 15 ESI+: 447
    298 15 ESI+: 447
    299 15 ESI+: 417
    300 15 ESI+: 523
    301 15 ESI+: 391
    302 20 ESI+: 433, 455 ([M + Na]+)
    303 20 ESI+: 433
    304 20 ESI+: 403
    305 20 ESI+: 509
    306 334 ESI+: 377
    307 334 ESI+: 389
    308 334 ESI+: 373
    309 334 ESI+: 439
    310 334 ESI+: 443, 445
    311 334 ESI+: 391
    312 334 ESI+: 465 ([M + Na]+), 467 ([M + Na]+)
    313 334 ESI+: 465 ([M + Na]+), 467 ([M + Na]+)
    314 334 ESI+: 461 ([M + Na]+)
    315 334 ESI+: 416
    316 334 ESI+: 410
    317 334 ESI+: 439
    318 334 ESI+: 437
    319 334 ESI+: 359
    320 334 ESI+: 405, 427 ([M + Na]+)
  • TABLE 90
    PEx Psyn Dat
    321 334 ESI+: 403
    322 334 ESI+: 377
    323 334 ESI+: 405
    324 334 ESI+: 403, 425 ([M + Na]+)
    325 334 ESI+: 391, 413 ([M + Na]+)
    326 334 ESI+: 379, 401 ([M + Na]+)
    327 334 ESI+: 403
    328 334 ESI+: 379, 401 ([M + Na]+)
    329 334 ESI+: 405.427 ([M + Na]+)
    330 334 ESI+: 389
    331 334 ESI+: 419
    332 334 ESI+: 401
    333 334 ESI+: 401
    334 334 ESI+: 416
    335 334 ESI+: 391, 413 ([M + Na]+)
    336 334 ESI+: 427
    337 339 ESI+: 345
    338 339 ESI+: 359
    339 339 ESI+: 407
    340 339 ESI+: 361
    341 339 ESI+: 389
    342 339 ESI+: 411, 413
    343 339 ESI+: 389
    344 344 ESI+: 365, 367
    345 345 ESI+: 451
    346 345 ESI+: 485, 487
    347 345 ESI+: 485, 487
    348 349 ESI+: 485, 487
    349 349 ESI+: 481
    350 349 ESI+: 481
    351 349 ESI+: 453
    352 349 ESI+: 509 ([M + Na]+), 511 ([M + Na]+)
    353 349 ESI+: 509 ([M + Na]+), 511 ([M + Na]+)
    354 349 ESI+: 509 ([M + Na]+), 511 ([M + Na]+)
    355 349 ESI+: 483
    356 349 ESI+: 483
    357 349 ESI+: 471
    358 349 ESI+: 471
    359 349 ESI+: 471
    360 349 ESI+: 531, 533
  • TABLE 91
    PEx Psyn Dat
    361 349 ESI+: 467
    362 349 ESI+: 467
    363 367 ESI+: 437
    364 367 ESI+: 403
    365 367 ESI+: 389
    366 367 ESI+: 375
    367 367 ESI+: 411, 413
    368 27 ESI+: 448
    369 38 ESI+: 451
    370 28 ESI+: 350
    371 29 ESI+: 393
    372 30 ESI+: 349
    373 31 ESI+: 331
    374 37 ESI+: 577
    375 375 ESI+: 383
    376 376 ESI+: 386
    377 377 ESI+: 425
    378 377 ESI+: 427
    379 379 ESI+: 417
    380 380 ESI+: 331
    381 381 NMR-C: 1.19 (3H, d, J = 6.6 Hz), 1.28 (3H, t, J = 7.1 Hz),
    2.75-2.89 (4H, m), 3.34-3.44 (1H, m), 3.51-3.65 (4H, m),
    3.69 (1H, dd, J = 8.7, 7.6 Hz), 3.93 (1H, dd, J = 8.7,
    4.1 Hz), 4.18 (2H, q, J = 7.1 Hz),
    6.66 (1H, s), 7.28 (1H, s)
    382 381 ESI+: 371, 373
    383 383 ESI+: 291
    384 383 ESI+: 291
    385 385 ESI+: 317
    386 386 ESI+: 301
    387 387 ESI+: 236
    388 388 ESI+: 277
    389 389 ESI+: 275
    390 390 ESI+: 293
    391 545 ESI+: 587
    392 7 ESI+: 374
    393 7 ESI+: 371, 373
    394 7 ESI+: 327, 329
    395 408 ESI+: 441, 443
    396 408 ESI+: 455
    397 408 ESI+: 457
    398 408 ESI+: 443, 445
    399 408 ESI+: 455, 457
    400 408 ESI+: 465; 467
  • TABLE 92
    PEx Psyn Dat
    401 408 ESI+: 491; 493
    402 408 ESI+: 467, 469
    403 408 ESI+: 455, 457
    404 408 ESI+: 443, 445
    405 408 ESI+: 467, 469
    406 408 ESI+: 443, 445
    407 408 ESI+: 469, 471
    408 408 ESI+: 413
    409 409 ESI+: 314, 316
    410 411 ESI+: 453; 455
    411 411 ESI+: 467; 469
    412 411 ESI+: 355, 357
    413 411 ESI+: 437; 439
    414 411 ESI+: 455
    415 411 ESI+: 529, 531
    416 411 ESI+: 467, 469
    417 411 ESI+: 455, 457
    418 411 ESI+: 479, 481
    419 411 ESI+: 409, 411
    420 411 ESI+: 455, 457
    421 411 ESI+: 467, 469
    422 411 ESI+: 467, 469
    423 411 ESI+: 479, 481
    424 411 ESI+: 479, 481
    425 549 ESI+: 435
    426 426 ESI+: 346
    427 427 FAB−: 395, 397
    428 427 ESI+: 353, 355
    429 23 ESI+: 369 ([M + Na]+)
    430 23 ESI+: 347, 369 ([M + Na]+)
    431 23 ESI+: 385 ([M + Na]+)
    432 23 ESI+: 361, 383 ([M + Na]+)
    433 11 ESI+: 439, 441
    434 11 NMR-C: 0.44-0.51 (2H, m), 0.95 (6H, s),
    0.97-1.06 (2H, m), 1.47 (9H, s),
    1.58-1.68 (1H, m), 2.69-2.78 (2H, m),
    3.04 (2H, s), 3.06-3.18 (4H, m), 3.21
    (3H, s), 3.29-3.36 (2H, m), 3.46-3.58
    (4H, m), 4.15-4.22 (2H, m), 6.48 (1H, s)
    435 11 ESI+: 383, 385
    436 11 ESI+: 377
    437 11 ESI+: 331
    438 11 ESI+: 345
    439 11 ESI+: 453, 455
    440 11 ESI+: 389
  • TABLE 93
    PEx Psyn Dat
    441 11 ESI+: 441, 443
    442 11 ESI+: 391
    443 11 ESI+: 465, 467
    444 11 ESI+: 387
    445 11 ESI+: 389
    446 11 ESI+: 339, 341
    447 11 ESI+: 397, 399
    448 11 ESI+: 413
    449 11 ESI+: 395, 397
    450 11 ESI+: 377
    451 11 ESI+: 377
    452 11 ESI+: 391
    453 11 ESI+: 441, 443
    454 11 ESI+: 389
    455 11 ESI+: 377
    456 11 ESI+: 365
    457 11 ESI+: 453, 455
    458 11 ESI+: 453, 455
    459 11 ESI+: 389
    460 11 ESI+: 365
    461 11 ESI+: 431
    462 11 ESI+: 471
    463 11 ESI+: 445
    464 11 ESI+: 333
    465 11 ESI+: 349
    466 11 ESI+: 347
    467 11 ESI+: 391
    468 11 ESI+: 405
    469 11 ESI+: 347
    470 11 ESI+: 361
    471 11 ESI+: 465, 467
    472 11 ESI+: 465
    473 11 ESI+: 431
    474 11 ESI+: 443
    475 11 ESI+: 429
    476 11 ESI+: 443
    477 11 ESI+: 401
    478 11 ESI+: 443
    479 11 ESI+: 465
    480 11 ESI+: 493
  • TABLE 94
    PEx Psyn Dat
    481 11 ESI+: 431
    482 11 ESI+: 405
    483 11 ESI+: 479
    484 11 ESI+: 309 ([M − Boc]+)
    485 11 ESI+: 515
    486 11 ESI+: 515
    487 11 ESI+: 477
    488 11 ESI+: 493
    489 11 ESI+: 449
    490 11 ESI+: 449
    491 11 ESI+: 377
    492 11 ESI+: 471
    493 11 ESI+: 471
    494 11 ESI+: 487, 489
    495 495 ESI+: 473, 475
    496 495 ESI+: 507, 509
    497 495 ESI+: 507, 509
    498 495 EI: 491, 493
    499 495 ESI+: 492, 493
    500 12 ESI+: 429; 431
    501 12 ESI+: 425
    502 12 ESI+: 413
    503 12 ESI+: 420
    504 12 ESI+: 463
    505 12 ESI+: 409
    506 19 ESI+: 303
    507 19 ESI+: 473
    508 19 ESI+: 405
    509 19 ESI+: 501
    510 19 ESI+: 495
    511 19 ESI+: 361
    512 19 ESI+: 347
    513 19 ESI+: 433
    514 19 ESI+: 393
    515 16 ESI+: 345
    516 16 ESI+: 319
    517 16 ESI+: 331
    518 16 ESI+: 319
    519 162 ESI+: 437, 439
    520 162 ESI+: 435, 437
  • TABLE 95
    PEx Psyn Dat
    521 18 ESI+: 417
    522 18 ESI+: 417
    523 13 ESI+: 479
    524 13 ESI+: 493
    525 13 ESI+: 479
    526 13 ESI+: 533
    527 13 ESI+: 497
    528 13 ESI+: 513
    529 13 ESI+: 493
    530 13 ESI+: 485
    531 13 ESI+: 485
    532 15 ESI+: 523
    533 15 ESI+: 537
    534 15 ESI+: 559
    535 15 ESI+: 431
    536 20 ESI+: 433
    537 20 ESI+: 509
    538 339 ESI+: 486
    539 540 ESI+: 526.4
    540 540 ESI+: 538
    541 540 ESI+: 467
    542 540 ESI+: 467
    543 543 ESI+: 531
    544 545 ESI+: 587
    545 545 ESI+: 543
    546 545 ESI+: 601
    547 408 ESI+: 455, 457
    548 408 ESI+: 455, 457
    549 549 ESI+: 435
    550 549 ESI+: 449
    551 11 ESI+: 465
    552 11 ESI+: 477
    553 11 ESI+: 479
    554 11 ESI+: 471
    555 11 ESI+: 487, 489
    556 11 ESI+: 493
    557 11 ESI+: 479
    558 11 ESI+: 465
    559 11 ESI+: 519
    560 11 ESI+: 479
  • TABLE 96
    PEx Psyn Dat
    561 11 ESI+: 483
    562 11 ESI+: 499, 501
    563 11 ESI+: 471
    564 11 ESI+: 471
    565 565 ESI+: 527
    566 565 ESI+: 527
    567 565 ESI+: 527
    568 565 ESI+: 561, 563
    569 565 ESI+: 563
    570 565 ESI+: 545
    571 19 ESI+: 433
    572 19 ESI+: 447
    573 20 ESI+: 363
    574 15 ESI+: 377
  • TABLE 97
    Ex Str
    1
    Figure US20130012496A1-20130110-C00584
    2 M
    Figure US20130012496A1-20130110-C00585
    3 M
    Figure US20130012496A1-20130110-C00586
    4
    Figure US20130012496A1-20130110-C00587
    5
    Figure US20130012496A1-20130110-C00588
    6 H
    Figure US20130012496A1-20130110-C00589
    7 M
    Figure US20130012496A1-20130110-C00590
    8 M
    Figure US20130012496A1-20130110-C00591
  • TABLE 98
    Ex Str
     9 M
    Figure US20130012496A1-20130110-C00592
    10 M
    Figure US20130012496A1-20130110-C00593
    11
    Figure US20130012496A1-20130110-C00594
    12 M
    Figure US20130012496A1-20130110-C00595
    13 H
    Figure US20130012496A1-20130110-C00596
    14 M
    Figure US20130012496A1-20130110-C00597
    15
    Figure US20130012496A1-20130110-C00598
    16
    Figure US20130012496A1-20130110-C00599
  • TABLE 99
    Ex Str
    17
    Figure US20130012496A1-20130110-C00600
    18
    Figure US20130012496A1-20130110-C00601
    19 M
    Figure US20130012496A1-20130110-C00602
    20 M
    Figure US20130012496A1-20130110-C00603
    21
    Figure US20130012496A1-20130110-C00604
    22 H
    Figure US20130012496A1-20130110-C00605
    23 H
    Figure US20130012496A1-20130110-C00606
    24 M
    Figure US20130012496A1-20130110-C00607
  • TABLE 100
    Ex Str
    25 H
    Figure US20130012496A1-20130110-C00608
    26 M
    Figure US20130012496A1-20130110-C00609
    27 M
    Figure US20130012496A1-20130110-C00610
    28 H
    Figure US20130012496A1-20130110-C00611
    29
    Figure US20130012496A1-20130110-C00612
    30
    Figure US20130012496A1-20130110-C00613
    31 M
    Figure US20130012496A1-20130110-C00614
    32 M
    Figure US20130012496A1-20130110-C00615
  • TABLE 101
    Ex Str
    33 M
    Figure US20130012496A1-20130110-C00616
    34 M
    Figure US20130012496A1-20130110-C00617
    35 M
    Figure US20130012496A1-20130110-C00618
    36
    Figure US20130012496A1-20130110-C00619
    37 M
    Figure US20130012496A1-20130110-C00620
    38 M
    Figure US20130012496A1-20130110-C00621
    39 M
    Figure US20130012496A1-20130110-C00622
    40 M
    Figure US20130012496A1-20130110-C00623
  • TABLE 102
    Ex Str
    41 M
    Figure US20130012496A1-20130110-C00624
    42 M
    Figure US20130012496A1-20130110-C00625
    43 M
    Figure US20130012496A1-20130110-C00626
    44 M
    Figure US20130012496A1-20130110-C00627
    45 M
    Figure US20130012496A1-20130110-C00628
    46
    Figure US20130012496A1-20130110-C00629
    47 M
    Figure US20130012496A1-20130110-C00630
  • TABLE 103
    Ex Str
    48 M
    Figure US20130012496A1-20130110-C00631
    49 M
    Figure US20130012496A1-20130110-C00632
    50
    Figure US20130012496A1-20130110-C00633
    51
    Figure US20130012496A1-20130110-C00634
    52 M
    Figure US20130012496A1-20130110-C00635
    53 M
    Figure US20130012496A1-20130110-C00636
    54 H
    Figure US20130012496A1-20130110-C00637
  • TABLE 104
    Ex Str
    55 M
    Figure US20130012496A1-20130110-C00638
    56
    Figure US20130012496A1-20130110-C00639
    57
    Figure US20130012496A1-20130110-C00640
    58
    Figure US20130012496A1-20130110-C00641
    59 M
    Figure US20130012496A1-20130110-C00642
    60
    Figure US20130012496A1-20130110-C00643
    61
    Figure US20130012496A1-20130110-C00644
  • TABLE 105
    Ex Str
    62 H
    Figure US20130012496A1-20130110-C00645
    63 M
    Figure US20130012496A1-20130110-C00646
    64
    Figure US20130012496A1-20130110-C00647
    65
    Figure US20130012496A1-20130110-C00648
    66 M
    Figure US20130012496A1-20130110-C00649
    67 M
    Figure US20130012496A1-20130110-C00650
  • TABLE 106
    Ex Str
    68 H
    Figure US20130012496A1-20130110-C00651
    69 H
    Figure US20130012496A1-20130110-C00652
    70 M
    Figure US20130012496A1-20130110-C00653
    71 M
    Figure US20130012496A1-20130110-C00654
    72 M
    Figure US20130012496A1-20130110-C00655
    73 H
    Figure US20130012496A1-20130110-C00656
  • TABLE 107
    Ex Str
    74 M
    Figure US20130012496A1-20130110-C00657
    75 H
    Figure US20130012496A1-20130110-C00658
    76 M
    Figure US20130012496A1-20130110-C00659
    77
    Figure US20130012496A1-20130110-C00660
    78 M
    Figure US20130012496A1-20130110-C00661
    79 M
    Figure US20130012496A1-20130110-C00662
    80 M
    Figure US20130012496A1-20130110-C00663
  • TABLE 108
    Ex Str
    81 M
    Figure US20130012496A1-20130110-C00664
    82 H
    Figure US20130012496A1-20130110-C00665
    83 M
    Figure US20130012496A1-20130110-C00666
    84 M
    Figure US20130012496A1-20130110-C00667
    85 M
    Figure US20130012496A1-20130110-C00668
    86
    Figure US20130012496A1-20130110-C00669
  • TABLE 109
    Ex Str
    87
    Figure US20130012496A1-20130110-C00670
    88 H
    Figure US20130012496A1-20130110-C00671
    89 M
    Figure US20130012496A1-20130110-C00672
    90 M
    Figure US20130012496A1-20130110-C00673
    91 M
    Figure US20130012496A1-20130110-C00674
    92 H
    Figure US20130012496A1-20130110-C00675
    93 M
    Figure US20130012496A1-20130110-C00676
  • TABLE 110
    Ex Str
     94 H
    Figure US20130012496A1-20130110-C00677
     95 M
    Figure US20130012496A1-20130110-C00678
     96
    Figure US20130012496A1-20130110-C00679
     97 M
    Figure US20130012496A1-20130110-C00680
     98 M
    Figure US20130012496A1-20130110-C00681
     99 H
    Figure US20130012496A1-20130110-C00682
    100
    Figure US20130012496A1-20130110-C00683
  • TABLE 111
    Ex Str
    101 M
    Figure US20130012496A1-20130110-C00684
    102 M
    Figure US20130012496A1-20130110-C00685
    103
    Figure US20130012496A1-20130110-C00686
    104 M
    Figure US20130012496A1-20130110-C00687
    105
    Figure US20130012496A1-20130110-C00688
    106 H
    Figure US20130012496A1-20130110-C00689
  • TABLE 112
    Ex Str
    107 M
    Figure US20130012496A1-20130110-C00690
    108 M
    Figure US20130012496A1-20130110-C00691
    109 M
    Figure US20130012496A1-20130110-C00692
    110 M
    Figure US20130012496A1-20130110-C00693
    111
    Figure US20130012496A1-20130110-C00694
    112 M
    Figure US20130012496A1-20130110-C00695
  • TABLE 113
    Ex Str
    113
    Figure US20130012496A1-20130110-C00696
    114 M
    Figure US20130012496A1-20130110-C00697
    115 M
    Figure US20130012496A1-20130110-C00698
    116 M
    Figure US20130012496A1-20130110-C00699
    117 M
    Figure US20130012496A1-20130110-C00700
    118 H
    Figure US20130012496A1-20130110-C00701
  • TABLE 114
    Ex Str
    119
    Figure US20130012496A1-20130110-C00702
    120 M
    Figure US20130012496A1-20130110-C00703
    121 H
    Figure US20130012496A1-20130110-C00704
    122
    Figure US20130012496A1-20130110-C00705
    123
    Figure US20130012496A1-20130110-C00706
    124
    Figure US20130012496A1-20130110-C00707
    125
    Figure US20130012496A1-20130110-C00708
  • TABLE 115
    Ex Str
    126
    Figure US20130012496A1-20130110-C00709
    127 M
    Figure US20130012496A1-20130110-C00710
    128 M
    Figure US20130012496A1-20130110-C00711
    129 M
    Figure US20130012496A1-20130110-C00712
    130 M
    Figure US20130012496A1-20130110-C00713
    131 M
    Figure US20130012496A1-20130110-C00714
    132 M
    Figure US20130012496A1-20130110-C00715
  • TABLE 116
    Ex Str
    133
    Figure US20130012496A1-20130110-C00716
    134 M
    Figure US20130012496A1-20130110-C00717
    135 M
    Figure US20130012496A1-20130110-C00718
    136 M
    Figure US20130012496A1-20130110-C00719
    137 M
    Figure US20130012496A1-20130110-C00720
    138 M
    Figure US20130012496A1-20130110-C00721
  • TABLE 117
    Ex Str
    139 M
    Figure US20130012496A1-20130110-C00722
    140 M
    Figure US20130012496A1-20130110-C00723
    141 H
    Figure US20130012496A1-20130110-C00724
    142 H
    Figure US20130012496A1-20130110-C00725
    143 H
    Figure US20130012496A1-20130110-C00726
    144 M
    Figure US20130012496A1-20130110-C00727
  • TABLE 118
    Ex Str
    145 M
    Figure US20130012496A1-20130110-C00728
    146 M
    Figure US20130012496A1-20130110-C00729
    147 M
    Figure US20130012496A1-20130110-C00730
    148 M
    Figure US20130012496A1-20130110-C00731
    149
    Figure US20130012496A1-20130110-C00732
    150 H
    Figure US20130012496A1-20130110-C00733
  • TABLE 119
    Ex Str
    151 M
    Figure US20130012496A1-20130110-C00734
    152 H
    Figure US20130012496A1-20130110-C00735
    153 H
    Figure US20130012496A1-20130110-C00736
    154 H
    Figure US20130012496A1-20130110-C00737
    155 M
    Figure US20130012496A1-20130110-C00738
    156 M
    Figure US20130012496A1-20130110-C00739
    157 M
    Figure US20130012496A1-20130110-C00740
  • TABLE 120
    Ex Str
    158 M
    Figure US20130012496A1-20130110-C00741
    159
    Figure US20130012496A1-20130110-C00742
    160 M
    Figure US20130012496A1-20130110-C00743
    161 M
    Figure US20130012496A1-20130110-C00744
    162 M
    Figure US20130012496A1-20130110-C00745
    163 M
    Figure US20130012496A1-20130110-C00746
  • TABLE 121
    Ex Str
    164 M
    Figure US20130012496A1-20130110-C00747
    165
    Figure US20130012496A1-20130110-C00748
    166
    Figure US20130012496A1-20130110-C00749
    167
    Figure US20130012496A1-20130110-C00750
    168
    Figure US20130012496A1-20130110-C00751
    169 M
    Figure US20130012496A1-20130110-C00752
  • TABLE 122
    Ex Str
    170 M
    Figure US20130012496A1-20130110-C00753
    171 M
    Figure US20130012496A1-20130110-C00754
    172 M
    Figure US20130012496A1-20130110-C00755
    173 M
    Figure US20130012496A1-20130110-C00756
    174 H
    Figure US20130012496A1-20130110-C00757
    175
    Figure US20130012496A1-20130110-C00758
  • TABLE 123
    Ex Str
    176
    Figure US20130012496A1-20130110-C00759
    177 M
    Figure US20130012496A1-20130110-C00760
    178 M
    Figure US20130012496A1-20130110-C00761
    179 M
    Figure US20130012496A1-20130110-C00762
    180 M
    Figure US20130012496A1-20130110-C00763
    181 H
    Figure US20130012496A1-20130110-C00764
  • TABLE 124
    Ex Str
    182 H
    Figure US20130012496A1-20130110-C00765
    183 M
    Figure US20130012496A1-20130110-C00766
    184 M
    Figure US20130012496A1-20130110-C00767
    185 M
    Figure US20130012496A1-20130110-C00768
    186 M
    Figure US20130012496A1-20130110-C00769
  • TABLE 125
    Ex Str
    187 M
    Figure US20130012496A1-20130110-C00770
    188 H
    Figure US20130012496A1-20130110-C00771
    189
    Figure US20130012496A1-20130110-C00772
    190
    Figure US20130012496A1-20130110-C00773
    191
    Figure US20130012496A1-20130110-C00774
    192 H
    Figure US20130012496A1-20130110-C00775
    193 H
    Figure US20130012496A1-20130110-C00776
  • TABLE 126
    Ex Str
    194 H
    Figure US20130012496A1-20130110-C00777
    195 M
    Figure US20130012496A1-20130110-C00778
    196 M
    Figure US20130012496A1-20130110-C00779
    197 M
    Figure US20130012496A1-20130110-C00780
    198 M
    Figure US20130012496A1-20130110-C00781
    199 M
    Figure US20130012496A1-20130110-C00782
  • TABLE 127
    Ex Str
    200 H
    Figure US20130012496A1-20130110-C00783
    201 M
    Figure US20130012496A1-20130110-C00784
    202
    Figure US20130012496A1-20130110-C00785
    203 M
    Figure US20130012496A1-20130110-C00786
    204 H
    Figure US20130012496A1-20130110-C00787
    205 H
    Figure US20130012496A1-20130110-C00788
  • TABLE 128
    Ex Str
    206 M
    Figure US20130012496A1-20130110-C00789
    207 M
    Figure US20130012496A1-20130110-C00790
    208 H
    Figure US20130012496A1-20130110-C00791
    209 H
    Figure US20130012496A1-20130110-C00792
    210 M
    Figure US20130012496A1-20130110-C00793
    211 M
    Figure US20130012496A1-20130110-C00794
  • TABLE 129
    Ex Str
    212 M
    Figure US20130012496A1-20130110-C00795
    213 M
    Figure US20130012496A1-20130110-C00796
    214 H
    Figure US20130012496A1-20130110-C00797
    215
    Figure US20130012496A1-20130110-C00798
    216 M
    Figure US20130012496A1-20130110-C00799
    217 H
    Figure US20130012496A1-20130110-C00800
  • TABLE 130
    Ex Str
    218 H
    Figure US20130012496A1-20130110-C00801
    219 H
    Figure US20130012496A1-20130110-C00802
    220 H
    Figure US20130012496A1-20130110-C00803
    221 M
    Figure US20130012496A1-20130110-C00804
    222 H
    Figure US20130012496A1-20130110-C00805
    223 H
    Figure US20130012496A1-20130110-C00806
  • TABLE 131
    Ex Str
    224 M
    Figure US20130012496A1-20130110-C00807
    225
    Figure US20130012496A1-20130110-C00808
    226
    Figure US20130012496A1-20130110-C00809
    227
    Figure US20130012496A1-20130110-C00810
    228 H
    Figure US20130012496A1-20130110-C00811
    229 M
    Figure US20130012496A1-20130110-C00812
    230
    Figure US20130012496A1-20130110-C00813
  • TABLE 132
    Ex Str
    231
    Figure US20130012496A1-20130110-C00814
    232 H
    Figure US20130012496A1-20130110-C00815
    233 H
    Figure US20130012496A1-20130110-C00816
    234 M
    Figure US20130012496A1-20130110-C00817
    235 M
    Figure US20130012496A1-20130110-C00818
    236 M
    Figure US20130012496A1-20130110-C00819
  • TABLE 133
    Ex Str
    237 M
    Figure US20130012496A1-20130110-C00820
    238 M
    Figure US20130012496A1-20130110-C00821
    239 M
    Figure US20130012496A1-20130110-C00822
    240 M
    Figure US20130012496A1-20130110-C00823
    241 M
    Figure US20130012496A1-20130110-C00824
    242 M
    Figure US20130012496A1-20130110-C00825
    243 M
    Figure US20130012496A1-20130110-C00826
  • TABLE 134
    Ex Str
    244 M
    Figure US20130012496A1-20130110-C00827
    245 M
    Figure US20130012496A1-20130110-C00828
    246 M
    Figure US20130012496A1-20130110-C00829
    247 M
    Figure US20130012496A1-20130110-C00830
    248 M
    Figure US20130012496A1-20130110-C00831
    249 M
    Figure US20130012496A1-20130110-C00832
  • TABLE 135
    Ex Str
    250
    Figure US20130012496A1-20130110-C00833
    251 H
    Figure US20130012496A1-20130110-C00834
    252
    Figure US20130012496A1-20130110-C00835
    253
    Figure US20130012496A1-20130110-C00836
    254 S
    Figure US20130012496A1-20130110-C00837
    255 H
    Figure US20130012496A1-20130110-C00838
  • TABLE 136
    Ex Str
    256 M
    Figure US20130012496A1-20130110-C00839
    257 H
    Figure US20130012496A1-20130110-C00840
    258 M
    Figure US20130012496A1-20130110-C00841
    259 M
    Figure US20130012496A1-20130110-C00842
    260 H
    Figure US20130012496A1-20130110-C00843
    261
    Figure US20130012496A1-20130110-C00844
  • TABLE 137
    Ex Str
    262
    Figure US20130012496A1-20130110-C00845
    263 H
    Figure US20130012496A1-20130110-C00846
    264
    Figure US20130012496A1-20130110-C00847
    265 H
    Figure US20130012496A1-20130110-C00848
    266 M
    Figure US20130012496A1-20130110-C00849
    267 T
    Figure US20130012496A1-20130110-C00850
  • TABLE 138
    Ex Str
    268 M
    Figure US20130012496A1-20130110-C00851
    269 H
    Figure US20130012496A1-20130110-C00852
    270 M
    Figure US20130012496A1-20130110-C00853
    271 M
    Figure US20130012496A1-20130110-C00854
    272 M
    Figure US20130012496A1-20130110-C00855
  • TABLE 139
    Ex Str
    273 M
    Figure US20130012496A1-20130110-C00856
    274 M
    Figure US20130012496A1-20130110-C00857
    275 M
    Figure US20130012496A1-20130110-C00858
    276 M
    Figure US20130012496A1-20130110-C00859
    277 M
    Figure US20130012496A1-20130110-C00860
  • TABLE 140
    Ex Str
    278
    Figure US20130012496A1-20130110-C00861
    279
    Figure US20130012496A1-20130110-C00862
    280 M
    Figure US20130012496A1-20130110-C00863
    281 M
    Figure US20130012496A1-20130110-C00864
    282 M
    Figure US20130012496A1-20130110-C00865
    283 H
    Figure US20130012496A1-20130110-C00866
  • TABLE 141
    Ex Str
    284 H
    Figure US20130012496A1-20130110-C00867
    285 H
    Figure US20130012496A1-20130110-C00868
    286 M
    Figure US20130012496A1-20130110-C00869
    287 M
    Figure US20130012496A1-20130110-C00870
    288 M
    Figure US20130012496A1-20130110-C00871
  • TABLE 142
    Ex Str
    289 H
    Figure US20130012496A1-20130110-C00872
    290 M
    Figure US20130012496A1-20130110-C00873
    291 H
    Figure US20130012496A1-20130110-C00874
    292 M
    Figure US20130012496A1-20130110-C00875
    293 M
    Figure US20130012496A1-20130110-C00876
    294 M
    Figure US20130012496A1-20130110-C00877
  • TABLE 143
    Ex Str
    295 M
    Figure US20130012496A1-20130110-C00878
    296 M
    Figure US20130012496A1-20130110-C00879
    297 M
    Figure US20130012496A1-20130110-C00880
    298 M
    Figure US20130012496A1-20130110-C00881
    299 M
    Figure US20130012496A1-20130110-C00882
  • TABLE 144
    Ex Str
    300 M
    Figure US20130012496A1-20130110-C00883
    301 M
    Figure US20130012496A1-20130110-C00884
    302 M
    Figure US20130012496A1-20130110-C00885
    303 M
    Figure US20130012496A1-20130110-C00886
    304 M
    Figure US20130012496A1-20130110-C00887
  • TABLE 145
    Ex Str
    305 M
    Figure US20130012496A1-20130110-C00888
    306 M
    Figure US20130012496A1-20130110-C00889
    307 M
    Figure US20130012496A1-20130110-C00890
    308 M
    Figure US20130012496A1-20130110-C00891
  • TABLE 146
    Ex Str
    309 M
    Figure US20130012496A1-20130110-C00892
    310 M
    Figure US20130012496A1-20130110-C00893
    311 S
    Figure US20130012496A1-20130110-C00894
    312 H
    Figure US20130012496A1-20130110-C00895
    313 H
    Figure US20130012496A1-20130110-C00896
  • TABLE 147
    Ex Str
    314 M
    Figure US20130012496A1-20130110-C00897
    315 M
    Figure US20130012496A1-20130110-C00898
    316 M
    Figure US20130012496A1-20130110-C00899
    317 M
    Figure US20130012496A1-20130110-C00900
    318
    Figure US20130012496A1-20130110-C00901
    319
    Figure US20130012496A1-20130110-C00902
  • TABLE 148
    Ex Syn Dat
    1 1 ESI+: 251, 253
    NMR: 2.44-2.53 (3H, m), 2.72-2.74 (4H, m), 2.79-2.85 (4H, m), 3.02-3.04 (2H, m),
    6.93 (1H, s), 9.20 (1H, s)
    mp: 165-167
    2 2 ESI+: 293, 295
    NMR: 0.96 (6H, d, J = 6.5 Hz), 1.69-1.75 (2H, m), 1.98-2.07 (1H, m), 2.67-2.70 (4H, m),
    2.90-2.95 (2H, m), 2.97-3.04 (6H, m), 3.10-3.65 (5H, m), 6.46 (2H, s), 6.81 (1H, s)
    mp: 159-163
    3 3 ESI+: 203
    NMR: 1.69-1.81 (2H, m), 2.57 (2H, t, J = 6.2 Hz), 2.75-2.86 (4H, m), 2.94-3.06 (4H, m),
    3.08-3.15 (2H, m), 6.23 (1H, s), 6.44 (2H, s), 6.62 (1H, s)
    4 4 ESI+: 231
    NMR: 2.49-2.56 (2H, m), 2.76-2.83 (2H, m), 2.98-3.20 (8H, m), 3.23 (3H, s), 6.97 (1H, s),
    7.05 (1H, s), 9.14 (2H, s)
    5 5 ESI+: 315
    NMR: 0.22-0.32 (1H, m), 0.38-0.49 (1H, m), 0.97-1.07 (2H, m), 1.50-1.70 (2H, m),
    2.17-2.30 (1H, m), 2.31-2.43 (1H, m), 2.51-2.61 (1H, m), 2.74-3.18 (8H, m), 3.30-3.42 (1H, m),
    3.34 (3H, s), 3.73 (1H, d, J = 14.3 Hz), 4.14 (1H, d, J = 14.3 Hz), 4.70-4.81 (1H, m), 6.85 (1H,
    s)
    6 6 ESI+: 275
    NMR: 1.23 (3H, t, J = 7.1 Hz), 1.78-1.86 (2H, m), 2.66 (2H, t, J = 6.6 Hz), 2.83-2.91 (4H, m),
    2.91-2.99 (4H, m), 3.61-3.67 (2H, m), 4.13 (2H, q, J = 7.1 Hz), 6.40 (1H, s), 6.88 (1H, s),
    7.43 (1H, s)
    mp: 178 (decomp.)
    7 7 ESI+: 274
    NMR: 1.78-1.86 (2H, m), 2.65 (2H, t, J = 6.7 Hz), 2.76-2.86 (10H, m), 2.86-2.94 (4H, m),
    3.36-3.41 (2H, m), 6.39 (1H, s), 6.56 (1H, s), 6.83 (1H, s)
    mp: 230 (decomp.)
    8 8 ESI+: 274
    NMR: 1.05 (3H, t, J = 7.1 Hz), 1.74-1.82 (2H, m), 2.62 (2H, t, J = 6.5 Hz), 2.89-2.97 (4H, m),
    3.01-3.15 (6H, m), 3.52 (2H, m), 6.45 (2H, s), 6.65 (1H, t, J = 5.4 Hz), 6.89 (1H, s), 7.25 (1H,
    s)
    mp: 174-176
    9 9 ESI+: 295
    NMR: 1.20 (3H, t, J = 7.3 Hz), 1.85-1.94 (2H, m), 2.73 (2H, t, J = 6.7 Hz), 2.91-3.00 (4H, m),
    3.00-3.10 (4H, m), 3.23 (2H, q, J = 7.3 Hz), 3.62-3.69 (2H, m), 6.45 (2H, s), 6.96 (1H, s),
    7.30 (1H, s)
    mp: 176 (decomp.)
    10 2 ESI+: 261
    NMR: 1.75-1.83 (2H, m), 2.55-2.62 (2H, m), 2.78-2.84 (2H, m), 2.84-2.90 (2H, m),
    2.94-3.06 (4H, m), 3.20-3.28 (2H, m), 3.26 (3H, s), 3.34-3.41 (2H, m), 3.44-3.50 (2H, m),
    6.40 (1H, s), 6.43 (2H, s), 6.65 (1H, s)
  • TABLE 149
    Ex Syn Dat
    11 5 ESI+: 313
    NMR: 0.26-0.33 (1H, m), 0.36-0.43 (1H, m), 0.82 (3H, d, J = 6.6 Hz), 0.92-1.05 (2H, m),
    1.15 (3H, d, J = 6.9 Hz), 1.48-1.70 (2H, m), 2.13-2.29 (1H, m), 2.32-2.45 (1H, m),
    2.50-2.59 (1H, m), 2.62-3.13 (9H, m), 3.35-3.45 (1H, m), 4.67-4.78 (1H, m), 6.84 (1H, s)
    12 2 ESI+: 237, 239.1
    NMR: 1.73-1.79 (2H, m), 2.64 (2H, t, J = 6.2 Hz), 2.74-4.34 (13H, m), 5.40 (1H, s), 6.44 (2H,
    s), 6.67 (1H, s)
    13 2 ESI+: 251, 253
    NMR: 1.72-1.78 (2H, m), 2.67-2.70 (5H, m), 2.85-2.92 (6H, m), 2.96-2.99 (2H, m),
    3.13-3.76 (4H, m), 6.40 (1H, s), 6.79 (1H, s)
    14 2 ESI+: 219
    NMR: 2.78 (3H, s), 2.81-2.87 (2H, m), 2.87-2.93 (2H, m), 2.98-3.09 (4H, m), 3.13-3.19 (2H,
    m), 4.15-4.21 (2H, m), 6.44 (2H, s), 6.50 (1H, s), 6.54 (1H, s)
    15 2 ESI+: 279, 281
    NMR: 1.58-3.32 (16H, m), 4.05-4.12 (0.35H, m), 4.51-4.58 (0.65H, m), 7.04 (0.35H, s),
    7.16 (0.65H, s), 9.06-9.18 (2H, br)
    16 2 ESI+: 265, 267
    NMR: 1.19 (3H, t, J = 6.9 Hz), 1.68-1.74 (2H, m), 2.69 (2H, t, J = 6.6 Hz), 2.85 (2H, q, J = 6.9 Hz),
    2.95-2.98 (2H, m), 3.00-3.02 (2H, m), 3.13-3.18 (4H, m), 3.29-3.32 (2H, m), 6.86 (1H,
    s), 9.01-9.20 (2H, br)
    mp: 221-223
    17 2 ESI+: 219
    NMR: 2.96-3.04 (4H, m), 3.05-3.14 (4H, m), 4.52 (2H, s), 6.72 (1H, s), 6.82 (1H, s),
    9.26-9.42 (2H, br), 10.71 (1H, s)
    18 2 ESI+: 233
    NMR: 3.01-3.19 (8H, m), 3.25 (3H, s), 4.61 (2H, s), 6.88 (1H, s), 7.05 (1H, s), 9.33-9.47 (2H,
    br)
    19 2 FAB+: 233
    NMR: 2.04 (3H, s), 2.78 (3H, s), 2.85-3.09 (8H, br), 3.12-3.23 (2H, m), 4.17-4.28 (2H, m),
    6.42 (1H, s), 6.44 (2H, s)
    20 2 FAB+: 205
    NMR: 2.75-2.89 (4H, br), 2.93-3.08 (4H, br), 3.15-3.31 (2H, m), 3.99-4.13 (2H, m),
    5.17-5.93 (0.7H, br), 6.36 (1H, s), 6.44 (1.8H, s), 6.46 (1H, s)
    mp: 192-195
    21 2 ESI+: 307, 309
    NMR: 0.73 (3H, d, J = 6.3 Hz), 1.07-1.19 (4H, m), 1.54-2.19 (2H, m), 2.38-2.75 (6H, m),
    3.07-3.39 (6H, m), 4.14-4.27 (0.15H, br), 4.49-4.55 (0.85H, br), 7.01-7.20 (1H, m),
    9.00-9.27 (2H, br)
    mp: 245-249
    22 2 ESI+: 279, 281
    NMR: 0.87 (3H, t, J = 7.3 Hz), 1.64-1.73 (4H, m), 2.65-2.68 (2H, m), 2.72-2.76 (2H, m),
    2.84-2.91 (6H, m), 2.96-2.98 (2H, m), 3.02-3.70 (4H, m), 6.41 (1H, s), 6.77 (1H, s)
    23 2 ESI+: 295, 297
    NMR: 1.69-1.75 (2H, m), 2.67 (2H, t, J = 6.4 Hz), 2.85-2.91 (6H, m), 2.98 (2H, t, J = 6.4 Hz),
    3.02-3.04 (2H, m), 3.10-3.60 (6H, m), 3.67 (2H, t, J = 6.4 Hz), 6.41 (1H, s), 6.78 (1H, s)
  • TABLE 150
    Ex Syn Dat
    24 2 ESI+: 217
    NMR: 1.79-1.90 (2H, m), 2.61 (2H, t, J = 6.2 Hz), 2.79 (3H, s), 2.74-2.93 (4H, m),
    2.94-3.07 (4H, m), 3.07-3.15 (2H, m), 6.40 (1H, s), 6.43 (2H, s), 6.67 (1H, s)
    25 2 FAB+: 219
    NMR: 2.02 (3H, s), 2.65-2.95 (8H, m), 3.15-3.28 (2H, m), 4.05-4.14 (2H, m), 5.32-5.54 (1H,
    br), 6.21 (1H, s), 6.37 (1H, s)
    26 2 FAB+: 233
    NMR: 1.04 (3H, t, J = 7.0 Hz), 2.78-2.94 (4H, br), 2.95-3.08 (4H, br), 3.15-3.24 (2H, m),
    3.28 (2H, q, J = 7.0 Hz), 4.06-4.18 (2H, m), 6.44 (2H, s), 6.49 (1H, s), 6.55 (1H, s)
    27 2 FAB+: 283, 285
    NMR: 2.81-2.90 (2H, m), 2.90-3.00 (4H, m), 3.11-3.20 (2H, m), 3.29-3.37 (2H, m),
    4.02-4.10 (2H, m), 5.31-5.39 (1H, br), 6.43 (1.3H, s), 6.57 (1H, s)
    28 2 ESI+: 219
    NMR: 1.99 (3H, s), 2.74-2.83 (2H, m), 2.86-2.97 (6H, m), 3.24-3.31 (2H, m), 3.98-4.06 (2H,
    m), 4.86-5.09 (1H, br), 6.37 (1H, s), 6.38 (1H, s)
    29 2 ESI+: 283
    NMR: 2.97-3.06 (4H, m), 3.07-3.18 (7H, m), 3.74-3.81 (2H, m), 4.20-4.28 (2H, m),
    6.80 (1H, s), 7.40 (1H, s), 9.28-9.42 (2H, br)
    30 2 ESI+: 247
    NMR: 1.12 (6H, d, J = 6.6 Hz), 2.87-3.14 (8H, br), 3.15-3.25 (2H, br), 4.02-4.20 (3H, m),
    6.57 (1H, s), 6.75 (1H, s), 9.31-9.52 (2H, br)
    31 2 ESI+: 233
    NMR: 2.19 (3H, s), 2.56 (3H, s), 2.88-2.94 (2H, m), 2.95-3.08 (8H, m), 4.04-4.11 (2H, m),
    6.44 (2H, s), 6.51 (1H, s)
    32 2 ESI+: 281, 283
    NMR: 1.69-1.80 (2H, m), 2.64 (2H, t, J = 6.2 Hz), 2.80-2.89 (2H, m), 2.89-3.01 (4H, m),
    3.13-3.21 (2H, m), 3.21-3.29 (2H, m), 6.42 (1.4H, s), 6.69 (1H, s)
    33 2 ESI+: 245
    NMR: 1.78-1.89 (2H, m), 2.15 (3H, s), 2.64 (2H, t, J = 6.6 Hz), 2.88-3.08 (8H, m), 3.64 (2H,
    t, J = 6.2 Hz), 6.44 (2H, s), 6.96 (1H, s)
    mp: 159-162
    34 2 ESI+: 231
    NMR: 1.03 (3H, t, J = 7.0 Hz), 1.78-1.87 (2H, m), 2.59 (2H, t, J = 6.2 Hz), 2.79-2.84 (2H, m),
    2.86-2.92 (2H, m), 2.96-3.06 (4H, m), 3.16 (2H, t, J = 5.5 Hz), 3.28 (2H, q, J = 7.0 Hz), 6.41 (1H,
    s), 6.43 (2H, s), 6.65 (1H, s)
    35 2 ESI+: 297, 299
    NMR: 2.72 (3H, s), 2.93-3.12 (8H, m), 3.23-3.33 (2H, m), 4.08-4.20 (2H, m), 6.46 (2H, s),
    6.72 (1H, s)
    mp: 200-204
    36 2 ESI+: 245
    NMR: 0.50-0.64 (2H, m), 0.99-1.12 (2H, m), 1.57-1.68 (1H, m), 2.90-3.01 (2H, m),
    3.04-3.17 (4H, m), 3.23-3.34 (2H, m), 3.36-3.47 (2H, m), 4.20-4.33 (2H, br), 6.62 (1H, s),
    9.19-9.38 (2H, br)
    mp: 193-197
  • TABLE 151
    Ex Syn Dat
    37 2 ESI+: 273
    NMR: 1.01 (6H, d, J = 6.6 Hz), 1.78-1.90 (2H, m), 2.64 (2H, t, J = 6.8 Hz), 2.91-3.14 (9H, m),
    3.64 (2H, t, J = 6.2 Hz), 6.46 (2H, s), 7.00 (1H, s), 7.09-7.24 (1H, br)
    38 2 ESI+: 259
    NMR: 0.89 (6H, d, J = 6.5 Hz), 1.76-1.84 (2H, m), 1.92-2.04 (1H, m), 2.60 (2H, t, J = 6.3 Hz),
    2.77-2.84 (2H, m), 2.85-2.91 (2H, m), 2.97 (2H, d, J = 7.4 Hz), 2.97-3.06 (4H, m),
    3.16-3.25 (2H, m), 6.33 (1H, s), 6.44 (2H, s), 6.65 (1H, s)
    39 2 ESI+: 305, 307
    NMR: 0.52-0.98 (4H, m), 1.43-2.77 (6H, m), 2.89-4.33 (11H,), 4.42-4.54 (1H, m), 6.48 (2H,
    s), 6.97-7.11 (1H, m)
    40 2 ESI+: 319, 321
    NMR: 1.39-4.80 (24H, m), 6.48 (2H, s), 6.99 (0.4H, s), 7.08 (0.6H, s)
    41 2 ESI+: 291, 293
    NMR: 0.17-0.20 (2H, m), 0.47-0.52 (2H, m), 1.04-1.15 (1H, m), 1.69-1.75 (2H, m),
    2.67 (2H, t, J = 6.7 Hz), 2.74 (2H, d, J = 6.4 Hz), 2.85-2.91 (6H, m), 3.05-3.80 (6H, m), 6.41 (1H,
    s), 6.78 (1H, s)
    42 2 ESI+: 305, 307
    NMR: 1.69-1.92 (6H, m), 1.99-2.05 (2H, m), 2.65-2.75 (3H, m), 2.82-3.95 (15H, m),
    6.46 (2H, s), 6.80 (1H, s)
    mp: 141-143
    43 2 ESI+: 333, 335
    NMR: 1.18-2.12 (10H, m), 2.32-2.75 (4H, m), 2.92-4.18 (11H, m), 4.18-4.29 (0.25H, br),
    4.48-4.59 (0.75H, br), 6.48 (2H, s), 6.99 (0.25H, s), 7.11 (0.75H, s)
    44 2 ESI+: 341, 343
    NMR: 11.68-1.83 (1H, br), 2.64-2.82 (2H, m), 2.82-4.02 (14H, m), 6.48 (2H, s), 7.08 (1H,
    s), 7.14-7.71 (5H, br)
    45 2 ESI+: 319, 321
    NMR: 1.30-1.38 (2H, m), 1.47-1.63 (4H, m), 1.70-1.77 (4H, m), 2.28 (1H, quint, J = 7.5 Hz),
    2.68 (2H, t, J = 6.7 Hz), 2.82 (2H, d, J = 7.3 Hz), 2.91-2.94 (2H, m), 2.99-3.05 (6H, m),
    3.11-3.71 (5H, m), 6.46 (2H, s), 6.81 (1H, s)
    mp: 151-153
    46 2 ESI+: 327, 329
    NMR: 1.72-1.78 (2H, m), 2.74 (2H, t, J = 6.6 Hz), 2.81-2.84 (2H, m), 3.05-3.07 (2H, m),
    3.15-3.20 (4H, m), 3.32-3.35 (2H, m), 4.09 (2H, s), 6.93 (1H, s), 7.28 (1H, t, J = 7.4 Hz), 7.37 (2H,
    t, J = 7.4 Hz), 7.54 (2H, d, J = 7.4 Hz), 9.0-9.30 (2H, br)
    47 2 ESI+: 347, 348
    NMR: 0.73-3.85 (26H, m), 4.13-4.24 (0.2H, br), 4.46-4.55 (0.8H, br), 6.45 (1H, s),
    6.93-7.00 (0.2H, br), 7.08 (0.8H, s)
    48 2 ESI+: 333, 335
    NMR: 0.94-1.04 (2H, m), 1.13-1.27 (3H, m), 1.62-1.75 (6H, m), 1.83 (2H, d, J = 12.8 Hz),
    2.66-2.72 (4H, m), 2.91-2.94 (2H, m), 2.99-3.03 (6H, m), 3.11-3.74 (5H, m), 6.46 (2H, s),
    6.81 (1H, s)
    49 2 ESI+: 217
    NMR: 1.69-1.79 (2H, m), 1.95 (3H, s), 2.61 (2H, t, J = 6.2 Hz), 2.79-2.87 (2H, m),
    2.93-3.05 (6H, m), 3.21 (2H, t, J = 5.3 Hz), 6.44 (2H, s), 6.54 (1H, s)
  • TABLE 152
    Ex Syn Dat
    50 2 ESI+: 219
    NMR: 1.33 (3H, d, J = 6.4 Hz), 2.91-3.22 (9H, m), 3.44-3.54 (1H, m), 4.26-4.37 (1H, m),
    6.75 (1H, s), 6.87 (1H, s), 9.36-9.58 (2H, br)
    mp: 193-194
    51 2 ESI+: 279
    NMR: 1.79-1.97 (2H, m), 2.58-2.69 (2H, m), 2.69-2.80 (2H, m), 2.93-3.08 (4H, m),
    3.08-3.23 (4H, m), 6.95 (1H, s), 7.15-7.29 (2H, m), 7.37-7.56 (3H, m), 9.11-9.33 (2H, m)
    52 2 FAB+; 231
    NMR: 1.67-1.79 (2H, m), 2.18 (3H, s), 2.53 (3H, s), 2.66 (2H, t, J = 6.6 Hz), 2.85-2.93 (2H,
    m), 2.93-3.06 (8H, m), 6.43 (2H, s), 6.67 (1H, s)
    53 2 ESI+: 263
    NMR: 2.80-2.94 (4H, m), 2.96-3.09 (4H, m), 3.26 (3H, s), 3.29-3.34 (2H, m), 3.38 (2H, t, J = 5.4 Hz),
    3.50 (2H, t, J = 5.4 Hz), 4.04-4.12 (2H, m), 6.44 (1.8H, s), 6.50 (1H, s), 6.54 (1H, s)
    54 2 ESI+: 233
    NMR-A: 1.26 (3H, d, J = 6.3 Hz), 2.74-2.98 (8H, m), 3.06-3.18 (4H, br), 3.19-3.26 (1H, m),
    4.18-4.28 (1H, m), 6.54 (1H, s), 6.56 (1H, s), 6.64 (1H, s), 8.65-8.98 (2H, br)
    55 2 ESI+: 261
    NMR: 1.05 (3H, d, J = 6.5 Hz), 1.12 (3H, d, J = 6.5 Hz), 1.26 (3H, d, J = 6.2 Hz), 2.63-2.73 (1H,
    m), 2.76-3.12 (8H, m), 3.19-3.30 (1H, m), 3.98-4.13 (2H, m), 6.44 (1.7H, s), 6.50 (1H,
    s), 6.62 (1H, s)
    56 2 ESI+: 259
    NMR: 0.18-0.32 (2H, m), 0.41-0.57 (2H, m), 0.92-1.08 (1H, m), 2.83-3.22 (10H, m),
    3.30-3.48 (2H, m), 4.10-4.24 (2H, m), 6.57 (1H, s), 6.73 (1H, s), 9.27-9.55 (2H, br)
    mp: 179-182
    57 2 ESI+: 275
    NMR: 1.06 (6H, d, J = 6.6 Hz), 2.94-3.04 (4H, m), 3.08-3.19 (5H, m), 3.80-3.90 (2H, m),
    4.16-4.28 (2H, m), 6.76 (1H, s), 7.25-7.86 (1H, br), 9.10-9.36 (2H, br)
    58 2 ESI+: 261
    NMR: 0.90 (6H, d, J = 6.7 Hz), 1.91-2.05 (1H, m), 2.82-2.99 (6H, m), 3.05-3.15 (4H, br),
    3.24-3.30 (2H, m), 4.07-4.12 (2H, m), 6.50 (1H, s), 6.52 (1H, s), 8.80-8.96 (2H, br)
    mp: 157
    59 2 ESI+: 277
    NMR: 1.68-1.80 (2H, m), 2.77-2.92 (4H, m), 2.96-3.09 (4H, m), 3.17-3.30 (7H, m),
    3.36 (2H, t, J = 6.1 Hz), 4.05-4.15 (2H, m), 6.44 (2H, s), 6.49 (1H, s), 6.51 (1H, s)
    mp: 141-145
    60 1 ESI+: 337
    NMR: 1.70-1.80 (2H, m), 2.36-2.42 (2H, m), 2.66-2.80 (4H, m), 2.86-2.93 (2H, m),
    2.97-3.07 (4H, m), 3.02 (3H, s), 3.11-3.17 (2H, m), 3.21-3.28 (2H, m), 6.82 (1H, s), 7.07-7.13 (2H,
    m), 7.28-7.34 (1H, m), 7.36-7.42 (2H, m)
    61 2 ESI+: 261
    NMR: 0.92 (3H, t, J = 7.3 Hz), 1.26-1.40 (2H, m), 1.45-1.58 (2H, m), 2.85-3.14 (8H, m),
    3.16-3.34 (4H, m), 4.08-4.23 (2H, m), 6.54 (1H, s), 6.60 (1H, s), 9.30-9.54 (2H, br)
    62 2 ESI+: 295
    NMR: 2.70-2.97 (8H, m), 3.22-3.31 (2H, m), 4.10-4.20 (2H, m), 4.42 (2H, s), 6.39 (1H, s),
    6.51 (1H, s), 6.55 (1H, s), 7.21-7.40 (5H, m)
  • TABLE 153
    Ex Syn Dat
    63 2 ESI+: 277
    NMR: 1.10 (3H, t, J = 6.9 Hz), 2.78-2.95 (4H, m), 2.97-3.10 (4H, m), 3.29-3.48 (6H, m),
    3.53 (2H, t, J = 5.7 Hz), 4.04-4.12 (2H, m), 6.44 (1.8H, s), 6.50 (1H, s), 6.55 (1H, s)
    64 2 ESI+: 303
    NMR: 1.17-1.32 (2H, m), 1.52-1.64 (2H, br), 1.85-2.00 (1H, m), 2.81-3.18 (10H, m),
    3.21-3.36 (4H, m), 3.79-3.92 (2H, m), 4.02-4.17 (2H, m), 6.51 (1H, s), 6.54 (1H, s), 9.30-9.52 (2H,
    br)
    65 2 ESI+: 281
    NMR: 2.59-2.70 (2H, m), 2.90-3.17 (6H, m), 3.20-3.32 (2H, m), 4.14-4.24 (2H, m), 6.73 (1H,
    s), 7.19-7.30 (2H, m), 7.39-7.54 (3H, m), 9.29-9.49 (2H, br)
    66 2 ESI+: 309
    NMR: 1.66-1.78 (2H, m), 2.51-2.58 (2H, m), 2.61-2.70 (2H, m), 2.82-2.95 (4H, m),
    2.97-3.12 (4H, m), 3.76 (3H, s), 6.43 (2H, s), 6.65 (1H, d, J = 2.0 Hz), 6.67 (1H, d, J = 7.7 Hz), 6.72 (1H,
    s), 6.94 (1H, dd, J = 2.0, 7.8 Hz), 7.38 (1H, dd, J = 7.7, 7.8 Hz)
    67 2 ESI+: 313, 315
    NMR: 1.64-1.80 (2H, m), 2.46-2.56 (2H, m), 2.66 (2H, t, J = 6.2 Hz), 2.79-2.93 (3H, m),
    2.94-3.02 (2H, m), 3.03-3.13 (2H, m), 3.88-3.99 (1H, br), 6.40 (1.5H, s), 6.73 (1H, s),
    7.03-7.10 (1H, m), 7.12-7.16 (1H, m), 7.40-7.46 (1H, m), 7.49 (1H, dd, J = 7.6, 7.9 Hz)
    mp: 159-162
    68 2 ESI+: 347, 349
    NMR: 1.66-1.78 (2H, m), 2.41-2.47 (2H, m), 2.65 (2H, t, J = 6.2 Hz), 2.72-2.84 (4H, m),
    2.84-2.94 (2H, m), 3.01-3.11 (2H, m), 4.08-4.15 (1H, br), 6.37 (1H, s), 6.71 (1H, s), 7.07 (1H, dd,
    J = 1.8, 8.2 Hz), 7.32 (1H, d, J = 1.8 Hz), 7.68 (1H, d, J = 8.2 Hz)
    69 2 ESI+: 371, 373
    NMR: 1.62-1.73 (2H, m), 2.38-2.45 (2H, m), 2.52-2.65 (4H, m), 2.66-2.73 (2H, m),
    2.74-2.83 (2H, m), 2.84-2.99 (6H, m), 2.95 (3H, s), 6.38 (1H, s), 6.84 (1H, s), 7.07-7.12 (1H, m),
    7.17-7.21 (1H, m), 7.38-7.50 (2H, m)
    70 2 ESI+: 405, 407
    NMR: 1.61-1.73 (2H, m), 2.39-2.74 (8H, m), 2.77-2.99 (8H, m), 2.96 (3H, s), 6.40 (0.8H, s),
    6.87 (1H, s), 7.13 (1H, dd), 7.41 (1H, d, J = 1.8 Hz), 7.70 (1H, d, J = 8.2 Hz)
    71 2 ESI+: 275
    NMR: 2.47-2.53 (2H, m), 2.71-2.80 (2H, m), 2.88-3.08 (8H, m), 3.24 (3H, s), 3.48 (2H, t, J = 6.1 Hz),
    4.02 (2H, t, J = 6.1 Hz), 6.44 (1.7H, s), 6.99 (1H, s), 7.01 (1H, s)
    mp: 164-166
    72 2 ESI+: 365
    NMR: 0.34 (3H, d, J = 6.8 Hz), 0.35 (3H, d, J = 6.8 Hz), 1.13-1.29 (1H, m), 1.58-1.78 (2H, m),
    2.18-2.36 (2H, m), 2.56-2.66 (2H, m), 2.71 (2H, t, J = 6.6 Hz), 2.81-3.09 (8H, m), 3.74 (3H, s),
    6.42 (2H, s), 6.63-6.73 (2H, m), 6.85 (1H, s), 6.88 (1H, dd, J = 1.8, 7.8 Hz), 7.30 (1H, dd, J = 7.7,
    7.8 Hz)
    73 2 ESI+: 367
    NMR: 1.61-1.73 (2H, m), 2.30-2.50 (4H, m), 2.53-2.60 (2H, m), 2.60-2.73 (4H, m),
    2.73-2.81 (2H, m), 2.82-2.97 (4H, m), 2.93 (3H, s), 3.75 (3H, s), 6.37 (1H, s), 6.66-6.70 (2H, m),
    6.80 (1H, s), 6.88-6.93 (1H, m), 7.33 (1H, dd, J = 7.9, 8.2 Hz)
    74 2 ESI+: 243
    NMR: 0.23-0.33 (2H, m), 0.98-1.08 (2H, m), 1.29-1.39 (1H, m), 1.70-1.81 (2H, m), 2.60 (2H,
    t, J = 6.2 Hz), 2.76-2.85 (2H, m), 2.92-3.08 (4H, m), 3.13-3.23 (2H, m), 3.23-3.29 (2H, m),
    4.97 (1H, s), 6.42 (2H, s), 6.57 (1H, s)
  • TABLE 154
    Ex Syn Dat
    75 2 ESI+: 355
    NMR: 1.70-1.81 (2H, m), 2.47-2.53 (2H, m), 2.61-2.66 (2H, m), 2.66-2.74 (2H, m),
    2.79 (2H, t, J = 6.6 Hz), 2.82-2.89 (2H, m), 2.90-3.05 (6H, m), 3.04 (3H, s), 6.47 (1H, s), 6.92 (1H,
    s), 7.01-7.10 (2H, m), 7.21-7.31 (1H, m), 7.51-7.60 (1H, dd, J = 7.1, 14.4 Hz)
    76 2 ESI+: 291
    NMR: 1.07 (6H, d, J = 6.1 Hz), 2.79-2.94 (4H, m), 2.96-3.10 (4H, m), 3.28-3.41 (4H, m),
    3.48-3.59 (3H, m), 4.04-4.13 (2H, m), 6.44 (1.8H, s), 6.50 (1H, s), 6.54 (1H, s)
    mp: 135
    77 2 ESI+: 289
    NMR: 1.51-1.64 (1H, m), 1.92-2.04 (1H, m), 2.54-2.65 (1H, m), 2.84-3.35 (12H, m),
    3.38-3.49 (1H, m), 3.58-3.68 (1H, m), 3.69-3.84 (2H, m), 4.06-4.15 (2H, m), 6.53 (1H, s),
    6.59 (1H, s), 9.28-9.54 (2H, br)
    78 2 ESI+: 353
    NMR: 2.34 (3H, s), 2.39-2.48 (2H, m), 2.54-2.65 (4H, m), 2.77-3.09 (11H, m),
    3.96-4.08 (2H, m), 6.40 (1.5H, s), 6.67 (1H, s), 6.93 (1H, d, J = 7.6 Hz), 6.98 (1H, s), 7.18 (1H, d, J = 7.6 Hz),
    7.33 (1H, t, J = 7.6 Hz)
    mp: 173-176
    79 2 ESI+: 295
    NMR: 2.35 (3H, s), 2.52-2.61 (2H, m), 2.81-2.97 (4H, m), 2.97-3.12 (2H, m), 3.12-3.25 (2H,
    m), 3.92-4.12 (3H, m), 6.42 (1.8H, s), 6.57 (1H, s), 6.92 (1H, d, J = 7.7 Hz), 6.95 (1H, s),
    7.19 (1H, d, J = 7.7 Hz), 7.36 (1H, t, J = 7.7 Hz)
    80 2 ESI+: 299
    NMR: 0.29-0.38 (2H, m), 0.81 (6H, d, J = 6.7 Hz), 0.89-1.00 (2H, m), 1.54-1.66 (1H, m),
    1.66-1.77 (2H, m), 1.84-1.99 (1H, m), 2.58 (2H, t, J = 6.3 Hz), 2.78-2.85 (2H, m), 2.92 (2H, d, J = 7.3 Hz),
    2.94-3.05 (4H, m), 3.07-3.17 (2H, m), 3.17-3.25 (2H, m), 6.40 (1H, s), 6.62 (1H,
    s)
    81 2 ESI+: 301
    NMR: 0.30-0.42 (2H, m), 0.93-1.04 (2H, m), 1.57-1.74 (3H, m), 2.61 (2H, t, J = 6.4 Hz),
    2.83-2.94 (2H, m), 2.98-3.32 (13H, m), 3.56 (2H, t, J = 6.2 Hz), 6.43 (2H, s), 6.65 (1H, s)
    82 2 ESI+: 291
    NMR: 1.29 (3H, d, J = 7.3 Hz), 2.73 (1H, dd, J = 12.0, 7.3 Hz), 2.80-3.00 (5H, m),
    3.11-3.18 (1H, m), 3.25 (3H, s), 3.53 (2H, t, J = 5.6 Hz), 4.01-4.12 (2H, m), 4.58 (2H, s), 6.44 (1H, s),
    6.79 (1H, s), 7.04 (1H, s)
    83 2 ESI+: 305
    NMR: 1.32 (3H, d, J = 7.4 Hz), 1.79 (2H, quint, J = 6.6 Hz), 2.80 (1H, dd, J = 13.0, 7.4 Hz),
    2.85-3.09 (5H, m), 3.20-3.28 (4H, m), 3.36 (2H, t, J = 6.6 Hz), 3.94 (2H, t, J = 6.6 Hz), 4.57 (2H,
    s), 6.48 (2H, s), 6.83 (1H, s), 6.96 (1H, s)
    84 2 ESI+: 277
    NMR: 1.27 (3H, d, J = 7.2 Hz), 2.77-2.88 (4H, m), 3.02-3.14 (3H, m), 3.26 (3H, s),
    3.31-3.33 (2H, m), 3.38-3.41 (2H, m), 3.51 (2H, t, J = 5.5 Hz), 4.07-4.09 (2H, m), 6.45 (2H, s), 6.48 (1H,
    s), 6.51 (1H, s)
    85 2 ESI+: 291
    NMR: 1.28 (3H, d, J = 7.2 Hz), 1.74 (2H, quint, J = 6.3 Hz), 2.76-2.89 (4H, m), 3.04-3.16 (3H,
    m), 3.22-3.29 (7H, m), 3.37 (2H, t, J = 6.3 Hz), 4.10-4.12 (2H, m), 6.45 (2H, s), 6.48 (1H,
    s), 6.50 (1H, s)
  • TABLE 155
    Ex Syn Dat
    86 2 ESI+: 289
    NMR: 1.53-1.62 (2H, br), 1.62-1.77 (2H, m), 2.84-3.15 (8H, m), 3.16-3.26 (2H, m),
    3.45 (2H, t, J = 11.2 Hz), 3.80-3.97 (3H, m), 4.05-4.14 (2H, m), 6.54 (1H, s), 6.75 (1H, s),
    9.24-9.48 (1.8H, br)
    87 2 ESI+: 245
    NMR: 1.31 (6H, d, J = 7.1 Hz), 1.83-1.95 (2H, m), 2.68-2.80 (2H, m), 2.97-3.27 (8H, m),
    3.27-3.45 (3H, m), 6.94 (1H, s), 9.27 (2H, s)
    88 2 ESI+: 303
    NMR: 0.41-0.48 (2H, m), 0.96-1.03 (2H, m), 1.56-1.64 (1H, m), 2.75-2.85 (2H, m),
    2.85-2.97 (4H, m), 3.08-3.18 (6H, m), 3.25 (3H, s), 3.62 (2H, t, J = 6.0 Hz), 3.97-4.03 (2H, m),
    6.38 (1H, s), 6.47 (1H, s)
    89 2 ESI+: 303
    NMR: 1.23 (6H, d, J = 7.1 Hz), 1.65-1.81 (2H, m), 2.63-2.70 (2H, m), 2.76-2.91 (4H, m),
    2.93-3.15 (8H, m), 3.29 (3H, s), 3.58 (2H, t, J = 6.2 Hz), 3.85-3.99 (1H, m), 6.43 (2H, s), 6.68 (1H,
    s)
    90 2 ESI+: 277
    NMR: 2.18 (3H, s), 2.80-2.86 (2H, m), 2.87-2.93 (2H, m), 2.94-3.10 (8H, m), 3.30 (3H, s),
    3.61 (2H, t, J = 5.8 Hz), 4.02-4.08 (2H, m), 6.42 (1.7H, s), 6.49 (1H, s)
    mp: 166-170
    91 2 ESI+: 273
    NMR: 1.46-1.84 (8H, m), 2.79-2.94 (4H, m), 2.95-3.07 (4H, m), 3.12-3.19 (2H, m),
    4.08-4.22 (3H, m), 6.43 (1.7H, s), 6.49 (1H, s), 6.67 (1H, s)
    92 2 ESI+: 281
    NMR: 2.66-2.74 (2H, m), 2.77-2.97 (6H, m), 3.60-3.70 (2H, m), 4.15-4.22 (2H, m),
    6.38 (1H, s), 6.62-6.66 (2H, br), 7.02-7.09 (1H, m), 7.18-7.25 (2H, m), 7.31-7.39 (2H, m)
    mp: 220-222
    93 2 ESI+: 317
    NMR: 0.43-0.49 (1H, m), 0.61-0.66 (1H, m), 0.98-1.05 (2H, m), 1.28 (3H, d, J = 7.4 Hz),
    1.60-1.67 (1H, m), 2.61-2.67 (2H, m), 2.90-2.93 (1H, m), 3.04-3.25 (8H, m), 3.32 (2H, dd, J = 13.2,
    4.8 Hz), 3.62 (2H, t, J = 5.9 Hz), 3.97-4.03 (2H, m), 4.14-4.20 (1H, m), 6.44-6.46 (3H,
    m)
    94 2 ESI+: 275
    NMR: 1.67-1.73 (2H, m), 2.15 (3H, s), 2.64 (2H, t, J = 6.7 Hz), 2.79-2.84 (4H, m),
    2.88-2.93 (6H, m), 3.02-3.04 (2H, m), 3.28 (3H, s), 3.59 (2H, t, J = 6.2 Hz), 6.37 (1H, s), 6.62 (1H, s)
    95 2 ESI+: 261
    NMR: 1.67-1.73 (2H, m), 2.17 (3H, s), 2.65 (2H, t, J = 6.7 Hz), 2.72 (2H, t, J = 6.7 Hz),
    2.89-2.91 (2H, m), 2.99-3.04 (8H, m), 3.66 (2H, t, J = 6.7 Hz), 6.43 (2H, s), 6.66 (1H, s)
    96 2 ESI+: 231
    NMR: 1.08 (3H, t, J = 7.3 Hz), 1.88-1.98 (2H, m), 2.62-2.79 (4H, m), 2.98-3.18 (8H, m),
    3.27-3.37 (2H, m), 6.92 (1H, s), 9.33 (2H, s)
    97 2 ESI+: 289
    NMR: 1.03 (3H, t, J = 7.4 Hz), 1.68-1.78 (2H, m), 2.66 (2H, t, J = 6.9 Hz), 2.72 (2H, q, J = 7.4 Hz),
    2.86 (2H, t, J = 6.3 Hz), 2.90-2.95 (2H, m), 2.95-3.05 (4H, m), 3.06-3.13 (4H, m), 3.30 (3H,
    s), 3.59 (2H, t, J = 6.3 Hz), 6.52 (2H, s), 6.69 (1H, s)
  • TABLE 156
    Ex Syn Dat
    98 2 ESI+: 291
    NMR: 1.04 (3H, t, J = 7.4 Hz), 2.71 (2H, q, J = 7.4 Hz), 2.84-2.93 (4H, m), 2.94-3.08 (8H, m),
    3.31 (3H, s), 3.61 (2H, t, J = 5.9 Hz), 4.06-4.12 (2H, m), 6.44 (2H, s), 6.50 (1H, s)
    mp: 159-163
    99 2 ESI+: 277
    NMR: 1.07 (3H, d, J = 6.7 Hz), 2.79-2.94 (4H, m), 2.97-3.09 (4H, m), 3.14-3.22 (2H, m),
    3.24 (3H, s), 3.32-3.39 (1H, m), 3.41-3.48 (1H, m), 4.01-4.11 (3H, m), 6.44 (2H, s), 6.50 (1H,
    s), 6.63 (1H, s)
    100 2 ESI+: 259
    NMR: 0.88 (6H, d, J = 6.6 Hz), 1.77-1.98 (3H, m), 2.54-2.78 (4H, m), 2.91-3.17 (8H, m),
    3.26-3.33 (2H, m), 6.88 (1H, s), 9.34 (2H, s)
    101 2 ESI+: 305
    NMR: 1.24 (6H, d, J = 7.4 Hz), 2.80-2.92 (4H, m), 2.98-3.13 (8H, m), 3.30 (3H, s), 3.60 (2H,
    t, J = 5.9 Hz), 3.80-3.97 (1H, m), 4.04-4.12 (2H, m), 6.43 (1.8H, s), 6.51 (1H, s)
    102 2 ESI+: 319
    NMR: 1.01 (3H, t, J = 7.2 Hz), 1.62-1.87 (2H, m), 2.62-2.82 (6H, m), 2.85-3.07 (8H, m),
    3.16-3.28 (2H, m), 3.26 (3H, s), 3.30 (2H, d, J = 5.5 Hz), 3.91-3.99 (1H, m), 6.43 (2H, s), 6.67 (1H,
    s)
    103 2 ESI+: 265
    NMR: 1.83-1.98 (2H, m), 2.85-3.00 (4H, m), 3.01-3.14 (4H, br), 3.22-3.29 (2H, m),
    3.29-3.37 (2H, m), 4.09-4.18 (2H, m), 4.53 (2H, dt, J = 47.4, 5.8 Hz), 6.54 (1H, s), 6.57 (1H, s),
    9.30-9.46 (2H, br)
    104 2 ESI+: 317
    NMR: 0.40-0.50 (2H, m), 0.96-1.05 (2H, m), 1.10 (3H, t, J = 7.0 Hz), 1.58-1.67 (1H, m),
    2.84-2.92 (2H, m), 2.99-3.18 (8H, m), 3.18-3.27 (2H, m), 3.43 (2H, q, J = 7.0 Hz), 3.65 (2H, t, J = 6.0 Hz),
    3.98-4.05 (2H, m), 6.44 (1.8H, s), 6.52 (1H, s)
    mp: 140-145
    105 2 ESI+: 343
    NMR: 0.35-0.56 (6H, m), 0.97-1.08 (2H, m), 1.64-1.75 (1H, m), 2.90-2.98 (2H, m),
    3.00-3.36 (15H, m), 4.04-4.13 (2H, m), 6.54 (1H, s), 9.24-9.38 (1.8H, br)
    mp: 166-167
    106 2 ESI+: 317
    NMR: 0.39-0.47 (2H, m), 0.95-1.03 (2H, m), 1.56-1.65 (1H, m), 1.82-1.92 (2H, m),
    2.78-2.85 (2H, m), 2.87-3.00 (6H, m), 3.02-3.08 (2H, m), 3.13-3.23 (5H, m), 3.34 (2H, t, J = 6.2 Hz),
    3.95-4.01 (2H, m), 6.37 (1H, s), 6.48 (1H, s)
    mp: 169-171
    107 2 ESI+: 351
    NMR: 1.29 (3H, d, J = 7.2 Hz), 1.84 (2H, quint, J = 6.3 Hz), 2.70 (2H, t, J = 6.3 Hz),
    2.72-2.88 (3H, m), 2.97-3.23 (4H, m), 3.69 (2H, t, J = 6.3 Hz), 5.17 (2H, s), 6.47 (2H, s), 6.92 (1H, s),
    7.31-7.42 (5H, m), 7.45 (1H, s)
    108 2 ESI+: 289
    NMR: 1.06-1.23 (3H, br), 161-1.74 (1H, br), 1.96-2.08 (4H, br), 2.62-2.70 (1H, m),
    2.91-3.13 (7H, m), 3.16-3.27 (2H, m), 3.52-4.29 (7H, m), 6.87 (1H, s)
    mp: 185-186
  • TABLE 157
    Ex Syn Dat
    109 2 ESI+: 288
    NMR: 0.98 (3H, t, J = 7.1 Hz), 1.73-1.84 (2H, br), 2.05 (3H, s), 2.56 (2H, t, J = 6.8 Hz),
    2.99-3.08 (6H, m), 3.11-3.18 (4H, m), 3.29-4.63 (5H, br), 5.88-6.09 (1H, br), 6.87 (1H, s)
    mp: 170-171
    110 112 ESI+: 293
    NMR: 1.82-1.95 (2H, m), 2.61-2.71 (2H, m), 2.74-2.87 (4H, m), 2.91-3.07 (4H, m),
    3.22-3.32 (2H, m), 4.45 (2H, s), 6.36 (1H, s), 6.42 (2H, s), 6.70 (1H, s), 7.17-7.37 (5H, m)
    mp: 148 (decomp.)
    111 112 ESI+: 325
    NMR: 2.85-2.94 (4H, m), 3.00-3.12 (4H, m), 3.24-3.28 (2H, m), 3.73 (3H, s), 4.12-4.19 (2H,
    m), 4.41 (2H, s), 6.56 (1H, s), 6.60 (1H, s), 6.79-6.89 (3H, m), 7.22-7.28 (1H, m),
    9.23-9.44 (2H, br)
    112 112 ESI+: 329, 331
    NMR: 2.78-2.88 (4H, m), 2.96-3.08 (4H, m), 3.27-3.34 (2H, m), 4.12-4.21 (2H, m),
    4.44 (2H, s), 6.47 (2H, s), 6.54 (1H, s), 6.56 (1H, s), 7.23-7.42 (4H, m)
    mp: 151 (decomp.)
    113 112 ESI+: 325
    NMR: 2.85-2.96 (4H, m), 3.01-3.11 (4H, m), 3.20-3.27 (2H, m), 3.73 (3H, s), 4.11-4.17 (2H,
    m), 4.36 (2H, s), 6.55 (1H, s), 6.66 (1H, s), 6.87-6.92 (2H, m), 7.20-7.27 (2H, m),
    9.30-9.49 (2H, br)
    114 112 ESI+: 329, 331
    NMR: 2.28 (4H, s), 2.72-2.82 (4H, m), 2.92-3.04 (4H, m), 3.24-3.33 (2H, m), 4.10-4.20 (2H,
    m), 4.42 (2H, s), 6.52 (1H, s), 6.54 (1H, s), 7.29-7.35 (2H, m), 7.37-7.42 (2H, m)
    mp: 178 (decomp.)
    115 112 ESI+: 325
    NMR: 2.28 (4H, s), 2.73-2.88 (4H, m), 2.94-3.05 (4H, m), 3.37-3.46 (2H, m), 3.63 (2H, t, J = 5.6 Hz),
    4.07-4.18 (4H, m), 6.51 (1H, s), 6.61 (1H, s), 6.89-6.98 (3H, m), 7.23-7.33 (2H,
    m)
    mp: 132-134
    116 112 ESI+: 296
    NMR: 2.73-2.86 (4H, m), 2.90-3.04 (4H, m), 3.40-3.48 (2H, m), 4.14-4.22 (2H, m),
    4.52 (2H, s), 6.43 (2H, s), 6.46 (1H, s), 6.54 (1H, s), 7.23-7.35 (2H, m), 7.70-7.79 (1H, m),
    8.50-8.57 (1H, m)
    117 112 ESI+: 302
    NMR: 2.78-2.90 (4H, m), 2.95-3.06 (4H, m), 3.38-3.45 (2H, m), 4.11-4.17 (2H, m),
    4.57 (2H, s), 6.44 (2H, s), 6.51 (1H, s), 6.66 (1H, s), 7.53 (1H, d, J = 2 Hz), 9.06 (1H, d, J = 2 Hz)
    mp: 134-138
    118 2 ESI+: 339
    NMR-A: 2.41-2.47 (2H, m), 2.54-2.67 (4H, m), 2.94 (3H, s), 2.96-3.03 (6H, m),
    3.13-3.20 (2H, m), 4.00-4.07 (2H, m), 6.63 (1H, s), 6.74 (1H, s), 7.15-7.21 (2H, m), 7.36-7.42 (1H,
    m), 7.44-7.50 (2H, m)
    mp: 199-201
  • TABLE 158
    Ex Syn Dat
    119 2 ESI+: 249
    NMR: 2.85-2.98 (4H, m), 3.03-3.12 (4H, m), 3.29 (2H, t, J = 6.1 Hz), 3.32-3.38 (2H, m),
    3.57 (2H, t, J = 6.1 Hz), 4.02-4.17 (2H, m), 5.33-5.89 (2H, br), 6.52 (1H, s), 6.56 (1H, s),
    9.17-9.42 (2H, br)
    120 2 ESI+: 303
    NMR: 0.35-0.39 (2H, m), 0.97-1.01 (2H, m), 1.59-1.72 (3H, m), 1.90-2.03 (2H, m),
    2.27 (4H, s), 2.61 (2H, t, J = 6.4 Hz), 2.82-2.84 (2H, m), 3.00-3.03 (2H, m), 3.05-3.09 (6H, m),
    3.19-3.22 (2H, m), 4.40 (1H, t, J = 5.8 Hz), 4.52 (1H, t, J = 5.8 Hz), 6.66 (1H, s)
    121 2 ESI+: 353, 355
    NMR: 2.42-2.48 (2H, m), 2.69-2.76 (2H, m), 2.92-3.01 (6H, m), 3.03 (3H, s), 3.23-3.35 (4H,
    m), 4.19 (2H, t, J = 5.4 Hz), 6.42 (1H, s), 7.09 (1H, s)
    mp: 99-104
    122 2 ESI+: 337
    NMR: 1.78-1.88 (2H, m), 2.67 (2H, t, J = 6.5 Hz), 2.95-3.05 (4H, m), 3.08-3.17 (4H, m),
    3.66-3.73 (2H, m), 5.17 (2H, s), 6.95 (1H, s), 7.28-7.44 (5H, m), 7.50 (1H, s), 9.20-9.43 (2H, br)
    mp: 185-188
    123 2 ESI+: 303
    NMR: 0.92 (6H, d, J = 6.8 Hz), 1.77-1.97 (3H, m), 2.68 (2H, t, J = 6.5 Hz), 2.95-3.04 (4H, m),
    3.10-3.18 (4H, m), 3.63-3.70 (2H, m), 3.90 (2H, d, J = 6.4 Hz), 6.96 (1H, s), 7.48 (1H, s),
    9.06-9.26 (2H, br)
    mp: 202-207
    124 2 ESI+: 245
    NMR: 1.12 (3H, t, J = 7.0 Hz), 2.46-2.52 (2H, m), 2.72-2.82 (2H, m), 3.00-3.24 (8H, m),
    3.88 (2H, q, J = 7.0 Hz), 6.99 (1H, s), 7.04 (1H, s), 9.26-9.50 (2H, br)
    mp: 241 (decomp.)
    125 2 ESI+: 259
    NMR: 0.87 (3H, t, J = 7.4 Hz), 1.47-1.61 (2H, m), 2.46-2.52 (2H, m), 2.73-2.82 (2H, m),
    3.00-3.21 (8H, m), 3.81 (2H, t, J = 7.5 Hz), 6.98 (1H, s), 7.04 (1H, s), 9.23-9.49 (2H, br)
    mp: 125-129
    126 2 ESI+: 307
    NMR: 2.61-2.70 (2H, m), 2.82-3.16 (10H, m), 5.11 (2H, s), 6.83 (1H, s), 7.06 (1H, s),
    7.18-7.35 (5H, m), 9.21-9.40 (2H, br)
    mp: 177-180
    127 2 ESI+: 273
    NMR: 0.83 (6H, d, J = 6.7 Hz), 1.84-1.97 (1H, m), 2.30 (4H, s), 2.45-2.54 (2H, m),
    2.73-2.81 (2H, m), 2.86-3.07 (8H, m), 3.72-3.80 (2H, m), 6.96 (1H, s), 7.01 (1H, s)
    mp: 142-144
  • TABLE 159
    Ex Syn Dat
    128 2 ESI+: 289
    NMR: 1.24 (6H, d, J = 6.2 Hz), 1.78-1.84 (2H, m), 2.29 (4H, s), 2.66 (2H, t, J = 6.5 Hz),
    2.87-2.89 (4H, br), 2.99-3.01 (4H, br), 3.61-3.64 (2H, m), 4.87 (1H, quint, J = 6.2 Hz), 6.90 (1H,
    s), 7.44 (1H, s)
    129 2 ESI+: 367, 369
    NMR: 1.52-1.67 (2H, m), 2.38-2.47 (2H, m), 2.71-2.82 (2H, m), 3.01-3.10 (9H, m),
    3.15 (2H, t, J = 6 Hz), 3.30-3.39 (2H, m), 4.06 (2H, t, J = 7.1 Hz), 6.47 (2H, s), 7.13 (1H, s)
    mp: 153-155
    130 2 ESI+: 331
    NMR: 2.93-3.10 (10H, m), 3.13-3.21 (2H, m), 3.24 (3H, s), 3.58 (2H, t, J = 5.9 Hz), 4.12 (2H,
    t, J = 4.4 Hz), 6.46 (2H, s), 6.91 (1H, s)
    mp: 180 (decomp.)
    131 2 ESI+: 329
    NMR: 1.66-1.81 (2H, m), 2.68 (2H, t, J = 6.4 Hz), 2.90-3.18 (12H, m), 3.20 (3H, s), 3.52 (2H,
    t, J = 6.0 Hz), 6.45 (2H, s), 7.02 (1H, s)
    mp: 175 (decomp.)
    132 2 ESI+: 261
    NMR: 0.88 (3H, t, J = 7.4 Hz), 1.49-1.63 (2H, m), 2.86-3.07 (8H, m), 3.77-3.88 (2H, m),
    4.57 (2H, s), 6.43 (2H, s), 6.84 (1H, s), 7.03 (1H, s)
    mp: 183 (decomp.)
    133 2 ESI+: 309
    NMR: 2.89-3.18 (8H, m), 3.32 (3H, s), 4.75 (2H, s), 5.12 (2H, s), 6.90 (1H, s), 6.94 (1H, s),
    7.21-7.36 (5H, m), 9.19-9.37 (2H, br)
    mp: 233 (decomp.)
    134 2 ESI+: 351
    NMR: 1.74-1.80 (2H, m), 2.30 (4H, s), 2.64 (2H, t, J = 6.6 Hz), 2.76-2.79 (2H, br),
    2.84-2.87 (2H, br), 2.93-2.99 (6H, m), 3.57-3.60 (2H, m), 4.33 (2H, t, J = 6.6 Hz), 6.88 (1H, s),
    7.21-7.33 (6H, m)
    135 2 ESI+: 341, 343
    NMR-A: 2.98-3.05 (4H, m), 3.07-3.13 (2H, m), 3.14-3.23 (4H, m), 3.28-3.35 (5H, m),
    3.74 (2H, t, J = 6.18 Hz), 4.10-4.16 (2H, m), 6.64 (2H, s), 6.77 (1H, s), 8.89 (2H, s)
    mp: 183 (decomp.)
    136 2 ESI+: 337, 339
    NMR: 0.70 (3H, t, J = 7.4 Hz), 1.29-1.45 (2H, m), 2.41-2.48 (2H, m), 2.72-2.80 (2H, m),
    3.00-3.11 (6H, m), 3.28-3.40 (2H, m), 3.98 (2H, t, J = 7.3 Hz), 6.47 (2H, s), 6.98 (1H, s)
    mp: 187 (decomp.)
    137 2 ESI+: 335
    NMR: 0.46 (3H, t, J = 7.4 Hz), 0.91-1.03 (2H, m), 2.30 (4H, s), 2.45-2.52 (2H, m),
    2.71-2.84 (6H, m), 2.89-3.11 (6H, m), 7.13 (1H, s), 7.16-7.23 (2H, m), 7.38-7.52 (3H, m)
    mp: 196-200
  • TABLE 160
    Ex Syn Dat
    138 2 ESI+: 339
    NMR: 2.28 (3H, s), 2.74-2.96 (8H, m), 3.72 (3H, s), 4.73 (2H, s), 5.08 (2H, s), 6.79-6.89 (5H,
    m), 7.18-7.29 (1H, m)
    mp: 188-189
    139 2 ESI+: 343, 345
    NMR: 2.29 (3H, s), 2.74-2.98 (8H, m), 4.75 (2H, s), 5.12 (2H, s), 6.83-6.89 (2H, m),
    7.21-7.26 (1H, m), 7.30-7.40 (3H, m)
    mp: 192-194
    140 2 ESI+: 299
    NMR: 0.25-0.36 (2H, m), 0.66 (3H, t, J = 7.4 Hz), 0.95-1.04 (2H, m), 1.24-1.36 (2H, m),
    1.81-1.99 (1H, m), 2.27-2.45 (8H, m), 2.60-2.74 (2H, m), 2.87-3.87 (8H, m), 6.94 (1H, s)
    mp: 170-171
    141 2 ESI+: 305
    NMR: 0.37-0.50 (2H, m), 0.95-1.04 (2H, m), 1.57-1.67 (1H, m), 1.95-2.11 (2H, m),
    2.78-2.85 (2H, m), 2.86-3.03 (6H, m), 3.03-3.10 (2H, m), 3.11-3.21 (2H, m), 3.99 (2H, t, J = 4.3 Hz),
    4.50 (2H, dt, J = 47.5, 5.8 Hz), 6.37 (1H, s), 6.49 (1H, s)
    mp: 144-147
    142 2 ESI+: 245
    NMR: 0.33-0.42 (2H, m), 0.81-0.95 (2H, m), 1.38-1.48 (1H, m), 2.70-2.79 (2H, m),
    2.84-2.98 (4H, m), 3.05-3.15 (2H, m), 3.17-3.26 (2H, m), 4.03-4.11 (2H, m), 5.32-5.62 (1H, br),
    6.24 (1H, s), 6.36 (1H, s)
    143 2 ESI+: 286
    NMR: 1.71-1.77 (2H, m), 2.29 (2H, s), 2.64 (2H, t, J = 6.4 Hz), 2.79-2.85 (4H, m),
    2.90-2.92 (2H, m), 3.04-3.07 (2H, m), 3.14-3.17 (2H, m), 3.27 (3H, s), 3.38 (2H, t, J = 6.3 Hz), 3.69 (2H,
    t, J = 6.3 Hz), 7.02 (1H, s)
    144 2 ESI+: 339
    NMR: 2.30 (4H, s), 2.78-2.99 (8H, m), 3.71 (3H, s), 4.71 (2H, m), 5.04 (2H, s), 6.84 (1H, s),
    6.85-6.91 (2H, m), 6.92 (1H, s), 7.19-7.24 (2H, m)
    mp: 173-176
    145 2 ESI+: 343, 345
    NMR: 2.81-3.03 (8H, m), 4.74 (2H, s), 5.11 (2H, s), 6.44 (2H, s), 6.86 (1H, s), 6.88 (1H, s),
    7.27-7.34 (2H, m), 7.36-7.43 (2H, m)
    mp: 207 (decomp.)
    146 2 ESI+: 343.2, 345.2
    NMR: 2.28 (3H, s), 2.71-2.96 (8H, m), 4.77 (2H, s), 5.11 (2H, s), 6.86 (1H, s), 6.88 (1H, s),
    7.04-7.09 (1H, m), 7.24-7.35 (2H, m), 7.50-7.54 (1H, m)
    mp: 119-127
  • TABLE 161
    Ex Syn Dat
    147 2 ESI+: 385, 387
    NMR: 1.74-1.80 (2H, m), 2.30 (4H, s), 2.64 (2H, t, J = 6.5 Hz), 2.78-2.81 (2H, br),
    2.85-2.87 (2H, br), 2.96-2.99 (4H, br), 3.09 (2H, t, J = 6.5 Hz), 3.57-3.60 (2H, m), 4.36 (2H, t, J = 6.5 Hz),
    6.88 (1H, s), 7.26-7.33 (3H, m), 7.39-7.46 (2H, m)
    mp: 187-188
    148 2 ESI+: 337
    NMR: 1.78-1.94 (2H, m), 2.65 (2H, t, J = 7.6 Hz), 2.89-3.12 (8H, m), 3.87 (2H, t, J = 7.5 Hz),
    4.58 (2H, s), 6.46 (2H, s), 6.85 (1H, s), 6.87 (1H, s), 7.15-7.35 (5H, m)
    mp: 218 (decomp.)
    149 2 ESI+: 339
    NMR: 2.97-3.20 (8H, m), 4.12-4.32 (4H, m), 4.62 (2H, s), 6.83-6.98 (4H, m), 7.18-7.34 (3H,
    m), 9.22-9.41 (2H, br)
    mp: 246 (decomp.)
    150 2 ESI+: 291
    NMR: 1.39 (3H, d, J = 6.7 Hz), 2.83-3.07 (8H, m), 3.24 (3H, s), 3.46-3.55 (2H, m),
    3.97-4.10 (2H, m), 4.63 (1H, q, J = 6.7 Hz), 6.41 (1H, s), 6.82 (1H, s), 7.06 (1H, s)
    mp: 189 (decomp.)
    151 2 ESI+: 273
    NMR: 0.42-0.50 (2H, m), 0.96-1.05 (2H, m), 1.17 (3H, t, J = 7.0 Hz), 1.61-1.70 (1H, m),
    2.85-2.99 (4H, m), 3.00-3.13 (6H, m), 3.19-3.28 (2H, m), 3.94-4.01 (2H, m), 6.45 (2H, s),
    6.53 (1H, s)
    mp: 174-177
    152 2 ESI+: 287
    NMR: 0.41-0.48 (2H, m), 0.86 (3H, t, J = 7.4 Hz), 0.95-1.03 (2H, m), 1.57-1.72 (3H, m),
    2.76-2.88 (4H, m), 2.88-2.98 (4H, m), 3.02-3.09 (2H, m), 3.11-3.20 (2H, m), 3.95-4.01 (2H,
    m), 6.37 (1H, s), 6.47 (1H, s)
    mp: 138-141
    153 2 ESI+: 289
    NMR: 0.39-0.47 (2H, m), 0.94-1.03 (2H, m), 1.55-1.65 (1H, m), 2.77-2.84 (2H, m),
    2.87-2.99 (4H, m), 3.03 (2H, t, J = 6.5 Hz), 3.10-3.20 (4H, m), 3.69 (2H, t, J = 6.5 Hz), 3.97-4.05 (2H,
    m), 6.37 (1H, s), 6.47 (1H, s)
    mp: 146-150
    154 2 ESI+: 277
    NMR: 1.23 (3H, d, J = 6.3 Hz), 2.75-2.81 (2H, m), 2.81-2.87 (2H, m), 2.90-3.03 (5H, m),
    3.25 (3H, s), 3.28-3.37 (2H, m), 3.38-3.55 (3H, m), 4.02-4.12 (1H, m), 6.39 (1H, s), 6.48 (1H,
    s), 6.51 (1H, s)
    mp: 170 (decomp.)
    155 2 ESI+: 329, 331
    NMR: 2.75-2.87 (4H, m), 2.91-3.06 (4H, m), 3.30-3.38 (2H, m), 4.16-4.24 (2H, m),
    4.48 (2H, s), 6.36 (1H, s), 6.43 (2H, s), 6.57 (1H, s), 7.26-7.35 (3H, m), 7.45-7.52 (1H, m)
    mp: 184 (decomp.)
  • TABLE 162
    Ex Syn Dat
    156 2 ESI+: 317
    NMR: 0.17-0.26 (1H, m), 0.59-0.69 (1H, m), 0.93-1.07 (2H, m), 1.23 (3H, d, J = 6.1 Hz),
    1.58-1.69 (1H, m), 2.52-2.58 (1H, m), 2.75-2.87 (1H, m), 2.89-3.05 (3H, m), 3.05-3.21 (5H,
    m), 3.25 (3H, s), 3.29-3.43 (2H, m), 3.54-3.67 (2H, m), 3.96-4.07 (1H, m), 6.44 (2H, s),
    6.51 (1H, s)
    mp: 102-103
    157 2 ESI+: 259
    NMR: 0.49-0.56 (2H, m), 0.96-1.05 (2H, m), 1.62-1.71 (1H, m), 2.77 (3H, s), 2.85-2.93 (2H,
    m), 2.99-3.12 (6H, m), 3.20-3.28 (2H, m), 3.97-4.03 (2H, m), 6.43 (2H, s), 6.53 (1H, s)
    mp: 211 (decomp.)
    158 2 ESI+: 353, 355
    NMR: 1.07-1.29 (3H, br), 1.62-1.77 (1H, br), 1.95-2.11 (1H, br), 2.63-2.77 (2H, br),
    2.86-3.42 (9H, m), 3.94-4.27 (3H, m), 7.08 (1H, s)
    mp: 187-189
    159 2 ESI+: 231
    NMR: 1.27 (6H, s), 1.84-1.91 (2H, m), 3.05-3.20 (8H, m), 3.26-3.32 (2H, m), 6.99 (1H, s),
    7.37 (1H, s), 9.36-9.59 (1.9H, br)
    mp: 288-290
    160 2 ESI+: 429, 431
    NMR: 1.60-2.08 (2H, m), 2.65-3.38 (12H, m), 3.93-4.41 (4H, m), 6.94-7.39 (6H, m)
    mp: 176-177
    161 2 ESI+: 245
    NMR: 1.19 (6H, s), 1.64-1.70 (2H, m), 2.81 (3H, s), 2.86-2.94 (4H, m), 2.99-3.15 (6H, m),
    6.39 (1H, s), 6.44 (1.8H, s), 6.93 (1H, s)
    mp: 197-200
    162 2 ESI+: 385, 387
    NMR: 1.74-1.81 (2H, m), 2.64 (2H, t, J = 6.6 Hz), 2.81-2.83 (2H, br), 2.88-2.90 (2H, br),
    2.95-3.01 (6H, m), 3.57-3.60 (2H, m), 4.34 (2H, t, J = 6.4 Hz), 6.45 (2H, s), 6.89 (1H, s),
    7.23-7.36 (5H, m)
    mp: 201 (decomp.)
    163 2 ESI+: 381
    NMR: 1.74-1.81 (2H, m), 2.64 (2H, t, J = 6.6 Hz), 2.82-2.84 (2H, br), 2.89-2.94 (4H, m),
    2.98-3.02 (4H, br), 3.57-3.60 (2H, m), 3.78 (3H, s), 4.28 (2H, t, J = 6.6 Hz), 6.45 (2H, s),
    6.86-6.90 (2H, m), 6.98 (1H, d, J = 7.9 Hz), 7.16-7.19 (1H, m), 7.21-7.25 (1H, m), 7.30 (1H, br)
    mp: 190 (decomp.)
    164 2 ESI+: 381
    NMR: 1.75-1.81 (2H, m), 2.64 (2H, t, J = 6.6 Hz), 2.81-2.83 (2H, br), 2.89-2.93 (4H, m),
    2.98-3.02 (4H, br), 3.58-3.61 (2H, m), 3.72 (3H, s), 4.33 (2H, t, J = 6.5 Hz), 6.45 (2H, s),
    6.79-6.84 (3H, m), 6.89 (1H, s), 7.22 (1H, t, J = 8.1 Hz), 7.26 (1H, br)
    mp: 196 (decomp.)
  • TABLE 163
    Ex Syn Dat
    165 2 ESI+: 325
    NMR: 2.81-2.94 (4H, m), 2.97-3.11 (4H, m), 3.28-3.37 (2H, m), 3.83 (3H, s), 4.09-4.20 (2H,
    m), 4.37 (2H, s), 6.45 (1H, s), 6.56 (1H, s), 6.85-6.93 (1H, m), 7.00-7.06 (1H, m),
    7.11-7.16 (1H, m), 7.21-7.30 (1H, m), 9.12-9.41 (2H, br)
    166 2 ESI+: 313
    NMR: 2.81-2.94 (4H, m), 2.98-3.15 (4H, m), 3.22-3.38 (2H, m), 4.09-4.24 (2H, m),
    4.46 (2H, s), 6.55 (1H, s), 6.57 (1H, s), 7.01-7.20 (3H, m), 7.32-7.45 (1H, m), 9.13-9.41 (2H, br)
    167 2 ESI+: 309
    NMR: 2.29 (3H, s), 2.84-2.95 (4H, m), 2.99-3.11 (4H, m), 3.23-3.31 (2H, m), 4.11-4.19 (2H,
    m), 4.39 (2H, s), 6.56 (1H, s), 6.60 (1H, s), 7.05-7.14 (3H, m), 7.22 (1H, t, J = 7.5 Hz),
    9.28-9.54 (2H, br)
    168 2 ESI+: 320
    NMR: 2.83-2.95 (4H, m), 2.99-3.13 (4H, m), 3.28-3.37 (2H, m), 4.14-4.24 (2H, m),
    4.49 (2H, s), 6.54 (1H, s), 6.58 (1H, s), 7.52-7.60 (1H, m), 7.63-7.69 (1H, m), 7.71-7.80 (2H, m),
    9.17-9.53 (2H, br)
    169 2 ESI+: 363
    NMR: 2.76-2.88 (4H, m), 2.94-3.07 (4H, m), 3.2-3.34 (2H, m), 4.13-4.21 (2H, m), 4.53 (2H,
    s), 6.44 (2H, s), 6.56 (1H, s), 6.58 (1H, s), 7.54-7.70 (4H, m)
    mp: 141-146
    170 2 ESI+: 289
    NMR: 1.18 (6H, s), 1.58-1.64 (2H, m), 2.85-2.93 (4H, m), 3.00-3.10 (4H, m), 3.24-3.30 (5H,
    m), 3.37-3.45 (2H, m), 3.46-3.52 (2H, m), 6.40 (1H, s), 6.44 (2H, s), 6.92 (1H, s)
    mp: 172-175
    171 2 ESI+: 385, 387
    NMR: 1.74-1.81 (2H, m), 2.64 (2H, t, J = 6.5 Hz), 2.81-2.83 (2H, br), 2.89-2.92 (2H, br),
    2.95 (2H, t, J = 6.4 Hz), 2.99-3.03 (4H, br), 3.57-3.60 (2H, m), 4.33 (2H, t, J = 6.4 Hz), 6.45 (2H,
    s), 6.89 (1H, s), 7.22 (1H, br), 7.30 (2H, d, J = 8.5 Hz), 7.37 (2H, d, J = 8.5 Hz)
    172 2 ESI+: 353
    NMR: 2.29 (4H, s), 2.73-2.75 (2H, br), 2.81-2.83 (2H, m), 2.93-2.98 (6H, m), 3.74 (2H, t, J = 4.5 Hz),
    4.14 (2H, t, J = 4.5 Hz), 4.37 (2H, t, J = 6.5 Hz), 6.67 (1H, s), 7.21-7.34 (5H, m),
    7.36-7.44 (1H, br)
    mp: 185-187
    173 2 ESI+: 387, 389
    NMR: 2.30 (4H, s), 2.73-2.75 (2H, br), 2.82-2.84 (2H, br), 2.94-2.98 (6H, m), 3.73 (2H, t, J = 4.5 Hz),
    4.14 (2H, t, J = 4.5 Hz), 4.37 (2H, t, J = 6.4 Hz), 6.67 (1H, s), 7.30-7.38 (5H, m)
    mp: 186 (decomp.)
    174 2 ESI+: 357
    NMR: 2.52-3.04 (17H, m), 3.97-4.12 (2H, m), 6.36 (1H, s), 6.71 (1H, s), 7.16-7.24 (1H,
    m), 7.26-7.34 (2H, m), 7.41-7.50 (1H, m)
    mp: 179-182
  • TABLE 164
    Ex Syn Dat
    175 2 ESI+: 355, 357
    NMR: 3.13-3.21 (6H, m), 3.23 (3H, s), 3.30-3.37 (2H, m), 3.52 (2H, t, J = 5.7 Hz), 4.09 (2H,
    t, J = 5.7 Hz), 4.73 (2H, s), 7.22 (1H, s), 9.19-9.38 (2H, br)
    mp: 244 (decomp.)
    176 2 ESI+: 341, 343
    NMR: 3.00-3.06 (2H, m), 3.07-3.15 (4H, m), 3.21-3.27 (5H, m), 3.35-3.40 (2H, m),
    3.42-3.53 (4H, m), 4.10-4.24 (2H, m), 6.64 (1H, s), 9.20-9.42 (2H, br)
    mp: 107-110
    177 2 ESI+: 387, 389
    NMR: 2.30 (4H, s), 2.75-2.77 (2H, br), 2.81-2.83 (2H, br), 2.93-2.97 (4H, br), 3.11 (2H, t, J = 6.4 Hz),
    3.74 (2H, t, J = 4.5 Hz), 4.14 (2H, t, J = 4.5 Hz), 4.40 (2H, t, J = 6.4 Hz), 6.67 (1H, s),
    7.26-7.33 (2H, m), 7.41-7.46 (3H, m)
    mp: 169-170
    178 2 ESI+: 387, 389
    NMR: 2.30 (4H, s), 2.74-2.76 (2H, br), 2.81-2.84 (2H, br), 2.93-3.00 (6H, m), 3.74 (2H, t, J = 4.5 Hz),
    4.14 (2H, t, J = 4.5 Hz), 4.39 (2H, t, J = 6.4 Hz), 6.67 (1H, s), 7.25-7.38 (5H, m)
    mp: 160-162
    179 2 ESI+: 383
    NMR: 2.30 (4H, s), 2.75-2.77 (2H, br), 2.81-2.84 (2H, br), 2.92-2.98 (6H, m), 3.73 (2H, t, J = 4.5 Hz),
    3.78 (3H, s), 4.14 (2H, t, J = 4.5 Hz), 4.32 (2H, t, J = 6.6 Hz), 6.67 (1H, s),
    6.87-6.90 (1H, m), 6.97-6.99 (1H, m), 7.18-7.25 (2H, m), 7.39-7.51 (1H, br)
    mp: 158-160
    180 2 ESI+: 383
    NMR: 2.30 (4H, s), 2.73-2.75 (2H, br), 2.81-2.84 (2H, br), 2.92-2.98 (6H, m), 3.72 (3H, s),
    3.74 (2H, t, J = 4.5 Hz), 4.14 (2H, t, J = 4.5 Hz), 4.37 (2H, t, J = 6.5 Hz), 6.67 (1H, s),
    6.79-6.82 (1H, m), 6.84-6.86 (2H, m), 7.22 (1H, t, J = 8.1 Hz), 7.35-7.44 (1H, br)
    mp: 134-136
    181 2 ESI+: 317
    NMR: 1.41 (3H, s), 1.88 (3H, s), 2.61-3.16 (12H, m), 3.25 (3H, s), 3.37-3.52 (2H, m),
    3.92-4.09 (2H, m), 5.06 (1H, s), 6.38 (1H, s), 6.55 (1H, s)
    mp: 173-176
    182 2 ESI+: 367
    NMR: 2.57-2.68 (2H, m), 2.83-3.10 (14H, m), 3.26 (3H, s), 3.58 (2H, t, J = 5.8 Hz),
    4.11-4.14 (2H, m), 6.44 (1H, s), 6.54 (1H, s), 7.15-7.34 (5H, m)
    183 2 ESI+: 305
    NMR: 0.96 (3H, t, J = 7.7 Hz), 1.28-1.45 (2H, m), 2.58-2.68 (2H, m), 2.78-3.09 (12H, m),
    3.31 (3H, s), 3.61 (2H, t, J = 6.3 Hz), 4.03-4.21 (2H, m), 6.40 (1H, s), 6.48 (1H, s)
    184 2 ESI+: 339
    NMR: 2.52-2.60 (2H, m), 2.85-2.99 (4H, m), 3.03-3.10 (2H, m), 3.28 (3H, s), 3.29-3.35 (2H,
    m), 3.41-3.58 (4H, m), 3.92-4.01 (2H, m), 6.42 (2H, s), 6.62 (1H, s), 7.05-7.14 (2H, m),
    7.27-7.33 (1H, m), 7.35-7.41 (2H, m)
    mp: 169 (decomp.)
  • TABLE 165
    Ex Syn Dat
    185 2 ESI+: 371
    NMR: 2.30 (4H, s), 2.75-2.77 (2H, br), 2.81-2.84 (2H, br), 2.94-2.98 (4H, br), 3.01 (2H, t, J = 6.4 Hz),
    3.73 (2H, t, J = 4.5 Hz), 4.14 (2H, t, J = 4.5 Hz), 4.37 (2H, t, J = 6.4 Hz), 6.67 (1H, s),
    7.14-7.20 (2H, m), 7.27-7.33 (1H, m), 7.36-7.47 (2H, m)
    mp: 186-187
    186 2 ESI+: 371
    NMR: 2.30 (4H, s), 2.73-2.75 (2H, br), 2.81-2.83 (2H, br), 2.93-2.98 (4H, br), 3.00 (2H, t, J = 6.4 Hz),
    3.73 (2H, t, J = 4.5 Hz), 4.14 (2H, t, J = 4.5 Hz), 4.39 (2H, t, J = 6.4 Hz), 6.67 (1H, s),
    7.03-7.08 (1H, m), 7.12-7.17 (2H, m), 7.32-7.43 (2H, m)
    mp: 162-164
    187 2 ESI+: 371
    NMR: 2.30 (4H, s), 2.74-2.76 (2H, br), 2.82-2.84 (2H, br), 2.94-2.98 (6H, m), 3.74 (2H, t, J = 4.5 Hz),
    4.14 (2H, t, J = 4.5 Hz), 4.36 (2H, t, J = 6.5 Hz), 6.67 (1H, s), 7.10-7.16 (2H, m),
    7.29-7.35 (2H, m), 7.35-7.44 (1H, br)mp: 179-181
    188 2 ESI+: 305
    NMR: 1.36 (6H, s), 2.81-3.02 (8H, m), 3.24 (3H, s), 3.50 (2H, t, J = 6.0 Hz), 4.04 (2H, t, J = 5.9 Hz),
    6.40 (1H, s), 6.78 (1H, s), 7.02 (1H, s)
    mp: 175-176
    189 2 ESI+: 287
    NMR: 2.85-3.00 (4H, m), 3.04-3.15 (4H, m), 3.37-3.48 (2H, m), 4.03-4.20 (4H, m),
    6.59 (1H, s), 6.73 (1H, s), 9.09-9.33 (2H, br)
    mp: 221-222
    190 2 ESI+: 365, 367
    NMR: 3.04-3.19 (8H, m), 3.33-3.39 (2H, m), 3.72 (2H, q, J = 9.3 Hz), 4.20-4.27 (2H, m),
    6.81 (1H, s), 9.17-9.38 (2H, br)
    mp: 214-215
    191 2 ESI+: 365, 367
    NMR: 2.99-3.17 (6H, m), 3.21-3.29 (2H, m), 3.46 (2H, t, J = 4.2 Hz), 4.13-4.26 (4H, m),
    6.83 (1H, s), 9.10-9.33 (2H, br)
    mp: 216-221
    192 2 ESI+: 345
    NMR-A: 2.57-2.68 (6H, m), 2.95-3.22 (11H, m), 4.00-4.08 (2H, m), 6.63 (1H, s), 6.72 (1H,
    s), 6.98 (1H, dd, J = 4.9, 1.2 Hz), 7.33 (1H, dd, J = 2.8, 1.2 Hz), 7.66 (1H, dd, J = 4.9, 2.8 Hz)
    mp: 200 (decomp.)
    193 2 ESI+: 345
    NMR: 2.65-2.79 (6H, m), 2.94-3.22 (11H, m), 4.02-4.10 (2H, m), 6.64 (1H, s), 6.78 (1H, s),
    6.97 (1H, dd, J = 3.5, 1.2 Hz), 7.18 (1H, dd, J = 5.3, 3.5 Hz), 7.69 (1H, dd, J = 5.3, 1.2 Hz)
    mp: 200 (decomp.)
  • TABLE 166
    Ex Syn Dat
    194 2 ESI+: 327
    NMR: 0.35-0.43 (2H, m), 0.86-0.96 (2H, m), 1.40-1.52 (1H, m), 2.77-2.86 (2H, m),
    2.86-2.98 (4H, m), 3.05-3.18 (2H, m), 3.36-3.42 (2H, m), 4.00-4.16 (4H, m), 6.37 (1H, s),
    6.57 (1H, s)
    mp: 177 (decomp.)
    195 2 ESI+: 289
    NMR: 1.16 (6H, s), 1.66 (2H, t, J = 6.6 Hz), 2.61 (2H, t, J = 6.6 Hz), 2.81-2.95 (4H, m),
    2.98-3.10 (4H, m), 3.30 (3H, s), 3.31-3.37 (2H, m), 3.38-3.44 (2H, m), 6.35 (1H, s), 6.44 (1.8H, s),
    6.71 (1H, s)
    mp: 156-158
    196 2 ESI+: 367
    NMR: 1.26 (3H, d, J = 7.0 Hz), 2.30 (4H, s), 2.71-2.72 (2H, br), 2.81-2.83 (2H, m),
    2.93-2.97 (4H, m), 3.10-3.19 (1H, m), 3.69-3.71 (2H, m), 4.09-4.12 (2H, m), 4.26 (2H, d, J = 7.1 Hz),
    6.66 (1H, s), 7.21-7.35 (6H, m)
    mp: 177-179
    197 2 ESI+: 367
    NMR: 1.26 (3H, d, J = 6.3 Hz), 2.29 (4H, s), 2.80-2.85 (4H, m), 2.91 (2H, d, J = 6.4 Hz),
    2.96-2.98 (4H, m), 3.64-3.69 (1H, m), 3.77-3.83 (1H, m), 3.99-4.04 (1H, m), 4.12-4.17 (1H, m),
    5.00-5.08 (1H, m), 6.67 (1H, s), 7.19-7.23 (3H, m), 7.27-7.31 (2H, m), 7.48 (1H, brs)
    mp: 85-87
    198 2 ESI+: 431, 433
    NMR: 2.31 (4H, s), 2.79-2.82 (2H, m), 2.91-2.99 (6H, m), 3.15-3.18 (2H, m), 3.76 (2H, t, J = 4.4 Hz),
    4.26 (2H, t, J = 4.4 Hz), 4.39 (2H, t, J = 6.5 Hz), 7.21-7.33 (5H, m), 7.39-7.45 (1H, br)
    mp: 142-143
    199 2 ESI+: 297, 299
    NMR: 2.29 (4H, s), 2.85-2.88 (2H, m), 2.95-2.99 (4H, m), 3.02-3.05 (2H, m), 3.25 (3H, s),
    3.35-3.38 (2H, m), 3.41-3.44 (2H, m), 3.49-3.51 (2H, m), 4.16-4.18 (2H, m), 6.56 (1H, s)
    mp: 139-141
    200 2 ESI+: 311, 313
    NMR: 1.26 (3H, t, J = 7.1 Hz), 2.28 (2H, s), 2.86-2.91 (6H, m), 3.08-3.11 (2H, m),
    3.82-3.84 (2H, m), 4.18 (2H, q, J = 7.1 Hz), 4.29-4.31 (2H, m), 7.61 (1H, brs); mp: 145-147
    201 2 ESI+: 393
    NMR: 0.38-0.43 (2H, m), 0.92-0.97 (2H, m), 1.46-1.53 (1H, m), 2.28 (4H, s), 2.74-2.77 (2H,
    m), 2.94-2.97 (4H, m), 3.01-3.03 (2H, m), 3.17-3.19 (2H, m), 3.70-3.72 (2H, m),
    4.16-4.18 (2H, m), 4.36 (2H, t, J = 6.5 Hz), 7.21-7.34 (6H, m)
    mp: 142-144
  • TABLE 167
    Ex Syn Dat
    202 2 ESI+: 313
    NMR: 2.84-2.99 (4H, m), 3.02-3.15 (4H, m), 3.34-3.40 (5H, m), 3.56-3.76 (4H, m),
    4.03-4.14 (2H, m), 6.57 (1H, s), 6.63 (1H, s), 9.06-9.25 (2H, br)
    mp: 172-173
    203 2 ESI+: 353
    NMR: 0.35-0.46 (2H, m), 0.97-1.06 (2H, m), 1.59-1.70 (1H, m), 2.83-2.91 (2H, m),
    2.96-3.10 (4H, m), 3.16-3.23 (5H, m), 3.24-3.31 (2H, m), 3.51 (2H, t, J = 13.3 Hz), 3.70 (2H, t, J = 16 Hz),
    4.08-4.16 (2H, m), 6.43 (2H, s), 6.52 (1H, s)
    mp: 163-165
    204 2 ESI+: 291
    NMR: 1.20 (6H, s), 2.71-2.77 (2H, m), 2.78-2.84 (2H, m), 2.87-2.96 (4H, m), 3.05 (2H, s),
    3.25 (3H, s), 3.39-3.45 (2H, m), 3.47-3.53 (2H, m), 6.37 (1H, s), 6.44 (1H, s), 6.50 (1H, s)
    mp: 194 (decomp.)
    205 2 ESI+: 283
    NMR-A: 1.81-2.00 (2H, m), 2.46-2.63 (3H, br), 2.75-2.90 (4H, m), 2.97-3.26 (8H, m),
    6.48-6.59 (1H, br), 6.63 (1H, s), 6.98-7.13 (1H, br), 7.63-7.78 (1H, br), 7.82-7.94 (1H, br)
    mp: 203 (decomp.)
    206 2 ESI+: 277
    NMR: 1.07 (3H, d, J = 6.5 Hz), 2.79-2.91 (4H, m), 2.98-3.07 (4H, m), 3.25-3.34 (4H, m),
    3.40-3.54 (4H, m), 3.86 (1H, dd, J = 10.4, 2.3 Hz), 3.93 (1H, dd, J = 10.4, 3.1 Hz), 6.43 (1.8H,
    s), 6.50 (1H, s), 6.53 (1H, s)
    mp: 133-136
    207 2 ESI+: 277
    NMR: 1.07 (3H, d, J = 6.5 Hz), 2.79-2.93 (4H, m), 2.98-3.07 (4H, m), 3.25-3.34 (4H, m),
    3.39-3.54 (4H, m), 3.86 (1H, dd, J = 10.4, 2.3 Hz), 3.93 (1H, dd, J = 10.4, 3.0 Hz), 6.44 (1.8H,
    s), 6.50 (1H, s), 6.53 (1H, s)
    mp.131-134
    208 2 ESI+: 429
    NMR: 2.26 (2H, s), 2.49-2.53 (2H, m), 2.77-2.79 (4H, m), 2.89-2.91 (2H, m), 2.98 (2H, t, J = 6.5 Hz),
    3.70-3.72 (2H, m), 4.01-4.03 (2H, m), 4.39 (2H, t, J = 6.5 Hz), 7.08-7.11 (2H, m),
    7.22-7.35 (6H, m), 7.37-7.41 (3H, m)
    mp: 169-171
    209 2 ESI+: 283
    NMR: 1.68-1.83 (2H, m), 2.03 (3H, s), 2.33-2.42 (2H, m), 2.71 (2H, t, J = 6.4 Hz),
    2.93-3.10 (6H, m), 3.11-3.24 (2H, m), 6.50 (1H, t, J = 2.1 Hz), 6.63 (1H, s), 7.00 (1H, s), 8.65-8.95 (2H,
    m)
    mp: 206 (decomp.)
  • TABLE 168
    Ex Syn Dat
    210 2 ESI+: 285
    NMR: 2.33 (3H, s), 2.82-2.89 (2H, m), 2.95-3.12 (6H, m), 3.12-3.22 (2H, m), 4.07-4.13 (2H,
    m), 6.51-6.52 (1H, m), 6.64 (1H, s), 6.75 (1H, s), 7.63-7.65 (1H, m), 7.81 (1H, t, J = 1.7 Hz),
    8.66-8.91 (2H, br)
    mp: 226 (decomp.)
    211 2 ESI+: 327
    NMR: 0.35-0.48 (2H, m), 0.97-1.08 (2H, m), 1.64-1.78 (1H, m), 2.84-2.94 (2H, m),
    2.98-3.11 (4H, m), 3.17-3.30 (4H, m), 3.93 (2H, q, J = 10 Hz), 4.12 (2H, t, J = 4.5 Hz), 6.44 (2H, s),
    6.55 (1H, s)
    mp: 174 (decomp.)
    212 2 ESI+: 395
    NMR: 0.90 (3H, t, J = 7.3 Hz), 1.30-1.39 (2H, m), 2.53-2.57 (2H, m), 2.80-2.82 (2H, m),
    2.95-3.01 (8H, m), 3.71-3.73 (2H, m), 4.16-4.18 (2H, m), 4.37 (2H, t, J = 6.5 Hz), 6.45 (2H, s),
    7.21-7.34 (6H, m)
    mp: 134-136
    213 2 ESI+: 401
    NMR: 0.87-0.97 (5H, m), 1.10-1.25 (3H, m), 1.31-1.41 (3H, m), 1.53 (2H, q, J = 6.6 Hz),
    1.59-1.71 (5H, m), 2.55-2.59 (2H, m), 2.88-2.91 (2H, m), 2.95-3.02 (6H, m), 3.76-3.78 (2H,
    m), 4.16 (2H, t, J = 6.6 Hz), 4.20-4.22 (2H, m), 6.44 (2H, s), 7.46 (1H, brs)
    mp: 139-141
    214 2 ESI+: 435
    NMR: 2.63-2.66 (2H, m), 2.77-2.82 (4H, m), 2.88-2.91 (2H, m), 2.96-2.99 (2H, m),
    3.71-3.73 (2H, m), 4.07-4.09 (2H, m), 4.39 (2H, t, J = 6.5 Hz), 6.40 (1H, s), 6.84 (1H, dd, J = 3.4, 1.1 Hz),
    7.10 (1H, dd, J = 5.2, 3.4 Hz), 7.21-7.34 (5H, m), 7.40-7.47 (1H, br), 7.59 (1H, dd, J = 5.2,
    1.1 Hz)
    mp: 215-216
    215 2 ESI+: 329
    NMR: 0.32-0.39 (1H, m), 0.54-0.62 (1H, m), 0.96-1.07 (2H, m), 1.33-1.44 (1H, m),
    1.58-1.67 (1H, m), 1.69-1.85 (2H, m), 1.91-2.01 (1H, m), 2.86-3.38 (11H, m), 3.46-3.55 (1H,
    m), 3.60-3.69 (1H, m), 3.72-3.80 (1H, m), 3.94-4.18 (3H, m), 6.53 (1H, s), 9.18-9.44 (2H,
    br)
    mp: 154-156
    216 2 ESI+: 317
    NMR: 0.32-0.41 (1H, m), 0.48-0.57 (1H, m), 0.96-1.10 (5H, m), 1.55-1.65 (1H, m),
    2.81-3.30 (14H, m), 3.34-3.42 (1H, m), 3.64-3.73 (1H, m), 3.96-4.08 (2H, m), 6.43 (2H, s),
    6.50 (1H, s)
    mp: 135-138
    217 2 ESI+: 305
    NMR: 0.31-0.41 (1H, m), 0.46-0.57 (1H, m), 0.95-1.04 (2H, m), 1.27 (3H, dd, J = 23.9, 6.3 Hz),
    1.55-1.65 (1H, m), 2.74-3.02 (6H, m), 3.04-3.31 (6H, m), 3.97-4.09 (2H, m),
    4.96-5.22 (1H, m), 6.37 (1H, s), 6.49 (1H, s)
    mp: 171-173
  • TABLE 169
    Ex Syn Dat
    218 2 ESI+: 301
    NMR-A: 2.24 (3H, s), 2.76-2.85 (2H, m), 2.93-3.11 (6H, m), 3.12-3.23 (2H, br),
    4.03-4.11 (2H, m), 6.63 (1H, s), 6.79 (1H, s), 6.98 (1H, dd, J = 3.4, 1.1 Hz), 7.16 (1H, dd, J = 5.1, 3.5 Hz),
    7.68 (1H, dd, J = 5.1, 1.1 Hz), 8.71-8.96 (2H, br)
    mp: 248-252
    219 2 ESI+: 295
    NMR-A: 2.09 (3H, s), 2.63-2.71 (2H, m), 2.95-3.09 (6H, m), 3.14-3.23 (2H, br),
    4.04-4.11 (2H, m), 6.64 (1H, s), 6.76 (1H, s), 7.19-7.24 (2H, m), 7.34-7.40 (1H, m), 7.43-7.49 (2H,
    m), 6.80 (2H, s)
    mp: 250 (decomp.)
    220 2 ESI+: 341, 343
    NMR: 1.69-1.75 (2H, m), 2.04-2.17 (2H, m), 2.27 (2H, s), 2.70 (2H, t, J = 6.7 Hz),
    2.85-2.91 (8H, m), 2.96-2.99 (2H, m), 3.20-3.22 (2H, m), 4.46 (1H, t, J = 5.9 Hz), 4.58 (1H, t, J = 5.9 Hz),
    6.83 (1H, s)
    221 2 ESI+: 317
    NMR: 0.29-0.35 (2H, br), 0.98-1.05 (2H, br), 1.62-1.75 (2H, m), 1.86-1.93 (1H, m),
    2.29 (4H, s), 2.36-2.39 (2H, m), 2.65-2.69 (2H, m), 2.90-2.94 (2H, br), 3.01-3.10 (4H, br),
    3.21-3.28 (2H, br), 4.06-4.29 (2H, br), 4.23 (1H, t, J = 5.8 Hz), 4.34 (1H, t, J = 5.8 Hz), 6.94 (1H, s)
    mp: 182 (decomp.)
    222 2 ESI+: 283
    NMR-A: 1.76-1.88 (2H, m), 2.38 (3H, s), 2.61-2.68 (2H, m), 2.73 (2H, t, J = 6.4 Hz),
    2.95-3.22 (8H, m), 6.44 (1H, d, J = 2.9 Hz), 6.60-6.65 (2H, m), 7.02 (1H, s), 7.78-7.84 (1H, m)
    mp: 180 (decomp.)
    223 2 ESI+: 353, 355
    NMR: 1.12 (3H, d, J = 6.3 Hz), 1.60-1.68 (1H, m), 1.76-1.86 (1H, m), 2.66-2.70 (2H, m),
    2.81 (1H, dd, J = 14.1, 3.4 Hz), 2.86-2.96 (7H, m), 3.22-3.25 (2H, m), 3.27 (3H, s),
    3.36-3.41 (2H, m), 3.81-3.89 (1H, m), 6.41 (2H, s), 6.82 (1H, s)
    mp: 161 (decomp.)
    224 2 ESI+: 315
    NMR: 0.28-0.35 (1H, m), 0.38-0.44 (1H, m), 0.95-1.00 (5H, m), 1.55-1.62 (1H, m),
    1.65-1.76 (2H, m), 2.57-2.60 (2H, m), 2.83-2.85 (2H, m), 2.99-3.13 (8H, m), 3.17 (3H, s),
    3.19-3.23 (2H, m), 3.52-3.59 (1H, m), 6.41 (2H, s), 6.63 (1H, s)
    225 2 ESI+: 261
    NMR: 1.00 (3H, t, J = 7.2 Hz), 1.33-1.47 (2H, m), 2.62-2.73 (2H, m), 2.81 (3H, s),
    2.94-3.15 (8H, m), 3.16-3.31 (2H, br), 4.21-4.35 (2H, br), 6.64 (1H, s), 9.42 (2H, s)
    mp: 151-152
    226 2 ESI+: 247
    NMR: 1.09 (3H, t, J = 7.4 Hz), 2.70-2.95 (5H, m), 2.97-3.17 (8H, m), 3.18-3.39 (2H, br),
    4.23-4.39 (2H, m), 6.67 (1H, s), 9.48 (2H, s)
    mp: 184-185
  • TABLE 170
    Ex Syn Dat
    227 2 ESI+: 329
    NMR: 0.30-0.40 (1H, m), 0.54-0.64 (1H, m), 0.96-1.06 (2H, m), 1.33-1.45 (1H, m),
    1.58-1.67 (1H, m), 1.70-1.85 (2H, m), 1.92-2.01 (1H, m), 2.85-3.37 (11H, m), 3.46-3.55 (1H,
    m), 3.61-3.69 (1H, m), 3.72-3.80 (1H, m), 3.95-4.03 (1H, m), 4.05-4.18 (2H, m), 6.53 (1H,
    s), 9.19-9.37 (2H, br)
    mp: 156-158
    228 2 ESI+: 305
    NMR: 0.32-0.41 (1H, m), 0.48-0.55 (1H, m), 0.95-1.04 (2H, m), 1.27 (3H, dd, J = 23.9, 6.3 Hz),
    1.56-1.65 (1H, m), 2.72-3.01 (6H, m), 3.04-3.31 (6H, m), 3.97-4.09 (2H, m),
    4.97-5.01 (1H, m), 6.38 (1H, s), 6.48 (1H, s)
    mp: 117 (decomp.)
    229 2 ESI+: 331
    NMR: 0.41-0.48 (2H, m), 0.97-1.04 (2H, m), 1.07 (6H, d, J = 6.1 Hz), 1.58-1.66 (1H, m),
    2.85-2.92 (2H, m), 2.99-3.18 (8H, m), 3.18-3.27 (2H, m), 3.47-3.57 (1H, m), 3.63 (2H, t,
    J = 5.9 Hz), 3.99-4.05 (2H, m), 6.43 (2H, s), 6.51 (1H, s)
    mp: 117 (decomp.)
    230 2 ESI+: 331
    NMR: 0.37-0.44 (2H, m), 0.96-1.03 (2H, m), 1.11 (6H, s), 1.63-1.72 (1H, m), 2.87-2.94 (2H,
    m), 3.04-3.16 (9H, m), 3.21-3.33 (4H, m), 4.10-4.17 (2H, m), 6.51 (1H, s), 8.99-9.17 (2H,
    br)
    mp: 155-156
    231 2 ESI+: 345
    NMR: 0.33-0.41 (2H, m), 0.90 (6H, s), 0.96-1.03 (2H, m), 1.65-1.74 (1H, m), 2.88-2.95 (2H,
    m), 3.00 (2H, s), 3.03-3.17 (9H, m), 3.22-3.30 (4H, m), 4.09-4.16 (2H, m), 6.50 (1H, s),
    9.22-9.35 (2H, br)
    mp: 141-145
    232 2 ESI+: 371
    NMR: 0.39-0.46 (2H, m), 0.97-1.04 (2H, m), 1.57-1.66 (1H, m), 2.76-2.82 (2H, m),
    2.84-2.97 (4H, m), 3.07-3.19 (6H, m), 3.88 (2H, t, J = 6.0 Hz), 3.99-4.12 (4H, m), 6.37 (1H, s),
    6.48 (1H, s)
    mp: 187 (decomp.)
    233 2 ESI+: 345
    NMR: 0.29-0.38 (1H, m), 0.51-0.60 (1H, m), 0.93-1.05 (2H, m), 1.57-1.66 (1H, m),
    2.72-3.25 (12H, m), 3.32-3.47 (2H, m), 3.55-3.74 (4H, m), 3.85-3.93 (1H, m), 3.95-4.08 (2H,
    m), 6.38 (1H, s), 6.47 (1H, s)
    mp: 204 (decomp.)
    234 2 ESI+: 233
    NMR: 0.96 (3H, t, J = 7.6 Hz), 1.48-1.66 (2H, m), 2.76-2.86 (4H, m), 2.89 (1H, dd, J = 11.8,
    7.7 Hz), 2.94-3.09 (4H, m), 3.27 (1H, dd, J = 11.8, 2.4 Hz), 3.77-3.86 (1H, m), 5.32-5.87 (1H,
    br), 6.37 (1H, s), 6.43 (2H, s), 6.48 (1H, s)
    mp: 193 (decomp.)
  • TABLE 171
    Ex Syn Dat
    235 2 ESI+: 249
    NMR: 2.76-2.87 (4H, m), 2.94-3.07 (5H, m), 3.25 (1H, dd, J = 11.9, 2.6 Hz), 3.30 (3H, s),
    3.41-3.52 (2H, m), 4.07-4.14 (1H, m), 5.40-5.83 (1H, br), 6.38 (1H, s), 6.43 (2H, s), 6.50 (1H,
    s)
    236 2 ESI+: 247
    NMR: 0.87-0.97 (3H, m), 1.32-1.63 (4H, m), 2.75-2.86 (4H, m), 2.90 (1H, dd, J = 11.8, 7.7 Hz),
    2.94-3.09 (4H, m), 3.26 (1H, dd, J = 11.8, 2.4 Hz), 3.86-3.94 (1H, m), 5.31-5.86 (1H, br),
    6.36 (1H, s), 6.43 (2H, s), 6.47 (1H, s)
    mp: 191 (decomp.)
    237 2 ESI+: 347
    NMR: 0.33-0.41 (1H, m), 0.46-0.54 (1H, m), 0.97-1.08 (2H, m), 1.54-1.62 (1H, m),
    2.84-2.98 (3H, m), 2.98-3.12 (5H, m), 3.14-3.25 (6H, m), 3.27-3.41 (6H, m), 3.61-3.70 (1H, m),
    3.96-4.08 (2H, m), 6.43 (2H, s), 6.51 (1H, s)
    mp: 150-154
    238 2 ESI+: 291
    NMR: 0.96 (3H, t, J = 7.5 Hz), 1.48-1.64 (2H, m), 2.79-2.93 (4H, m), 2.97-3.10 (5H, m),
    3.25 (3H, s), 3.27-3.39 (2H, m), 3.40-3.55 (3H, m), 3.80-3.89 (1H, m), 6.44 (2H, s), 6.52 (1H,
    s), 6.53 (1H, s)
    mp: 147 (decomp.)
    239 2 ESI+: 305
    NMR: 0.88-0.96 (3H, m), 1.34-1.60 (4H, m), 2.79-2.93 (4H, m), 2.95-3.10 (5H, m),
    3.25 (3H, s), 3.29-3.38 (2H, m), 3.39-3.55 (3H, m), 3.89-3.97 (1H, m), 6.44 (2H, s), 6.51 (1H, s),
    6.53 (1H, s)
    mp: 151 (decomp.)
    240 2 ESI+: 247
    NMR: 0.97 (3H, t, J = 7.5 Hz), 1.50-1.67 (2H, m), 2.78 (3H, s), 2.80-2.92 (5H, m),
    2.97-3.07 (4H, m), 3.22 (1H, dd, J = 11.6, 2.4 Hz), 3.97-4.05 (1H, m), 6.43 (2H, s), 6.51 (1H, s), 6.53 (1H,
    s)
    mp: 166 (decomp.)
    241 2 ESI+: 261
    NMR: 0.88-0.97 (3H, m), 1.33-1.63 (4H, m), 2.78 (3H, s), 2.80-2.93 (5H, m), 2.96-3.09 (4H,
    m), 3.21 (1H, dd, J = 11.6, 2.3 Hz), 4.04-4.14 (1H, m), 6.44 (2H, s), 6.50 (1H, s), 6.53 (1H,
    s)
    mp: 152-153
    242 2 ESI+: 347
    NMR: 0.31-0.42 (1H, m), 0.44-0.57 (1H, m), 0.95-1.11 (2H, m), 1.53-1.64 (1H, m),
    2.80-2.97 (3H, m), 2.98-3.13 (5H, m), 3.13-3.26 (6H, m), 3.27-3.42 (6H, m), 3.62-3.70 (1H, m),
    3.96-4.09 (2H, m), 6.43 (2H, s), 6.51 (1H, s)
    mp: 156-158
  • TABLE 172
    Ex Syn Dat
    243 2 ESI+: 317
    NMR: 0.30-0.42 (1H, m), 0.46-0.59 (1H, m), 0.95-1.09 (5H, m), 1.55-1.67 (1H, m),
    2.80-3.30 (14H, m), 3.33-3.43 (1H, m), 3.62-3.75 (1H, m), 3.95-4.09 (2H, m), 6.42 (2H, s),
    6.50 (1H, s)
    mp: 133-136
    244 2 ESI+: 247
    NMR: 1.17 (3H, t, J = 7.3 Hz), 2.16 (3H, s), 2.66 (2H, q, J = 7.3 Hz), 2.87-3.09 (10H, m),
    3.98-4.04 (2H, m), 6.44 (2H, s), 6.50 (1H, s)
    mp: 200 (decomp.)
    245 2 ESI+: 291
    NMR: 1.82-1.92 (2H, m), 2.15 (3H, s), 2.63-2.71 (2H, m), 2.79-3.03 (10H, m), 3.23 (3H,
    s), 3.40 (2H, t, J = 5.2 Hz), 3.99-4.06 (2H, m), 6.37 (1H, s), 6.46 (1H, s)
    mp: 160-163
    246 2 ESI+: 291
    NMR: 1.13 (3H, t, J = 6.9 Hz), 2.19 (3H, s), 2.83 (2H, t, J = 6.2 Hz), 2.87-3.12 (10H, m),
    3.48 (2H, q, J = 6.9 Hz), 3.65 (2H, t, J = 6.2 Hz), 3.99-4.09 (2H, m), 6.44 (2H, s), 6.50 (1H, s)
    mp: 152-155
    247 2 ESI+: 279
    NMR: 1.94-2.11 (2H, m), 2.16 (3H, s), 2.69-2.79 (2H, m), 2.88-3.10 (10H, m),
    4.01-4.08 (2H, m), 4.55 (2H, dt, J = 48.1, 6.9 Hz), 6.44 (2H, s), 6.51 (1H, s)
    mp: 187-190
    248 2 ESI+: 327
    NMR: 0.28-0.32 (1H, m), 0.44-0.48 (1H, m), 0.97-0.99 (2H, m), 1.30-1.39 (1H, m),
    1.56-1.79 (5H, m), 1.87-1.94 (1H, m), 2.58-2.61 (2H, m), 2.85-2.86 (2H, m), 2.99-3.08 (6H, m),
    3.17-3.47 (4H, m), 3.58-3.64 (1H, m), 3.70-3.76 (1H, m), 4.02-4.09 (1H, m), 6.42 (2H, s),
    6.64 (1H, s)
    249 2 ESI+: 327
    NMR: 0.28-0.32 (1H, m), 0.44-0.48 (1H, m), 0.97-0.99 (2H, m), 1.30-1.39 (1H, m),
    1.56-1.79 (5H, m), 1.87-1.94 (1H, m), 2.58-2.61 (2H, m), 2.85-2.86 (2H, m), 2.99-3.08 (6H, m),
    3.17-3.47 (4H, m), 3.58-3.64 (1H, m), 3.70-3.76 (1H, m), 4.02-4.09 (1H, m), 6.42 (2H, s),
    6.64 (1H, s)
    250 2 ESI+: 343
    NMR: 0.36-0.50 (2H, m), 0.97-1.06 (2H, m), 1.13-1.29 (2H, m), 1.56-1.74 (3H, m),
    1.90-2.06 (1H, m), 2.84 (2H, d, J = 7.3 Hz), 2.89-2.98 (2H, m), 3.03-3.18 (6H, m), 3.23-3.35 (4H,
    m), 3.79-3.87 (2H, m), 4.00-4.08 (2H, m), 6.53 (1H, s), 9.13-9.41 (2H, br)
    mp: 153-155
  • TABLE 173
    Ex Syn Dat
    251 2 ESI+: 343
    NMR: 0.28-0.40 (1H, m), 0.50-0.62 (1H, m), 0.94-1.03 (2H, m), 1.10-1.25 (1H, m),
    1.33-1.62 (5H, m), 1.71-1.80 (1H, m), 2.24 (2H, s), 2.70-3.10 (10H, m), 3.10-3.21 (1H, m),
    3.30-3.48 (2H, m), 3.63-3.70 (1H, m), 3.82-3.89 (1H, m), 3.93-4.07 (2H, m), 6.46 (1H, s)
    mp: 171 (decomp.)
    252 2 ESI+: 303
    NMR: 1.43-1.54 (1H, m), 1.73-1.90 (2H, m), 2.00-2.06 (1H, m), 2.25 (3H, s), 2.83-3.23 (11H,
    m), 3.35-3.45 (1H, m), 3.66-3.84 (2H, m), 4.10-4.30 (3H, m), 6.57 (1H, s), 9.57 (2H, br)
    253 2 ESI+: 303
    NMR: 1.41-1.53 (1H, m), 1.70-1.88 (2H, m), 1.94-2.05 (1H, m), 2.23 (3H, s), 1.77-2.85 (2H,
    m), 2.93-3.16 (9H, m), 3.31-3.42 (1H, m), 3.65-3.89 (2H, m), 4.06-4.25 (3H, m), 6.54 (1H,
    s), 9.40 (2H, s)
    254 2 ESI+: 331
    NMR: 0.34-0.49 (2H, m), 0.92 (3H, d, J = 6.7 Hz), 0.96-1.03 (2H, m), 1.57-1.69 (1H, m),
    2.08-2.23 (1H, m), 2.80 (1H, dd, J = 13.4, 7.8 Hz), 2.86-2.99 (3H, m), 3.02-3.14 (6H, m),
    3.14-3.21 (4H, m), 3.21-3.26 (2H, m), 3.30 (1H, dd, J = 9.2, 5.0 Hz), 3.95-4.08 (2H, m), 6.48 (3H,
    s), 6.52 (1H, s)
    255 2 ESI+: 329
    NMR: 0.37-0.50 (2H, m), 0.93-1.05 (2H, m), 1.50-1.68 (2H, m), 1.92-2.04 (1H, m),
    2.53-2.65 (1H, m), 2.76-2.85 (2H, m), 2.86-3.22 (10H, m), 3.37-3.47 (1H, m), 3.57-3.79 (3H,
    m), 3.97-4.09 (2H, m), 6.37 (1H, s), 6.48 (1H, s)
    mp: 117-118
    256 2 ESI+: 279
    NMR: 1.31 (3H, dd, J = 5.87, 24.2 Hz), 2.19 (3H, s), 2.70-3.17 (12H, m), 4.03-4.12 (2H, m),
    4.96-5.19 (1H, m), 6.44 (2H, s), 6.51 (1H, s)
    mp: 165-168
    257 2 ESI+: 335
    NMR: 0.46-0.62 (2H, m), 0.89-1.01 (2H, m), 1.64-1.76 (1H, m), 2.25 (2H, s), 2.75-2.85 (2H,
    m), 2.88-3.02 (6H, m), 3.11-3.22 (2H, m), 3.86-3.98 (2H, m), 4.19 (2H, s), 6.54 (1H, s),
    7.24-7.31 (1H, m), 7.33-7.40 (2H, m), 7.42-7.49 (2H, m)
    mp: 107-110
    258 2 ESI+: 369, 371
    NMR: 0.47-0.62 (2H, m), 0.87-1.00 (2H, m), 1.65-1.78 (1H, m), 2.28 (4H, s), 2.82-2.92 (2H,
    m), 2.94-3.13 (6H, m), 3.17-3.29 (2H, m), 3.90-4.01 (2H, m), 4.20 (2H, s), 6.58 (1H, s),
    7.32-7.45 (3H, m), 7.50-7.54 (1H, m)
    mp: 139-141
  • TABLE 174
    Ex Syn Dat
    259 2 ESI+: 369, 371
    0.41-0.56 (2H, m), 0.72-0.85 (2H, m), 1.52-1.63 (1H, m), 2.28 (4H, s), 2.81-2.93 (2H, m),
    2.98-3.12 (6H, m), 3.16-3.27 (2H, m), 3.94-4.04 (2H, m), 4.23 (2H, s), 6.60 (1H, s), 7.33 (1H,
    dt, J = 1.61, 7.48 Hz), 7.40-7.49 (2H, m), 7.80-7.88 (1H, m)
    mp: 106-109
    260 2 ESI+: 353
    0.47-0.63 (2H, m), 0.83-1.00 (2H, m), 1.60-1.74 (1H, m), 2.25 (4H, s), 2.76-2.85 (2H, m),
    2.88-3.05 (6H, m), 3.11-3.26 (2H, m), 3.87-3.99 (2H, m), 4.21 (2H, s), 6.55 (1H, s),
    7.07-7.14 (1H, m), 7.24-7.32 (2H, m), 7.38-7.45 (1H, m)
    mp: 102-105
    261 2 ESI+: 301
    NMR: 1.85-2.01 (1H, m), 2.80 (3H, s), 2.94-3.26 (11H, m), 3.74-3.92 (2H, m),
    4.10-4.31 (4H, m), 5.66 (1H, s), 6.69 (1H, s), 9.38-9.62 (2H, br)
    262 2 ESI+: 301
    NMR: 0.37-0.51 (2H, m), 0.91 (6H, d, J = 6.6 Hz), 0.96-1.04 (2H, m), 1.58-1.71 (1H, m),
    1.92-2.08 (1H, m), 2.72-2.83 (2H, m), 2.89-2.99 (2H, m), 3.03-3.19 (6H, m), 3.23-3.34 (2H,
    m), 3.99-4.07 (2H, m), 6.53 (1H, s), 9.24-9.42 (2H, br)
    mp: 160-162
    263 2 ESI+: 343
    NMR: 0.30-0.49 (2H, m), 0.90-1.05 (2H, m), 1.12-1.27 (1H, m), 1.41-1.67 (3H, m),
    1.73-1.85 (1H, m), 1.91-2.05 (1H, m), 2.66-2.99 (8H, m), 3.00-3.21 (5H, m), 3.22-3.32 (1H, m),
    3.71-3.78 (1H, m), 3.82-3.90 (1H, m), 3.96-4.08 (2H, m), 6.37 (1H, s), 6.47 (1H, s)
    mp: 186-189
    264 2 ESI+: 293
    NMR: 1.07 (3H, t, J = 7.3 Hz), 1.95-2.15 (2H, m), 2.68 (2H, q, J = 7.3 Hz), 2.80-2.92 (2H, m),
    2.93-3.18 (10H, m), 4.07-4.19 (2H, m), 4.56 (2H, dt, J = 47.4, 5.7 Hz), 6.55 (1H, s),
    9.24-9.52 (2H, br)
    mp: 153-154
    265 2 ESI+: 353
    NMR: 0.46-0.57 (2H, m), 0.84-0.96 (2H, m), 1.64-1.74 (1H, m), 2.80-3.07 (8H, m),
    3.14-3.25 (2H, m), 3.88-3.97 (2H, m), 4.24 (2H, s), 6.38 (1H, s), 6.54 (1H, s), 7.13-7.28 (2H, m),
    7.30-7.39 (1H, m), 7.66 (1H, dt, J = 1.66, 7.68 Hz)
    mp: 133-136
    266 2 ESI+: 331
    NMR: 0.37-0.52 (2H, m), 0.95-1.06 (2H, m), 1.43-1.55 (2H, m), 1.58-1.74 (3H, m),
    2.82-2.95 (4H, m), 2.98-3.12 (6H, m), 3.16-3.27 (5H, m), 3.33 (2H, t, J = 6.4 Hz), 3.94-4.02 (2H,
    m), 6.43 (2H, s), 6.51 (1H, s)
  • TABLE 175
    Ex Syn Dat
    267 2 ESI+: 393
    NMR: 0.28-0.43 (1H, m), 0.44-0.58 (1H, m), 0.94-1.10 (2H, m), 1.52-1.64 (1H, m),
    2.81-3.09 (6H, m), 3.09-3.25 (3H, m), 3.25-3.34 (2H, m), 3.34-3.46 (1H, m), 3.94-4.17 (3H, m),
    4.29 (1H, dd, J = 11.5, 2.4 Hz), 4.53-4.63 (1H, m), 6.42 (1.5H, s), 6.52 (1H, s), 6.69-6.76 (1H,
    m), 6.77-6.87 (3H, m)
    mp: 179-182
    268 2 ESI+: 365
    NMR: 0.40-0.52 (2H, m), 0.98-1.10 (2H, m), 1.61-1.71 (1H, m), 2.85-2.93 (2H, m),
    2.98-3.12 (4H, m), 3.17-3.29 (4H, m), 3.33-3.41 (2H, m), 4.02-4.10 (2H, m), 4.25 (2H, t, J = 5.9 Hz),
    6.44 (2H, s), 6.53 (1H, s), 6.90-6.97 (3H, m), 7.24-7.32 (2H, m)
    269 2 ESI+: 305
    NMR: 1.04 (3H, t, J = 7.4 Hz), 1.14 (3H, t, J = 7.0 Hz), 2.71 (2H, q, J = 7.4 Hz), 2.76-2.95 (10H,
    m), 2.98-3.07 (2H, m), 3.49 (2H, q, J = 7.0 Hz), 3.64 (2H, t, J = 5.9 Hz), 4.04-4.11 (2H, m),
    6.38 (1H, s), 6.45 (1H, s)
    mp: 179-181
    270 2 ESI+: 379
    NMR: 0.46-0.57 (2H, m), 0.84-0.97 (2H, m), 1.25 (3H, t, J = 7.09 Hz), 1.60-1.72 (1H, m),
    2.87-2.95 (2H, m), 2.97-3.15 (6H, m), 3.20-3.33 (2H, m), 3.85-3.93 (2H, m), 3.97 (2H, q, J = 7.09 Hz),
    4.16 (2H, s), 6.45 (2H, s), 6.56 (1H, s), 6.93-6.00 (2H, m), 7.24 (1H, dt, J = 1.42, 7.34 Hz),
    7.55 (1H, dd, J = 1.42.8.22 Hz)
    mp: 215 (decomp.)
    271 2 ESI+: 309
    NMR: 0.38-0.49 (2H, m), 1.01-1.15 (2H, m), 1.62-1.75 (1H, m), 2.87-2.94 (2H, m),
    2.99-3.10 (4H, m), 3.11-3.17 (2H, m), 3.20-3.27 (2H, m), 3.35 (2H, dt, J = 4.3, 15.2 Hz),
    4.04-4.12 (2H, m), 6.22-6.40 (1H, m), 6.44 (2H, s), 6.55 (1H, s)
    mp: 198-201
    272 2 ESI+: 415
    NMR: 0.48-0.59 (2H, m), 0.88-0.98 (2H, m), 1.69-1.80 (1H, m), 2.89-2.97 (2H, m),
    3.01-3.17 (6H, m), 3.23-3.32 (2H, m), 3.91-4.00 (2H, m), 4.30 (2H, s), 6.48 (2H, s), 6.58 (1H, s),
    7.22-7.27 (1H, m), 7.30-7.35 (1H, m), 7.38-7.42 (1H, m)
    mp: 200 (decomp.)
    273 2 ESI+: 415
    NMR: 0.48-0.64 (2H, m), 0.91-1.01 (2H, m), 1.64-1.80 (1H, m), 2.86-3.17 (8H, m),
    3.21-3.33 (2H, m), 3.88-3.99 (2H, m), 4.21 (2H, s), 6.45 (2H, s), 6.59 (1H, s), 7.28 (1H, dd, J = 1.22,
    8.36 Hz), 7.41 (1H, d, J = 8.36 Hz), 7.46 (1H, d, J = 1.22 Hz)
    mp: 161-164
    274 2 ESI+: 377
    NMR: 0.46-0.64 (2H, m), 0.93-1.10 (2H, m), 1.67-1.81 (1H, m), 2.87-3.00 (4H, m),
    3.01-3.35 (8H, m), 3.88-3.99 (2H, m), 4.09 (2H, s), 4.46-4.59 (2H, m), 6.45 (2H, s), 6.57 (1H, s),
    6.73 (1H, d, J = 8.17 Hz), 7.11-7.16 (1H, m), 7.29 (1H, s)
    mp: 215 (decomp.)
  • TABLE 176
    Ex Syn Dat
    275 2 ESI+: 393
    NMR: 0.40-0.63 (2H, m), 0.78-1.00 (2H, m), 1.56-1.77 (1H, m), 2.83-2.96 (2H, m),
    2.99-3.17 (6H, m), 3.20-3.34 (2H, m), 3.84-3.93 (2H, m), 4.14 (2H, s), 4.17-4.25 (4H, m),
    6.44 (2H, s), 6.56 (1H, s), 6.76 (1H, dd, J = 1.37, 8.27 Hz), 6.84 (1H, t, J = 8.27 Hz),
    7.10 (1H, dd, J = 1.37, 8.27 Hz)
    mp: 184-187
    276 2 ESI+: 349
    NMR: 0.45-0.58 (2H, m), 0.75-0.88 (2H, m), 1.55-1.66 (1H, m), 2.17 (3H, s), 2.84-2.96 (2H,
    m), 2.99-3.14 (6H, m), 3.19-3.29 (2H, m), 3.93-4.01 (2H, m), 4.14 (2H, s), 6.42 (2H, s),
    6.59 (1H, s), 7.14-7.17 (2H, m), 7.21-7.28 (1H, m), 7.68-7.75 (1H, m)
    mp: 163-166
    277 2 ESI+: 349
    NMR: 0.50-0.63 (2H, m), 0.92-1.03 (2H, m), 1.67-1.78 (1H, m), 2.31 (3H, s), 2.88-2.99 (4H,
    m), 3.03-3.15 (4H, m), 3.24-3.33 (2H, m), 3.91-3.99 (2H, m), 4.16 (2H, s), 6.45 (2H, s),
    6.58 (1H, s), 7.05-7.11 (1H, m), 7.22-7.29 (3H, m)
    mp: 192-195
    278 4 ESI+: 245
    NMR: 1.20 (6H, s), 2.31 (2H, s), 2.95-3.18 (8H, m), 6.69 (1H, s), 7.12 (1H, s), 9.24-9.38 (1.8H,
    br), 10.12 (1H, s)
    mp: 270-272
    279 4 ESI+: 231
    NMR: 1.32 (6H, s), 1.78-1.89 (2H, m), 2.72-2.81 (2H, m), 3.00-3.21 (8H, m), 6.90-7.16 (2H,
    m), 9.29-9.48 (2H, br)
    mp: 270-273
    280 282 ESI+: 353, 355
    NMR: 1.27 (3H, d, J = 7.2 Hz), 1.69-1.79 (2H, m), 2.61-2.77 (4H, m), 2.93-3.46 (9H, m),
    3.28 (3H, s), 3.72 (2H, t, J = 6.5 Hz), 6.47 (2H, s), 6.85 (1H, s)
    mp: 188 (decomp.)
    281 282 ESI+: 315
    NMR: 0.32-0.43 (2H, m), 0.97-1.01 (2H, m), 1.27 (3H, d, J = 7.2 Hz), 1.59-1.77 (3H, m),
    2.62-2.70 (2H, m), 2.77-2.84 (1H, br), 3.03-3.28 (8H, m), 3.23 (3H, s), 3.43-3.58 (2H, m),
    3.56 (2H, t, J = 6.3 Hz), 6.43 (2H, s), 6.67 (1H, s)
    mp: 195 (decomp.)
    282 282 ESI+: 353, 355
    NMR: 1.24 (3H, d, J = 7.4 Hz), 1.69-1.76 (2H, m), 2.62-2.75 (4H, m), 2.90-3.31 (8H, m),
    3.28 (3H, s), 3.72 (2H, t, J = 6.5 Hz), 3.84-3.89 (1H, m), 6.49 (2H, s), 6.79 (1H, s)
    mp: 184 (decomp.)
    283 2 ESI+: 371
    NMR: 0.46-0.60 (2H, m), 0.81-0.95 (2H, m), 1.61-1.75 (1H, m), 2.78-2.89 (2H, m),
    2.91-3.01 (4H, m), 3.01-3.08 (2H, m), 3.14-3.25 (2H, m), 3.91-3.99 (2H, m), 4.22 (2H, s),
    6.40 (1H, s), 6.55 (1H, s), 7.12-7.30 (2H, m), 7.41-7.52 (1H, m)
    mp: 195 (decomp.)
  • TABLE 177
    Ex Syn Dat
    284 2 ESI+: 371
    NMR: 0.46-0.55 (2H, m), 0.84-0.94 (2H, m), 1.64-1.75 (1H, m), 2.81-3.09 (8H, m),
    3.14-3.25 (2H, m), 3.88-3.99 (2H, m), 4.28 (2H, s), 6.38 (1H, s), 6.55 (1H, s), 7.20-7.29 (1H, m),
    7.30-7.40 (1H, m), 7.44-7.52 (1H, m)
    mp: 157-159
    285 2 ESI+: 387, 389
    NMR: 0.41-0.56 (2H, m), 0.79-0.93 (2H, m), 1.61-1.75 (1H, m), 2.78-3.09 (8H, m),
    3.15-3.24 (2H, m), 3.92-3.98 (2H, m), 4.27 (2H, s), 6.39 (1H, s), 6.55 (1H, s), 7.25-7.32 (1H, m),
    7.47-7.55 (1H, m), 7.62-7.70 (1H, m)
    mp: 181-184
    286 2 ESI+: 377
    NMR: 0.44-0.62 (2H, m), 0.85-1.02 (2H, m), 1.62-1.79 (1H, m), 2.83-3.38 (12H, m),
    3.83-3.99 (2H, m), 4.10 (2H, s), 4.49 (2H, t, J = 8.51 Hz), 6.47 (2H, s), 6.57 (1H, s), 6.81-6.90 (1H,
    m), 7.14 (1H, d, J = 6.8 Hz), 7.30 (1H, d, J = 8.1 Hz)
    mp: 190 (decomp.)
    287 2 ESI+: 335
    NMR: 0.29-0.43 (1H, m), 0.43-0.57 (1H, m), 0.92-1.10 (2H, m), 1.56-1.68 (1H, m),
    2.82-2.92 (2H, m), 2.95-3.39 (13H, m), 3.69-3.86 (1H, m), 3.96-4.11 (2H, m), 4.32-4.65 (2H,
    m), 6.43 (2H, s), 6.52 (1H, s)
    288 2 ESI+: 379
    NMR: 0.54-0.62 (2H, m), 0.94-1.04 (2H, m), 1.68-1.79 (1H, m), 2.90-3.17 (8H, m),
    3.24-3.34 (5H, m), 3.90-3.98 (2H, m), 4.20 (2H, s), 4.41 (2H, s), 6.44 (2H, s), 6.58 (1H, s),
    7.15-7.24 (1H, m), 7.29-7.42 (3H, m)
    mp: 190-193
    289 2 ESI+: 371
    NMR: 0.44-0.56 (2H, m), 0.85-0.96 (2H, m), 1.65-1.75 (1H, m), 2.80-3.08 (8H, m),
    3.14-3.26 (2H, m), 3.88-3.98 (2H, m), 4.20 (2H, s), 6.38 (1H, s), 6.54 (1H, s), 7.13 (1H, dt, J = 2.5,
    8.5 Hz), 7.18-7.26 (1H, m), 7.64-7.72 (1H, m)
    mp: 220 (decomp.)
    290 2 ESI+: 387, 389
    NMR: 0.44-0.58 (2H, m), 0.82-0.96 (2H, m), 1.64-1.75 (1H, m), 2.89-2.97 (2H, m),
    3.00-3.16 (6H, m), 3.21-3.32 (2H, m), 3.90-4.01 (2H, m), 4.22 (2H, s), 6.45 (2H, s), 6.58 (1H, s),
    7.22-7.29 (1H, m), 7.38-7.44 (1H, m), 7.69 (1H, dd, J = 6.7, 3.0 Hz)
    mp: 165-168
    291 2 ESI+: 393
    NMR: 0.47-0.60 (2H, m), 0.92-1.02 (2H, m), 1.65-1.76 (1H, m), 2.81-3.04 (8H, m),
    3.17-3.27 (2H, m), 3.86-3.95 (2H, m), 4.06 (2H, s), 4.22 (4H, s), 6.38 (1H, s), 6.54 (1H, s),
    6.79-6.89 (2H, m), 6.91-6.95 (1H, m)
    mp: 165-168
  • TABLE 178
    Ex Syn Dat
    292 2 ESI+: 317
    NMR: 0.14-0.25 (1H, m), 0.58-0.68 (1H, m), 0.91 (3H, d, J = 6.9 Hz), 0.97-1.09 (2H, m),
    1.55-1.68 (1H, m), 2.75-3.19 (8H, m), 3.25 (3H, s), 3.28-3.48 (3H, m), 3.61 (2H, t, J = 6.1 Hz),
    3.86 (1H, dd, J = 10.5, 1.6 Hz), 3.92 (1H, dd, J = 10.6, 2.3 Hz), 6.43 (2H, s), 6.52 (1H, s)
    mp: 183 (decomp.)
    293 2 ESI+: 379
    NMR: 0.43-0.55 (2H, m), 0.76-0.87 (2H, m), 1.53-1.65 (1H, m), 2.86-3.12 (8H, m),
    3.18-3.29 (5H, m), 3.88-3.97 (2H, m), 4.23 (2H, s), 4.36 (2H, s), 6.44 (2H, s), 6.60 (1H, s),
    7.20-7.29 (1H, m), 7.31-7.43 (2H, m), 7.82 (1H, d, J = 7.8 Hz)
    mp: 180 (decomp.)
    294 2 ESI+: 335
    NMR: 0.31-0.43 (1H, m), 0.44-0.54 (1H, m), 0.94-1.10 (2H, m), 1.55-1.67 (1H, m),
    2.82-2.93 (2H, m), 2.95-3.40 (13H, m), 3.68-3.86 (1H, m), 3.97-4.12 (2H, m), 4.33-4.65 (2H,
    m), 6.43 (2H, s), 6.52 (1H, s)
    295 2 ESI+: 367
    NMR: 0.43-0.46 (2H, m), 1.00-1.06 (2H, m), 1.60-1.67 (1H, m), 2.82-2.85 (2H, m),
    2.98-3.03 (4H, m), 3.15-3.17 (2H, m), 3.20-3.23 (2H, m), 3.38-3.41 (2H, m), 4.05-4.07 (2H, m),
    4.60 (2H, t, J = 6.1 Hz), 6.42 (2H, s), 6.51 (1H, s), 8.20 (2H, s), 8.22 (1H, s)
    mp: 170 (decomp.)
    296 2 ESI+: 438
    NMR: 0.44-0.48 (2H, m), 1.05-1.10 (2H, m), 1.63-1.70 (1H, m), 2.84-2.86 (2H, m),
    2.98-3.04 (4H, m), 3.18-3.23 (4H, m), 3.41-3.44 (2H, m), 3.94 (3H, s), 4.06-4.09 (2H, m),
    4.46-4.49 (2H, m), 6.42 (2H, s), 6.52 (1H, s), 6.99 (1H, d, J = 7.1 Hz), 7.71 (1H, d, J = 10.9 Hz)
    mp: 125-128
    297 2 ESI+: 426
    NMR: 0.42-0.46 (2H, m), 0.97-1.02 (2H, m), 1.57-1.64 (1H, m), 2.83-2.85 (2H, m),
    2.98-3.03 (4H, m), 3.16-3.21 (4H, m), 3.34-3.37 (2H, m), 4.05-4.07 (2H, m), 4.56-4.59 (2H, m),
    6.41 (2H, s), 6.52 (1H, s), 7.82-7.90 (2H, m)
    mp: 178 (decomp.)
    298 2 ESI+: 365
    NMR: 0.42-0.56 (2H, m), 0.78-0.91 (2H, m), 1.57-1.68 (1H, m), 2.83-3.14 (8H, m),
    3.21-3.33 (2H, m), 3.72 (3H, s), 3.85-3.96 (2H, m), 4.15 (2H, s), 6.45 (2H, s), 6.57 (1H, s),
    6.93-7.04 (2H, m), 7.22-7.30 (1H, m), 7.53-7.61 (1H, m)
    mp: 195 (decomp.)
    299 2 ESI+: 365
    NMR: 0.51-0.64 (2H, m), 0.93-1.03 (2H, m), 1.68-1.78 (1H, m), 2.84-3.15 (8H, m),
    3.22-3.33 (2H, m), 3.74 (3H, s), 3.86-3.97 (2H, m), 4.18 (2H, s), 6.44 (2H, s), 6.57 (1H, s),
    6.81-6.88 (1H, m), 6.96-7.04 (2H, m), 7.24-7.31 (1H, m)
    mp: 220 (decomp.)
  • TABLE 179
    Ex Syn Dat
    300 2 ESI+: 419
    NMR: 0.44-0.58 (2H, m), 0.78-0.91 (2H, m), 1.55-1.67 (1H, m), 2.87-3.15 (8H, m),
    3.21-3.33 (2H, m), 3.87-3.98 (2H, m), 4.27 (2H, s), 6.45 (2H, s), 6.66 (1H, s), 7.33-7.39 (1H, m),
    7.41-7.52 (2H, m), 7.84-7.91 (1H, m)
    mp: 210 (decomp.)
    301 2 ESI+: 379
    NMR: 0.45-0.56 (2H, m), 0.82-0.95 (2H, m), 1.58-1.69 (1H, m), 2.27 (3H, s), 2.86-3.15 (8H,
    m), 3.22-3.32 (2H, m), 3.68 (3H, s), 3.78-3.96 (2H, m), 4.10 (2H, s), 6.45 (2H, s), 6.56 (1H,
    s), 6.86 (1H, d, J = 8.3 Hz), 7.05 (1H, dd, J = 1.8, 8.3 Hz), 7.38 (1H, d, J = 1.8 Hz)
    mp: 205 (decomp.)
    302 2 ESI+: 383
    NMR: 0.44-0.60 (2H, m), 0.76-0.89 (2H, m), 1.55-1.66 (1H, m), 2.89-2.96 (2H, m),
    3.00-3.12 (6H, m), 3.21-3.30 (2H, m), 3.72 (3H, s), 3.91-3.97 (2H, m), 4.11 (2H, s), 6.45 (2H, s),
    6.58 (1H, s), 6.95-7.01 (1H, m), 7.04-7.11 (1H, m), 7.35-7.42 (1H, m)
    mp: 189-192
    303 2 ESI+: 399, 401
    NMR: 0.39-0.57 (2H, m), 0.74-0.89 (2H, m), 1.53-1.68 (1H, m), 2.81-3.15 (8H, m),
    3.20-3.32 (2H, m), 3.73 (3H, s), 3.88-3.99 (2H, m), 4.10 (2H, s), 6.45 (2H, s), 6.58 (1H, s), 7.01 (1H,
    d, J = 8.7 Hz), 7.31 (1H, dd, J = 2.6, 8.7 Hz), 7.59 (1H, d, J = 2.59 Hz)
    mp: 193-196
    304 2 ESI+: 427
    NMR: 0.34-0.50 (2H, m), 0.97-1.07 (2H, m), 1.60-1.67 (1H, m), 2.82-2.85 (2H, m),
    2.96-3.05 (4H, m), 3.09-3.46 (6H, m), 3.22 (3H, s), 3.46-3.53 (2H, m), 4.03-4.05 (2H, m),
    4.83-4.86 (1H, m), 6.42 (2H, s), 6.47 (1H, s), 6.92-6.97 (1H, m), 7.08-7.22 (3H, m)
    mp: 132-133
    305 2 ESI+: 427
    NMR: 0.34-0.49 (2H, m), 0.99-1.11 (2H, m), 1.61-1.68 (1H, m), 2.82-2.86 (2H, m),
    2.89-3.43 (10H, m), 3.22 (3H, s), 3.44-3.52 (2H, m), 3.97-4.06 (2H, m), 4.81-4.87 (1H, m),
    6.42 (2H, s), 6.45 (1H, s), 6.73-6.78 (3H, m), 7.25-7.31 (1H, m)
    mp: 174 (decomp.)
    306 2 ESI+: 427
    NMR: 0.35-0.51 (2H, m), 0.97-1.09 (2H, m), 1.60-1.67 (1H, m), 2.80-3.51 (14H, m),
    3.21 (3H, s), 3.97-4.06 (2H, m), 4.71-4.76 (1H, m), 6.43 (2H, s), 6.47 (1H, s), 6.91-6.95 (2H, m),
    7.07-7.11 (2H, m)
    mp: 138-140
    307 2 ESI+: 445
    NMR: 0.35-0.50 (2H, m), 0.97-1.08 (2H, m), 1.59-1.66 (1H, m), 2.79-2.86 (2H, m),
    2.89-3.43 (10H, m), 3.21 (3H, s), 3.44-3.52 (2H, m), 4.03-4.05 (2H, m), 4.75-4.80 (1H, m),
    6.43 (2H, s), 6.47 (1H, s), 6.95-7.00 (1H, m), 7.17 (1H, td, J = 9.3, 5.6 Hz), 7.26 (1H, ddd, J = 11.5,
    8.7, 2.9 Hz)
    mp: 150-151
  • TABLE 180
    Ex Syn Dat
    308 2 ESI+: 463
    NMR: 0.35-0.46 (2H, m), 0.97-1.12 (2H, m), 1.61-1.68 (1H, m), 2.78-3.58 (14H, m),
    3.21 (3H, s), 3.96-4.05 (2H, m), 4.77-4.82 (1H, m), 6.43 (3H, s), 6.84-6.88 (2H, m)
    mp: 155 (decomp.)
    309 2 ESI+: 461, 463
    NMR: 0.34-0.39 (1H, m), 0.46-0.51 (1H, m), 0.98-1.10 (2H, m), 1.61-1.68 (1H, m),
    2.80-3.42 (12H, m), 3.21 (3H, s), 3.45-3.53 (2H, m), 4.02-4.07 (2H, m), 4.83-4.88 (1H, m),
    6.43 (2H, s), 6.48 (1H, s), 7.12-7.21 (2H, m), 7.41 (1H, dd, J = 8.3, 3.0 Hz)
    mp: 149 (decomp.)
    310 2 ESI+: 367
    NMR: 0.43-0.47 (2H, m), 1.03-1.07 (2H, m), 1.63-1.70 (1H, m), 2.83-2.86 (2H, m),
    2.99-3.05 (4H, m), 3.18-3.22 (4H, m), 3.35-3.38 (2H, m), 4.05-4.07 (2H, m), 4.58 (2H, t, J = 6.1 Hz),
    6.42 (2H, s), 6.52 (1H, s), 7.14 (1H, t, J = 4.8 Hz), 8.60 (2H, d, J = 4.8 Hz)
    mp: 188 (decomp.)
    311 2 ESI+: 386
    NMR: 0.42-0.46 (2H, m), 1.01 (6H, d, J = 6.3 Hz), 1.60-1.69 (3H, m), 2.57-2.61 (2H, m),
    2.71-2.74 (2H, m), 2.88-2.90 (2H, m), 3.03-3.11 (8H, m), 3.23-3.24 (2H, m), 3.41-3.50 (4H,
    m), 4.01-4.03 (2H, m), 6.48 (3H, s), 6.52 (1H, s)
    mp: 129 (decomp.)
    312 2 ESI+: 371
    NMR: 0.49-0.60 (2H, m), 0.85-1.00 (2H, m), 1.61-1.74 (1H, m), 2.78-3.07 (8H, m),
    3.13-3.27 (2H, m), 3.87-4.00 (2H, m), 4.17 (2H, s), 6.38 (1H, s), 6.55 (1H, s), 7.25-7.51 (3H, m)
    mp: 230 (decomp.)
    313 2 ESI+: 371
    NMR: 0.49-0.60 (2H, m), 0.85-0.95 (2H, m), 1.62-1.72 (1H, m), 2.81-3.06 (8H, m),
    3.17-3.25 (2H, m), 3.92-4.01 (2H, m), 4.21 (2H, s), 6.38 (1H, s), 6.56 (1H, s), 7.09-7.22 (3H, m)
    mp: 191-194
    314 2 ESI+: 459
    NMR: 0.43-0.47 (2H, m), 0.95-1.00 (2H, m), 1.15 (3H, t, J = 7.0 Hz), 1.53-1.60 (1H, m),
    2.85-2.87 (2H, m), 3.00-3.05 (4H, m), 3.17-3.22 (4H, m), 3.31-3.34 (2H, m), 3.47 (2H, q, J = 7.0 Hz),
    4.05-4.07 (2H, m), 4.38-4.40 (4H, m), 6.42 (2H, s), 6.53 (1H, s), 7.06-7.12 (2H, m)
    mp: 138-139
    315 2 ESI+: 331
    NMR: 0.30-0.42 (1H, m), 0.46-0.59 (1H, m), 0.93-1.12 (8H, m), 1.53-1.65 (1H, m),
    2.79-3.58 (14H, m), 3.71-3.83 (1H, m), 3.94-4.12 (2H, m), 6.42 (2H, s), 6.50 (1H, s)
    mp: 157-160
    316 2 ESI+: 317
    NMR: 0.14-0.27 (1H, m), 0.57-0.68 (1H, m), 0.91 (3H, d, J = 6.9 Hz), 0.96-1.09 (2H, m),
    1.55-1.68 (1H, m), 2.76-3.19 (9H, m), 3.25 (3H, s), 3.28-3.48 (2H, m), 3.61 (2H, t, J = 6.1 Hz),
    3.80-3.97 (2H, m), 6.43 (2H, s), 6.52 (1H, s)
    mp: 186 (decomp)
  • TABLE 181
    Ex Syn Dat
    317 2 ESI+: 349
    NMR: 0.32-0.43 (1H, m), 0.44-0.55 (1H, m), 0.93-1.15
    (5H, m), 1.55-1.67 (1H, m), 2.82-2.92 (2H, m), 2.94-3.30
    (9H, m), 3.33-3.48 (2H, m), 3.57-3.67 (1H, m), 3.79-3.94
    (1H, m), 3.98-4.13 (2H, m), 4.31-4.60 (2H, m), 6.43
    (2H, s), 6.52 (1H, s)
    318 2 ESI+: 291
    NMR: 0.91 (3H, d, J = 6.8 Hz), 2.01-2.15 (1H, m),
    2.83-3.31 (17H, m), 4.05-4.14 (2H, m), 6.51 (1H, s),
    6.52 (1H, s), 9.24-9.50 (2H, br)
    mp: 129-132
    319 2 ESI+: 277
    NMR: 1.1 (3H, t, J = 6.2 Hz), 2.85-2.93 (2H, m), 2.93-3.00
    (2H, m), 3.01-3.12 (4H, m), 3.12-3.46 (7H, m), 3.53-3.64
    (1H, m), 4.02-4.13 (2H, m), 6.52 (1H, s), 6.54 (1H, s),
    9.32-9.48 (2H, br)
  • TABLE 182
    Figure US20130012496A1-20130110-C00903
    Figure US20130012496A1-20130110-C00904
    Figure US20130012496A1-20130110-C00905
    Figure US20130012496A1-20130110-C00906
    Figure US20130012496A1-20130110-C00907
    Figure US20130012496A1-20130110-C00908
    Figure US20130012496A1-20130110-C00909
    Figure US20130012496A1-20130110-C00910
    Figure US20130012496A1-20130110-C00911
    Figure US20130012496A1-20130110-C00912
  • TABLE 183
    Figure US20130012496A1-20130110-C00913
    Figure US20130012496A1-20130110-C00914
    Figure US20130012496A1-20130110-C00915
    Figure US20130012496A1-20130110-C00916
    Figure US20130012496A1-20130110-C00917
    Figure US20130012496A1-20130110-C00918
    Figure US20130012496A1-20130110-C00919
    Figure US20130012496A1-20130110-C00920
    Figure US20130012496A1-20130110-C00921
    Figure US20130012496A1-20130110-C00922
  • TABLE 184
    Figure US20130012496A1-20130110-C00923
    Figure US20130012496A1-20130110-C00924
    Figure US20130012496A1-20130110-C00925
    Figure US20130012496A1-20130110-C00926
    Figure US20130012496A1-20130110-C00927
    Figure US20130012496A1-20130110-C00928
    Figure US20130012496A1-20130110-C00929
    Figure US20130012496A1-20130110-C00930
    Figure US20130012496A1-20130110-C00931
    Figure US20130012496A1-20130110-C00932
  • TABLE 185
    Figure US20130012496A1-20130110-C00933
    Figure US20130012496A1-20130110-C00934
    Figure US20130012496A1-20130110-C00935
    Figure US20130012496A1-20130110-C00936
    Figure US20130012496A1-20130110-C00937
    Figure US20130012496A1-20130110-C00938
    Figure US20130012496A1-20130110-C00939
    Figure US20130012496A1-20130110-C00940
    Figure US20130012496A1-20130110-C00941
    Figure US20130012496A1-20130110-C00942
  • TABLE 186
    Figure US20130012496A1-20130110-C00943
    Figure US20130012496A1-20130110-C00944
    Figure US20130012496A1-20130110-C00945
    Figure US20130012496A1-20130110-C00946
    Figure US20130012496A1-20130110-C00947
    Figure US20130012496A1-20130110-C00948
    Figure US20130012496A1-20130110-C00949
    Figure US20130012496A1-20130110-C00950
    Figure US20130012496A1-20130110-C00951
    Figure US20130012496A1-20130110-C00952
    Figure US20130012496A1-20130110-C00953
    Figure US20130012496A1-20130110-C00954
  • TABLE 187
    Figure US20130012496A1-20130110-C00955
    Figure US20130012496A1-20130110-C00956
    Figure US20130012496A1-20130110-C00957
    Figure US20130012496A1-20130110-C00958
    Figure US20130012496A1-20130110-C00959
    Figure US20130012496A1-20130110-C00960
    Figure US20130012496A1-20130110-C00961
    Figure US20130012496A1-20130110-C00962
    Figure US20130012496A1-20130110-C00963
    Figure US20130012496A1-20130110-C00964
    Figure US20130012496A1-20130110-C00965
    Figure US20130012496A1-20130110-C00966
  • TABLE 188
    Figure US20130012496A1-20130110-C00967
    Figure US20130012496A1-20130110-C00968
    Figure US20130012496A1-20130110-C00969
    Figure US20130012496A1-20130110-C00970
    Figure US20130012496A1-20130110-C00971
    Figure US20130012496A1-20130110-C00972
    Figure US20130012496A1-20130110-C00973
    Figure US20130012496A1-20130110-C00974
    Figure US20130012496A1-20130110-C00975
    Figure US20130012496A1-20130110-C00976
    Figure US20130012496A1-20130110-C00977
    Figure US20130012496A1-20130110-C00978
  • TABLE 189
    Figure US20130012496A1-20130110-C00979
    Figure US20130012496A1-20130110-C00980
    Figure US20130012496A1-20130110-C00981
    Figure US20130012496A1-20130110-C00982
    Figure US20130012496A1-20130110-C00983
    Figure US20130012496A1-20130110-C00984
    Figure US20130012496A1-20130110-C00985
    Figure US20130012496A1-20130110-C00986
    Figure US20130012496A1-20130110-C00987
    Figure US20130012496A1-20130110-C00988
    Figure US20130012496A1-20130110-C00989
    Figure US20130012496A1-20130110-C00990
    Figure US20130012496A1-20130110-C00991
    Figure US20130012496A1-20130110-C00992
  • TABLE 190
    Figure US20130012496A1-20130110-C00993
    Figure US20130012496A1-20130110-C00994
    Figure US20130012496A1-20130110-C00995
    Figure US20130012496A1-20130110-C00996
    • INDUSTRIAL APPLICABILITY
  • The compound of the formula (I) or a salt thereof, or the compound of the formula (II) or a salt thereof has a 5-HT2C receptor agonist activity and can be used as an agent for preventing or treating 5-HT2C receptor-related diseases.
  • Here, examples of the 5-HT2C receptor-related diseases include incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like.

Claims (18)

1. A pharmaceutical composition comprising a compound of the formula (I) or a salt thereof and a pharmaceutically acceptable excipient:
Figure US20130012496A1-20130110-C00997
(wherein
R1a and R1b are the same or different and each represents —H or C1-6 alkyl, or are combined to form oxo,
R2a and, R2b are the same or different and each represents —H or C1-6 alkyl which may be substituted with —O—C1-6 alkyl,
R3 represents —H, C1-6 alkyl which may be substituted, C3-8 cycloalkyl, aryl which may be substituted, —SO2—C1-6 alkyl, or a hetero ring which may be substituted,
R4 represents —H, halogen, cyano, C1-6 alkyl which may be substituted, C2-6 alkenyl, aryl which may be substituted, C3-8 cycloalkyl which may be substituted, an aromatic hetero ring, or an oxygen-containing hetero ring,
R5 represents —H, halogen, C1-6 alkyl, C3-8 cycloalkyl, aryl, or an aromatic hetero ring,
R6 and R7 are the same or different and each represents —H or C1-6 alkyl,
X represents —C(RA)(RB)— or —O—, and
RA and RB are the same or different and each represents —H or C1-6 alkyl).
2. A pharmaceutical composition as described in claim 1, wherein R1a and R1b are respectively —H or are combined to form oxo,
R2a is —H or C1-6 alkyl,
R2b is —H
R3 is —H, C1-6 alkyl, halogeno-C1-6 alkyl, C1-6 alkylene-OH, (C1-6 alkylene which may be substituted)-O—C1-6 alkyl, C1-6 alkylene-cycloalkyl which may be substituted, C1-6 alkylene-aryl which may be substituted, C1-6 alkylene-hetero ring group which may be substituted, —CO—C1-6 alkyl, —CO—C1-6 alkylene-O—C1-6 alkyl, —CO-cycloalkyl which may be substituted, —CO-aryl which may be substituted, —CO—NR8R9, —CO—O—C1-6 alkyl, —CO—O—C1-6 alkylene-aryl which may be substituted, —SO2—C1-6 alkyl, aryl which may be substituted, or a hetero ring which may be substituted,
R8 and R9 are the same or different and each is —H or C1-6 alkyl,
R4 is —H, C1-6 alkyl, halogen, halogeno-C1-6 alkyl, cycloalkyl which may be substituted, or aryl which may be substituted, and
R5 are the same as or different from each other and are —H or C1-6 alkyl.
3. A pharmaceutical composition as described in claim 1, wherein R3 is —H, C1-6 alkyl which may be substituted, C3-8 cycloalkyl, aryl which may be substituted, —SO2—C1-6 alkyl, or an oxygen-containing hetero ring, and
R4 is —H, halogen, cyano, C1-6 alkyl which may be substituted, C2-6 alkenyl, aryl which may be substituted, C3-8 cycloalkyl, an aromatic hetero ring, or an oxygen-containing hetero ring.
4. A compound of the formula (II) or a salt thereof:
Figure US20130012496A1-20130110-C00998
(wherein
R11a and R11b are respectively the same or different and each represents —H or C1-6 alkyl, or are combined to form oxo,
R21a and R21b are respectively the same or different and each represents —H or C1-6 alkyl which may be substituted with —O—C1-6 alkyl,
R31 represents —H, C1-6 alkyl which may be substituted, C3-8 cycloalkyl, aryl which may be substituted, —SO2—C1-6 alkyl, or a hetero ring which may be substituted,
R41 represents —H, halogen, cyano, C1-6 alkyl which may be substituted, C2-6 alkenyl, aryl which may be substituted, C3-8 cycloalkyl which may be substituted, an aromatic hetero ring, or an oxygen-containing hetero ring,
R51 represents —H, halogen, C1-6 alkyl, C3-8 cycloalkyl, aryl, or an aromatic hetero ring,
R61 and R71 are the same or different and each represents —H or C1-6 alkyl,
X1 represents —C(RA1)(RB1)— or —O—, and
RA1 and RB1 are the same or different and each represents —H or C1-6 alkyl,
provided that
(i) in the case where R11a, R11b, R21a, R21b, R41, R51, R61, and R71 are respectively —H and X1 is —O—, R31 is a group other than —H, —CO-methyl, or —SO2-methyl, and
(ii) in the case where R11a and R11b are combined to form oxo, R21a, R21b, R41, R51, R61, and R71 are respectively —H, and X1 is —O—, R31 is a group other than —H or methyl).
5. A compound or a salt thereof as described in claim 4, wherein R11a and R11b are respectively —H or are combined to form oxo,
R21a is —H or C1-6 alkyl,
R21b is —H,
R31 is —H, C1-6 alkyl, halogeno-C1-6 alkyl, C1-6 alkylene-OH, (C1-6 alkylene which may be substituted)-O—C1-6 alkyl, C1-6 alkylene-cycloalkyl which may be substituted, C1-6 alkylene-aryl which may be substituted, C1-6 alkylene-hetero ring group which may be substituted, —CO—C1-6 alkyl, —CO—C1-6 alkylene-O—C1-6 alkyl, —CO-cycloalkyl which may be substituted, —CO-aryl which may be substituted, —CO—NR81R91, —CO—O—C1-6 alkyl, —CO—O—C1-6 alkylene-aryl which may be substituted, —SO2—C1-6 alkyl, aryl which may be substituted, or a hetero ring which may be substituted,
R81 and R91 are the same or different and each is —H or C1-6 alkyl,
R41 is —H, C1-6 alkyl, halogen, halogeno-C1-6 alkyl, cycloalkyl which may be substituted, or aryl which may be substituted, and
R51 are the same as or different from each other and are —H or C1-6 alkyl.
6. A compound or a salt thereof as described in claim 4, wherein R31 is —H, C1-6 alkyl which may be substituted, C3-8 cycloalkyl, aryl which may be substituted, —SO2—C1-6 alkyl, or an oxygen-containing hetero ring, and
R41 is —H, halogen, cyano, C1-6 alkyl which may be substituted, C2-6 alkenyl, aryl which may be substituted, C3-8 cycloalkyl, an aromatic hetero ring, or an oxygen-containing hetero ring.
7. A compound or a salt thereof as described in claim 6, wherein R31 is a group other than —H, methyl, —CO-methyl, or —SO2-methyl.
8. A compound or a salt thereof as described in claim 7, wherein R11a is —H or methyl, and R11b, R21a, R21b, R51, R61, and R71 are respectively —H.
9. A compound or a salt thereof as described in claim 8, wherein R41 is —H, halogen, or C3-8 cycloalkyl.
10. A compound or a salt thereof as described in claim 9, wherein R41 is cyclopropyl.
11. A compound or a salt thereof as described in claim 10, wherein R31 is C1-6 alkyl which may be substituted with one or more groups selected from the group consisting of (a) halogen, (b) —O—C1-6 alkyl, (c) phenoxy which may be substituted with one or more groups selected from the group consisting of halogen and cyano, (d) an oxygen-containing hetero ring, and (e) phenyl which may be substituted with one or more groups selected from the group consisting of C1-6 alkyl which may be substituted with —O—C1-6 alkyl, halogen, and —O—C1-6 alkyl.
12. A compound or a salt thereof as described in claim 4, which is
11-cyclopropyl-1-(2-methoxyethyl)-2,3,4,6,7,8,9,10-octahydro-1H-azepino[4,5-g]quinoline,
4-(3-methoxypropyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine,
5-cyclopropyl-4-(2-methoxyethyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine,
5-cyclopropyl-4-(2-ethoxyethyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine,
5-cyclopropyl-4-(3-methoxypropyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine,
5-cyclopropyl-4-(3-fluoropropyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine,
1-isobutyl-2,3,4,6,7,8,9,10-octahydro-1H-azepino[4,5-g]quinoline,
5-bromo-4-(2-methoxyethyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine,
5-cyclopropyl-4-[(2S)-tetrahydrofuran-2-ylmethyl]-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine,
5-cyclopropyl-4-[(2R)-2-methoxypropyl]-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine,
5-cyclopropyl-4-(2-fluorobenzyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine,
5-cyclopropyl-4-[(2S)-3-fluoro-2-methoxypropyl]-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine,
4-(3-chlorobenzyl)-5-cyclopropyl-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine,
5-cyclopropyl-4-(tetrahydro-2H-pyran-3-ylmethyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine,
5-cyclopropyl-4-(2,3-dihydro-1,4-benzodioxin-2-ylmethyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine,
5-cyclopropyl-4-(2-phenoxyethyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine,
5-cyclopropyl-4-(2-methylbenzyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine,
5-cyclopropyl-4-(3-methylbenzyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine,
5-cyclopropyl-4-(2,5-difluorobenzyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine,
5-cyclopropyl-4-[3-(methoxymethyl)benzyl]-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine,
4-(5-chloro-2-fluorobenzyl)-5-cyclopropyl-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine,
5-cyclopropyl-4-(2,3-dihydro-1,4-benzodioxin-6-ylmethyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine,
(3S)-5-cyclopropyl-4-(2-methoxyethyl)-3-methyl-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine,
4-[2-(5-cyclopropyl-2,3,7,8,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepin-4(6H)-yl)ethoxy]-3,5-difluorobenzonitrile,
5-cyclopropyl-4-(3-methoxybenzyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine,
5-cyclopropyl-4-(3,5-difluorobenzyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine, or
5-cyclopropyl-4-[(2R)-2-ethoxypropyl]-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine or a salt thereof.
13. A pharmaceutical composition comprising a compound or a salt thereof as described in claim 4 and a pharmaceutically acceptable excipient.
14. A pharmaceutical composition for preventing or treating 5-HT2C receptor-related diseases, comprising a compound or a salt thereof as described in claim 4.
15. A pharmaceutical composition as described in claim 14, which is a pharmaceutical composition for preventing or treating incontinence.
16. Use of a compound or a salt thereof as described in claim 4 for preparation of a pharmaceutical composition for preventing or treating incontinence.
17. A compound or a salt thereof as described in claim 4 for use in the prevention or treatment of incontinence.
18. A method for preventing or treating incontinence, comprising administering to a subject an effective amount of a compound or a salt thereof as described in claim 4.
US13/583,410 2010-03-12 2011-03-11 Benzazepine compound Abandoned US20130012496A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/583,410 US20130012496A1 (en) 2010-03-12 2011-03-11 Benzazepine compound

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31313310P 2010-03-12 2010-03-12
US13/583,410 US20130012496A1 (en) 2010-03-12 2011-03-11 Benzazepine compound
PCT/JP2011/055759 WO2011111817A1 (en) 2010-03-12 2011-03-11 Benzazepine compound

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2011/055759 A-371-Of-International WO2011111817A1 (en) 2010-03-12 2011-03-11 Benzazepine compound

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/044,080 Continuation-In-Part US20110269744A1 (en) 2010-03-12 2011-03-09 Benzazepine Compound
US13/613,948 Continuation-In-Part US9108977B2 (en) 2010-03-12 2012-09-13 Benzazepine compound

Publications (1)

Publication Number Publication Date
US20130012496A1 true US20130012496A1 (en) 2013-01-10

Family

ID=44563615

Family Applications (4)

Application Number Title Priority Date Filing Date
US13/044,080 Abandoned US20110269744A1 (en) 2010-03-12 2011-03-09 Benzazepine Compound
US13/583,410 Abandoned US20130012496A1 (en) 2010-03-12 2011-03-11 Benzazepine compound
US13/613,948 Active 2031-09-04 US9108977B2 (en) 2010-03-12 2012-09-13 Benzazepine compound
US14/797,277 Active US9598434B2 (en) 2010-03-12 2015-07-13 Benzazepine compound

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US13/044,080 Abandoned US20110269744A1 (en) 2010-03-12 2011-03-09 Benzazepine Compound

Family Applications After (2)

Application Number Title Priority Date Filing Date
US13/613,948 Active 2031-09-04 US9108977B2 (en) 2010-03-12 2012-09-13 Benzazepine compound
US14/797,277 Active US9598434B2 (en) 2010-03-12 2015-07-13 Benzazepine compound

Country Status (24)

Country Link
US (4) US20110269744A1 (en)
EP (1) EP2546255B1 (en)
JP (1) JP5747910B2 (en)
KR (1) KR101769642B1 (en)
CN (1) CN102869665B (en)
AU (1) AU2011225108C1 (en)
BR (1) BR112012022915B1 (en)
CA (1) CA2792918C (en)
CY (1) CY1118268T1 (en)
DK (1) DK2546255T3 (en)
EA (1) EA023039B1 (en)
ES (1) ES2605466T3 (en)
HR (1) HRP20161529T1 (en)
HU (1) HUE031082T2 (en)
IL (1) IL221737A (en)
LT (1) LT2546255T (en)
MX (1) MX338130B (en)
PL (1) PL2546255T3 (en)
PT (1) PT2546255T (en)
RS (1) RS55362B1 (en)
SI (1) SI2546255T1 (en)
TW (1) TWI495640B (en)
UA (1) UA110479C2 (en)
WO (1) WO2011111817A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150135123A1 (en) * 2013-11-13 2015-05-14 International Business Machines Corporation Cursor-based character input interface
US20180096039A1 (en) * 2016-09-30 2018-04-05 Google Inc. Systems and methods for context-sensitive data annotation and annotation visualization

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
JP6556225B2 (en) * 2014-09-17 2019-08-07 セルジーン シーエーアール エルエルシー MK2 inhibitors and uses thereof
US20210052600A1 (en) * 2017-12-27 2021-02-25 Takeda Pharmaceutical Company Limited Therapeutic agents for stress urinary incontinence and incotinence of feces

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2002074746A1 (en) * 2001-03-16 2004-07-08 山之内製薬株式会社 Benzoazepine derivatives
US6953787B2 (en) 2002-04-12 2005-10-11 Arena Pharmaceuticals, Inc. 5HT2C receptor modulators
WO2005003096A1 (en) 2003-06-17 2005-01-13 Arena Pharmaceuticals, Inc. Benzazepine derivatives useful for the treatment of 5ht2c receptor associated diseases
US20080009478A1 (en) 2003-10-22 2008-01-10 Arena Pharmaceuticals, Inc. Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2c Receptor Associated Diseases
US20070275949A1 (en) 2003-10-22 2007-11-29 Arena Pharmaceuticals, Inc. Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2C Receptor Associated Diseases
US8022062B2 (en) * 2004-02-25 2011-09-20 Eli Lilly And Company 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists
GB0412314D0 (en) 2004-06-02 2004-07-07 Glaxo Group Ltd Compounds
TW201031661A (en) 2009-02-17 2010-09-01 Targacept Inc Fused benzazepines as neuronal nicotinic acetylcholine receptor ligands

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150135123A1 (en) * 2013-11-13 2015-05-14 International Business Machines Corporation Cursor-based character input interface
US20180096039A1 (en) * 2016-09-30 2018-04-05 Google Inc. Systems and methods for context-sensitive data annotation and annotation visualization

Also Published As

Publication number Publication date
LT2546255T (en) 2016-12-12
TW201144321A (en) 2011-12-16
AU2011225108A1 (en) 2012-09-27
HUE031082T2 (en) 2017-06-28
MX338130B (en) 2016-04-04
US20110269744A1 (en) 2011-11-03
CA2792918A1 (en) 2011-09-15
MX2012010570A (en) 2012-11-23
BR112012022915B1 (en) 2021-02-02
CA2792918C (en) 2018-09-04
JP5747910B2 (en) 2015-07-15
ES2605466T3 (en) 2017-03-14
KR101769642B1 (en) 2017-08-18
PT2546255T (en) 2016-12-07
EP2546255B1 (en) 2016-08-31
CN102869665B (en) 2015-05-27
EP2546255A4 (en) 2014-09-03
EA023039B1 (en) 2016-04-29
TWI495640B (en) 2015-08-11
EA201290905A1 (en) 2013-03-29
US9108977B2 (en) 2015-08-18
SI2546255T1 (en) 2017-05-31
WO2011111817A1 (en) 2011-09-15
US20150315208A1 (en) 2015-11-05
RS55362B1 (en) 2017-03-31
BR112012022915A2 (en) 2018-05-22
KR20130038242A (en) 2013-04-17
AU2011225108B2 (en) 2014-11-06
US20130059837A1 (en) 2013-03-07
DK2546255T3 (en) 2016-12-19
UA110479C2 (en) 2016-01-12
AU2011225108C1 (en) 2015-05-07
US9598434B2 (en) 2017-03-21
PL2546255T3 (en) 2017-02-28
CN102869665A (en) 2013-01-09
JPWO2011111817A1 (en) 2013-06-27
HRP20161529T1 (en) 2016-12-30
CY1118268T1 (en) 2017-06-28
EP2546255A1 (en) 2013-01-16
IL221737A (en) 2016-10-31

Similar Documents

Publication Publication Date Title
US8916565B2 (en) Pyrrolopyrazine-spirocyclic piperidine amides as modulators of ion channels
US8674096B2 (en) Substituted imidazo[1,5-a]quinoxalin-4-ones as phosphodiesterase 9 inhibitors
US9598434B2 (en) Benzazepine compound
WO2016105484A1 (en) Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis
WO2016105477A1 (en) Derivatives of 5-phenyl- or 5-heteroarylthiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis
US20130029973A1 (en) Tetrahydrobenzothiophene compound
HUE028038T2 (en) Pyrazoloquinoline compounds
KR20090114439A (en) Acylguanidine derivative
US20210040066A1 (en) Tetrahydroisoquinoline compound, preparation method therefor, pharmaceutical composition containing same, and use thereof
EP3828174A1 (en) Pyridazinone derivative
KR20080044273A (en) Acylguanidine derivative or salt thereof
US10301286B2 (en) Piperazine derivative
US20230002383A1 (en) Novel functionalized lactams as modulators of the 5-hydroxytryptamine receptor 7 and their method of use
US20240051946A1 (en) Targeted protein degradation of parp14 for use in therapy
US9670219B2 (en) Tetrahydrooxepinopyridine compound

Legal Events

Date Code Title Description
AS Assignment

Owner name: ASTELLAS PHARMA INC., JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KOSHIO, HIROYUKI;ASAI, NORIO;TAKAHASHI, TAISUKE;AND OTHERS;SIGNING DATES FROM 20120807 TO 20120820;REEL/FRAME:028917/0314

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION